Synthesis and Transition Metal-catalysed Reactivity of Enantioenriched Allenes and Enynes by Zamani, Farzad
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
2017+ University of Wollongong Thesis Collections 
2019 
Synthesis and Transition Metal-catalysed Reactivity of Enantioenriched 
Allenes and Enynes 
Farzad Zamani 
University of Wollongong 
Follow this and additional works at: https://ro.uow.edu.au/theses1 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Zamani, Farzad, Synthesis and Transition Metal-catalysed Reactivity of Enantioenriched Allenes and 
Enynes, Doctor of Philosophy thesis, School of Chemistry and Molecular Bioscience, University of 
Wollongong, 2019. https://ro.uow.edu.au/theses1/535 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
 
 
Synthesis and Transition Metal-catalysed Reactivity of 













Dr. Christopher J. T. Hyland 






This thesis is presented as part of the requirement for the conferral of the degree: 









The University of Wollongong 










List of Abbreviations..................................................................................................................xv 
Part 1. Synthesis and Reactivity of Allenylaziridines, Allenyloxazolidinones and Allenes 
with Pendant Heteroatoms...........................................................................................................1  
Chapter 1. Introduction .................................................................................................................1 
1.1. Aziridines and Oxazolidinones Bearing an Unsaturated Carbon−Carbon 
Bond..................................................................................................................................1 
1.2. Allenes Bearing a Single Pendant Heteroatom..........................................................9 
1.2.1. Allenylation and Propargylation Reactions via Direct Addition.....................12 
1.2.2. Allenylation and Propargylation Reactions via Isomerisation Mechanism.....14 
1.3. Metal-catalysed Cyclisation Reactions of Allenes with a Single Pendant 
Heteroatom......................................................................................................................20 
1.4. Allenes Bearing Two Pendant Heteroatom...............................................................24 
1.5. Aims of the Project (I)...............................................................................................28 
Chapter 2. Results and Discussion..............................................................................................31 
2.1. Synthesis of 2-Allenyl-N-benzylaziridine................................................................31  
2.2. Reactivity of 2-Allenyl-N-benzylaziridine...............................................................35  
2.3. Synthesis of Allenyl 1,2-Amino Alcohols: Direct Access to 5-Allenyloxazolidinones 
and 2,5-Dihydrofurans.....................................................................................................40  
2.4. Summary...................................................................................................................62 
Part 2. Synthesis of Unconjugated Chiral (E)-enediynes from 5-Allenyloxazolidinones and 
Their Application in Au(I)-Cycloaromatisation Reactions.....................................................64 
Chapter 3. Introduction................................................................................................................64 
 ii 
3.1. 1,3-Enynes................................................................................................................65
  3.1.1. Synthesis of 1,3-Enynes via Metal-catalysed Cross-coupling...................66 
  3.1.2. Synthesis of 1,3-Enynes via Metal-catalysed Cross-dimerisation.............67 
  3.1.3. Synthesis of 1,3-Enynes via Wittig Olefination and Dehydration 
Reactions.............................................................................................................69 
 3.2. Heteroatom-tethered 1,3-Enynes and 1,4-Enynes....................................................71 
3.3. Carbon- and Heteroatom-tethered 1,6-Enynes.........................................................73 
3.4. Metal-catalysed Cycloisomerisation Reactions of 1,6-Enynes.................................74 
3.5. Au(I)-Catalysed Cycloisomerisation of 1,6-Enynes..................................................76 
3.6. 1,6-Enynes Bearing Extra π-Bond Substitutions.......................................................80 
3.7. Aims of the Project (II) .............................................................................................83  
Chapter 4. Results and Discussion...............................................................................................85 
4.1. Synthesis of 1,3-(E)-Enynes Bearing a Pendant Nitrogen........................................85 
4.2. Synthesis of Unconjugated Enediynes and Au(I)-Catalysed Cycloisomerisation.....88 
4.3. Mechanistic Study of Au(I)-Catalysed Cycloisomerisation Reaction of Unconjugated 
Enediynes.......................................................................................................................106 
4.4. Conclusion..............................................................................................................119 
4.5. Future Directions and Summary..............................................................................120 
Chapter 5. Experimental Section...............................................................................................124 
List of References........................................................................................................................241 
Appendix.....................................................................................................................................252







List of Tables  
Table 2.1. Optimisation conditions for the Appel reaction of 181...............................................35 
Table 2.2. Attempted nucleophilic ring opening reactions of the 2-allenylaziridine 182 using 
different organometallic reagents, and with or without BF3·OEt2................................................38 
Table 2.3. Optimisation of the zinc-catalysed allenylation reaction conditions...........................44 
Table 2.4. Reaction scope of syn N-Boc allenylamino alcohol.....................................................53 
Table 2.5. Reaction scope of 5-allenyl oxazolidinones.................................................................55 
Table 2.6. Reaction scope of 2,5-dihydrofurans............................................................................58 
Table 2.7.  Determination of ee values of the oxazolidinones using (S)-10-camphorsulfonyl 
chloride.........................................................................................................................................60 
Table 4.1. Reaction scope for 1,3-(E)-enynes 253a-e...................................................................87 
Table 4.2. Optimisation of Au(I)-catalysed cycloisomerisation reaction of enediyne 254a.........90 
Table 4.3. Reaction scope for the isoindolines 255.......................................................................93 
Table 4.4. Optimisation of Au(I)-catalysed cycloisomerisation reaction of enediyne 380d.........99 
Table 4.5. Reaction scope of isoindolinones 381.........................................................................101 
Table 4.6. Expanding the structural diversity of the unconjugated (E)-enediynes.......................103 









List of Schemes 
Scheme 1.1. (a) Carbon–carbon multiple bond functionalised aziridines. (b) General 
transformations of vinylaziridines. (c) General ring-opening reactions of ethynylaziridines.........2 
Scheme 1.2. (a) Palladium-catalysed asymmetric transformation of the vinylaziridine 9 with 
nucleophiles. (b) Total synthesis of bromopyrrole alkaloids..........................................................3 
Scheme 1.3. (a) Organocopper-mediated ring-opening reactions of ethynylaziridines. (b) Pd-
catalysed stereoselective ring-opening reactions of ethynylaziridines using InI and 
aldehydes........................................................................................................................................4 
Scheme 1.4. Pd-catalysed dearomative cycloaddition of vinylaziridine to 
3‑nitroindoles..................................................................................................................................5 
Scheme 1.5. Examples of (a) direct aziridination of an diene and (b,c) cyclisations of amino 
alcohol derivatives to aziridines......................................................................................................6 
Scheme 1.6. (a,b) Selected examples regarding the utility of oxazolidinone as a latent aziridine 
equivalent in ring-opening reactions...............................................................................................7 
Scheme 1.7. Synthesis and reactivity of 5-vinyloxazolidinone 48 in cycloaddition reactions with 
benzylidenemalononitrile 49 in the presence of Pd2(dba)3·CHCl3.................................................7 
Scheme 1.8. Platinum-catalysed cyclisation of N-allyl carbamates for the synthesis of 5-
vinyloxazolidinones........................................................................................................................8 
Scheme 1.9. Proposed synthesis of the 2-allenylaziridine and allenyloxazolidinone from allenyl 
amino alcohols................................................................................................................................9 
Scheme 1.10. General metal-catalysed nucleophilic addition reactions of carbonyl compounds 
and imines.....................................................................................................................................11 
Scheme 1.11. Catalytic regioselective and enantioselective allenylation reactions of N-protected 
isatins 70 using allenylboronic acid pinacol ester.........................................................................12 
Scheme 1.12. Catalytic enantioselective allenylation reaction of trifluoromethyl and 
pentafluoroethyl ketones 74 using allenylboronic acid pinacol ester............................................13 
  
 iii 
Scheme 1.13. Catalytic asymmetric synthesis of α-allenyl alcohols from aldehydes and a 
(trimethylsilyl)propargylboronic acid pinacol ester......................................................................13 
Scheme 1.14. Regioselective allenylation reaction of isatins in aqueous media...........................14 
Scheme 1.15. Indium-mediated reactions of aldehydes with trialkylsilyl propargyl 
bromides.......................................................................................................................................15 
Scheme 1.16. Allenylation of aldehydes using a combination of tin(IV) iodide and 
tetrabutylammonium iodide..........................................................................................................15 
Scheme 1.17. Silver-catalysed allenylation and propargylation reactions of methyl 
phenylglyoxylate 100 using allenylboronic acid pinacol ester.....................................................16 
Scheme 1.18. Catalytic asymmetric allenylation of N,O-aminals 103..........................................17 
Scheme 1.19. Regioselective copper-catalysed allenylation reactions of ketones using 
(trimethylsilyl)propargylboronic acid pinacol ester......................................................................17 
Scheme 1.20. Zinc-catalysed allenylation reactions of aldehydes and ketones using allenylboronic 
acid pinacol ester...........................................................................................................................18 
Scheme 1.21. Mechanistic pathways for zinc-catalysed allenylation reactions............................19 
Scheme 1.22. The zinc-catalysed regioselective allenylation reaction of ketones using zinc amide 
catalyst..........................................................................................................................................20 
Scheme 1.23. Possible pathways for metal-catalysed cyclisation reactions of allenes tethered to a 
heteroatom....................................................................................................................................21 
Scheme 1.24. First reported silver-catalysed cyclisation reactions of racemic α-allenols and 
racemic β-allenols.........................................................................................................................22 
Scheme 1.25. Palladium-catalysed insertion-cyclisation reaction of α-allenols...........................22 
Scheme 1.26. Enantioselective cycloisomerisation of racemic allenyl alcohols or amines. PNB = 
para-nitrobenzyl, dppm = 1,1-bis(diphenylphosphanyl)methane, Mts = 
mesitylenesulfonyl........................................................................................................................23 
Scheme 1.27. Au(I) and Ag(I)-catalysed cyclisation of racemic β-amino allenes........................23 
Scheme 1.28. Regio- and stereoselective allenylation of azetidine-2,3-diones.............................25 
 iv 
Scheme 1.29. The borono-Mannich reactions of α-hydroxy aldehydes with primary or secondary 
amines in the presence of allenylboronic acid pinacol ester..........................................................25 
Scheme 1.30. The borono-Mannich reactions of α-hydroxy aldehydes and glyoxylic acid 
(monohydrate) with primary or secondary amines in the presence of allenylboronic acid...........26 
Scheme 1.31. Proposed synthetic pathway for the zinc-catalysed allenylation reaction of 
enantioenriched chiral α-amino aldehydes in the presence of allenylboronic acid pinacol 
ester...............................................................................................................................................27 
Scheme 1.32. Racemisation of N-protected α-amino aldehydes...................................................28 
Scheme 1.33. (a) Proposed synthetic pathway for preparation and reactivity of 2-allenylaziridine. 
(b) Proposed synthetic pathway for preparation and reactivity of 5-
allenyloxazolidinone.....................................................................................................................30 
Scheme 2.1. Synthesis of the allenyl amino alcohol 181..............................................................31 
Scheme 2.2. (a) Attempted Mitsunobu reaction of allenyl amino alcohol 181. (b) O-
Tosylation/intramolecular SN2 displacement of allenyl amino alcohol 181..................................32 
Scheme 2.3. Cyclisation of allenyl amino alcohol 181 under Appel reaction conditions.............33 
Scheme 2.4. Mechanism for the Appel reaction of allenyl amino alcohol 181.............................34 
Scheme 2.5. (a) Reported Pd(II)-catalysed ring-opening of vinylaziridines 189. (b) Our study 
regarding ring-opening of the 2-allenylaziridine 182....................................................................36 
Scheme 2.6. (a) General pathway for palladium-catalysed allylation of allenes. (b) Our study 
regarding palladium(0)-catalysed ring-opening of the 2-allenylaziridine 182..............................37 
Scheme 2.7. An example of the Lewis acid-catalysed ring-opening reaction of aziridinyl enoates 
199 with organocyanocuprates......................................................................................................37 
Scheme 2.8. Overview of the reaction steps to synthesise 5-allenyloxazolidinones and 2,5-
dihydrofurans................................................................................................................................41 
Scheme 2.9. Synthesis of N-Boc α-amino alanal 205a.................................................................41 
Scheme 2.10. Zinc-catalysed allenylation reaction of N-Boc α-amino alaninal 205a...................42 
Scheme 2.11. Synthesis of different N-protected amino aldehydes..............................................46 
Scheme 2.12. Determination of relative configuration of the allenyl products.............................47 
 v 
Scheme 2.13. Cram–chelation and Felkin–Anh models for the nucleophilic addition to chiral α-
amino aldehyde.............................................................................................................................51 
Scheme 2.14. Proposed mechanism for the zinc-catalysed allenylation reaction of N-protected α-
amino aldehydes...........................................................................................................................52 
Scheme 2.15. Synthesis of N-Boc α-amino aldehydes 205a-g from L-α-amino acids.................53 
Scheme 2.16. Zinc-catalysed allenylation reaction of O-protected α-hydroxy aldehydes............54 
Scheme 2.17. Structures of oxazolidinone-based eperezolid and linezolid..................................56 
Scheme 2.18. Synthesis of N-Bn,N-Boc α-amino aldehydes from L-α-amino acids....................57 
Scheme 2.19. Structures of 2,5-dihydrofuran-based Elvucitabine................................................59 
Scheme 2.20. Chiral HPLC results for the racemic and pure α-amino alcohols 249a and the 
corresponding 2,5-dihydrofuran 250a..........................................................................................62 
Scheme 3.1. Potential approach for the reactivity of the 5-allenyloxazolidinones 230 as a 
precursor to synthesise chiral 1,3-(E)-enynes, enediynes and isoindolines..................................65 
Scheme 3.2. General pathways to synthesise 1,3-enynes.............................................................65 
Scheme 3.3. Synthesis of 1,3-(E)-enynes using alkynyl bromide and styrenes catalyzed by 
Pd(OAc)2......................................................................................................................................66 
Scheme 3.4. Synthesis of 1,3-(E)-enynes using alkynyl bromides and alkenylboronic acids 
catalyzed by CuF2O4 nanoparticles...............................................................................................66 
Scheme 3.5. Synthesis of 1,3-enynes using vinyl iodides and acetylenes catalyzed by Cu(I) 
catalyst..........................................................................................................................................67 
Scheme 3.6. Synthesis of 1,3-(E)-enynes using acetylenes catalyzed by a Rh pincer complex..68 
Scheme 3.7. Pd-catalysed synthesis of 1,3-(E)-enynes using acetylenes......................................68 
Scheme 3.8. Rh-catalysed hetero-dimerisation of acetylenes.......................................................69 
Scheme 3.9. Z-selective Wittig reactions of propargyl aldehydes and phosphorous ylides.........69 
Scheme 3.10. Z-Selective Fe(III)-catalysed dehydration reaction of propargyl alcohols.............70 
Scheme 3.11. NaOH-promoted direct synthesis of 1,3-(E)-enynes 285 from allenols 284..........70 
Scheme 3.12. NaH-mediated direct synthesis of 1,3-(E)-enynes 288 from allenols 287..............71 
 vi 
Scheme 3.13. Synthesis of pyrroles 293 via coupling of enyne-imines 291 with Fischer 
complexes.....................................................................................................................................72 
Scheme 3.14. KOtBu-promoted three-component coupling reaction of aldehydes and alkynes to 
synthesise (Z)-2-en-4-yn-1-ols 297 and (E)-1-en-4-yn-3-ols 298................................................72 
Scheme 3.15. (a) Synthesis of GSK1360707 300. (b) General procedures for synthesis of 1,6-
enynes...........................................................................................................................................74 
Scheme 3.16. Three main mechanisms for the metal-catalysed cycloisomerisation of 1,6-
enynes...........................................................................................................................................75 
Scheme 3.17. (a) Cycloisomerisation of 1,6-enynes with non-skeletal rearrangement approach. 
(b) Cycloisomerisation of 1,6-enynes with skeletal rearrangement approach..............................77 
Scheme 3.18. Enantioselective synthesis of derivatives 330 via Au(I)-catalysed 
cycloisomerisation reaction of 1,6-enynes....................................................................................78 
Scheme 3.19. Synthesis of tricyclic compounds 333 via Au(I)-catalysed cycloisomerisation 
reaction of nitrogen- and oxygen-tethered alkylidenecyclopropanes 332.....................................79 
Scheme 3.20. Au(I)-catalysed cycloisomerisation of 1,6-enyne 337 via single- and double-
cleavage rearrangements...............................................................................................................79 
Scheme 3.21. The cis-selective single-cleavage rearrangement of (E)- and (Z)-1,6-enynes bearing 
electron-donating substitution on terminal alkene carbon.............................................................80 
Scheme 3.22. Au(I)-catalysed Diels–Alder reaction of dienyne 347.............................................81 
Scheme 3.23. Au(I)-catalysed intramolecular formal [4 + 2] cycloisomerisation of 1,6-enynes 
352................................................................................................................................................82 
Scheme 3.24. Rh(I)-catalysed intramolecular [4 + 2] cycloaddition of an acyloxy-pendant 
enediyne 357.................................................................................................................................82 
Scheme 3.25. Rh-catalysed Diels−Alder-type reaction cycloaddition and oxidation of dienyne 
362................................................................................................................................................83 
Scheme 3.26. (a) Proposed reaction pathways to direct access chiral isoindoline. (b) Two 
examples of bioactive isoindolines................................................................................................84 
 vii 
Scheme 4.1. Direct synthesis of 1,3-(E)-enyne 253a from N-Bn,N-Boc allenyl amino alcohol 
218a..............................................................................................................................................85 
Scheme 4.2. Speculated auto-oxidation reaction pathway of the isoindoline 
255................................................................................................................................................94 
Scheme 4.3. Effect of carbonyl group on the stability of isoindolines reported by Sarpong and co-
workers.........................................................................................................................................94 
Scheme 4.4. Examples of bioactive isoindolinones......................................................................95 
Scheme 4.5. Synthesis of enediyne 380d as the model substrate.................................................96 
Scheme 4.6. Test reaction for the Au(I)-catalysed cycloaromatisation reaction of enediyne 
380d..............................................................................................................................................97 
Scheme 4.7. Possibility of a new reaction pathway based on the formation of unexpected 
isoindolinone isomer...................................................................................................................107 
Scheme 4.8. (a) General reaction pathways for dual gold catalysis. (b) General modes of gold σ-
activation of alkyne. (c) Known reactivity of (Z)-enediynes. (d) Proposed intermediate for the 
Au(I)-catalysed cycloisomerisation reaction of enediynes 380 and 385.....................................108 
Scheme 4.9. Mechanistic experiments towards the proposed dual gold activation 
mechanism..................................................................................................................................109 
Scheme 4.10. Deuterium labeling study using the enediyne 385c..............................................110 
Scheme 4.11. Deuterium labeling study using the enediyne 385c-d´..........................................111 
Scheme 4.12. (a) Known concerted [4 + 2] cycloaddition reaction of conjugated (E)-enediyne. 
(b,c) Attempted [4 + 2] cycloaddition reactions of unconjugated (E)-enediyne.........................112 
Scheme 4.13. Synthesis of gold acetylide intermediate and associated control experiments......114 
Scheme 4.14. Proposed mechanism of the Au(I)-catalysed cycloaromatisation of unconjugated 
(E)-enediyne...............................................................................................................................115 
Scheme 4.15. (a) Calculated mechanism for the cascade cycloaromatisation reaction. (b) Selected 
pathway for aromatisation and protodemetallation pathways from deuterated 380a-d'. The relative 
Gibbs energies obtained from M06-CPCM/6-31+G(d,p)//B3LYP-CPCM/6-31G(d) calculations 
are given in kcal/mol. (Performed by Prof. Brian F. Yates, Dr. Alireza Ariafard, and Mr. Rasool 
 viii 
Babaahmadi (PhD student) from University of Tasmania) in conjunction with detailed feedback 
and guidance by the UOW group)..............................................................................................118 
Scheme 4.16. Deutero-deauration process of 386-d-Au in the C-7 position by 385c-d............118 
Scheme 4.17. (a) Reactivity of allenyloxazolidinones with boronic acids under Pd(0) catalysis. 
(b) Proposed intramolecular Diels-Alder reaction of the tethered 1,3-diene to give an 
isoindolinone scaffold.................................................................................................................121 
Scheme 4.18. Proposed synthetic route for 3,4-dihydroisoquinolinone via gold-catalysed 
cycloisomerisation of N-butynoic enediyne................................................................................122 















List of Figures 
Figure 2.1. 1H NMR spectrum (500 MHz, CDCl3) of the 2-allenylaziridine 182...........................33 
Figure 2.2. 1H NMR spectrum (500 MHz, CDCl3) of the diene 201 (R = Bu)..............................39 
Figure 2.3. 1H NMR spectrum (500 MHz, CDCl3) of the isolated N-Boc allenylamino alcohol 
206a and the propargyl regioisomer 207a.....................................................................................43 
Figure 2.4. 1H NMR spectrum (500 MHz, CDCl3) of the N-Boc propargylamino alcohol 
207a..............................................................................................................................................45 
Figure 2.5. 1H NMR spectrum (500 MHz, CDCl3) of the NH allenyloxazolidinone 229a...........48 
Figure 2.6. 1H NMR spectrum (500 MHz, CDCl3) of the NBn allenyloxazolidinone 230a.........48 
Figure 2.7. 1D NOE difference spectrum of the NH allenyloxazolidinone 229a after irradiation at 
H4..................................................................................................................................................49 
Figure 2.8. 1D NOE difference spectrum of the NBn allenyloxazolidinone 230a after irradiation 
at H4..............................................................................................................................................50 
Figure 2.9. An example of determining the ee value of the leucine-derived allenyl oxazolidinone 
229c by measuring the ratios of the diastereoisomers by 1H NMR spectroscopy on the crude 
reaction mixture............................................................................................................................60 
Figure 4.1. 1H NMR spectrum (400 MHz, CDCl3) of the 1,3-(E)-enyne 253a............................86 
Figure 4.2. 1H NMR spectrum (500 MHz, CDCl3) of the enediyne 254a....................................88 
Figure 4.3. 1H NMR spectrum (500 MHz, CDCl3) of the 5-membered ring intermediate 
365................................................................................................................................................91 
Figure 4.4. 1H NMR spectrum (500 MHz, CDCl3) of the isoindoline 255a................................92 
Figure 4.5. 1H NMR spectrum (400 MHz, CDCl3) of the enediyne 380d...................................96 
Figure 4.6. 1H NMR spectrum (400 MHz, CDCl3) of the isoindolinone 381d............................98 
Figure 4.7. Chiral HPLC analysis of the isoindolinone 381a. (Phenomenex Lux Cellulose-3 
column; hexane/isopropyl alcohol (90:10); flow rate = 0.5 mL/min; 254 nm; single peak, t = 16.75 
min, >99% ee. Racemic isoindolinone 381a showed two peaks at t = 16.11 min and t = 16.84 min 
(peak area ratios = 1:1) with the same solvent system and flow rate).........................................102 
 x 
Figure 4.8. 1H NMR spectrum (400 MHz, CDCl3) of the isoindolinone 386c...........................105 
Figure 4.9. HMBC spectrum (400 MHz, CDCl3) of the isoindolinone 386c..............................105 
Figure 4.10. X-ray crystal structure of isoindolinone 386c (CCDC 1867833, performed by A/Prof 
Michael Gardiner). Data were collected at 100 K on a crystal mounted on a Hampton Scientific 
cryoloop at the MX2 beamline, Australian Synchrotron, Victoria. The thermal parameters of all 
hydrogen atoms were estimated as Uiso(H) = 1.2Ueq(C) except for CH3 where Uiso(H) = 1.5Ueq(C). 


































An allenylamino alcohol was synthesised via a known borono-Mannich method in which the 
amine group was next to the allene bond. A novel 2-allenylaziridine was then successfully 
obtained from the allenylamino alcohol under mild reaction conditions. The reactivity of the 
aziridine towards a number of ring-opening reactions was investigated. However, these ring-
opening reactions proved to be capricious, and for the majority of these reactions no product could 
be isolated, along with many side products being formed. Therefore, the investigation was shifted 
to synthesise 5-allenyloxazolidinones, which could participate in nucleophilic ring-opening 
reactions as equivalent analogues of 2-allenylaziridines. To obtain these unique allenyl 
heterocycles, a series of new allenylamino alcohols was required in which the hydroxy group 
should be adjacent to the allene bond, as the borono-Mannich method provides a nitrogen 
heteroatom next to the allene bond. The first examples of simultaneous control of 
diastereoselectivity and regioselectivity in zinc-catalysed allenylation reactions of N-protected α-
amino aldehydes of high enantiomeric purity using an allenylboronic acid pinacol ester were 
developed to obtain a wide range of novel anti and syn allenylamino alcohols. The resulting 
allenyl products demonstrated high reactivity in NaH-induced and Au-catalysed intramolecular 
cyclisation reactions to obtain novel 5-allenyloxazolidinones and 2,5-dihydrofurans, respectively, 
in high yields. It was described that N-Bn allenyloxazolidinones can be selectively transformed 
into novel chiral 1,3-(E)-enynes upon treatment with an excess amount of NaH through a 
decarboxylative conjugate elimination process. Addition of an extra triple bond to the enynes by 
incorporation of either propargyl or propiolic groups provided a series of novel unconjugated (E)-
enediynes. We explored the potential of these versatile scaffolds to undergo cascade Au(I)-
catalysed cycloaromatisation reactions to offer enantioenriched versions of a wide range of 
biologically relevant isoindolines and isoindolinones. The cycloisomerisation reaction of the 
propargylated enediynes likely involved a known single cleavage skeletal rearrangement 
mechanism and gave the corresponding isoindolines. However, the N-propiolic enediynes 
 xii 
underwent the Au(I)-catalysed cycloaromatisation through a new dual-gold reaction mechanism, 







 First and foremost, I would like to express my most sincere appreciation to my 
supervisors, Dr. Christopher Hyland and Professor Stephen G. Pyne for providing me 
with the invaluable opportunity of carrying out my PhD under their supervision. Their 
diligence, untiring efforts and innovative spirit have been an inspiring driving force to 
me during my research.  
        I am also grateful to all the other members in the Hyland and Pyne groups for their 
contribution to my learning, progress and happiness throughout the years: Jie Xiang Yin, 
YiSing Gee, Daniel Rivinoja, Ronald Brown, Melanie Drew, Srinivas Thadkapally, 
Melissa Bird, Bairavee Ramachandran, Liam Joyce, Nina Blazeska, Thanaphat Thaima, 
Anthony Carrol, Pham Quoc Hoang and Steven Wales. 
        Special thanks also go to Dr. Wolford Lie from the NMR Laboratory, and Dr. 
Celine Kelso, Dr. Alan Maccarone and Ms Karin Maxwell from the Mass Spectrometry 
Laboratory. I also thank Mrs Roza Dimeska, Mr Joe Daunt and Mr Travis Naylor from 
the HPLC and IR Laboratories. 
         I would also like to thank the University of Wollongong for funding support (UPA 
and IPTA scholarships).  
         Finally, my deep and sincere gratitude to my family for their continuous and 
unparalleled love, help and support. I am forever indebted to my parents for giving me 
the opportunities and experiences that have made me who I am. They selflessly 
encouraged me with unfailing emotional support to explore new directions in life and 
seek my own destiny. It was their love that raised me up again when I got weary. I am 
also grateful to my dear brother and sister for always being there for me as my best 
friends. There are also no proper words to convey my deep gratitude and respect to my 
aunt, Parvaneh, for her emotional support and heart-warming kindness. This journey 





I, Farzad  Zamani , declare that this thesis submitted in fulfilment of the requirements for 
the conferral of the degree Doctor of Philosophy, from the University of Wollongong, is wholly 
my own work unless otherwise referenced or acknowledged. This document has not been submitted 
















List of Abbreviations 
[M]+   molecular ion 
[𝛼]D   specific rotation 
Ac   acetyl 
amu   atomic mass units 
Ar   aromatic ring 
Bn   benzyl 
Boc   tert-butyloxycarbonyl 
br.   broad 
BQ   1,4-benzoquinone 
Bu   butyl 
Bz   benzoyl 
c   concentration in g/100 mL 
ca   circa 
cat.   catalyst 
Cbz   carboxybenzyl 
13C NMR  carbon nuclear magnetic resonance spectroscopy 
COD   1,5-cyclooctadiene 
COSY   correlation spectroscopy 
d   doublet 
DABCO  1,4-diazobicyclo[2.2.2]octane 
dba   dibenzylideneacetone 
DBU   1,8-diazobicyclo[5.4.0]undec-7-ene 
DCC   N,N'-dicyclohexylcarbodiimide 
DCE   1,2-dichloroethane 
DDQ   2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
dd   doublet of doublets 
 
 xvi 
DIAD   diisopropyl azodicarboxylate 
DIBAL-H  diisobutylaluminium hydride 
DIPEA   diisopropylethylamine 
DMAP   4-dimethylaminopyridine 
DMB   dimethoxybenzene 
DMF   dimethylformamide 
DMP   Dess-Martin periodinane 
DMSO   dimethyl sulfoxide 
Dpp   diphenylphosphine oxide 
dr   diastereomeric ratio 
ee   enantiomeric excess 
equiv.   equivalents 
Et   ethyl 
Fmoc   fluorenylmethyloxycarbonyl 
hfacac   hexafluoroacetylacetone 
HMBC   heteronuclear multiple bond coherence 
1H NMR  proton nuclear magnetic resonance spectroscopy 
HPLC   high-performance liquid chromatography    
HRMS (ESI)  high resolution mass spectroscopy (electrospray ionization)  
HSQC   heteronuclear single quantum coherence 
Hz   hertz 
IBX   2-iodoxybenzoic acid 
i-Bu   isobutyl 
i-Pr   isopropyl 
IPrAuCl  chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]gold(I) 
 J   coupling constant 
LA   Lewis acid 
LAH   lithium aluminum hydride 
 
 xvii 
LDA   lithium diisopropylamide 
m   multiplet 
m   meta 
M   molar 
Me   methyl 
m.p.   melting point 
m/z   mass/charge ratio 
mol   mole 
MOM   methoxymethyl 
Ms   mesyl, methanesulfonyl 
NMO   4-methylmorpholine N-oxide 
NOE   nuclear overhauser effect 
NOESY  nuclear overhauser enhancement spectroscopy 
Ns   nosyl, 4-nitrobenzenesulfonyl 
OTf   triflate, trifluoromethanesulfonate 
Pd/C   palladium on carbon 
Ph   phenyl 
Phen   1,10-phenanthroline 
Piv   pivaloyl 
PMB   p-methoxybenzyl 
PMP   p-methoxyphenyl 
31P NMR  phosphorous nuclear magnetic resonance spectroscopy 
ppm   parts per million 
PTSA   p-toluenesulfonic acid 
q   quartet 
Rf   retention factor 
r.t   room temperature 
s   singlet 
 
 xviii 
SN2   bimolecular nucleophilic substitution 
t   triplet 
 t-   tert- 
TBS   tert-butyldimethylsilyl 
TBDPS   tert-butyldiphenylsilyl    
TEA   triethylamine 
TES   tetraethylsilyl 
TEMPO  2,2,6,6-tetramethyl-1-piperidinyloxy 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
TMS   trimethylsilyl or tetramethylsilane 
TMSCl   trimethylsilyl chloride or chlorotrimethylsilane 
Tr   triphenylmethyl 






Part 1. Synthesis and Reactivity of Allenylaziridines, 
Allenyloxazolidinones and Allenes with Pendant 
Heteroatoms 
 
Chapter 1. Introduction 
1.1. Aziridines and Oxazolidinones Bearing an Unsaturated Carbon−Carbon 
Bond 
Heterocyclic compounds form one of the largest and most important family of organic 
compounds. Within this family, small-ring heterocycles (n = 3 and 4) are a key structural feature 
in numerous biologically active molecules having synthetic, pharmaceutical and industrial 
applications. The small heterocyclic ring is also of great importance both as versatile substrates 
in organic synthesis of more elaborate structures and as desired targets of synthesis.1  
In particular, aziridines are valuable three-membered ring building blocks in organic 
synthesis that can be used to synthesise more complex N-containing heterocyclic molecules.2 
The reactivity of aziridines can be diversified by introducing an unsaturated carbon-carbon 
bond at C-2 on the ring to create vinylaziridines 1 or ethynylaziridines 2 (Scheme 1.1a). Due 
to the presence of both a carbon-carbon multiple bond and a three-membered ring in these 
molecules, interesting reactivity toward a large number of different reagents could be expected. 
Since these aziridines are usually stable enough to be isolated and stored for a long period of 
time, they are widely utilized for the synthesis of biologically active compounds and natural 
products.2 Vinylaziridines generally participate in two major classes of transformations in the 
presence of low-valent transition metals, such as palladium(0); (i) 1,3-dipolar cycloadditions; 
and (ii) nucleophilic addition reactions (Scheme 1.1b).3 The vinylaziridine is first activated by 
an addition of a low-valent transition metal to form the zwitterionic 1,3-dipole 3 (Scheme 1.1b). 
This dipole (3) is then able to undergo nucleophilic addition reactions or 1,3-dipolar 





In contrast, ethynylaziridines 2 can also participate in ring-opening reactions to afford the allene 
adduct 6 and the propargyl product 8 (Scheme 1.1c).  
 
 
Scheme 1.1. (a) Carbon–carbon multiple bond functionalised aziridines. (b) General transformations of vinylaziridines. (c) 
General ring-opening reactions of ethynylaziridines. 
 
The Trost group described palladium-catalysed asymmetric ring-opening 
transformations of vinylaziridines 9 with substituted 1H-pyrroles 10 and 1H-indoles 12 as 
nucleophiles to give ring-opened adducts 11 and 13, respectively, in high yields and high regio- 
and enantioselectivities (Scheme 1.2a).4 As illustrated in Scheme 1.2, these reactions proceed 
via nucleophilic attack of the heterocycle onto the Pd-allyl complex 14 (Scheme 1.2a). 
Furthermore, the synthetic application of this ring-opening protocol in natural products 
synthesis was developed for the preparation of the two important bromopyrrole alkaloids 
agesamide A and B (18 and 19, Scheme 1.2b), in which pyrrole 16 with methyl ester 
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anion in the π-allyl Pd intermediate 14 and the ester group of the pyrrole 16 to form cycloadduct 
17. 
 
Scheme 1.2. (a) Palladium-catalysed asymmetric transformation of the vinylaziridine 9 with nucleophiles. (b) Total synthesis of 
bromopyrrole alkaloids. 
 
Organocopper-mediated ring-opening reactions of 3-alkyl-2-ethynylaziridines to 
synthesise chiral N-protected amino allenes was reported Ohno and co-workers (Scheme 1.3a).5 
In this study, the ring-opening reaction of 2,3-trans-3-alkyl-2-ethynylaziridines 20 exclusively 
provided the (S,Sa)-amino allenes 21, whereas the reaction of 2,3-cis-3-alkyl-2-
ethynylaziridines 22 provided the (S,Ra)-amino allenes 23 in high yields via the general 
mechanistic rationale shown in Scheme 1.1c. Mechanistically, the aziridines 20 and 22 undergo 
ring-opening reactions upon the nucleophilic attack of organocopper, providing the 
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In another study, Tanaka et al. described ring-opening reaction of 3-alkyl-2-
ethynylaziridines 24 with aldehydes in the presence of InI/Pd(PPh3)4 via initial oxidative 
addition and transmetalation to provide 2-ethynyl-1,3-amino alcohols 26 in good yields 
(Scheme 1.3b).6 The allenylindium complex 25 first formed via treatment of 3-alkyl-2-
ethynylaziridines with InI in the presence of Pd(PPh3)4 and H2O. Stereoselective addition of the 
allenylindium to the aldehyde then occurred to give the final product 26.  
 
 
Scheme 1.3. (a) Organocopper-mediated ring-opening reactions of ethynylaziridines. (b) Pd-catalysed stereoselective ring-
opening reactions of ethynylaziridines using InI and aldehydes. 
 
As an example of a [3 + 2] cycloaddition reaction of vinylaziridines, via their 
corresponding 1,3-zwitterionic dipoles, a diastereoselective synthesis of densely functionalised 
pyrroloindolines 30 and 31 was disclosed by the Hyland group. This process proceeded via a 
Pd-catalysed cycloaddition of vinylaziridine 27 with electron-deficient 3-nitroindoles 28 
(Scheme 1.4).7 The vinylaziridine 27 first undergoes a ring-opening process through oxidative 
addition of the Pd(0) catalyst to form the π-allyl Pd(II) complex 29. The intermediate 29 then 
attacks to the electron-deficient indole 28 to form the pyrroloindoline. The cis and trans 
diastereoselectivity of this reaction is dependent on the substitution of the indole ring, but 
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Scheme 1.4. Pd-catalysed dearomative cycloaddition of vinylaziridine to 3‑nitroindoles. 
 
Vinylaziridines and ethynylaziridines can be synthesised by a series of different 
methods.2-3 For example, direct aziridination of a conjugated diene via the 1,2-addition of a 
nitrene species is a traditional method for the synthesis of vinylaziridines.2 the direct 
aziridination of the 1,3-diene 34 by 1,2-addition of alkoxycarbonylnitrene 33 was described by 
Hafner and co-workers, generated by photolysis of the methoxycarbonyl azide 32, to the diene 
(Scheme 1.5a).8 This methodology was highly stereospecific as the direct aziridination of 1,3-
diene 34 provided the corresponding trans-dimethylaziridine 35. Intramolecular cyclisation of 
1,2-amino alcohols is another efficient method for the synthesis of aziridines.2 Aziridines can 
be generally formed in two steps by this approach; activation of the OH in order to make it a 
good leaving group, followed by intramolecular SN2 nucleophilic reaction of the NH to form 
the aziridine ring. Initial investigations of the ring-closure of vinyl- or ethynyl-substituted 
amino alcohols were based on the Mitsunobu reaction using PPh3 and DEAD.9 However, low 
to moderate yields were obtained, mainly due to the formation of a carbamate byproduct 
resulting from the reaction between the amino alcohol and DEAD.9 This could be prevented by 
changing the ethyl group of DEAD to a bulkier isopropyl group as in DIAD.10-11 For example, 
Somfai and co-workers developed the intramolecular cyclisation of the N-trityl allyl amino 
alcohol 36 to give aziridine 37 in excellent yield under Mitsunobu reaction conditions (Scheme 
1.5b).12 In 1977, Manisse and Chuche reported the preparation of 2-ethynyl-3-vinylaziridine 39 
via the intramolecular cyclisation of the amino alcohol 38 under Appel reaction conditions 
using PPh3 and CCl4 (Scheme 1.5c).13 It was shown that the reaction was stereospecific, and 
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Scheme 1.5. Examples of (a) direct aziridination of an diene and (b,c) cyclisations of amino alcohol derivatives to aziridines. 
  
 
Interestingly, it has been shown that oxazolidinones could undergo ring cleavage 
pathways in a similar manner as aziridines. In 1992, the utility of 2-oxazolidinone as a latent 
aziridine equivalent in ring-opening reactions was reported by Poindexter and co-workers.14 
They demonstrated that oxazolidinones could readily undergo ring-opening reactions without 
yielding the same undesired polyamino by-products as in the case of aziridines.14 For example, 
when the ring-opening reaction occurs in the presence of HCl, the oxazolidinone 40 can 
generate the same product 41 as the aziridine 42 by a decarboxylation reaction process (Scheme 
1.6a). More recently, Iseki et al. explored the nucleophilic ring-opening of oxazolidinone for 
the synthesis of a PGI2 receptor agonist.15 Decarboxylative ring-opening of oxazolidinone 43 
using 4-piperidinol 45 under heating in DMSO provided the diamine 46 without any significant 
side products (Scheme 1.6b). They also showed that the same diamine 46 could be obtained 
using the corresponding aziridine analogue 44. However, because of the toxic and carcinogenic 
properties of the aziridine, they focused their synthesis based on oxazolidinone precursors. It 
should be mentioned that the diamine 46 was employed as a key substrate to synthesise the 


































In a similar vein, vinyloxazolidinones are shown to be equivalents of vinylaziridines 
after decarboxylative oxidative addition through the same zwitterionic dipole intermediate. Ooi 
and co-workers reported the synthesis and reactivity of 5-vinyloxazolidinone 48 in a 
cycloaddition reaction with benzylidenemalononitrile 49 in the presence of Pd2(dba)3·CHCl3 
catalyst and ligand 51 (Scheme 1.7).16 The oxazolidinone 48 was synthesised in four steps from 
N-Boc-glycine N'-methoxy-N'-methylamide 47. In this study, the chiral ligand 51 showed a 
remarkable ability to control the stereoselectivity of the cycloaddition reaction allowing the 
catalytic asymmetric synthesis of densely functionalised pyrrolidines 50 in high to excellent 
yields. 
 
Scheme 1.7. Synthesis and reactivity of 5-vinyloxazolidinone 48 in cycloaddition reactions with benzylidenemalononitrile 49 in 





























1) R1MgI (2.00 equiv.), THF, 0 oC
2)                  (2.50 equiv.), Et2O, 0 oC
3) KOtBu (1.30 equiv.), THF, 0 oC
4) NaH (2.00 equiv.), NsCl (1.30 equiv.)



















































The Jang group described the synthesis of 5-vinyloxazolidinones 54 via platinum-
catalysed cyclisation of N-allyl carbamates 53 in good yields (Scheme 1.8).17 The reaction was 
initiated by formation of the electrophilic allyl-platinum intermediate 55 followed by 
nucleophilic attack of the oxygen. The role of SnCl2 in this reaction mechanism was proposed 
as a promoter for the C–O bond cleavage in the carbamate, and as a catalyst activator. 
 
 
Scheme 1.8. Platinum-catalysed cyclisation of N-allyl carbamates for the synthesis of 5-vinyloxazolidinones. 
 
Taking all these studies into consideration, a proposal was designed for the synthesis 
of 2-allenylaziridine 59 from the cyclisation reaction of allenyl amino alcohols 57 (Scheme 1.9) 
and subsequent investigation of these systems reactivity. Although the synthetic methods and 
the reactivity of vinylaziridines 1 and ethynylaziridines 2 have been broadly studied, those for 
the analogous allenylaziridine 59 skeleton is still unexplored. Allenylaziridines provide one 
extra π-bond compared to a vinylaziridine, potentially leading to a diene product in metal-
catalysed ring-opening pathways. The ability to exploit further manipulation of the resulting 
diene would make these compounds potentially powerful scaffolds in organic synthesis. 
Furthermore, since oxazolidinones can undergo ring cleavage pathways in a similar manner as 
aziridines, it was envisioned to synthesise and investigate the reactivity of 5-
allenyloxazolidinones 60 as equivalent analogues of the 2-allenylaziridines 59 in ring-opening 
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in the literature; therefore, a synthetic approach was required to be established for the 
preparation of these unique heterocycles and the subsequent investigation of their reactivity.    
 
Scheme 1.9. Proposed synthesis of the 2-allenylaziridine and allenyloxazolidinone from allenyl amino alcohols. 
 
The allenyl amino alcohols 57 and 58, which are the proposed precursors to the 
allenylaziridines and allenyloxazolidinones, are intriguing motifs given the presence of two 
heteroatoms. Allenes bearing a single pendant heteroatom have been widely investigated in 
terms of their synthesis and subsequent cyclisation reactions. However, systems such as 57 and 
58 with two pendant heteroatoms are far less investigated, in part due to a lack of methods for 
their preparation. An overview of the key methods for the synthesis of allenes bearing a single 
heteroatom are now detailed, followed by an overview of the limited investigations of their two 
heteroatom counterparts. 
 
1.2. Allenes Bearing a Single Pendant Heteroatom 
Many methods for the synthesis of allenes bearing a single pendant heteroatom have been 
reported in the literature.18-19 Allenylation of carbonyl compounds and imines with allenyl or 
propargyl organometallic reagents are amongst the most commonly employed methods for the 
synthesis of such allenes.19-23 The easy access to starting materials and reagents, as well as mild 
and efficient reaction conditions make these methodologies particularly attractive for synthesis 
of heteroatom-functionalised allenes.18-20 However, these methods are also quite challenging 
due to the requirement for control of regioselectivity between propargyl 64 and allenyl 65 
isomers (Scheme 1.10), as well as control of enantiomeric purity of the products. Despite these 

































carbonyl compounds and imines with control of enantio- and regioselectivity.19, 22-23 Carbonyl 
compounds and imines 61 can generally undergo 1,2-addition reactions with organometallic 
reagents in the presence of transition metal catalysts, Lewis or Brønsted acids, or Lewis bases, 
providing propargyl and allenyl products 64 and 65 (Scheme 1.10). The regioselectivity of these 
reactions for allenyl versus propargyl products mainly depends upon the nature of the metal, 
the substituents on the organometallic reagents, the reaction temperature, and the solvent – as 
well as the allenylation reagent employed.18-19  
There are two different mechanistic pathways for the allenylation and propargylation 
reactions of carbonyl compounds and imines with organometallic reagents (Scheme 1.10). The 
allenylation and propargylation reactions involving the direct addition mechanism (Scheme 
1.10a) typically proceed via the direct addition of the organometallic reagent to the electrophile 
by an SE2′-type mechanism in the presence of a Lewis acid or Lewis base. Coordination of the 
Lewis acid to the carbonyl or imine group can render it sufficiently electrophilic to undergo the 
nucleophilic addition reaction. On the other hand, Lewis bases generally activate the 
organometallic species by binding to the metal.24 Therefore, in the direct addition mechanism 
with the allenyl reagent 62, the propargyl product 64 forms preferentially – in contrast, the use 
of propargyl reagent 63 gives allenyl product 65. The regiochemical outcome of these reactions 
can be explained by the coordination between the metal and the carbonyl oxygen (X = O) or 
the imine nitrogen (X = NR) (Scheme 1.10a).25-26 These intermediates can be used to explain 
the general direct addition pathways in which allenyl organometallic reagents afford 
homopropargylic alcohol (or amine) products, and propargyl organometallics favour α-allenyl 
alcohol (or amine) products. These reactions usually proceed with boron, tin, silicon, zinc, or 







Scheme 1.10. General metal-catalysed nucleophilic addition reactions of carbonyl compounds and imines. 
 
On the other hand, allenylation and propargylation reactions involving the 
isomerisation mechanism (Scheme 1.10b) typically proceed by an initial transmetalation step, 
followed by the addition to the electrophile (Scheme 1.10b). The reaction of allenyl reagent 66 
or propargyl reagent 67 with the metal catalyst first generates the propargyl 68 and allenyl 69 
complexes, respectively, which can slowly equilibrate (Scheme 1.10b), in which the allenyl 
intermediate 69 is generally more thermodynamically stable. The final product distributions are 
determined by a balance between rate of the isomerisation and relative stability of the allenyl- 
69 and propargyl-metal 68 intermediates.22 These intermediates can react with the electrophilic 
carbonyl compounds or imines via an SE2′-type process to give the corresponding allenyl 65 or 
propargyl 64 products, respectively. Tuning the regioselectivity of the reaction has been a 
critical challenge in organic synthesis, since the metallotropic rearrangement between the 
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studies have explored methods to fully control the regiochemistry of these organometallic 
reactions.18-22   
 
1.2.1. Allenylation and Propargylation Reactions via Direct Addition 
In 2013, the Hoveyda group demonstrated the catalytic enantioselective allenylation reactions 
of N-protected isatins 70 using allenylboronic acid pinacol ester 71 catalysed by the 
aminophenol catalyst 72, and NaOtBu under mild reaction conditions (Scheme 1.11).27 These 
reactions were highly regioselective for the allenyl products 73 (>98%) and proceeded in high 
yields (90-91%), as well as affording allenyl products in excellent enantiomeric purities (92-
96% ee). However, the scope of the process was quite limited since only a few N-protected 
isatins 70 were accessible. 
 
 
Scheme 1.11. Catalytic regioselective and enantioselective allenylation reactions of N-protected isatins 70 using allenylboronic 
acid pinacol ester. 
 
Hoveyda and co-workers also described the catalytic enantioselective allenylation 
reactions of fluoro-substituted ketones 74 using allenylboronic acid pinacol ester 71 in the 
presence of the triphenylsilyl-substituted aminophenol catalyst 75 (Scheme 1.12).28 The 
reactions involve the propargylboron intermediate 77 in which the boron is attached to the 
phenol oxygen and the benzylamino group of the catalyst (Scheme 1.12). The protonated 
nitrogen increases the Lewis acidity of the boron, facilitating C–C bond formation. 
Furthermore, high enantioselectivities (83-98% ee) were obtained because of the rigid catalyst–










R1 = PMB, Bn
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Scheme 1.12. Catalytic enantioselective allenylation reaction of trifluoromethyl and pentafluoroethyl ketones 74 using 
allenylboronic acid pinacol ester. 
 
A chiral Brønsted-acid catalysed asymmetric allenylation of aldehydes 78 using 
(trimethylsilyl)propargylboronic acid pinacol ester 79 was developed by Reddy (Scheme 
1.13).29 This methodology exhibited high efficiency towards a broad range of aryl, aliphatic, 
and heteroaryl aldehydes with high yields (89-94%) and excellent ees (82-99%). The TMS 
group of the final allene product was readily removed by treatment with tetrabutylammonium 
fluoride (TBAF). It was proposed that H-bonding between the phosphonic acid and the 
pseudoaxial oxygen of the propargyl reagent (intermediate 81) led to the final allene products 
80 being obtained in high ee. 
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1.2.2. Allenylation and Propargylation Reactions via the Isomerisation 
Mechanism 
The allenylation reaction of isatins 82 with propargyl bromides 83 in the presence of different 
metals (indium, tin, zinc) and additives in aqueous media was reported by Alcaide et al. 
(Scheme 1.14).30 They demonstrated that the steric effect of the substituent (R2 = Me or Ph) on 
the propargyl bromide was responsible for high regioselectivity of the allenyl products 86 as 
the allenyl species 85 could be destabilised due to an unfavourable steric strain interaction.  
     
 
Scheme 1.14. Regioselective allenylation reaction of isatins in aqueous media. 
 
An interesting approach towards allenic alcohols 90 or homopropargylic alcohols 91 
using the indium-catalysed reaction of trialkylsilyl propargyl bromides 89 with various 
aldehydes 88 was developed by Loh et al. (Scheme 1.15).31 They showed that changing the size 
of the silyl group and the reaction conditions, either the allenic 90 or homopropargylic 91 
alcohols could be provided in good to excellent yields and high regioselectivities. The sterically 
smaller TMS group favoured the propargyl product 91 at higher temperatures while the larger 
TIPS and TBDPS groups provided the allenyl products 90 at room temperature. It was also 
hypothesised that the coordination of the silicon with the halogen of the indium salt may play 
a significant role in the selectivity of the final products (93, Scheme 1.15).   
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Scheme 1.15. Indium-mediated reactions of aldehydes with trialkylsilyl propargyl bromides. 
 
In another study, it was described that a mixture of a tin(IV) salt and 
tetrabutylammonium  iodide  could  be  used  for allenylation  of  aldehydes 95 with 2-propynyl 
mesylates 94 in CH2Cl2 at room temperature (Scheme 1.16).32 This technique showed that the 
regioselectivity towards the allenic product could be controlled by placing a methyl group on 
the R2 position of the 2-propynyl mesylate 94. 
 
 
Scheme 1.16. Allenylation of aldehydes using a combination of tin(IV) iodide and tetrabutylammonium iodide. 
 
The silver-catalysed allenylation and propargylation reactions of methyl 2-oxo-2-
phenylacetate100 using allenylboronic acid pinacol ester 71 under mild reaction conditions was 
reported by Jarvo and co-workers (Scheme 1.17).33 Initially, B/Ag exchange results in an 
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These silver species react with the carbonyl via an SE2´ pathway to provide the propargyl and 
allenyl products 101 and 102. They demonstrated that in the absence of an additional additive, 
the allenyl product 102 was the major isomer (allene/propargyl = 5.8:1). However, the addition 
of Bu4NI led to a switch in regioselectivity favouring the propargyl product 101 
(allene/propargyl = 1:14.4). They reported that the cause of the change in the regioselectivity 
by the addition of the halide additive was not fully understood and was under investigation, 




Scheme 1.17. Silver-catalysed allenylation and propargylation reactions of methyl phenylglyoxylate 100 using allenylboronic 
acid pinacol ester. 
 
The allenylation reaction of N,O-aminals 103 using allenylboronic acid pinacol ester 
71 catalysed by a combination of indium(I) chloride and the chiral silver BINOL phosphate 
ligand 106 under mild conditions was reported by Kobayashi and co-workers (Scheme 1.18).34 
The reaction proceeded with high asymmetric induction for the allene products, but with only 
moderate regioselectivity. The regiochemical outcome would suggest that the reaction follows 
the general isomerisation mechanism pathway (Scheme 1.10b), in which B/In transmetalation 
initially occurs to form the corresponding allenyl and propargyl indium intermediates. Indium 
activation of the methoxy leaving group generates a stabilised carbenium ion intermediate that 
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Scheme 1.18. Catalytic asymmetric allenylation of N,O-aminals 103. 
 
In another study, the Fandrick group demonstrated the regioselective allenylation 
reactions of aldehydes and ketones 107 using (trimethylsilyl)propargylboronic acid pinacol 
ester 79 in the presence of copper(II) isobutyrate, LiOtBu, and the chiral bidentate diphosphine 
ligand 109 (Scheme 1.19).35 Although the regioselectivities for the allenes 108 were good to 
excellent (83-99%), the ees of the allenyl products were poor to moderate (ca. 5–64%). The 
regioselectivity of this reaction follows the general isomerisation mechanism pathway (Scheme 




Scheme 1.19. Regioselective copper-catalysed allenylation reactions of ketones using (trimethylsilyl)propargylboronic acid 
pinacol ester. 
 
The zinc-catalysed regioselective allenylation reaction of aldehydes and ketones was 
developed by the Fandrick group using allenylboronic acid pinacol ester 71 and a catalytic 
amount of Et2Zn in toluene under mild conditions (Scheme 1.20).36 This methodology worked 
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several reactive functional groups including esters, carbamates, and primary bromides and 
chlorides. Furthermore, in terms of economical point of view, zinc is a non-precious metal 
catalyst highlighting the importance of this method.  The regioselectivity of this reaction was 
dependent upon the amount (mol%) of Et2Zn, the reaction temperature, and the solvent. For 
example, the allenyl/propargyl ratio decreased from 93:7 to 54:46 in favour of the propargyl 
product 112 with increasing catalyst loading from 2 mol% to 13 mol%. In the polar solvent 
THF, low catalyst loadings (7 mol %) also favoured formation of the propargyl product 112 
(allene/propargyl = 30:70). The temperature was found to have a minimal effect on the 
regioselectivity since using 7 mol% of Et2Zn at 0 oC and 20 oC resulted in the regioselectivity 
for the allene decrease by only 3%. 
 
 
Scheme 1.20. Zinc-catalysed allenylation reactions of aldehydes and ketones using allenylboronic acid pinacol ester. 
 
Based on earlier studies,22-23, 36 the zinc-catalysed allenylation reaction was found to 
proceed via the general isomerisation mechanism pathway (Scheme 1.10b). Initially, B/Zn 
exchange results in an equilibrium between propargylzinc 113 and allenylzinc 114 
intermediates (Scheme 1.21). The propargyl zinc species 113 is kinetically favoured as this is 
initially formed upon boron to zinc transmetalation. This zinc species reacts with the 
electrophile under kinetic control conditions via an SE2´ pathway to provide the allene product 
117. In contrast, the more thermodynamically stable allenylzinc intermediate 114 is formed by 
isomerisation of the initially formed propargylzinc and then reacts with the electrophile to give 
the propargyl isomer 118 – again by the SE2´ pathway. As expected for a transmetalation 
process, the regioselectivity in the Et2Zn-catalysed reactions mainly depends on the rate of 
isomerisation in the equilibrium between the organozinc intermediates. Increasing the amount 
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towards the more thermodynamically stable allenylzinc reagent 114, more propargyl product is 
observed when the concentration of the zinc catalyst is increased.36 Furthermore, more 
electrophilic aldehydes bearing electron-withdrawing groups next to the carbonyl typically 
offered higher regioselectivity for the allene product because they underwent faster addition 
with the propargylzinc reagent 113, before significant isomerization could occur.36 Moreover, 
the isomerisation also occurs rapidly in the polar solvent THF, favouring the more stable 
allenylzinc intermediate 114 to favour formation of the corresponding propargyl product 118 
(Scheme 1.21). 
   
 
Scheme 1.21. Mechanistic pathways for zinc-catalysed allenylation reactions. 
 
Kobayashi and co-workers subsequently disclosed a related zinc-catalysed 
regioselective allenylation reaction of ketones using allenylboronic acid pinacol ester 120 in 
the presence of a catalytic amount of Zn(HMDS)2 (Scheme 1.22).37 In this study, the zinc amide 
catalyst (Zn(HMDS)2) was found to undergo a faster rate of B/Zn exchange than Et2Zn, which 
enables the reaction to be conducted under milder conditions. However, the zinc amide catalyst 
is not commercially available and should be prepared, handled and stored in a glove box at −30 
oC. Allenyl products 121 were obtained using 2 mol% of the zinc amide catalyst at −40 oC in 
toluene with high to excellent regioselectivity (Scheme 1.22). Performing the reaction in the 
non-coordinating solvent toluene and at low temperature favoured the allene product via 
reaction of the propargylzinc intermediate. The mechanistic results are consistent with those of 














































Scheme 1.22. The zinc-catalysed regioselective allenylation reaction of ketones using zinc amide catalyst. 
 
 
1.3. Metal-catalysed Cyclisation Reactions of Allenes with a Single Pendant 
Heteroatom 
The allenes tethered to a heteroatom prepared via the methods described in Schemes 1.11-1.22 
can participate in powerful heterocyclic-ring-forming reactions. The intramolecular additions 
of heteroatoms to allene systems is a powerful strategy to directly access a wide variety of 
highly functionalised and complex heterocyclic molecules in an atom-economical manner.38 
Different regiochemical outcomes can simply be achieved in intramolecular reactions by using 
different reaction conditions or by changing the tether length of substituents between the 
heteroatom and the allene bond (Scheme 1.23). Importantly, substituted allenes have axial 
chirality and can often be prepared  in  high  enantiomeric purities leading to enantioriched 
products upon cyclisation. Therefore, heteroatom-tethered allenes play a particularly 
significant role in organic synthesis, since they can be converted under mild conditions into 
biologically active chiral heterocycles via cyclisation reactions.38-43 
The general reaction pathways for the cyclisation of allenes bearing a pendant 
heteroatom 123 in the presence of a transition metal catalyst are illustrated in Scheme 1.23. The 
metal can coordinate to either of the two 𝜋-bonds of the allene via η2-coordination, activating 
cyclisation via the endo- or exo- attack mode to the internal or terminal carbons by the pendant 
nucleophile to provide different heterocyclic structures.38, 40, 44-45 In such reactions, one of the 
allene double bonds remains in the final product as an alkene, which can be manipulated further 
by other chemical transformations. 
!
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Scheme 1.23. Possible pathways for metal-catalysed cyclisation reactions of allenes tethered to a heteroatom. 
 
 
The cyclisation reaction of allenes has been extensively explored with a wide variety 
of pendant nitrogen and oxygen nucleophiles.38, 45-47 In particular, the cyclisation reactions of 
allenols and amino allenes provide a large number of O- or N-heterocycles, and have been 
broadly investigated for the synthesis of natural products.39, 44, 46, 48 In this section, some 
representative examples regarding the cyclisation reactions of heteroatom-pendant allenes will 
be discussed. 
 In 1979, the cyclisation reactions of α-allenols 130 and β-allenols 131 in the presence 
of catalytic amounts of a silver salt were first explored by Claesson and Olsoon  (Scheme 
1.24).49 α-Allenols provided 2,5-dihydrofurans 132 in the presence of AgBF4 or AgNO3 via 5-
endo-trig attack of the pendant oxygen nucleophile to the distal double bond, whereas β-
allenols 131 gave 5,6-dihydro-2H-pyrans 133 via 6-endo-trig cyclisation. In another study, Ma 
and Zhao reported the diastereoselective synthesis of optically active trans-2,3-disubstituted 
vinylic oxiranes 136 via Pd-catalysed insertion-cyclisation reaction of α-allenols 134 with 
aryliodides (Scheme 1.25).50 The 𝜋-allyl-Pd complex 135 is formed as the intermediate, which 
undergoes cyclisation with the pendant heteroatom. The reaction proceeded with excellent 
regioselectivity for the epoxide ring, with no five-membered ring dihydrofuran 137 observed 
in this reaction, presumably because a trans 𝜋-allyl complex is favoured and this can only 




































Scheme 1.25. Palladium-catalysed insertion-cyclisation reaction of α-allenols. 
 
Toste and co-workers developed Au(I)-catalysed enantioselective cyclisation reaction 
of allenes with a pendant hydroxyamine or hydrazine group 138 (Scheme 1.26).51 In this 
methodology, chiral vinyl isoxolidines, oxazines, and pyrazolidines 139 were afforded in the 
presence of a Au(I)/Ag(I) catalyst system using chiral ligands (L*, 140) and the chiral anion 
(S)-trip with moderate to excellent yields and high enantiomeric excesses. These heterocycles 
could serve as potential precursors in natural products synthesis as they appear frequently in 
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Scheme 1.26. Enantioselective cycloisomerisation of racemic allenyl alcohols or amines. PNB = para-nitrobenzyl, dppm = 1,1-
bis(diphenylphosphanyl)methane, Mts = mesitylenesulfonyl. 
 
 
Recently, our group reported the synthesis of pyrrolines 143a,143b and 
tetrahydropyridines 144 from the cyclisation reactions of β-amino allenes 142 using the Au(I) 
and Ag(I) catalyst combination (Scheme 1.27).52 It was shown that the (PPh3)AuCl/AgBF4 
catalyst (10 mol%) in CH2Cl2 at room temperature favoured the 5-endo-dig cyclisation reaction 
pathway, before rapid rearrangement of 143a to the product 143b with an endocyclic alkene 
(Scheme 1.27a). Conversely, AgBF4 (10 mol%) favours the 6-endo-trig cyclisation mode in 
toluene at room temperature to provide the 6-membered ring product 144 (Scheme 1.27b). The 
reason for the regioselectivity of this reaction is uncertain, but presumably it appears that silver 
binds preferentially to the distal 𝜋-bond of the allene and gold to the proximal.   
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1.4. Allenes Bearing Two Pendant Heteroatoms  
In the previous section, the synthesis and selected reactivity of allenes containing a single 
heteroatom for the synthesis of heterocycles were discussed. The development of efficient 
reactions that enable the formation of molecules, in particular heterocycles, with multiple 
heteroatoms in a highly efficient way is of significant interest for synthesis of complex organic 
targets. In this regard, introducing a second pendant heteroatom element to the allene would be 
highly desirable. Allenes bearing two pendant heteroatoms not only provide more active sites 
in a single molecule, but also offer more diversity in further cyclisation pathways. In addition, 
the ability to exploit further manipulation of the resulting heterocycles – at either the exocyclic 
free heteroatom or at the remaining double bond – would make these compounds versatile 
intermediates in natural product synthesis. As proposed in Scheme 1.9, allenes bearing two 
pendant heteroatoms could also act as potential precursors to synthesise the allenylaziridine 59 
and allenyloxazolidinone 60 that are the primary subject of this thesis. 
Despite extensive reports of allenes with a single heteroatom in the literature, methods 
to prepare allenes with multiple pendant heteroatoms are rare, and the reported studies have not 
been catalytic.53-55 Therefore, the synthesis of such powerful scaffolds is a highly desirable goal.  
Some of the few existing methods for the synthesis of these allenic skeletons is now discussed. 
 Alcaide and co-workers described metal-mediated allenylation of azetidine-2,3-diones 
145 with differently substituted propargyl bromides 146 in the presence of Zn, In, and Sn 
(Scheme 1.28).53 A series of allenyl-substituted 3-hydroxy-lactams 147 were obtained in low 
to high yields with excellent regioselectivity and diastereoselectivity. The stereoselectivity of 
this reaction could be attributed to the chiral auxiliary at C-4 blocking one face of the ketone, 
which forces the organometallic reagent to attack from the less hindered side (148, Scheme 







Scheme 1.28. Regio- and stereoselective allenylation of azetidine-2,3-diones. 
 
The Pyne group disclosed the three component, one-pot borono-Mannich reaction of 
α-hydroxy aldehydes 150 (as their cyclic acetal dimers 151) with primary or secondary amines 
149 in the presence of allenylboronic acid pinacol ester 71 under mild conditions (Scheme 
1.29).54 These reactions were highly regioselective (>98%) and provided exclusively the anti 
allenyl α-hydroxy amines 152 in moderate to high yields (54-92%). Furthermore, 
enantiomerically enriched α-hydroxy aldehydes 150 gave the allenyl products with high 
enantiomeric excess (ee > 96%). The stereoselectivity of the reaction was explained based on 
the intermediate 153 in which A1,3-strain about the iminium ion intermediate is minimized.54 
  
 
Scheme 1.29. The borono-Mannich reactions of α-hydroxy aldehydes with primary or secondary amines in the presence of 
allenylboronic acid pinacol ester. 
 
Soon after the initial investigation by Pyne, the Petasis group reported similar findings 
using α-hydroxy aldehydes 155 and glyoxylic acid (monohydrate) 156 with primary or 
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that the nature of the amine substrate determined the regiochemical outcomes of the reaction. 
Although secondary amines exclusively provided the α-allenyl amino acids (158a,b), most 
primary amines formed the α-propargyl amino acids (159a,b), with less regioselectivity for 
bulkier substrates. These general trends could be explained by some mechanistic insights. It 
was shown that the intermediate 160 formed from the primary amines were electrostatically 
more favoured to attack from the γ-position of the allene moiety to generate propargyl products 
159a,b. In the case of the secondary amines (intermediate 161), however, the α-addition to the 
iminium species was more favourable providing allenyl products 158a,b exclusively. It was 
also found that the bulkier the amine components, the lower were the isolated yields.  
 
 
Scheme 1.30. The borono-Mannich reactions of α-hydroxy aldehydes and glyoxylic acid (monohydrate) with primary or 
secondary amines in the presence of allenylboronic acid. 
 
Although these reactions can be performed under mild conditions with high yields and 
selectivities, there are some limitations regarding these techniques. Most of the allenyl products 
consist of two alkyl groups on the nitrogen, which restricts them from further synthetic 
manipulation – for example, a cyclisation reaction would require a free N-H moiety. 
Furthermore, a large range of the chiral α-hydroxy aldehyde precursors are not generally 
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nitrogen next to the allenyl unit – meaning the allenyloxazolidinone (Scheme 1.9) – as an 
aziridine equivalent – could not be formed by this method. 
Inspired by the study carried out by the Fandrick group (Schemes 1.20),36 it was 
proposed in this PhD study that enantiomerically enriched α-amino aldehydes 162 could be 
utilised as the carbonyl precursors using this technique in order to afford chiral α-allenylamino 




Scheme 1.31. Proposed synthetic pathway for the zinc-catalysed allenylation reaction of enantioenriched chiral α-amino 
aldehydes in the presence of allenylboronic acid pinacol ester. 
 
α-Amino aldehydes are powerful building blocks because of their ready accessibility 
in both enantiomeric forms for synthesis of enantiomerically enriched compounds in natural 
products and pharmaceuticals.56-59 The presence of a formyl group and an amino functionality 
in a single molecule enable α-amino aldehydes to be exploited for further manipulation to 
construct complex chiral structures. In general, the major challenge in the synthesis of α-amino 
aldehydes is the labile nature of the α-stereogenic centre, which is prone to undergo 
racemisation in the presence of base or acid, or upon chromatographic purification and 
storage.56, 59 The acidic α-hydrogen of the α-amino aldehyde 164 enables the aldehyde to form 
the enol 165 under acidic and enolate 166 under basic conditions (Scheme 1.32). This 
phenomenon results in an extensive loss in enantiomeric purity of the α-amino aldehyde due to 
forming a mixture of (R) and (S) enantiomers. Therefore, maintaining enantiomerically purities 
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Scheme 1.32. Racemisation of N-protected α-amino aldehydes. 
 
Consequently, in the proposed chemistry, several challenges need to be considered to 
achieve efficient zinc-catalysed allenylation reactions of α-amino aldehydes. Regioselectivity 
issues can be challenging, as both the allene and the propargyl isomers may be formed via the 
general isomerisation mechanism process. The ability to control the diastereoselectivity of the 
reaction would be another potential issue because of the formation of a new stereogenic centre. 
The enantiomeric purity of the final allene product can also be challenging, as the 
enantiomerically enriched α-amino aldehydes can potentially undergo racemisation, leading to 
products of low enantiopurities. However, it was anticipated that under the very mild zinc-
catalysed allenylation reaction conditions that the racemisation of the α-amino aldehydes would 
be unlikely, which is one reason why this particular method was chosen for investigation.   
 
1.5. Aims of the Project (I) 
The first aim of this project was the development of an efficient synthetic route to an 
allenylaziridine. Inspired by previously reported synthesis of allenyl amino alcohols 170 via 
borono-Mannich reaction of α-hydroxy aldehydes 168, amines 169 and allenylboronic acid 
pinacol ester 71,54 it was envisioned to utilise these allenyl scaffolds in the synthesis of the 2-
allenylaziridines 171 (Scheme 1.33a). Based on the general reactivity of aziridines, it was 
assumed that these aziridines might participate in metal-catalysed ring-opening reactions 
through the formation of the vinyl-π-allylpalladium intermediate 172. This intermediate could 
undergo an allylic nucleophilic substitution reaction to form the chiral diene 174 containing a 





































aziridines in different ring-opening reaction conditions. On the other hand, in order to obtain 5-
allenyloxazolidinones, having an OH group adjacent to the allene bond was necessary. 
Therefore, it was intended to investigate the possible synthetic routes for the synthesis of these 
allenes bearing two pendant heteroatoms by the zinc-catalysed allenylation of readily accessible 
α-amino aldehydes 162 (Scheme 1.33b). α-Amino aldehydes are susceptible to racemisation 
under acidic or basic conditions, or even upon chromatographic purification and storage. It was 
therefore aimed to investigate whether the proposed methodology would show retention of the 
enantiomeric purity of the aldehyde during the reaction steps. Due to the creation of the new 
chiral centre in the zinc-catalysed allenylation reaction of α-amino aldehyde, the 
diastereoselectivity of the reaction may also need to be investigated. These allenyl amino 
alcohols 163 could be used as powerful chiral building blocks in the synthesis of 5-
allenyloxazolidinone 175, as well as cyclisation reactions catalysed by electrophilic transition 
metals, such as Au(I). Furthermore, as the equivalent analogues of the 2-allenylaziridines 171, 
the 5-allenyloxazolidinone 175 should also display similar reactivity via a decarboxylative ring 
cleavage pathway to generate the chiral nitrogen-pendant diene 178 (Scheme 1.33b).  
 






Scheme 1.33. (a) Proposed synthetic pathway for preparation and reactivity of 2-allenylaziridine. (b) Proposed synthetic pathway 
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Chapter 2. Results and Discussion 
2.1. Synthesis of 2-Allenyl-N-benzylaziridine  
In order to prepare the allenyl amino alcohols, which is required to synthesise the unexplored 
allenylaziridines (Scheme 1.33), the borono-Mannich reaction was first investigated. At the 
beginning of the project, the borono-Mannich reaction was performed using glycolaldehyde 
dimer 179, benzylamine 180, and allenylboronic acid pinacol ester 71 under microwave 
condition. The allenyl amino alcohol 181 was obtained after purification by column 
chromatography in moderate yield (54%) and with excellent regioselectivity (Scheme 2.1). 
Having the model substrate 181 in hand, different methods were examined in order to obtain 
the desired 2-allenylaziridine by intramolecular ring-closure.     
 
 
Scheme 2.1. Synthesis of the allenyl amino alcohol 181. 
  
Initially, the intramolecular SN2 cyclisation of the allenyl amino alcohol 181 under 
Mitsunobu reaction conditions was investigated. The substrate 181 was subjected to reaction 
conditions similar to those reported in the literature using PPh3 and DIAD (Scheme 2.2a).12 The 
reaction mixture was stirred at room temperature for 3 h, but no conversion was observed by 
TLC analysis. The reaction was stirred and heated at reflux for 18 h, with the reaction monitored 
by TLC analysis. 1H NMR analysis of the crude reaction mixture showed 100% conversion of 
the starting material, and that a complex mixture of products had been formed. No 1H NMR 
resonances for the expected aziridine product 182 were observed. Also, no discrete products 
could be isolated after purification by column chromatography.  
A simple procedure had been developed for the preparation of a wide range of 
aziridines, particularly N-benzyl aziridines, in a single step using TsCl and DMAP/Et3N.60 The 






















advantage of this procedure compared to the Mitsunobu methodology is that these reactions 
typically proceed at room temperature. Therefore, the allenyl amino alcohol 181 was treated 
with TsCl and DMAP/Et3N in CH2Cl2 at room temperature for 24 h (Scheme 2.2b). However, 
no aziridine product was detected, and a complex mixture of products resulted as evidenced 
from 1H NMR analysis.  
    
 
Scheme 2.2. (a) Attempted Mitsunobu reaction of allenyl amino alcohol 181. (b) O-Tosylation/intramolecular SN2 displacement 
of allenyl amino alcohol 181. 
 
 
 Cyclisation of the allenyl amino alcohol 181 under Appel reaction conditions using 
PPh3 in combination with CCl4 or CBr4 was next explored.61 The allenyl amino alcohol 181 was 
treated with PPh3 and CBr4 in the presence of Et3N in CH2Cl2 at room temperature (Scheme 
2.3). The reaction was observed to be fast, with complete consumption of the starting material 
detected after 10 min based on TLC analysis. Although complete conversion of the starting 
material was obtained in the reaction, the 1H NMR spectrum of the crude reaction product 
showed resonances for only a small amount of the desired aziridine product, along with 
resonances for other unidentified products – these products could not be isolated in their pure 
form by column chromatography due to their instability. Based-washed silica gel was used for 
column chromatography to avoid potential acid-catalysed decomposition of the 
allenylaziridine. The formation of the aziridine 182 was evidenced by a multiplet 1H NMR 
resonance at 2.05-2.08 ppm in the 1H NMR spectrum that corresponds to the CH (H-2) between 
the allene bond and NBn group of the ring (Figure 2.1). The two multiplet 1H NMR resonances 
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pair of doublet 1H NMR resonances at 1.66 ppm and 1.89 ppm were associated with the 
diastereotopic methylene protons at C-3 of the three-membered ring (Figure 2.1). The 13C NMR 
spectrum of the purified product also demonstrated the characteristic resonance for the allene 
carbon (210.0 ppm). The HRMS (ESI) of the purified product showed an [M + H]+ ion peak at 
m/z 172.1132, which also supported the structure of 182.     
 
 
Scheme 2.3. Cyclisation of allenyl amino alcohol 181 under Appel reaction conditions. 
 
 
Figure 2.1. 1H NMR spectrum (500 MHz, CDCl3) of the 2-allenylaziridine 182. 
 
The activation of the primary alcohol of the allenyl amino alcohol 181 occurs via a 
known mechanism.61 The reaction is initiated by the reaction of PPh3 with CBr4 leading to the 
formation of the bromotriphenylphosphonium ion 183 and tribromomethanide 184 (Scheme 
2.4). The basic anion 184 removes the proton of the amino alcohol forming the alkoxide 
intermediate 185, which reacts with bromotriphenylphosphonium 183, resulting in the 
PPh3 (1.1 equiv.), CBr4 (1.1 equiv.)











oxyphosphonium intermediate 186. Intramolecular nucleophilic substitution to yield the 2-
allenylaziridine 182 occurs with loss of triphenylphosphine oxide 188 (Scheme 2.4). 
  
 
Scheme 2.4. Mechanism for the Appel reaction of allenyl amino alcohol 181. 
 
With this preliminary result in hand, it was envisioned to optimise the reaction 
conditions. The reaction was performed in the absence of base and no aziridine product 182 
was formed, which highlighted the importance of the base in this reaction (Table 2.1, entry 1). 
When the reaction was performed in anhydrous Et2O, although complete conversion occurred 
by TLC analysis; only a low yield of 15% the product 182 was isolated (Table 2.1, entry 3). 
Instead, formation of several byproducts was observed. Performing the reaction at 0 oC in 
CH2Cl2 resulted in a less complex crude reaction mixture based on 1H NMR analysis but only 
a trace of the desired aziridine product was isolated (3%) (Table 2.1, entry 5). When the reaction 
was then carried out under reflux conditions in CH2Cl2, the isolated yield was significantly 
increased to 45%, along with a trace amount of the previously observed byproducts (Table 2.1, 
entry 6). Different amounts of reagents were then utilised in order to improve the reaction 
efficiency (entries 7-9). Using 1.3 equivalents of the reagents with respect to CCl4 and PPh3 
gave the best result for the desired aziridine (54%), with only trace amounts of a byproduct 
observed in the 1H NMR spectrum of the crude reaction product (Table 2.1, entry 7). The 
cyclisation reaction was subsequently explored by increasing the amount of base from 1.0 




































the best result of a 67% yield of 182 (Table 2.1, entry 10). Therefore, the conditions consisting 
of PPh3 (1.3 eq.), CBr4 (1.3 eq.), and Et3N (1.5 eq.) in CH2Cl2 at reflux were selected as the 
optimum reaction conditions (Table 2.1, entry 10). 
 
 
2.2. Reactivity of 2-Allenyl-N-benzylaziridine 
With the desired 2-allenylaziridine 182 in hand, the reactivity of this novel aziridine in 
nucleophilic ring-opening reactions using organotransition-metal catalysts was investigated. 
Recently, palladium(II)-catalysed addition of arylboronic acids to vinylaziridines 189 has been 
developed by the Hyland group (Scheme 2.5a).62 The cationic palladium complex 190, which 
resulted from the interaction between 1,10-phenanthroline-ligand, Pd(OAc)2, AgSbF6, and the 
boronic acid, can activate the aziridine ring to ring-opening. A subsequent migratory insertion 
and β-H-elimination occurred to provide (Z)-allylsulfonamides 191. Inspired by this work, it 
was intended for the reactivity of the aziridine 182 to be tested in the palladium(II)-catalysed 
ring-opening pathway (Scheme 2.5b) in order to obtain the desired product 192. Therefore, the 
reaction of the 2-allenylaziridine 182 was performed using the standard conditions reported by 
our group. However, the 1H NMR analysis of the crude reaction mixture indicated 
decomposition of the starting material had occurred, and no discrete products could be 
observed. 
Table 2.1. Optimisation conditions for the Appel reaction of 181. 
 
Entry Solvent Temperature PPh3 (eq.) CBr4 (eq.) Et3N (eq.) Yielda,b (%) 
1 CH2Cl2 r.t 1.1 1.1 - - 
2 CH2Cl2 r.t 1.1 1.1 1.0 20 
3 Et2O r.t 1.1 1.1 1.0 15 
5 CH2Cl2 0 °C 1.1 1.1 1.0 3 
6 CH2Cl2 40 °C 1.1 1.1 1.0 45 
7 CH2Cl2 40 °C 1.3 1.3 1.0 54 
8 CH2Cl2 40 °C 1.5 1.5 1.0 23 
9 CH2Cl2 40 °C 2 2 1.0 - 
10 CH2Cl2 40 °C 1.3 1.3 1.5 67 
11 CH2Cl2 40 °C 1.3 1.3 2.0 38 
aIsolated yield (Et3N was used during packing the silica of column chromatography). b100% consumption of the starting material 












Scheme 2.5. (a) Reported Pd(II)-catalysed ring-opening of vinylaziridines 189. (b) Our study regarding ring-opening of the 2-
allenylaziridine 182. 
 
Palladium-catalysed substitution reactions of allenes bearing an adjacent leaving group 
have been investigated with a wide range of carbon- and nitrogen-based nucleophiles and with 
very high levels of asymmetric induction.63 Allenes 193 bearing leaving groups, e.g. acetate or 
phosphonate, can generate a vinyl-π-allylpalladium 194 in the presence of palladium(0) leading 
to products arising from allylic nucleophilic substitution reactions (Scheme 2.6a).63 Inspired by 
these reports, it was anticipated that the ring-opening of the aziridine in the presence of a 
palladium catalyst could provide the related vinyl-π-allylpalladium intermediate 196, which 
could then undergo an allylic nucleophilic substitution reaction (Scheme 2.6b). This process 
would also be atom-efficient as the nitrogen is retained in the product giving access to a highly 
functionalised N-containing allene 198. In this regard, the 2-allenylaziridine 182 was treated 
with pyrrolidine as the nitrogen-based nucleophile in the presence of catalytic Pd2(dba)3·CHCl3, 
PPh3, and Cs2CO3 (Scheme 2.6b) in anhydrous THF at room temperature for 24 h. However, 
the 1H NMR spectrum of the crude reaction mixture indicated the presence of many products 
along with the unreacted starting material 182. No identifiable products could be obtained after 
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Scheme 2.6. (a) General pathway for palladium-catalysed allylation of allenes. (b) Our study regarding palladium(0)-catalysed 
ring-opening of the 2-allenylaziridine 182. 
   
Given the lack of success with palladium-catalysed reactions, it was envisioned for the 
aziridine 182 to be investigated in ring-opening reactions with organometallic reagents in the 
presence of a catalytic amount of a Lewis acid. Lewis acids can activate the aziridine ring to 
nucleophilic attack by an organometallic reagent.3 For example, aziridinyl enoates 199 undergo 
Lewis acid-catalysed ring-opening reactions with organocyanocuprates in THF under mild 
conditions to give amides 200 (Scheme 2.7).64  
 
 
Scheme 2.7. An example of the Lewis acid-catalysed ring-opening reaction of aziridinyl enoates 199 with organocyanocuprates. 
 
In the light of these results, the 2-allenylaziridine 182 was treated with several 
organometallic nucleophiles as well as Lewis acids (Table 2.2). BF3·OEt2 was selected as it is 
commonly used as a Lewis acid for the nucleophilic ring-opening reactions of aziridines 
(Scheme 2.7).3, 64  
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R1 = R2 = R3 = H, Me
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As the first attempt, 2-allenylaziridine 182 was treated with PhMgBr (2.0 equiv.) and 
CuCN (0.2 equiv.) in THF at room temperature under a N2 atmosphere for 18 h (Table 2.2, 
entry 1). The 1H NMR spectrum of the crude reaction mixture indicated a multitude of products 
had formed along with the significant amount of unreacted starting material. No desired product 
was obtained after purification by column chromatography. Subsequently, the same reaction 
was repeated but with increased amounts of the reagents, as well as adding BF3·OEt2 in order 
to facilitate the aziridine ring-opening (Table 2.2, entry 2). However, a complex crude reaction 
mixture was again detected with complete consumption of the starting material. Organo-
cyanocuprates (RCu(CN)Li), which are softer carbon-based nucleophiles compared to 
Grignard reagents, were next investigated. Using 4.0 equivalents of n-BuLi and 4.0 equivalents 
of CuCN at −78 oC showed significant decomposition of the aziridine; however, a trace amount 
(6%) of the desired diene product 201 was isolated by column chromatography (Table 2.2, 
entry 3).  
 
 
The product 201 (R = Bu) was verified by the appearance of a doublet 1H NMR 
resonance (6.19 ppm, J = 15.0 Hz, 1H) corresponding to the proton H-3 of the internal trans 
Table 2.2. Attempted nucleophilic ring opening reactions of the 2-allenylaziridine 182 using different organometallic 
reagents, and with or without BF3·OEt2. 
     
Entry Nucleophile (eq.) CuCN (eq.) BF3·OEt2 (eq.) Time Yieldb (%) 
1 PhMgBr (2.0) 0.2 - 18 ha -c 
2 PhMgBr (4.0) 2.0 1.5  18 ha -d 
3 n-BuLi (4.0) 4.0 - 30 mine 6d 
4 n-BuLi (2.0) 2.0 - 18 ha -c 
5 n-BuLi (2.0) 4.0 - 18 ha -c 
6 n-BuLi (4.0) 4.0 - 3.5 hf -d 
7 n-BuLi (4.0) 2.0 1.0 18 ha 55d 
8 n-BuLi (4.0) 2.0 1.5 18 ha 40d 
9 n-BuLi (4.0) 2.0 2.0 18 ha 38d 
10 MeLi (4.0)  2.0 1.0 18 ha -d 
aReaction initiated at −78 oC and then stirred at room temperature. bIsolated yield. cComplex 1H NMR spectrum of the crude 
reaction mixture along with the unreacted starting material. dComplex 1H NMR spectrum of the crude reaction mixture with 















double bond (Figure 2.2). In addition, the singlet resonance for the two benzyl group protons 
(3.79 ppm, s, 2H) suggested the occurrence of ring-opened product as they are no longer 
diastereotopic (Figure 2.2). The HRMS (ESI) showed an [M + H]+ ion peak at m/z 230.1908, 
which supported the NMR-determined structure of diene 201 (R = Bu).  
 
 
Figure 2.2. 1H NMR spectrum (500 MHz, CDCl3) of the diene 201 (R = Bu). 
 
 Changing the equivalents of the reagents did not help to improve the reaction yield, 
and decomposition of the aziridine occurred (Table 2.2, entries 4-6). The investigation was then 
shifted to the use of higher-order organo-cyanocuprates (R2Cu(CN)Li2), which generally have 
higher reactivity than the lower order cyanocuprates.3,65 Performing the reaction in the presence 
of n-Bu2Cu(CN)Li2 and BF3·OEt2 was quickly found to be effective in this reaction (Table 2.2, 
entry 7). Although the 1H NMR spectrum of the crude reaction mixture was relatively complex, 
the diene 201 (R = Bu) was isolated in good yield (55%). However, by increasing the amount 
of BF3·OEt2 from 1.0 equivalent to 2.0 equivalents, a declining trend in the yield of the product 





eq.), CuCN (2.0 eq.), and BF3·OEt2 (1.0 eq.) in THF at room temperature were selected as the 
optimal conditions.  
A second organo-cyanocuprate (Me2Cu(CN)Li2) was then applied to the reaction in 
order to test the possibility of the extension of the reaction scope. However, no product was 
obtained under the optimum conditions, and a complex 1H NMR spectrum of the crude reaction 
mixture resulted, with complete consumption of the starting material (Table 2.2, entry 10). 
Upon several repetitions, the ring-opening reaction proved to be capricious, and for all the 
repeated reactions no desired product could be isolated, with 100% consumption of the starting 
material. At this point, it was concluded that the ring-opening process of the allenylaziridine 
was not easy to reproduce and no discrete product was obtained from the attempted reactions. 
Therefore, the project was shifted to investigate the synthesis and reactivity of 
allenyloxazolidinones as equivalents to allenylaziridines as it was thought that they may be 
more stable.   
 
2.3. Synthesis of Allenyl 1,2-Amino Alcohols: Direct Access to 5-
Allenyloxazolidinones and 2,5-Dihydrofurans  
While the synthesis and reactivity of the novel 2-allenylaziridine 182 were investigated in 
Sections 2.1 and 2.2, unfortunately, the ring-opening reactions proved to be capricious, and for 
the majority of the reactions no desired product could be isolated, along with many side 
products being formed. The investigation was then shifted towards the synthesis of 5-
allenyloxazolidinones; analogues of 2-allenylaziridines, which should display similar reactivity 
via decarboxylative ring cleavage pathways. These substrates were anticipated to be more 
stable as they have less ring-strain than aziridines and should only be activated in the presence 
of the catalyst to undergo decarboxylation. Towards this goal, this section describes the 
synthesis of enantiomerically enriched allenyl 1,2-amino alcohols derived from N-protected 
chiral α-amino aldehydes as the borono-Mannich method provides a nitrogen heteroatom next 





These allenyl products 163 could effectively undergo cyclisation reactions to provide highly 
functionalised chiral 5-allenyloxazolidinones 175 and their cyclisation reactions in the presence 
of cationic transition metals investigated. The allenyloxazolidinones (equivalents of 
allenylaziridines) could have their own distinctive reactivity but have yet to be investigated. 
  
 
Scheme 2.8. Overview of the reaction steps to synthesise 5-allenyloxazolidinones and 2,5-dihydrofurans. 
 
Based on the study carried out by the Fandrick group (Schemes 1.20),36 the aim was to 
utilise enantiomerically enriched α-amino aldehydes as the carbonyl precursors in this process 
in order to afford chiral allenyl 1,2-amino alcohols. Therefore, N-Boc α-alaninal 205a was 
chosen as the model substrate for the optimisation of the allenylation reaction conditions. This 
aldehyde was easily synthesised in three synthetic steps starting from naturally occurred L-α-
alanine (Scheme 2.9). The amino acid was transformed into the corresponding ester 203a via 
esterification with SOCl2/MeOH. The α-alanine methyl ester 203a was then converted to the 
N-Boc α-alanine methyl ester 204a through N-protection using di-tert-butyl dicarbonate 
((Boc)2O) in the presence of Et3N. The N-Boc α-amino ester 204a was then reduced with 
DIBAL-H in THF at −78 °C to afford the N-Boc α-alanal 205a in excellent yield (98%). This 
compound was immediately utilised in the zinc-catalysed allenylation reaction without further 
purification, since chiral α-amino aldehydes are known to racemise upon chromatographic 
purification or storage.56  
 
 



























































In the next step, it was intended to test the reactivity of the α-amino aldehyde 205a in 
a zinc-catalysed allenylation reaction (Scheme 2.10). Therefore, the allenylation reaction of the 
aldehyde 205a was performed via the standard conditions reported by the Fandrick group using 
Et2Zn (10 mol%) and allenylboronic acid pinacol ester 71 (1.1 equiv.) in toluene at 0 °C.36 The 
1H NMR spectrum of the resulting crude reaction mixture indicated complete consumption of 
the α-amino aldehyde 205a and formation of a mixture of allene and propargyl regioisomers 
(allenyl (206a)/propargyl (207a) = 92:8); almost exclusively in favour of the desired allenyl 
product. The allenyl product 206a was isolated by column chromatography in high yield (92%) 




Scheme 2.10. Zinc-catalysed allenylation reaction of N-Boc α-amino alanal 205a. 
 
 
The allene product 206a was verified by the appearance of two multiplet 1H NMR 
resonances at 4.80-4.90 ppm (2H) and 5.17-5.28 ppm (1H) attributed to the protons of the allene 
bond (Figure 2.3). The 13C NMR spectrum of the purified product demonstrated the 
characteristic resonance for the central allene carbon (major diastereoisomer at 207.4 ppm and 
minor diastereoisomer at 207.9 ppm). The existence of two diastereoisomers was evidenced by 
a series of pairs of resonances in both the 1H NMR and 13C NMR spectra. In the 1H NMR 
spectrum (Figure 2.3), distinct doublet resonances at 1.12 ppm (CH3) and 1.20 (CH3) ppm were 
observed for the major and minor diastereoisomers, respectively. The propargyl regioisomer 
207a was confirmed by the appearance of singlet and multiplet 1H NMR resonances at 2.00 
ppm (1H) and 2.39-2.42 ppm (2H) assigned to the sp and sp2 protons of the propargyl moiety, 
respectively (Figure 2.3). The HRMS (ESI) of the purified allene product showed an [M – H]+ 
ion peak at m/z 212.1289, which supported the structure of 206a. Determination of the syn and 
anti stereochemistry of these diastereomeric allene products will be discussed later in this 
Chapter.  
Et2Zn (10 mol%)
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Figure 2.3. 1H NMR spectrum (500 MHz, CDCl3) of the isolated N-Boc allenylamino alcohol 206a and the propargyl 
regioisomer 207a. 
 
Based on these preliminary results, the focus was then directed towards further 
optimisation of the reaction conditions in order to increase the diastereoselectivity of the allene 
product and potentially reverse the regiochemistry. A series of experiments were conducted 
with different reaction parameters, such as catalyst loading, solvent, temperature, and the nature 
of the N-protecting group (Table 2.3). Initially, the allenylation reaction of N-Boc α-alanal 205a 
with allenylboronic acid pinacol ester 71 was performed in toluene in the absence of the Et2Zn 
(Table 2.3, entry 1), which gave only the propargyl amino alcohol 207a in a low yield (12%) 
and but with the same moderate diastereoselectivity (dr = 2.6:1). This indicated that Et2Zn plays 
a key role in controlling the regioselectivity and the rate of this reaction is consistent with the 
previously accepted mechanism which shows allenyl reagents lead to propargyl products. In 
the absence of the zinc catalyst, the reaction mechanism would follow the general direct 
addition pathway in which the allenylboronic reagent gives the propargyl product upon 
nucleophilic addition to the carbonyl group.23 The addition of 5 mol% of the Et2Zn catalyst 
provided the allene 206a with excellent control of allenyl to propargyl regioselectivity 
(allene/propargyl = 97:3), but with modest syn diastereoselectivity (syn/anti 2.6:1)  (Table 2.3, 





of regioselectivity to favour the propargyl product 207a along with a decrease in 
diastereoselectivity (Table 2.3, entries 3 and 4). These results were consistent with the previous 
studies by Fandrick that showed polar solvents increased the rate of equilibration of the 
allenyl/propargyl intermediates.36-37 An increase in the amount of catalyst from 5 to 10 mol % 
in toluene improved the yield significantly from 77% (entry 2) to 92% (entry 5), but still 
resulted in moderate diastereoselectivity. It was thought that at lower temperatures, this might 
lead to increased diastereoselectivity. However, no reaction occurred when the reaction was 
performed at −40 °C (Table 2.3, entry 6). 
 
 
Due to the reversal of regioselectivity, it was possible to isolate the propargyl product 
207a, the structure of which was confirmed by the appearance of singlet and multiplet 1H NMR 
resonances at 2.09 ppm (1H) and 2.39-2.44 ppm (2H) assigned to the terminal alkyne proton 
and propargylic CH2 of the propargyl group, respectively (Figure 2.4). These resonances also 
Table 2.3. Optimisation of the zinc-catalysed allenylation reaction conditions.a 
 
Entry NR1R2 Solvent Catalyst (mol %) Yieldb % (allene:propargyl)c dr
c 
(syn:anti) 
1 NHBoc PhMe 0 12 (0:100) 2.6:1 
2 NHBoc PhMe 5 77 (97:3) 2.6:1 
3 NHBoc THF 5 60 (5:95) 1.1:1 
4 NHBoc CH2Cl2 5 38 (71:29) 2.0:1 
5 NHBoc PhMe 10 92 (92:8) 2.6:1 
6 NHBocd PhMe 10 0 0 
7 NHTs PhMe 10 0e 0 
8 NHFmoc PhMe 10 0f 0 
9 NHTr PhMe 10 82 (84:16) 1.3:1 
10 NBnBocg PhMe 10 96 (89:11) 1:19h 
11 NBnTsg PhMe 10 54i (94:6) 1:1.5 
12 NBn2g PhMe 10 50i (94:6) 1:1.3 
aReaction conditions: 71 (1.10 equiv.), Et2Zn, solvent, 0 oC, 18 h. bIsolated yield of allene and propargyl products. 
cRegioselectivity of determined by 1H NMR analysis of the crude reaction product – stereochemistry of propargyl products 
not determined. dThe reaction was carried out at −40 °C. eDecomposition of starting material. fRecovery of SM. g1.3 equiv. of 
71 was used. hDetermined by 1H NMR analysis of N-Boc deprotected crude reaction mixture. iIsolated yield for the major 








205a: R1 = H, R2 = Boc
208: R1 = H, R2 = Ts
211: R1 = H, R2 = Fmoc
214: R1 = H, R2 = Tr
217a: R1 = Bn, R2 = Boc
220: R1 = Bn, R2 = Ts
223: R1 = Bn, R2 = Bn
206a: R1 = H, R2 = Boc 
209: R1 = H, R2 = Ts
212: R1 = H, R2 = Fmoc
215: R1 = H, R2 = Tr
218a: R1 = Bn, R2 = Boc
221: R1 = Bn, R2 = Ts

















corresponded to those of the minor propargyl regioisomer assigned in Figure 2.3 providing 
support to our estimation of the regioselectivity. The HRMS (ESI) analysis of the purified 
propargyl product showed an [M + H]+ ion peak at m/z 214.1446, which further supported the 
structure of 207a.  
 
 
Figure 2.4. 1H NMR spectrum (500 MHz, CDCl3) of the N-Boc propargylamino alcohol 207a. 
 
Based on the above results, toluene was taken as the solvent of choice as well as 10 
mol% of Et2Zn (Table 2.3, entry 5), and these conditions were used for further optimisation of 
the reaction conditions. Accordingly, the effect of alternate protecting groups on the nitrogen 
in the allenylation reaction was investigated in an attempt to further enhance or switch the 
reaction diastereoselectivity. A series of common nitrogen protecting groups were screened for 
compatibility with this methodology (Table 2.3, entries 7-12). The N-protected amino 
aldehydes (208, 211, 214) could be easily prepared starting from the α-alanine methyl ester 







Scheme 2.11. Synthesis of different N-protected amino aldehydes. 
 
 The N-Ts and N-Fmoc alanals 208 and 211 (Table 2.3, entries 7 and 8) did not undergo 
the desired allenylation/propargylation reaction, which was possibly due to the more acidic 
proton on the NHTs and NHFmoc group being deprotonated by Et2Zn, thereby deactivating the 
zinc catalyst. When the triphenylmethyl (Tr) group was employed as the protecting group 
(Table 2.3, entry 8), the corresponding allenyl product 215 was provided in high yield (82%) 
and high regioselectivity (allene/propargyl = 84:16), but essentially no diastereoselectivity (dr 
= 1.3:1). It was then decided to increase the steric bulk around the nitrogen atom using two 
protecting groups (Table 2.3, entries 10−12). Interestingly, introducing a second bulky 
protecting group on nitrogen reversed the diastereochemical outcome in favour of the anti 
allene product (Table 2.3, entries 10−12). Doubly protecting the nitrogen with N-Bn,N-Ts or 
N-Bn,N-Bn protecting group combinations gave comparable yields of the allene 221 and 224 
with high regioselectivities, but with poor diastereoselectivities (Table 2.3, entries 11 and 12). 
It should be mentioned that in these cases the major diastereoisomers could be isolated in pure 
form after column chromatography. Employing the N-Bn,N-Boc protecting group resulted in a 
dramatic increase in the diastereoselectivity (syn:anti = 1:19), along with high yield (96%) and 

































































To establish the relative configuration of the major isomer of the allene products, the 
corresponding oxazolidinones 229a and 230a were synthesised via base-catalysed (NaH) 
cyclisation (Scheme 2.12). Critically, the major diastereoisomer of the oxazolidinones could be 
separated by column chromatography. The structure of oxazolidinone 229a was verified by the 
appearance of two multiplet 1H NMR resonances at 4.93-5.00 ppm (2H) and 5.30-5.36 ppm 
(1H) attributed to the protons H-7 and H-9 of the allene bond, respectively (Figure 2.5). The 
oxazolidinone 230a was confirmed by the existence of two multiplet 1H NMR resonances at 
4.80-4.98 ppm (2H) and 5.18-5.25 ppm (1H) attributed to the H-7 and H-9 of the allene bond, 
respectively (Figure 2.6). The 13C NMR spectra of the purified products also demonstrated the 
characteristic signals for the allene central carbon (C-8, 209.2 ppm and 209.7 for 229a and 
230a, respectively) and the oxazolidinone carbonyl (158.9 ppm and 157.5 for 229a and 230a, 
respectively). Furthermore, the IR spectra of the purified products 229a and 230a showed C=O 
stretching bands at 1739 cm-1 and 1743 cm-1 for the oxazolidinones 229a and 230a, respectively. 
The HRMS (ESI) analysis of the purified oxazolidinone products showed [M + Na]+ ion peaks 
at m/z 162.0537 and [M + H]+ at 252.1003, which supported the structures of 229a and 230a, 
respectively. It should be mentioned that it is advantageous to convert the N-Bn,N-Boc allenyl 
1,2-amino alcohol 218a to the corresponding NBn oxazolidinone 230a so as to resolve the issue 
of the rotamers in the 1H NMR spectra. 
 
 












































Figure 2.5. 1H NMR spectrum (500 MHz, CDCl3) of the NH allenyloxazolidinone 229a. 
 
 
Figure 2.6. 1H NMR spectrum (500 MHz, CDCl3) of the NBn allenyloxazolidinone 230a. 
 
The trans stereochemistry of 229a was established from its 1D NOESY spectrum, 





(Figure 2.7). In contrast, the cis stereochemistry of 230a was indicated from its 1D NOESY 
spectrum of the oxazolidinone 230a according to a correlation between H-4 and H-5 for the 
major isomer, which confirmed the anti-configuration of 218a (Figure 2.8).66 The magnitudes 
of the J4,5 coupling constants (J4,5 = 6.0 Hz for 229a and J4,5 = 7.2 Hz for 230a) were consistent 
with these assignments.54, 66 It should be mentioned that a subsequent PhD student in our group 
who is working on the reactivity of the oxazolidinones (Ronald Brown, data obtained by 
A/Professor Michael Gardiner) obtained a crystal structure of the trans-oxazolidinone further 
confirming this stereochemical assigned. 
 
 







Figure 2.8. 1D NOE difference spectrum of the NBn allenyloxazolidinone 230a after irradiation at H4. 
 
To explain the divergent stereochemical outcomes in the zinc-catalysed allenylation 
reactions of the α-amino aldehyde, two common stereochemical models regarding asymmetric 
nucleophilic addition of organometallics to carbonyl compounds, known as the Cram-chelation 
and the Felkin–Anh models can be invoked.67 In these models, the facial preference of the 
nucleophilic reaction to the carbonyl group is controlled by an adjacent stereocentre. In the 
Cram-chelation model, the chelation between the carbonyl group and one of the substituents of 
the α-stereocenter, facilitated by a metal cation, can lock the substrate into the conformation 
231 (Scheme 2.13a). The nucleophile then preferentially attacks the carbonyl group anti to the 
largest group R1 or R2 from the opposite side of the coordinated α-substituent L leading to the 
syn isomer 232 as the major diastereoisomeric product.67 On the other hand, this chelation 
cannot happen because of the crucial steric interaction between the large α-substituent L and 
the carbonyl group, resulting in the formation of the proposed conformation 233 (Scheme 
2.13b). Subsequently, L is oriented anti to the carbonyl group, and the nucleophile 
preferentially attacks from the side of the small substituent R1 affording the anti isomer 234 as 






Scheme 2.13. Cram–chelation and Felkin–Anh models for the nucleophilic addition to chiral α-amino aldehyde. 
 
On the basis of these models, it can be proposed that the zinc-catalysed allenylation 
reaction of N-mono protected α-amino aldehydes follows a Cram–chelation–like model, where 
a H-bonding interaction between the aldehyde and the Boc N−H drives the direction of 
nucleophilic attack, affording the syn isomer as the major diastereoisomer product (Scheme 
2.13a).66, 68 The dr for the uncatalysed reaction (Table 2.3, entry 1) is identical to the catalysed 
reaction offering some support for this H-bond model, rather than Zn playing a role in 
chelation.66 In contrast, N,N-doubly protected α-amino aldehydes favour Felkin–Anh control 
as H-bonding is no longer possible and chelation less likely, resulting to the anti diastereisomer 
as the major adduct  (Scheme 2.13b).66 In other words, the presence of the bulky electronegative 
group (N-Bn,N-Boc) on the α-carbon to the aldehyde drives the direction of nucleophilic attack, 
in which the nucleophile prefers to attack away from the large group forming the anti-
diastereomer as the major product.  
The proposed mechanism for the zinc-catalysed allenylation reactions is illustrated in 
Scheme 2.14, which is in agreement with the previously reported studies.36-37 The first step is 
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235, which reacts in an SE2′ fashion with the aldehyde 237 under Cram-chelation-like or 
Felkin–Ahn control to form the corresponding zinc alkoxide intermediate 238. The reaction is 
catalytic in zinc since the alkoxide 238 can undergo boronate-to-zinc exchange with the 
allenylboronate 71 to give the propargylzinc species 235 as well as the boronate complex of 
allenyl alcohol 239. In contrast, the propargylzinc intermediate 235 isomerises under 
thermodynamic conditions to form the more stable allenylzinc species 236. This equilibration 
has been shown to be second order in [Zn], while the competition of the propargyl 235 and 
allenylzinc 236 intermediates for the addition to the electrophile are first order in these 
organozinc species.36 The allenyl species 236 then reacts with the aldehyde 237 in an SE2′ 
fashion to finally form the corresponding propargyl amino alcohol 241 after aqueous workup. 
To achieve high regioselectivity for the allenylation reaction after the formation of the 
propargyl zinc species 235 in the first step, the related addition to the aldehyde 237 has to 
effectively compete with the propargyl to allenylzinc equilibration. This isomerisation is slow 
in non-polar solvents, such as toluene, or with low catalyst loadings, allowing the propargyl-
zinc addition to compete with this equilibration.  
 
 




























syn for R1= Boc, R2= H
















With the optimised reaction conditions in hand, the substrate scope with regard to the 
protecting group on nitrogen was investigated in order to provide two types of the anti and syn 
N-protected allenylamino alcohols. A range of N-Boc α-amino aldehydes 205a-g were prepared 
from their corresponding L-α-amino acids (Scheme 2.15), and were subjected in the zinc-
catalysed allenylation reaction using 10 mol% Et2Zn in toluene at 0 °C (Table 2.4). In all cases, 
the syn N-Boc allenylamino alcohols 206a-g were obtained in high yields (78-92%), high 
regioselectivities (allene/propargyl = 89:11-95:5) and moderate to good diastereoselectivities 
(syn/anti = 2.5:1-9:1). It was also observed that the dr improved as the size of the R side chain 
group increased from Me (206a, dr = 2.6:1) to i-Pr (206e, dr = 9:1) – consistent with the 
proposed Cram-chelate-like model. Furthermore, the allenyl tryptophan derivative 206g was 
synthesised in high yield (78%) and excellent regioselectivity (95:5), which is an interesting 
example of a heterocyclic analogue.  
 
 
Scheme 2.15. Synthesis of N-Boc α-amino aldehydes 205a-g from L-α-amino acids. 
 



























L-α-amino acid 93-99% 93-98% 91-99%
HCl


































































Having demonstrated the ability to control diastereoselectivity of the zinc-catalysed 
allenylation reaction by changing the N-protecting group of the α-amino aldehydes, the 
influence of α-heteroatom of the aldehydes was next investigated. Therefore, O-protected α-
hydroxy aldehydes were chosen as analogues of the α-amino aldehydes to undergo the zinc-
catalysed allenylation reaction under the optimised reaction conditions. A range of O-protected 
α-hydroxy aldehydes 242 was prepared from readily available L-lactic acid ethyl ester (Scheme 
2.16). Based on the stereochemical outcomes for the α-amino aldehydes, it was hypothesised 
that the diastereoselectivity would be protecting group dependent. Although high yields and 
excellent regioselectivities were obtained for the α-hydroxy allene products 243, the reactions 
showed almost no preferred diastereoselectivity for any of the different O-protected aldehydes 
(Scheme 2.16). Due to poor diastereoselectivities of the allenylation reaction of O-protected α-
hydroxy aldehydes, further investigations were not carried out, and the stereochemistry of the 
allene products was not determined.            
 
 
Scheme 2.16. Zinc-catalysed allenylation reaction of O-protected α-hydroxy aldehydes. 
 
N-Boc allenylamino alcohols 206 would offer great potential and utility for heterocycle 
synthesis due to the presence of two pendant heteroatoms and the allene bond in a single 
molecule. As discussed previously in this Chapter, despite extensive investigations of allenes 
with a single heteroatom in the literature, methods to prepare allenes with multiple pendant 
heteroatoms are extremely rare. There were only two major papers reported by Pyne54 and 
Et2Zn (10 mol%)
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aDiastereoisomers could not be seperated.





Petasis55 regarding the preparation of allenes with two heteroatoms (Schemes 1.29 and 1.30). 
Therefore, the synthesis of such powerful scaffolds, such as 206, is significant.  
To demonstrate the utility of such allenes, it was found that the N-Boc allenylamino 
alcohols 206 could undergo base-induced cyclisation reactions offering a convenient method 
to direct access to the chiral 5-allenyloxazolidinones 229 (Table 2.5). A series of the N-Boc 
allenylamino alcohols 206a-g underwent base-induced cyclisations to provide 5-
allenyloxazolidinones 229a-g in yields ranging from 50−74%. For the majority of cases, 
diastereomerically enriched oxazolidinone products were isolated after chromatographic 
purification (up to >98% dr).66   
 
 
This is the first example of oxazolidinones bearing a potentially reactive C5 allenyl 
side chain along with the free NH, which could be powerful synthetic intermediates for the 
synthesis of biologically active compounds. Furthermore, diastereoselective methods to 
prepare oxazolidinones with pendant unsaturated moieties are severely limited in the 
literature.69 As discussed earlier, oxazolidinones can also undergo ring cleavage pathways in a 
similar manner as an aziridine. Therefore, a synthetic method to synthesise the novel chiral 5-
allenyl oxazolidinones 229 as equivalent analogues of the 2-allenylaziridine was developed. 
Table 2.5. Reaction scope of 5-allenyl oxazolidinones.a,b 
 
 
aIsolated yield. bReaction initiated at 0 oC and then stirred at room temperature for 1.5 h. cA mixture of two diastereomers.  



























































Oxazolidinones are a chemical class of synthetic antimicrobial agents exhibiting unique 
bacteriostatic activity against many human pathogens.70-71 For example, eperezolid 245 and 
linezolid 246 are the most common and effective synthetic antibiotics derived from an 
oxazolidinone, which are used for the treatment of diseases caused by many Gram-positive 
pathogens (Scheme 2.17).71-73  
  
 
Scheme 2.17. Structures of oxazolidinone-based eperezolid and linezolid. 
 
The substrate scope of the allenylation reaction of the N-Bn,N-Boc α-amino aldehydes 
217 was next explored. A range of the aldehydes 217a-h were prepared from their 
corresponding L-α-amino acids (Scheme 2.18), and were subjected to the zinc-catalysed 































Scheme 2.18. Synthesis of N-Bn,N-Boc α-amino aldehydes from L-α-amino acids. 
 
 In all cases, the anti N-Bn,N-Boc allenylamino alcohols 218a-h were obtained in high 
yields (71-96%). However, except for the alanine-derived allene product 218a, investigation of 
the 1H NMR spectra for both the pure allene products and in the crude reaction mixture was 
complicated due to the presence of rotamers (caused by restricted carbamate C−N rotation of 
the Boc), diastereoisomers and regioisomers. Examination of the 1H NMR spectra at elevated 
temperature (70 °C in DMSO) with the aim to coalesce the rotamer peaks was also 
unsuccessful. Furthermore, the direct N-Boc deprotection of these allenes was not 
straightforward as decomposition of the starting material often occurred. Therefore, it was 
intended to explore the utility of the allenylamino alcohols 218 as building blocks for the 
synthesis of more intricate systems through direct conversion of the initial product to a system 

































1) K2CO3, Et2O, r.t
2) Benzaldehyde, MgSO4, 
    CH2Cl2, r.t
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cyclisation reaction was chosen as the desirable reaction for direct conversion of the 
allenylamino alcohols to 2,5-dihydrofurans.         
 
 
After the zinc-catalysed allenylation reaction of the aldehydes 217, the resulting allene 
crude reaction mixture was subjected to the Au(I)-catalysed cyclisation reaction in the presence 
of AuPPh3NTf2 (10 mol%, Table 2.6). Subsequently, N-Boc deprotection was carried out on 
the resulting crude reaction mixture using TMSCl/MeOH to give the 2,5-dihydrofurans 250 in 
good yields (48-68%) over the three steps. These products could then be easily analysed by 1H 
NMR analysis as the rotamer problem was no longer present. Therefore, the ratio of 
diastereoisomers could be easily determined using 1H NMR analysis. In four cases, the products 
(250a, 250e, 250f and 250g) could be obtained as single diastereoisomers after purification by 
column chromatography. The N-Boc protected proline-derived amino aldehyde 217h showed 
good reactivity in the allenylation reaction to give 218h, and then the corresponding cyclised 
product 250h. However, as reported previously the N-Boc deprotected derivative of 250h 
proved unstable, and could not be isolated.66  






aIsolated yields over three steps without any intermediate purification. bDiastereomeric ratio determined by 1H NMR 









1) AuPPh3NTf2 (10 mol%),
    DCE, 60 oC, 8 h
2) TMSCl (5 equiv.), MeOH,
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2,5-Dihydrofurans are one of the key building blocks in natural product synthesis and 
pharmaceuticals, exhibiting beneficial biological activities as anti-cancer, HIV, and antifungal 
agents.74-75 For example, elvucitabine 251 and 252 (D and L forms) is an antiviral drug based 
on a 2,5-dihydrofuran derivative and is used in the treatment of HBV and HIV infections 
(Scheme 2.19).76-77 Despite the importance of these structures, there is no general method to 
prepare 2,5-dihydrofurans with a pendant nitrogen atom in a stereodefined fashion, therefore 
the method presented here should be a useful addition to the chemical literature.40, 47 
 
 
Scheme 2.19. Structures of 2,5-dihydrofuran-based Elvucitabine. 
 
 Having established mild and effective conditions for the zinc-catalysed allenylation 
reactions of N-protected α-amino aldehydes, the study was next focused on the determination 
of the enantiomeric excess of the final heterocyclic products. As discussed earlier, α-amino 
aldehydes are susceptible to racemisation under acidic or basic conditions, or even upon 
chromatographic purification and storage. It was therefore aimed to investigate whether the 
developed methodology would show retention of the enantiomeric purity of the aldehyde 
during the reaction steps.    
One of the most rapid and reliable techniques for the determination of enantiomeric 
excess (ee) values is using a chiral derivatising agent, in which a enantiomerically pure reagent 
is used to convert a mixture of enantiomers into diastereomers in order to analyse the quantities 
of each enantiomer present in a sample.78-79 This technique enables the accurate determination 
of the ee value by measuring the ratios of the diastereoisomers in the 1H NMR spectrum. 10-
Camphorsulfonyl chloride is an inexpensive and readily available chiral derivatizing agent 
widely used for the assay of enantiomeric purity of alcohols and amines79-80 and  was used 




















pure allenyl oxazolidinone (Table 2.7).80 The ee of the oxazolidinone was determined by 
integration of clearly resolved resonances arising from the corresponding α-methylene sulfonyl 
(CHaHaSO2) protons in each diastereomer in the 1H NMR spectrum of the crude reaction 
mixture (Figure 2.9). The 1H NMR resonances for the corresponding camphorsulfonyl 





Figure 2.9. An example of determining the ee value of the leucine-derived allenyl oxazolidinone 229c by measuring the ratios of 
the diastereoisomers by 1H NMR spectroscopy on the crude reaction mixture. 




aEnantiomeric excess was determined by 1H NMR analysis of the resulting diastereomeric (S)-camphorsulfonamide 





























































In the majority of cases, high enantiomeric excess values were obtained for the 
diastereomerically pure allenyl oxazolidinones. However, the phenylglycine-derived 
oxazolidinone 229f showed extensive loss of enantiomeric purity (8% ee), which can be 
explained as the α-proton in the phenylglycinal is extremely acidic due to the adjacent carbonyl 
and the phenyl groups, therefore, the aldehyde can easily undergo the α-deprotonation and 
partial racemisation. 
Having determined the enantiomeric excess (ee) for the diastereomerically pure allenyl 
oxazolidinones (Table 2.7), the α-amino aldehyde 205a was chosen as the model substrate to 
investigate the possibility of racemisation of the aldehyde during the reaction steps in our 
methodology. In this case the ee value of the aldehyde was investigated by chiral normal phase 
HPLC. A comparison between the enantiomeric purity of the final oxazolidinone product 229c 
(86% ee, determined from its chiral sulfonamide derivative by 1H NMR analysis in Figure 2.9) 
and the corresponding aldehyde 205c (86% ee, determined by chiral HPLC of the 
corresponding alcohol obtained by immediate NaBH4 reduction of the aldehyde and in 
comparison to a racemic standard) showed no erosion of enantiomeric purity of the aldehyde 
during the reaction steps, indicating the zinc allenylation was not responsible for the slight loss 
of ee. 
The chiral derivative method was not suitable for the 2,5-dihydrofuran products due to 
instability of the corresponding sulfonamide derivatives, so chiral HPLC was employed. The 
diastereomerically pure product 250a was tested as the model compound by comparing the 
enantiomeric excess of the final product (91% ee, determined by chiral HPLC in comparison 
to a synthesised racemic standard) and the aldehyde 217a (91% ee, determined by chiral HPLC 
of the corresponding alcohol), which proved no erosion of the enantiomeric purity of the 
aldehyde during the reaction steps (Scheme 2.20).66 It should be mentioned that the α-amino 
aldehydes were reduced to their corresponding α-amino alcohols (racemic and pure), and then 
they were analysed by chiral HPLC, because of the tendency of these aldehydes to racemize 












In summary, the synthesis of the novel 2-allenylaziridine 182 from the allenyl amino alcohol 
181 has been developed. The aziridine was prepared in good yield under mild reaction 
conditions and a series of ring-opening reactions of 182 were investigated. Unfortunately, the 
ring-opening reactions proved to be capricious, and for the majority of these reactions no 
product could be isolated, along with many side products being formed. According to previous 
studies (Scheme 1.6 and 1.7), oxazolidinones could undergo ring cleavage pathways in a similar 
manner as an aziridine, and therefore, it was envisioned to use the previously unknown 5-
allenyloxazolidinones (229 and 230) as equivalent analogues of the 2-allenylaziridines 182 in 
nucleophilic ring-opening reactions (Scheme 1.33). These compounds have not been reported 
in the literature, therefore, a synthetic approach was required to be established for the 
preparation of these unique allenyl heterocycles. Herein, we have developed the first example 
of simultaneous control of diastereoselectivity and regioselectivity in zinc-catalysed 
allenylation reactions of N-protected α-amino aldehydes. These methodologies provided high 
regiochemical control to favour the allene products. Stereoinduction with the N-protected α-
amino aldehydes was significantly protecting group dependent. In the presence of two sterically 
hindered groups on nitrogen, Felkin–Ahn control was observed affording anti allenylamino 
alcohols. However, employing a single protecting group (Boc) overrides the Felkin–Ahn 
control by forming H-bonding between the NH of the Boc group and the carbonyl group to 



























resulting allene products demonstrated high reactivity in NaH-induced and Au-catalysed 
intramolecular cyclisation reactions to obtain novel 5-allenyl oxazolidinones and 2,5-
dihydrofurans. Although diastereoselective methods to prepare oxazolidinones with pendant 
unsaturated bonds are extremely rare, most of the final heterocyclic products could be obtained 
as single diastereoisomers in high enantiomeric excess after simple column chromatography. 
The existence of a reactive allenyl side chain along with the free NH also make these 
oxazolidinones as potentially powerful synthetic intermediates for the synthesis of biologically 
active compounds. Au-catalysed cyclisation of allenes to 2,5-dihydrofurans is also known in 
the literature, however, using this same method to synthesise heterocycles with a pendant 
nitrogen is unknown.  
As discussed in this Chapter, oxazolidinones can potentially participate in organic 
reactions through the same nucleophilic ring-opening pathways as aziridines. In Chapter 4, the 














Part 2. Synthesis of Unconjugated Chiral (E)-enediynes 
from 5- Allenyloxazolidinones and Their Application in 
Au(I)-Cycloaromatisation Reactions 
 
Chapter 3. Introduction 
In Part 1 of Chapter 2, novel and enantiomerically enriched 5-allenyloxazolidinones 229 were 
successfully synthesised via base-induced (NaH) cyclisation of allenyl amino alcohols 206.66 It 
was previously discussed that oxazolidinones could undergo ring cleavage pathways 
considered as equivalent analogues of aziridines. During the synthesis of the 5-
allenyloxazolidinone 230a from allenyl amino alcohol 218a in Chapter 2 (Scheme 2.12), 
decarboxylative ring-opening reaction of the N-Bn oxazolidinone 230a simultaneously 
occurred upon a treatment with an excess amount of NaH under mild reaction conditions, 
resulting in the formation of the novel 1,3-(E)-enyne 253 (Scheme 3.1). This unexpected 
reactivity of the oxazolidinone in the presence of the base shifted the project towards 
investigation of potential Au(I)-catalysed reactions rather than the initially planned Pd(0)-
catalysed chemistry. The free NH moiety in these enynes could be propargylated to form the 
novel unconjugated enediyne 254. These unique compounds could be potentially utilised in 
Au(I)-catalysed cycloaromatisation reactions to form the chiral isoindoline 255. In this Chapter, 
literature background regarding the synthesis of enynes and enediynes and their reactivity in 







Scheme 3.1. Potential approach for the reactivity of the 5-allenyloxazolidinones 230 as a precursor to synthesise chiral 1,3-(E)-
enynes, enediynes and isoindolines. 
 
3.1. 1,3-Enynes 
1,3-Enynes are versatile building blocks in organic synthesis, undergoing numerous 
transformations to generate structurally diverse products.81-86 They can be also found in many 
biologically active natural products mainly used as antifungal and antitumor agents.87-88 
Therefore, extensive protocols have been investigated to develop efficient strategies to 
synthesise 1,3-enynes – despite this there are relatively few methods for preparing 
enantiomerically enriched enynes with a pendant heteroatom.89-98 There are four classical 
methods to prepare the 1,3-enynes 256 including the metal-catalysed cross-coupling reaction 
between alkynes and alkenes (Scheme 3.2a), cross-dimerisation of alkynes (Scheme 3.2b), 
Wittig olefination reactions of alkynyl aldehydes and ketones (Scheme 3.2c), and dehydration 
reactions of propargyl alcohols (Scheme 3.2d). A select number of these methods are now 
discussed to put the new method uncovered in this thesis in context. 
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3.1.1. Synthesis of 1,3-Enynes via Metal-catalysed Cross-coupling 
Jiang et al. demonstrated the stereoselective cross-coupling synthesis of a range of 1,3-(E)-
enynes 259 catalysed by Pd(OAc)2 using unactivated styrenes 258 and alkynyl bromides 257 
(Scheme 3.3).94 This protocol could tolerate a variety of functional groups on both substrates, 
with the enynes 259 obtained in good to excellent yields (41-95%) and stereoselectivities (E/Z 
= 75:25 to 100:0). The reaction pathway involves the formation of an alkynylpalladium(II) 
intermediate 260 through oxidative addition of the alkynyl bromide 257 to Pd(0) followed by 
a Heck cross-coupling reaction.  
 
 
Scheme 3.3. Synthesis of 1,3-(E)-enynes using alkynyl bromide and styrenes catalyzed by Pd(OAc)2. 
 
 Ranu and co-workers reported the Cu-catalysed Suzuki-type cross-coupling reaction 
of alkynyl bromides 257 and alkenylboronic acids 261 in the presence of CuFe2O4 nanoparticles 
to provide unsymmetric 1,3-enynes 262 (Scheme 3.4).95 In this study, aliphatic, aromatic, and 
heteroaromatic alkynyl bromides were treated with various substituted trans alkenylboronic 
acids to access a wide range of trans 1,3-enynes 262 in moderate to high yields (54-89%). 
 
 
Scheme 3.4. Synthesis of 1,3-(E)-enynes using alkynyl bromides and alkenylboronic acids catalyzed by CuF2O4 nanoparticles. 
 
 Venkataraman and co-workers disclosed a Sonogashira-type copper(I)-catalysed 
procedure for the synthesis of both cis and trans 1,3-enynes using vinyl iodides 264 and 
terminal acetylenes 263 (Scheme 3.5).97 This methodology tolerated a wide range of substrates 
R1 Br +
Ar
Pd(OAc)2  (5 mol%)

































and functional groups, providing the 1,3-enynes 265 in moderate to excellent yields with 
stereochemical retention of the starting vinyl iodides. [Cu(phen)(PPh3)2]NO3 and 
[Cu(bipy)PPh3Br] were shown to be effective in these coupling reactions. In the majority of 
cases, [Cu(phen)(PPh3)2]NO3 (10 mol%) was utilised as the catalyst in the presence of K2CO3 
(2.0 equiv.). However, in examples where the vinyl iodide was an (E)-alkene, 
[Cu(bipy)PPh3Br] (10 mol%) was employed using Cs2CO3 (2.0 equiv.) as the base.    
 
 
Scheme 3.5. Synthesis of 1,3-enynes using vinyl iodides and acetylenes catalyzed by Cu(I) catalyst. 
 
3.1.2. Synthesis of 1,3-Enynes via Metal-catalysed Cross-dimerisation 
Transition-metal catalysed cross-dimerisation coupling of terminal alkynes to form 1,3-enynes 
is an attractive strategy due to the ready availability of the alkyne precursors.90 However, 
control over the stereo- or regioselectivity of the enyne product could be highly challenging as 
homo- or cross-coupling of two alkynes can occur. Rhodium and palladium complexes are the 
two most common catalyst systems employed to promote the cross-dimerisation coupling of 
alkynes to give enynes with high levels of stereo- or regioselective control.90  
 The Ozerov group described the efficient cross-dimerisation coupling of acetylenes 
266 with excellent stereo- or regioselectivities, catalyzed by the dihydrido-Rh pincer complex 
267, providing the (E)-1,3-enynes 268 as the major products (Scheme 3.6).99 It was suggested 
that the stereochemical outcomes might be due to the steric interactions between the bulky 
groups of the Rh complex and the other substituents forming the intermediate 269 during the 










R2 = H, Me, Ph
R3 = Ar, CO2Et, CO2Me
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Scheme 3.6. Synthesis of 1,3-(E)-enynes using acetylenes catalyzed by a Rh pincer complex. 
 
 Gevorgyan and Rubina disclosed the Pd-catalysed (E)-selective dimerisation reactions 
of aryl alkynes 270 to give 1,3-(E)-enynes 271 in good yields and excellent regioselectivies 
under mild conditions (Scheme 3.7).100 The methodology was shown to be effective for aryl 
acetylenes, but not for alkyl-substituted substrates. It was also proposed that the E-selective 
stereochemical outcome of the coupling process to be due to possible coordination of the 
palladium with the triple bond (Scheme 3.7). 
 
 
Scheme 3.7. Pd-catalysed synthesis of 1,3-(E)-enynes using acetylenes. 
 
  The cross-dimerisation reaction can also occur between two different alkynes acting as 
donor and acceptor species resulting in a hetero-coupled enyne. Miura et al. reported (E)-
selective dimerisation reactions between a series of acetylenes 274 as acceptor species and 
HR
catalyst (0.5 mol%)



































































donor triisopropylsilylacetylene 273 in the presence of [RhI(COD)]2 in good yields and 
excellent stereoselectivities (Scheme 3.8).101 Xanthphos was found to be the best phosphine 
ligand regarding the selectivity, possibly because of the biggest bite angle related to the catalyst 
derived from this ligand.101 
 
 
Scheme 3.8. Rh-catalysed hetero-dimerisation of acetylenes. 
 
3.1.3. Synthesis of 1,3-Enynes via Wittig Olefination and Dehydration Reactions 
The Schlosser group described stereoselective Wittig olefination reactions of propargyl 
aldehydes 279 employing different phosphorous ylides 278 under mild reaction conditions 
(Scheme 3.9).102 This protocol was highly Z-selective giving the 1,3-(Z)-enynes 280 in high 
yields and good to excellent stereoselectivities.   
 
 
Scheme 3.9. Z-selective Wittig reactions of propargyl aldehydes and phosphorous ylides. 
 
 There are several examples of the dehydration pathway, which is most similar to the 
synthesis developed in this thesis. For example, Shi and co-workers reported a 1,2,3-traizole-
promoted Fe(III)-catalysed dehydration reaction of the propargyl alcohol 281 (Scheme 3.10).103 
H(i-Pr)3Si
[RhI(COD)]2 (1.5 mol%), Xantphos (3.0 mol%)
(i-Pr)3Si
R57-85%
E/Z = 92:4 to 99:1
+ R H
o-xylene, reflux, 3-6 h
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The 1,3-enynes 282 were prepared in good to excellent yields (46-95%) for a wide range of 
substrates. This protocol also offered excellent stereoselectivity, providing enynes in which 
only the Z-isomer was formed. It was shown that the combined σ-donor properties of the 
nitrogen lone-pair electrons and the π-receptor properties of the highly electron-deficient 
triazole ring enables the 1,2,3-triazole ligand 283 to increase the reactivity of the Lewis acidic 
Fe(III) catalyst.  
 
 
Scheme 3.10. Z-Selective Fe(III)-catalysed dehydration reaction of propargyl alcohols. 
 
Alcaide et al. disclosed a stereoselective synthesis of (E)-2-aryl-but-1-en-3-ynes 285 
from aryl-substituted α-allenols 284 by treatment with acetyl chloride in an aqueous 
NaOH/CH2Cl2 biphasic mixture (Scheme 3.13).104 The reaction mechanism could be explained 
based on the elimination of acetic acid via δ-deprotonation and elimination of the acetate group 
in the α-allenic acetate intermediate 286. 
 
 
Scheme 3.11. NaOH-promoted direct synthesis of 1,3-(E)-enynes 285 from allenols 284. 
 
In another similar study, the Sawama group described a phosphate-promoted synthesis 
of a variety of disubstituted enyne 288 from α-allenols 287 using trimethyl phosphate in the 
R3 FeCl3 (10 mol%), ligand (20 mol%)
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presence of NaH (Scheme 3.12).105 The proposed reaction mechanism was similar to that 
previously reported in the study by Alcaide,104 through the transformation of the hydroxy group 
into a good leaving group followed by the conjugate elimination. This concept could also 
explain the formation of 1,3-(E)-enyne 253 via the decarboxylative conjugate elimination of 
the N-Bn oxazolidinone 230a upon a treatment with an excess amount of NaH (Scheme 3.1). 
 
 
Scheme 3.12. NaH-mediated direct synthesis of 1,3-(E)-enynes 288 from allenols 287. 
 
3.2. Heteroatom-tethered 1,3-Enynes and 1,4-Enynes 
Heteroatom-tethered 1,3-enynes are of great interest as versatile building blocks for the 
construction of diversity-oriented complex molecules. Classical strategies for synthesis of 
highly functionalised heterocycles are often limited by poor functional group tolerance, lack of 
regioselectivity, inadequate substrate scope, and harsh reaction conditions.106-108 Therefore, 
such heteroatom-pendant enyne scaffolds have attracted significant interest regarding atom-
economical protocols in organic synthesis due to easily accessible starting materials, low 
toxicity, high functional group tolerance, and mild reaction conditions.98   
Zhang and Herndon reported the formation of alkenylpyrroles 293 through the coupling 
reactions of enyne-imines 291 with Fischer complexes 292 (Scheme 3.13).109 The (Z)-enyne 
precursors 291 were synthesised from ketones 290 in three steps with moderate to excellent 
yields. The majority of the enyne-imines 291 were used in the next cyclisation reaction step 
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CPME = cyclopentyl methyl ether
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Scheme 3.13. Synthesis of pyrroles 293 via coupling of enyne-imines 291 with Fischer complexes. 
 
Gabriele et al. described the KOtBu-promoted one-pot, three-component coupling 
reactions of alkynes (294 and 296) and aldehydes (295) to rapidly access (Z)-2-en-4-yn-1-ols 
297 and (E)-1-en-4-yn-3-ols 298 under mild reaction conditions (Scheme 3.14).110 
Interestingly, they demonstrated that when the crude reaction mixture was quenched with 10% 
H2SO4 aqueous solution, the (Z)-2-en-4-yn-1-ol 297 could be obtained via a rearrangement of 
the allylic alcohol. However, using only H2O in the workup process gave the (E)-1-en-4-yn-3-
ol 298 in high yields and excellent stereoselectivities.  
 
Scheme 3.14. KOtBu-promoted three-component coupling reaction of aldehydes and alkynes to synthesise (Z)-2-en-4-yn-1-ols 
297 and (E)-1-en-4-yn-3-ols 298. 
 
Although many methods have been investigated for the synthesis of heteroatom-
tethered 1,3-enynes and 1,4-enynes, most of the strategies offered racemic 1,3-(Z)-enynes as 




1) PBr3 (2.34 equiv.), DMF, CHCl3, 0 oC
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intramolecular cyclisation.98 Therefore, a method for the synthesis of chiral heteroatom-
containing 1,3-(E)-enynes is highly desirable in organic synthesis.    
 
3.3. Carbon- and Heteroatom-tethered 1,6-Enynes 
Carbon- and heteroatom-tethered 1,6-enynes are versatile building blocks in organic synthesis 
due to their unique highly unsaturated bond systems. Compared with 1,3-enynes, these 
scaffolds have attracted considerable attention owing to their application to the one-step 
formation of a diverse array of carbo- and heterocyclic products, from these relatively simple 
starting materials, in an atom-economical fashion.111 1,6-Enynes are also widely employed in 
the synthesis of bioactive molecules for various medicinal purposes.112-114 For example, 
GSK1360707 300 is a common anti-depressive agent representing a well-balanced activity for 
depression and anxiety treatment, which can be prepared from the Au-catalysed cyclisation of 
the 1,6-enyne 299 (Scheme 3.15a).115  
Synthesis of carbon- and heteroatom-tethered 1,6-enynes will be not discussed in detail  
in this Chapter as they can be easily prepared via several classical strategies under mild 







Scheme 3.15. (a) Synthesis of GSK1360707 300. (b) General procedures for synthesis of 1,6-enynes. 
 
3.4. Metal-catalysed Cycloisomerisation Reactions of 1,6-Enynes 
Carbon- and heteroatom-tethered 1,6-enynes can readily participate in numerous tandem 
reactions due to the double and triple bond units in these structures, which offer versatile 
approaches to a variety of products by simple manipulation. Among the astonishing diversity 
of transformations, metal-catalysed cycloisomerisation reactions of 1,6-enynes are growing in 
importance as powerful tools for the synthesis of many cyclic compounds in an one-pot process 
under mild reaction conditions.111, 119 As such, these reactions are fundamentally atom- 
economical with a concomitant increase in molecular complexity.111 Thus, cycloisomerisation 
reactions of 1,6-enynes have significant potential for applications in the synthesis of natural 
products and pharmaceuticals.120-121  
Cycloisomerisation reactions of 1,6-enynes 311 have been extensively investigated 
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b) General common procedures for synthesis of carbon- and heteroatom-tethered 1,6-enynes





1) LAuCl (2.75-5.5 mol%),
















































substrate and the metal, there are three general approaches proposed for these 
cycloisomerisation reactions (Scheme 3.16).119 The concurrent complexation of the metal to the 
alkene or alkyne leads favourably to the metallacycle 312 via an oxidative coupling pathway 
(Scheme 3.16, pathway a). The presence of a functional group in the allylic position enables 
the generation of a π-allyl-metal complex 313 (Scheme 3.16, pathway b), which then further 
reacts with the triple bond to form the desired cyclo 1,n-dienes 315. In the presence of a metal 
hydride as the catalyst, the cycloisomerisation reaction proceeds through a hydrometalation of 
the alkyne motif generating the corresponding vinylmetal species 314, carbometalation of the 
olefin then occurs if an appropriate substitution at the allylic position is present (Scheme 3.16, 
pathway c). 
 
Scheme 3.16. Three main mechanisms for the metal-catalysed cycloisomerisation of 1,6-enynes. 
 
The majority of the established transformations of 1,6-enynes require coordination of 
both π-bonds to a single metal centre, which restrict diversity of the stereochemical outcomes 
of these reactions.111, 120, 122 Furthermore, it has been generally established that metal catalysts 
favouring ligation of a single π-system are more reactive and selective.122  
Au(I) complexes have proved to be the one of the most efficient catalyst species for the 
activation of 1,6-enynes, even in the presence of different functional groups or stereochemical 
elements. 86, 122-123 Mechanistically, Au(I)-cycloisomerisation reactions of 1,6-enynes are 
initiated by selective activation of alkynes through coordination of the metal to the alkyne 




Z = NR, O, C(CO2Et)2, C(SO2Ph)2
M = Rh, Pt, Pd, Ti, Fe


























3.5. Au(I)-Catalysed Cycloisomerisation of 1,6-Enynes 
Cationic Au(I) complexes have emerged as versatile carbophilic π-acid catalysts in 
cycloisomerisation of 1,6-enynes providing various molecular skeletons which are often 
challenging to achieve via other transition-metal catalysis.124 The strong Lewis acidity of 
cationic Au(I), low oxophilicity, as well as its potential to stabilise cationic reaction 
intermediates offer unique reactivity to such catalysts in synthetic reactions.125 The existence 
of contraction of the 6s orbitals and expansion of the 5d orbitals in the cationic gold(I) species 
enable it to interact with various ligands.125 
As mentioned earlier, in metal-catalysed cycloisomerisation reactions of 1,6-enynes, 
most metal complexes require coordination of the metal to both the alkyne and the alkene 
bonds, resulting in products arising from a non-skeletal rearrangement mechanism (Scheme 
3.16 and Scheme 3.17a). This reaction is initiated by coordination of the transition metal to 
both π-bonds of the enyne to generate species 317 followed by an oxidative cyclometalation to 
give the metallacycle intermediate 318. β-Hydrogen elimination from one of the alkyl chains 
then occurs to form species 319, which finally undergoes reductive elimination to provide the 
observed product 320. 
Considering the mechanistic basis of the Au(I)-catalysed cycloisomerisation of 1,6-
enynes, there are two main pathways involving skeletal rearrangements generated through 
either exo or endo addition of the pendant alkene to the gold π-alkyne complex 321 (Scheme 
3.17b).86, 123-124 According to the skeletal rearrangement mechanism, Au(I) cannot coordinate 
to the both π-bonds at the same time. The complexation of Au(I) to the triple bond provides a 
(η2-alkyne)metal complex 321 acting as an electrophile, which then react with the alkene 
moiety through either 5-exo-dig or 6-endo-dig cyclisation mode to form the corresponding 
cyclopropyl gold carbenes 322 or 323, respectively (Scheme 3.17b). In the absence of internal 
and external nucleophiles, the reaction proceeds via different skeletal rearrangements 
depending on the enyne structure and gold catalyst.126 In the case of the single cleavage 





compound 324 or the 6-membered ring compound 325 via carbon-migration (R3 and R4 
groups). For the double cleavage rearrangement, diene 326 is formed by a formal insertion of 
the terminal carbon of the alkene into the alkyne carbon followed by α-proton elimination. In 
contrast, the six-membered ring intermediate 323 from 6-endo-dig cyclisation can proceed to 
generate a [4.1.0]hept-2-ene structure 327 by protodeauration. Furthermore, the cyclopropane 
of the Au(I) 323 can also be expanded to afford cyclobutene derivative 328 (Scheme 3.17b). 
 
 
Scheme 3.17. (a) Cycloisomerisation of 1,6-enynes with non-skeletal rearrangement approach. (b) Cycloisomerisation of 1,6-
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b) Au(I)-cycloisomerisation of 1,6-enynes via skeletal rearrangement




M = Rh, Pt, Pd, Ti, Fe
Z = O, NR, C(CO2Et)2, C(SO2Ph)2 











































































The regioselectivity between the 5-exo-dig and 6-endo-dig addition modes is highly 
dependent on the enyne substitution pattern. For example, DFT calculations of the 
cycloisomerisation reaction of heteroatom-tethered 1,6-enynes have indicated that the Au(I) 
species often dissymmetrically coordinates to the two carbons of the alkyne bond, which 
indicates that the regioselectivity between the five- and the six-membered ring intermediates is 
already decided at the ring closing step.127 The dissymmetry is dependent upon on the 
substituents on the triple bond. Therefore, in cycloisomerisation of heteroatom-tethered 1,6-
enynes, the generation of five-membered ring intermediates is kinetically favored for terminal 
alkynes, while the formation of 6-membered cyclic compounds is preferred for internal 
alkynes.127 For example, the Michelet group reported the enantioselective Au(I)-catalysed 
cycloisomerisation reactions of heteroatom-tethered 1,6-enynes 329 in the presence of 
AuCl/AgOTf under mild reaction conditions (Scheme 3.18).128 The enynes 329 with an internal 
alkyne bond exclusively underwent the 6-endo-dig addition reaction pathway to give 
derivatives 330 in high yields and excellent ee.  
 
Scheme 3.18. Enantioselective synthesis of derivatives 330 via Au(I)-catalysed cycloisomerisation reaction of 1,6-enynes. 
 
The Au(I)-catalysed cycloisomerisation of nitrogen- and oxygen-tethered 
alkylidenecyclopropanes 332 to tricyclic compounds 333 in the presence of [(t-
BuXPhos)Au(NCMe)]SbF6 catalyst 336 was disclosed by Shi and co-workers (Scheme 
3.19).129 They demonstrated that when the alkyne moiety has no terminal substitution, the 
corresponding five-membered ring 1,3-diene 335 could be obtained in high yield, through the 
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Scheme 3.19. Synthesis of tricyclic compounds 333 via Au(I)-catalysed cycloisomerisation reaction of nitrogen- and oxygen-
tethered alkylidenecyclopropanes 332. 
 
In contrast, the regioselectivity between single cleavage and double cleavage 
rearrangements (Scheme 3.17b) can be more challenging. Mechanistic studies reported by the 
Echavarren group proposed that 1,6-enynes 337 bearing electron-donating substituents on the 
alkyne moiety underwent Au(I)-catalysed single cleavage skeletal rearrangement, whereas 
substrates with electron-withdrawing substituents undergo double cleavage rearrangement 
(Scheme 3.20).130 
   
 
Scheme 3.20. Au(I)-catalysed cycloisomerisation of 1,6-enyne 337 via single- and double-cleavage rearrangements. 
 
In the majority of 1,6-enynes with disubstituted alkenes, these skeletal rearrangements 
are stereospecific pathways in which the configuration of the alkene is retained. However, 
Echavarren et al. showed that the cycloisomerisation reactions of 1,6-enynes with strongly 
electron-donating substituents at the terminal alkene carbon are non-stereospecific, in which Z-
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either (E)-341 or (Z)-343 enynes (Scheme 3.21).131 They demonstrated that the carbocationic 
intermediate 345 could be formed from both (E)-341 and (Z)-343 enynes and that bond rotation 
is faster than the rearrangement because of the electron-donating R group.  
 
 
Scheme 3.21. The cis-selective single-cleavage rearrangement of (E)- and (Z)-1,6-enynes bearing electron-donating substitution 
on terminal alkene carbon. 
 
Despite considerable investigations and progress in the Au(I)-catalysed 
cycloisomerisation of 1,6-enynes,86, 111, 120, 123-124, 126 these reactions are still demanded in organic 
synthesis to construct complex molecules from easily accessible 1,6-enynes. Furthermore, it is 
essential to develop strategic protocols to prepare chiral 1,6-enynes substrates, as synthetic 
methodologies for these chiral precursors are rare in the literature.120, 124 As an extension of this 
research area, the association of carbon- and heteroatom-tethered 1,6-enyne skeleton with an 
extra π-bond system could offer useful advances in the skeletal diversity of the heterocyclic 
products. However, such unique systems are rarely employed in cycloisomerisation reactions 
similar to those types discussed above. There are a few isolated examples of other conjugated 
systems, which will be discussed in the following section. 
 
3.6. 1,6-Enynes Bearing Extra π-Bond Substitutions 
As discussed earlier, carbon- or heteroatom-tethered 1,6-enynes have emerged as versatile 
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economy in natural product synthesis and pharmaceuticals, introducing an extra pendant π-
bond to such 1,6-enynes could offer more molecular complexity in both atom and step 
economical ways.  
In 2007, the Au(I)-catalysed intramolecular Diels–Alder reaction of the 1,6-enyne 
bearing an extra double bond substitution at the alkene position was reported by Fürstner and 
Stimson (Scheme 3.22a).132 Dienyne 347 smoothly underwent the cyclisation reaction to 
generate the corresponding 1,4-cyclohexadienes 348 in moderate to high yields. 
Mechanistically, the cycloaddition reaction is initiated by Au(I)-activation of the triple bond 
followed by attack of the internal alkene bond to generate an electrophilic metal carbene 350 
(Scheme 3.22b). This intermediate then undergoes cyclisation to form cation species 351, 
which finally gives the observed product. 
 
 
Scheme 3.22. Au(I)-catalysed Diels–Alder reaction of dienyne 347. 
 
The Echavarren group described the Au(I)-catalysed intramolecular formal [4 + 2] 
cycloisomerisation of alkenyl-substituted 1,6-enynes 352 to afford bicyclic products 353 
(Scheme 3.23).133 Initially, the dienyne 352 undergoes a cycloisomerisation reaction via a 
formal 5-exo-dig pathway to give the cyclopropyl Au(I)-carbene intermediate 354, which 
undergoes ring expansion to form the allyl cation 355. Subsequent deprotonation and 
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Scheme 3.23. Au(I)-catalysed intramolecular formal [4 + 2] cycloisomerisation of 1,6-enynes 352. 
 
The Rh(I)-catalysed intramolecular [4 + 2] cycloaddition of acyloxy-pendant enediyne 
357 to give the cyclic ketone 358 was developed (Scheme 3.24).134 Mechanistically, they 
proposed that Rh catalysed the 1,3-acyloxy migration of the propargyl ester to generate the η4-
vinylallene 359 (Scheme 3.24). An oxidative cyclisation then occurs to provide the alkylidene 
metallacyclopentene 360. Subsequently, incorporation of the pendent alkyne bond into the 
metallacycle 360 gave the metallacycloheptatriene intermediate 361 which, upon reductive 
elimination, generated the bicyclic ketone product 358. 
 
 
Scheme 3.24. Rh(I)-catalysed intramolecular [4 + 2] cycloaddition of an acyloxy-pendant enediyne 357. 
 
A Rh-catalysed intramolecular Diels–Alder-type reaction of the dienyne 362 for the 














R = H = 72%

















Z = O, NTs, C(CO2Et)2, CH2
R1 = alkyl, aryl

































electron-demand Diels–Alder reaction in which the electron-deficient dienoate moiety (diene) 
reacted with the electron-rich alkyne bond (dienophile) in a Diels−Alder-type reaction 
cycloaddition. In order to produce the indanes 364, a subsequent oxidation step with DDQ was 
needed to facilitate aromatisation (Scheme 3.25). 
 
 
Scheme 3.25. Rh-catalysed Diels−Alder-type reaction cycloaddition and oxidation of dienyne 362. 
 
Taking all the above examples into consideration, it should be mentioned that none of 
these systems are similar to the novel unconjugated enediyne 254 in this project. 
  
3.7. Aims of the Project (II)  
As mentioned earlier in this Chapter, during the synthesis of 5-allenyloxazolidinones (229 and 
230) from allenyl amino-alcohols (206 and 218), it was noticed that the N-Bn oxazolidinone 
230 was transformed into the novel chiral 1,3-(E)-enyne 253 upon treatment with an excess 
amount of NaH under mild reaction conditions. Having these readily accessible novel chiral 
enyne precursors in hand, a proposal was designed for the synthesis of enantioenriched 
unconjugated enediynes 254 through introducing an additional unsaturated triple bond to the 
1,3-enyne. The presence of a nitrogen-pendant-containing 1,3-enyne linked to a triple bond 
offers a unique unconjugated enediyne scaffold, which has not been investigated before in 
terms of metal cycloisomerisation and direct access to a range of heterocyclic compounds in an 
atom efficient manner. In light of the known general reaction mechanism pathways reported by 
Echavarren (Scheme 3.17), it was proposed that enediynes 254 could act as potential substrates 
to undergo the cycloisomerisation reaction to give the five-membered ring structure 365 
R1
R1 = H, Me, TMS, Br 
R2 = H, Me


















(Scheme 3.26a). This intermediate would provide an extra triple bond compared to those related 
dienes in the literature offering the possibility of a cycloaromatisation reaction to produce the 
enantioenriched isoindoline 255 in a single step (Scheme 3.26a). Such a process has not been 
described before, so would represent a new cascade cycloaromatisation process to important 
biologically active heterocycles.  
 
 
Scheme 3.26. (a) Proposed reaction pathways to direct access chiral isoindoline. (b) Two examples of bioactive isoindolines. 
 
Isoindolinones are highly privileged structures due to their presence as a motif in a 
diverse rage of medicinally and biologically active natural products and other synthetic 
compounds (Scheme 3.26b).136-138 Despite the importance of these compounds, in comparison 
to other important bioactive heterocyclic skeletons, there are relatively few known methods for 
the synthesis of isoindolines in either an enantioenriched or racemic form.139-143 Therefore, the 























a) Proposed reaction pathways to isoindoline
























Chapter 4. Results and Discussion 
4.1. Synthesis of 1,3-(E)-Enynes Bearing a Pendant Nitrogen  
The alanine-derived N-Bn,N-Boc allenyl amino alcohol 218a was chosen as the model substrate 
to investigate the proposed cycloaromatisation reaction pathway (Scheme 4.1). The allene 218a 
was efficiently converted to the 1,3-(E)-enyne 253a upon treatment with an excess amount of 
NaH (2.00 equiv.) under mild reaction conditions with excellent E-selectivity. It was assumed 
that the reaction likely proceeded via in-situ formation of N-Bn allenyl oxazolidinone 230a, 
followed by a decarboxylative conjugate elimination to give the enyne 253a. To support this 
proposed mechanism, the oxazolidinone 230a was isolated from the reaction mixture and 
treated with NaH under the same reaction conditions, and the desired enyne product 253a was 
once again obtained. Furthermore, the proposed decarboxylative conjugate elimination 
mechanism was also supported by that previously reported study by Alcaide et al. in which 1,3-
(E)-enynes were synthesised by the elimination of acetic acid via δ-deprotonation and 
elimination of the acetate group in the O-acetyl protected α-allenols (Chapter 3, Scheme 
3.11).104 Mechanistically, the reaction of allene 218a with NaH generates the corresponding 
oxazolidinone 230a via deprotonation of the hydroxy group, followed by nucleophilic attack 
of the resulting alkoxide on the Boc carbonyl group. The excess amount of base then abstracts 
the distal allenic proton of the allenyl oxazolidinone 230a providing the N-pendant 1,3-(E)-




Scheme 4.1. Direct synthesis of 1,3-(E)-enyne 253a from N-Bn,N-Boc allenyl amino alcohol 218a. 
 
The formation of enyne product 253a was verified by the appearance of a doublet of 
doublet 1H NMR resonance at 2.85 ppm (dd, J = 2.2, 0.6 Hz, 1H) attributed to the terminal 



























5.61 ppm (ddd, J = 16.0, 2.3, 1.1 Hz, 1H, E isomer) and 6.10-6.16 ppm (ddd, J = 16.0, 7.7, 0.6 
Hz, 1H, E isomer) were assigned to the protons of the double bond group. The disappearance 
of the distinctive allene carbon resonance (around 209.0 ppm) in the 13C NMR spectrum also 
supported the formation of the enyne. The HRMS (ESI) of the purified enyne product showed 
an [M + H]+ ion peak at m/z 186.1279, which supported the structure of enyne 253a. 
 
 
Figure 4.1. 1H NMR spectrum (400 MHz, CDCl3) of the 1,3-(E)-enyne 253a. 
 
Encouraged by the potential efficiency of this method to prepare 1,3-enyne 253a with 
excellent E selectivity, the investigation was then aimed to evaluate the substrate scope of this 
1,3-(E)-enyne synthesis using a range of the N-Bn,N-Boc allenyl amino alcohols 218 – the 
synthesis of which were reported in Chapter 2. When these allenyl amino alcohols were treated 
with NaH, their corresponding enyne products 253a-e were successfully obtained in good to 
high yields and with excellent E-selectivity (Table 4.1). In all cases, only the desired enyne was 
observed in the 1H NMR spectrum of the crude reaction mixture, without any intermediate 
oxazolidinone being observed when an excess amount of NaH was used. As mentioned earlier 





218 was complicated due to the presence of a mixture of rotamers (caused by carbamate C−N 
rotation of Boc), diastereoisomers and regioisomers. Therefore, after the Zn-catalysed 
allenylation reaction of α-amino aldehydes, the crude reaction mixture was subjected to a short 
silica column in order to remove unreacted reagents and the catalyst. The resulting semi-
purified product mixture was then used for the NaH-mediated synthesis of the enynes in order 
to establish a protocol that gave excellent overall yields for the two steps.  
 
Table 4.1. Reaction scope for 1,3-(E)-enynes 253a-e.a,b 
 
 
aIsolated yield over three steps. bEnantiomeric excess (ee) of 253a was determined as >99% using chiral HPLC 
analysis. 
 
The allenyl products 218 are obtained in enantiomerically-enriched form as they 
originate from naturally occurring L-α-amino acids and little or no erosion of the enantiomeric 
purities during the reaction steps is observed vide supra.66 At this point, it was intended to see 
whether this methodology would also show retention of enantiopurity of the allene products 
during the formation of the enyne. Therefore, the enantiomeric excess of the chiral enyne 253a 
was measured as a model compound using chiral HPLC analysis, and was compared with its 
corresponding racemic enyne prepared from the racemic N-Bn,N-Boc alanal 217a. 
Gratifyingly, the enantiomeric excess of 253a was observed as >99%, which indicated no 
erosion of the enantiomeric purity during the enyne formation process (see Experimental 




































4.2. Synthesis of Unconjugated Enediynes and Au(I)-Catalysed 
Cycloisomerisation 
Having the novel enantiomerically-enriched enynes 253a-e in hand, the investigation then 
focused on introducing an additional unsaturated triple bond to the enyne system; with 253a 
chosen as the model substrate. N-Propargylation of the enyne 253a with propargyl bromide 
mediated by K2CO3 in CH3CN provided the corresponding alkenyl-substituted 1,6-enyne 
(enediyne) 254a in good yield (Table 4.2). The formation of this desired product was verified 
by the appearance of a singlet 1H NMR resonance at 2.21 ppm (1H) attributed to the new 
terminal alkyne proton of the enendiyne (Figure 4.2). Furthermore, an AB quartet resonance at 
3.26 ppm (2H, JAB = 15.0 Hz ) was assigned to the diastereotopic CH2 protons of the N-
propargyl group. The HRMS (ESI) of the purified enediyne product showed a [M + Na]+ ion 
peak at m/z 246.1267, which supported the structure of 254a. 
 
 
Figure 4.2. 1H NMR spectrum (500 MHz, CDCl3) of the enediyne 254a. 
 
A reaction optimisation was performed with enediyne (254a) by employing various 





solvents, reaction temperature, and quantities of catalyst (Table 4.2). Initial optimisation 
reactions were carried out in DCE, as a polar halogenated solvent, under an inert atmosphere 
(Table 4.2, entries 1-6). Running the reaction using 5 mol% of AuPPh3Cl/AgBF4 at room 
temperature showed no conversion to product(s) and only unreacted starting material was 
recovered (Table 4.2, entry 1). The reaction was then conducted using 10 mol% 
AuPPh3Cl/AgBF4 at 50 oC, but no reaction occurred (Table 4.2, entry 2). Employing the N-
heterocyclic carbene gold catalyst system IPrAuCl/AgBF4 also resulted in no reaction being 
observed (Table 4.2, entry 3) and increasing the catalyst loading to 20 mol% at 50 oC resulted 
in complete decomposition of the starting material (Table 4.2, entry 4). The reaction was then 
performed using 10 mol% of IPrAuCl/AgBF4 under reflux in DCE, and the 1H NMR analysis 
of the crude reaction mixture indicated decomposition of the enediyne substrate (Table 4.2, 
entry 5). However, when the reaction was conducted under reflux conditions in the presence of 
IPrAuCl but with AgSbF6 instead of AgBF4, the isoindoline 255a was obtained as the major 
product in 25% yield along with a small amount (28%) of the 5-membered ring product dienyne 
365 (Table 4.2, entry 6). Although the role of the counteranion in homogeneous gold catalysis 
remains unclear,144 it has been shown that the weakly coordinating and more moisture tolerant 
SbF6− counteranion is practically more efficient compared to BF4−.144 With an effective catalyst 
system identified, the solvent was then varied in an attempt to increase the yield. Switching to 
toluene as a less polar solvent showed a noticeable increase in the reaction conversion (Table 
4.2, entry 7), although 1H NMR analysis of the crude reaction mixture indicated a trace amount 
of the 5-membered dienyne 365. Increasing the reaction temperature to reflux pushed the 
reaction to completion and gratifyingly the isoindoline 255a was isolated in a 70% yield (Table 
4.2, entry 8), with no trace of the 5-membered ring dienyne 365. Lowering the catalyst loading 
from 10 mol% to 5 mol% had a negative impact on the reaction efficiency resulting in a 56% 
yield of the desired product 255a (Table 4.2, entry 9). In order to compare the effect of Au(I)-
phosphine complex with the NHC-stabilised Au(I) complex on this reaction, 





observed (Table 4.2, entry 10). Furthermore, the reaction did not proceed using either IPrAuCl 
or AgSbF6 alone at reflux in toluene (Table 4.2, entries 11 and 12).  
 
The formation of the 5-membered intermediate 365 provides some evidence that the 
reaction proceeds through the known 5-exo-dig cyclisation (single cleavage) mode as shown in 
Scheme 3.17b. The intermediate 365 was verified by the disappearance of the 1H NMR 
resonances of the terminal alkyne protons and the alkene group of the enediyne starting material 
(Figure 4.3). Furthermore, the appearance of two sets of alkene 1H NMR resonances clearly 
indicated the presence of a mixture of E/Z (1.5:1.0 ratio, Ja,b = 11.0 Hz and Ja',b' = 16.0 Hz) 
isomers of the 5-membered ring intermediate 365. Unfortunately, this compound proved 
unstable towards purification and further characterisation could not be performed. Moreover, 
many further attempts to isolate the 5-membered ring intermediate were unsuccessful. 
 
Table 4.2. Optimisation of Au(I)-catalysed cycloisomerisation reaction of enediyne 254a.a 
 
Entry Catalyst (mol%) Temperature Solvent Yieldb (%) 
Products ratiof 
365 (%) 255a (%) 
1 AuPPh3Cl/AgBF4 (5) r.t  DCE N.R.c - - 
2 AuPPh3Cl/AgBF4 (10) 50 oC DCE N.R.c - - 
3 IPrAuCl/AgBF4 (10) 50 oC DCE N.R.c - - 
4 IPrAuCl/AgBF4 (20)  50 oC DCE -d - - 
5 IPrAuCl/AgBF4 (10) reflux DCE -d - - 
6 IPrAuCl/AgSbF6 (10) reflux DCE 25 28e 72 
7 IPrAuCl/AgSbF6 (10) 85 oC toluene 47 8 92 
8 IPrAuCl/AgSbF6 (10) reflux toluene 70 - 100 
9 IPrAuCl/AgSbF6 (5)  reflux toluene 56 - 100 
10 AuPPh3Cl/AgSbF6 (10) reflux toluene N.R.c - - 
11 IPrAuCl (10) reflux toluene N.R.c - - 
12 AgSbF6 (10) reflux toluene N.R.c - - 
aReactions performed under nitrogen atmosphere for 24 h. bIsolated yield of isoindoline 255a. cNo reaction occurred. 

















Figure 4.3. 1H NMR spectrum (500 MHz, CDCl3) of the 5-membered ring intermediate 365. 
 
The isoindoline product 255a was confirmed by the disappearance of the 1H NMR 
resonances of the terminal alkyne protons and the alkene group of the enendiyne starting 
material (Figure 4.4). Furthermore, the presence of four new aromatic 1H NMR resonances in 
the 7.12 ppm to 7.42 ppm range provided support for the formation of a new aromatic ring. 
This was further supported by the total number of 10 C(sp2) resonances in the aromatic region 
of the 13C NMR spectrum. The HRMS (ESI) of the purified enediyne product showed an [M + 






Figure 4.4. 1H NMR spectrum (500 MHz, CDCl3) of the isoindoline 255a. 
 
Having the optimised reaction conditions in hand, the substrate scope of the Au(I)-
catalysed cycloisomerisation reaction was evaluated using a series of the enediynes 254b-g 
(Table 4.3). A range of the novel (E)-enediynes 254a-g was prepared in moderate to high yields 
using propargyl bromide and K2CO3 in CH3CN at reflux. These enediynes were then subjected 
to the optimised cycloisomerisation reaction conditions – however, it was quickly realised that 
the isoindoline products 255 are likely highly unstable towards autoxidation and the reactions 
were therefore capricious. Employing the enediynes (254) in the Au(I)-catalysed 
cycloisomerisation reaction resulted in no desired product for each case, and the 1H NMR 
spectrum of the crude reaction mixture indicated complete decomposition of the enediyne 
starting material. In an attempt to synthesise a dihydroisoquinoline, the possible gold-catalysed 
cycloaromatisation reaction of N-butynoic enediyne 254e was also investigated which resulted 
in no desired product. The phenylalanine-derived isoindoline 255d was obtained in low yield 
(24%), although the 1H NMR spectrum of the crude reaction mixture only showed the product. 
Unfortunately, this compound rapidly decomposed and satisfactory 13C NMR and IR spectra 





the enediynes 254a-g, but no product was isolated and the 1H NMR spectra of the crude reaction 
mixtures showed no clear resonances for any significant organic product.  
 
Upon further in-depth analysis of the literature, the instability of N-aryl and N-alkyl 
isoindolines was noted as they have a high tendency to undergo autoxidation in  solution to 
form isoindoles 368.145-148 These isoindoles are highly susceptible to being further oxidised to 
cyclic endo peroxides 369,148 followed by decomposition of the cyclic compound to unstable 
Table 4.3. Reaction scope for the isoindolines 255. 
 
   Enediyne 254              Isoindoline 255 
 
aThese isolated yields obtained only once and the repeated reactions showed decomposition of starting material. bComplete 

























































fragments. On this basis, it was speculated that the auto-oxidation of the isoindolines 255 leads 
to unstable volatile fragments as there were no clear signals detected in the 1H NMR spectra of 
the crude reaction mixtures (Scheme 4.2).  
   
 
Scheme 4.2. Speculated auto-oxidation reaction pathway of the isoindoline 255. 
 
Having an electron-withdrawing group on or next to the nitrogen could be an effective 
solution for this problem.145 For example, Sarpong et al. reported the synthesis of a range of 
isoindolines and isoindolinones via the direct C–N coupling between benzylic carbon groups 
and amines (Scheme 4.3).147 Due to the high instability of the isoindoline products 372, the 
yields were only determined by 1H NMR analysis using hexamethylenetetramine as an internal 
standard. However, it was shown that by introducing a carbonyl group in the structure of the 
starting materials, the corresponding isoindolines 375 and isoindolinones 376 could be isolated 
in good to high yields without decomposition (Scheme 4.3). 
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At this point, the investigation switched to introducing a propiolamide into the enyne 
structure, as the presence of a carbonyl group next to the nitrogen would increase stability and 
avoid autoxidation. Furthermore, the potential isoindolinone final product is highly desirable 
in organic synthesis as they are found in many pharmaceuticals and natural products that exhibit 
important biological activities as shown in the examples in Scheme 4.4.149-150 The N-benzyl 
substituted isoindolinone scaffold is particular of interest to medicinal chemistry because of its 
presence in a variety of biologically active compounds and pharmaceutical target molecules.151-
153 Since enantiomers could interact differently with biological systems, the synthesis of these 
biologically active isoindolinones in enantiomerically enriched form is highly desired. For 
example, it has been showed that the stereospecificity of N-benzyl isoindolinones plays a 
significant role in MDM2-p53 PPI inhibitory activity.153  
 
 
Scheme 4.4. Examples of bioactive isoindolinones. 
 
1,3-(E)-Enyne 253d was chosen as the model substrate to investigate the proposed 
strategy in the Au(I)-catalysed cycloaromatisation reaction (Scheme 4.5). The unconjugated 
(E)-enediyne 380d was prepared using a DCC-amide coupling reaction of the enyne 253d and 
propiolic acid under mild reaction conditions (Scheme 4.5). Although the 1H NMR spectrum 
of the crude reaction mixture showed 100% conversion of the starting material to the enediyne, 
only a moderate yield was obtained due to the difficulty in removing the urea byproduct formed 
in the DCC-amide coupling reaction. After completion of the reaction, the solvent was 
evaporated, and the mixture was re-dissolved in a minimum amount of CH2Cl2 and then cooled 
in a freezer for 18 h. The cooled mixture was then filtered to remove the precipitated urea, 



























Scheme 4.5. Synthesis of enediyne 380d as the model substrate. 
 
The enediyne product 380d was further verified by the appearance of two singlet 1H 
NMR resonances at 3.05 ppm and 3.16 ppm (a 2:1 mixture of two rotamers) attributed to the 
new terminal alkyne proton of the enendiyne (Figure 4.5). Furthermore, two 13C NMR 
resonances at 153.6 ppm and 154.0 ppm (two rotamers) were assigned to the carbonyl of the 
propiolamide group. The HRMS (ESI) of the purified enediyne product showed an [M + Na]+ 
ion peak at m/z 336.1357, which supported the structure of 380d. 
 
 
Figure 4.5. 1H NMR spectrum (400 MHz, CDCl3) of the enediyne 380d. 
 
The model substrate 380d was subjected to the cycloisomerisation reaction under 
similar conditions employed for the synthesis of isoindoline 381d (Scheme 4.6). The 1H NMR 



















product, along with a large number of unidentified byproducts. Unfortunately, these byproducts 
could not be isolated and characterised due to their instability. However, analysis of the 1H 
NMR spectrum of the crude reaction mixture clearly showed that no five-membered ring 
intermediate 382 was formed. The 1H NMR spectrum of the enediyne product 380d also 
showed a mixture of two rotamers (ca. 2:1 ratio) caused by restricted carbamate C−N rotation 
of the propiolic substituent. Examination of the 1H NMR spectrum at elevated temperature (70 
°C in DMSO), in an attempt to coalesce rotamer peaks, was also unsuccessful. It was speculated 
that the presence of the carbonyl group next to the triple bond might result in a potential change 
in the cycloaromatisation reaction mechanism. Due to the change in the nature of the electronics 
on the triple bond, the terminal alkyne proton would be more acidic than the triple bond of the 
enyne. Therefore, deprotonation of the terminal alkyne by the gold catalyst could offer the 
possible formation of the gold acetylide intermediate 383 (Scheme 4.6). The generation of gold 
acetylides is a known process in homogeneous gold catalysis where an alkyne acidic proton is 
replaced by a gold species.154 Due to the presence of another triple bond in the enediyne 
structure, the formation of a dual gold intermediate is possible. The triple bond of the acetylide 
part can then act as a nucleophile to react with the other Au-activated electrophilic triple bond. 
The proposed reaction mechanism will be discussed in detail later in this Chapter.  
 
  




Ph AuPPh3Cl/AgSbF6 (5 mol%)































The isoindolinone product 381d was confirmed by the disappearance of the 1H NMR 
resonances of the terminal alkyne protons and the alkene group of the enendiyne starting 
material (Figure 4.6). Furthermore, the presence of four new aromatic resonances in the 6.87 
ppm to 8.00 ppm range provided support for the formation of a new aromatic ring. The chemical 
shift of H-7 was significantly downfield consistent with its close proximity to an ortho-carbonyl 
group. This structure was further supported by the total number of 14 C(sp2) resonances in the 
13C NMR spectrum. The lack of rotamers in the 1H NMR spectrum also indicated the formation 
of the isoindolinone product. The HRMS (ESI) of the purified enediyne product showed an [M 
+ H]+ ion peak at m/z 314.1541, which supported the structure of 381d. 
 
 
Figure 4.6. 1H NMR spectrum (400 MHz, CDCl3) of the isoindolinone 381d. 
 
In light of this preliminary result, it was intended to optimise the reaction conditions in 
order to increase the reaction efficiency. The investigation was initiated using two common 
electron-rich ligand coordinated gold complexes AuPPh3Cl and IPrAuCl. Initial optimisation 
was performed in CH2Cl2 as a polar solvent under a nitrogen atmosphere (Table 4.4, entries 1-
4). Increasing the temperature to reflux using 5 mol% of AuPPh3Cl/AgSbF6 did not improve 





lower byproduct formation (Table 4.4, entry 2). In order to calculate the NMR yields, a 
stoichiometric amount of 3,5-difluorobenzaldehyde (1.0 equiv.), as an internal standard, was 
added to the crude reaction mixture and the ratio between the aldehyde carbonyl resonance 
(9.95 ppm, s, 1H) and the corresponding product peaks in 1H NMR spectrum of the crude 
reaction mixture gave the NMR yield. When the reaction was conducted with a higher catalyst 
loading (10 mol%), no improvement was observed for the yield of the desired isoindolinone 
381d (Table 4.4, entry 3). Under the same conditions, the NHC ligand containing Au(I)-
complex obtained from IPrAuCl/AgSbF6 was completely ineffective, showing no isoindolinone 
formation (Table 4.4, entry 4). Toluene was then evaluated as a less polar solvent in the 
cycloisomerisation reaction (Table 4.4, entries 5-9). This reaction modification gave a low 
NMR yield (4.6%) of 381d along with a high amount of byproduct formation in the presence 
of AuPPh3Cl/AgSbF6 (10 mol%) at room temperature (Table 4.4, entry 5). Switching to 
IPrAuCl/AgSbF6 had also a negative effect, leading to no reaction at room temperature (Table 
4.4, entry 6). However, when the reaction was performed in toluene under reflux conditions, a 
noticeable decrease in by-product formation was observed (Table 4.4, entry 7). It is important 
to note that the mentioned byproduct was a complex mixture of compounds which could not be 
isolated or readily identified in the 1H NMR spectrum of the crude reaction mixture.   
 
 
Table 4.4. Optimisation of Au(I)-catalysed cycloisomerisation reaction of enediyne 380d. 
 
Entry Catalyst (mol%) Temperature Solvent Time Yielda 
1 AuPPh3Cl/AgSbF6 (5) r.t CH2Cl2 24 h 9% 
2 AuPPh3Cl/AgSbF6 (5) reflux CH2Cl2 24 h 11% 
3 AuPPh3Cl/AgSbF6 (10) reflux CH2Cl2 24 h 10% 
4 IPrAuCl/AgSbF6 (5) r.t to reflux CH2Cl2 24 h -b 
5 AuPPh3Cl/AgSbF6 (10) r.t toluene 24 h 4.6% 
6 IPrAuCl/AgSbF6 (10) r.t toluene 24 h N.R.c 
7 IPrAuCl/AgSbF6 (5) reflux toluene 24 h 32%d 
8 [(Ph3PAu)3O]BF4 (5) r.t to reflux toluene 4 h 75%d 
9 [(Ph3PAu)3O]BF4 (2.5) reflux toluene 6 h 77%d 
aNMR yield based on crude reaction using 3,5-difluorobenzaldehyde as internal standard. bNo product detected in the 1H 












A cationic gold-oxo trimer, [(Ph3PAu)3O]BF4, was then evaluated in the 
cycloisomerisation reaction. It was anticipated that this electron-rich gold complex would be 
sufficiently basic to facilitate the formation of a gold acetylide. Interestingly, the reaction 
efficiently proceeded with a shorter reaction time and resulted in a significant improvement in 
the yield (Table 4.4, entry 8). The 1H NMR spectrum of the crude reaction mixture showed the 
exclusive formation of isoindolinone 381d with no trace of byproducts, suggesting that a more 
basic Au(I) complex might offer further benefits including formation of a gold acetylide. 
Reducing the amount of catalyst from 5 mol% to 2.5 mol% also led to a similar yield, but 
required a longer reaction time – these conditions were therefore selected as optimal (Table 4.4, 
entry 9). 
A range of novel enantiomerically enriched propiolamide enediynes 380a-e were then 
prepared from the corresponding 1,3-(E)-enynes 253a-e (Table 4.5). Treating the enediynes 
380 under the optimised cycloisomerisation reaction conditions efficiently provided the 


















As discussed earlier in Table 4.1, there was no erosion of the enantiomeric purity during 
the formation of 1,3-(E)-enyne 253a from the corresponding N-Bn,N-Boc allenyl amino alcohol 
218a. At this point, it was intended to see whether this cycloisomerisation methodology would 
also show the retention of enantiomeric purity of the enyne starting materials for the 
isoindolinone final products. Therefore, the enantiomeric excess (ee) of the isoindolinone 381a 
was investigated by chiral HPLC analysis as the model compound to compare with that of 
previously measured for the 1,3-(E)-enyne 253a. The ee of the chiral isoindolinone 381a was 
observed as >99% by comparing with its corresponding racemic isoindolinone prepared from 
racemic 1,3-(E)-enyne (Figure 4.7). This result clearly indicated that no erosion of the 
enantiomeric purity occurred during the Au(I)-catalysed cycloisomerisation reaction.  
 
Table 4.5. Reaction scope of isoindolinones 381. 
 
(E)-N-(hex-3-en-5-yn-2-yl)propiolamidesb 380 Isoindolinones 381 
  
 




















































Figure 4.7. Chiral HPLC analysis of the isoindolinone 381a. (Phenomenex Lux Cellulose-3 column; n-hexane/isopropyl alcohol 
(90:10); flow rate = 0.5 mL/min; 254 nm; single peak, t = 16.75 min, >99% ee. Racemic isoindolinone 381a showed two peaks 
at t = 16.11 min and t = 16.84 min (peak area ratios = 1:1) with the same solvent system and flow rate). 
 
In order to increase the structural diversity of the substrates for the cycloisomerisation 
reaction, the Sonogashira cross-coupling reaction was utilised to introduce aromatic 
substituents on the terminal alkyne of the enyne unit (Table 4.6). A range of 1,3-(E)-enynes 
384 bearing different aromatic groups on the terminal alkyne was prepared using standard 
Sonogashira conditions with catalytic PdCl2(PPh3)2 and CuI. Aryl iodides bearing p-electron 
withdrawing groups (NO2, F and CHO) gave the best yields (Table 4.6). These substituted 
enynes were then employed as the starting materials to synthesise the corresponding 
propiolamide enediynes 385 via DCC-amide coupling reactions (Table 4.6). 
As mentioned earlier, although the 1H NMR spectrum of the crude reaction mixture 
showed 100% conversion of the starting material to the enediyne, only a moderate yield was 

















































































































































To further explore the scope of the protocol, with respect to the aromatic substitution 
on the enyne motif, the enediynes 385 were subjected to the cycloisomerisation reaction under 
optimised conditions (Table 4.7). Substrates with a phenyl group, bearing either an electron-
donating or electron-withdrawing substituent gave the corresponding isoindolinone products 
386 in good to high yields (Table 4.7). The enediynes 385f and 385g having respectively a 
thiophene and the sterically demanding naphthalene group, were also well tolerated, providing 
the isoindolinones 386f and 386g in high yield. 
Table 4.6. Expanding the structural diversity of the unconjugated (E)-enediynes.a,b 
 
 
a(i) ArI (1.20 equiv.), PdCl2(PPh3)2 (0.02 equiv.), CuI (0.04 equiv.), Et3N (2.00 equiv.), THF, r.t, 18 h. (ii) propiolic acid 



















































































































The structure of the isoindolinone product 386c, derived from the aryl-substituted 
enediyne 385c, was verified by the disappearance of the 1H NMR resonances of the terminal 
alkyne protons and the alkene group of the enendiyne starting material (Figure 4.8). The 
presence of a distinctive singlet 1H NMR resonance at 8.07 ppm (1H) clearly indicated the 6-
substituted isoindolinone structure 386c. The HRMS (ESI) of the purified enediyne product 










































Figure 4.8. 1H NMR spectrum (400 MHz, CDCl3) of the isoindolinone 386c. 
 
 
Figure 4.9. HMBC spectrum (400 MHz, CDCl3) of the isoindolinone 386c. 
  
The 6-substituted isoindolinone structure 386c was confirmed by HMBC analysis, 





NMR resonance (Figure 4.9). Single crystal X-ray crystallography was also taken to verify the 
structure of the isoindolinone 386c (Figure 4.10). The X-ray crystallography was performed by 




Figure 4.10. X-ray crystal structure of isoindolinone 386c (CCDC 1867833, performed by A/Prof Michael Gardiner). Data were 
collected at 100 K on a crystal mounted on a Hampton Scientific cryoloop at the MX2 beamline, Australian Synchrotron, Victoria. 
The thermal parameters of all hydrogen atoms were estimated as Uiso(H) = 1.2Ueq(C) except for CH3 where Uiso(H) = 1.5Ueq(C). 
Blue = N, red = O, grey = H, black = C. 
 
4.3. Mechanistic Study of Au(I)-Catalysed Cycloisomerisation Reaction of 
Unconjugated Enediynes 
Based on the general skeletal rearrangement mechanism of the Au(I)-catalysed 
cycloisomerisation reactions,123, 131 the formation of lactam intermediate 387 through 5-exo-dig 
cyclisation mode was initially anticipated. This, in turn, would lead to a [2p+2p+2p] cyclisation 
reaction to give the 4-substituted isoindolinone 388 (Scheme 3.35). However, the reaction 
interestingly proceeded via an unexpected regiochemical pathway, providing exclusively the 
6-substituted isoindolinone 386, which strongly suggested that the cycloisomerisation reaction 






Scheme 4.7. Possibility of a new reaction pathway based on the formation of unexpected isoindolinone isomer. 
 
Recently, there have been significant investigations on uncovering and exploiting gold 
σ,𝜋-dual-activation chemistry that come to be known as dual gold catalysis.154-155 In this new 
class of Au(I)-catalysed cyclisation reactions, two gold centres are involved in the reaction 
mechanism. In most cases, one alkyne group is σ-bonded to one gold species and another alkyne 
bond is π-coordinated to a second gold centre (390, Scheme 4.8a). The σ-activation of the 
alkyne bond generates a nucleophilic Au-acetylide, which reacts with the electrophilic π-
complex moiety, leading to different gold intermediates (391, 392, or 393). The use of Au-
acetylides as nucleophiles in Au-catalysed reactions has emerged as an important activation 
mode in the field.154-155 There are two general types of σ-activation to form the Au-acetylides, 
including deprotonation with a base additives and ligand exchange (Scheme 4.8b). In both 
cases, the acidity of the terminal alkyne hydrogen plays a crucial role in the reaction initiation. 
σ-Activation by ligand exchange results in the well-defined formation of Au-acetylide and π-
activated alkyne, leading to high reaction efficiency (Scheme 4.8b).155 Furthermore, as a 
consequence, a fast initiation process, side products are minimised and reaction rates are higher 





































Scheme 4.8. (a) General reaction pathways for dual gold catalysis. (b) General modes of gold σ-activation of alkyne. (c) Known 
reactivity of (Z)-enediynes. (d) Proposed intermediate for the Au(I)-catalysed cycloisomerisation reaction of enediynes 380 and 
385. 
 
The Zhang group reported gold-catalysed cyclisation reactions of conjugated (Z)-
enediynes providing highly efficient formation of a range of fused-aromatic structures (Scheme 
4.8c).156 The reaction mechanism was proposed to proceed via gold σ,𝜋-dual-activation where 





































d) Proposed dual gold intermediates for the current project



























































R2 = H, aryl
380 and 385
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399. Their subsequent C−H insertion reaction was proposed to give fused polycyclic structures 
400 and 401, respectively.  
Based on these known dual gold activation processes, it was proposed that the 
mechanism for the formation of the isoindolinones reported in this thesis could follow a novel 
dual-gold cascade cycloisomerisation via the allenyl Au(I)/vinylidene Au(I) species 403 
(Scheme 4.8d). It was also anticipated that highly selective formation of the Au(I)-acetylide 
occurred on the propiolic position due to the pKa differences between the propiolic amide and 
the alkyne unit in the enediyne substrate in compounds 380a-e.  
Preliminary mechanistic studies commenced by evaluation of the proposed selective 
formation of Au(I)-acetylide in the dual gold activation mechanism. The enediyne 380b-Me 
bearing a methyl substitution on the terminal alkyne of propiolamide unit was prepared and 
subjected to the cycloisomerisation reaction under optimised reaction conditions (Scheme 
4.9a). The reaction did not proceed to the corresponding isoindolinone and only the unreacted 
starting material was recovered. This observation strongly suggested that the initial formation 
of the Au(I)-acetylide could selectively occur on the terminal alkyne of the propiolamide, 
potentially due to the pKa difference between the propiolic amide and the alkyne unit on 
substrates 380a-e. A comparison between the gold catalysts also showed that the N-heterocyclic 
carbene based catalyst system IPrAuCl/AgSbF6 was significantly less effective than the 
tris(phosphinegold)oxonium complex [(Ph3PAu)3O]BF4 in promoting the reaction (Scheme 
4.9b). These results indicated that the intrinsically basic [(Ph3PAu)3O]BF4 was important in 
facilitating deprotonation of the terminal propiolic amide to form the Au(I)-acetylide species.  
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Deuterium labeling studies were next investigated to gain further mechanistic 
information. The alkyne terminus of enediyne 385c was deuterated using K2CO3 and D2O in 
CH3CN at room temperature with excellent deuterium incorporation (98%) (385c-d, Scheme 
4.10). The cycloaromatisation reaction with the D-labeled 385c-d led to 42% incorporation of 
the deuterium atom at the C-7 position of the final isoindolinone 386c-d, with only minor 
incorporation at C-4 and C-5. The observed significant loss of deuterium could be attributed to 




Scheme 4.10. Deuterium labeling study using the enediyne 385c. 
 
Deuterated 385c-d´ was next synthesised with 100% deuterium incorporation, and its 
reactivity under the cycloaromatisation conditions was examined (Scheme 4.11). Surprisingly, 
the reaction resulted in significant loss of the deuterium in the final isoindolinone 386c-d´, and 
the deuterium incorporation predominantly occurred at C-4 and C-5, with relatively little at C-




















































Scheme 4.11. Deuterium labeling study using the enediyne 385c-d´. 
 
A simple example of a [4 + 2] cycloaddition reaction of enediynes to form an aryl ring 
has been reported as a thermal process. In this work, Echavarren and co-workers showed the 
concerted intramolecular [4 + 2] cycloaddition of enediyne 404 at 150 °C in xylenes afforded 
fluoranthene 405 (Scheme 4.12a).157 This thermal reaction could also be promoted by using a 
Lewis acid catalyst to obtain the desired product at room temperature. In order to clarify the 
possibility of a thermal process in the current cycloaromatisation project, a number of control 
experiments were conducted. The enediyne 385c was first heated at reflux in toluene for 18 h 
in the absence of the gold catalyst (Scheme 4.12b). Only trace conversion to the isoindolinone 
386c (<2%) could be detected in the 1H NMR spectrum of the crude reaction mixture, indicating 
a thermal Diels–Alder cycloaddition process is not favoured in this case. It is well-known that 
concerted [4 + 2] cycloaddition reactions are promoted by oxophilic Lewis acids or Brønsted 
acids.158 Therefore, the strong Brønsted acid Tf2NH (pKa = −11.9) was utilised in the control 
experiment to rule out the possibility that gold catalyst or in-situ generated Brønsted acid maybe 
facilitating the reaction by coordination to the C=O bond. Treatment of the enediyne 380a with 
nPr
NBnBoc
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a catalytic amount of Tf2NH (5 mol%) in toluene at room temperature resulted in no conversion 
of the starting material to the desired isoindolinone 381a (Scheme 4.12c). Subsequently, 
heating the reaction in the presence of this strong acid at reflux temperature in toluene over 18 
h showed only ~6% conversion to the isoindolinone (Scheme 4.12c). This result suggested that 
a Brønsted acid-catalysed [4 + 2] cycloaddition appears to be unfavourable for the unconjugated 
enediynes in the current project. 
 
 
Scheme 4.12. (a) Known concerted [4 + 2] cycloaddition reaction of conjugated (E)-enediyne. (b,c) Attempted [4 + 2] 
cycloaddition reactions of unconjugated (E)-enediyne. 
 
 
Having excluded the skeletal rearrangement for the current cycloaromatisation 
reaction, an NMR experiment was conducted under milder conditions to monitor the possibility 
of formation of known intermediates related to the skeletal rearrangement. The enediyne 385c 
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was treated with [(PPh3Au)3O]BF4 (5 mol%) in an NMR tube in toluene-d8 at room 
temperature. The experiment showed slow conversion to the final isoindolinone product 386c 
(<2%) after 24 h, and no clear cyclopropyl or olefinic resonances, corresponding to the common 
intermediates of the skeletal rearrangement (Scheme 3.17, Chapter 3), were observed. 
In order to further support the proposed dual-gold mechanism, an attempt to replicate 
the reaction pathway was examined by synthesising the proposed gold-acetylide intermediate 
385e-Au. It has been shown that gold-acetylide intermediates are quite stable and can be 
isolated.154 Gratifyingly, treatment of the enediyne 385e with a stoichiometric amount of 
PPh3AuCl (0.90 equiv.) in CH2Cl2/Et3N (4:1) at room temperature provided the corresponding 
gold-acetylide 385e-Au in high yield (89%, Scheme 4.13a). With this acetylide intermediate in 
hand, it was first aimed to investigate the possibility of the Au-activated alkyne facilitating the 
thermal [4 + 2] cycloaddition process. Therefore, the acetylide 385e-Au was heated at reflux 
in toluene for 18 h in the absence of gold catalyst (Scheme 4.13b). No conversion to the 
isoindolinone 386e could be detected in the 1H NMR spectrum of the crude reaction mixture, 
which indicated a thermal Diels-Alder [4 + 2] cycloaddition of the gold-acetylide is not 
occurring in this reaction. Furthermore, DFT calculations showed that a [4 + 2] cycloaddition 
of Au-acetylide proceeds via a higher energy transition state than the dual gold pathway 
(Scheme 4.15). On the other hand, treatment of the acetylide 385e-Au with a catalytic amount 
of PPh3AuCl/AgBF4 (5 mol%) resulted in the formation of gold-aryl complex 386e-Au (27% 
yield) and the desired isoindolinone 386e (69%) at room temperature in 5 min (Scheme 4.13c). 





   
Scheme 4.13. Synthesis of gold acetylide intermediate and associated control experiments. 
 
Consideration of all these results led us to tentatively propose the new Au(I)-catalysed 
cycloaromatisation reaction mechanism presented in Scheme 4.14. The σ,π dual activation 
cycle is initiated by the catalyst generating the acetylide 407. The subsequent step is 
nucleophilic attack from the β-position of the gold acetylide to the double bond of the enyne, 
which forms the 5-membered ring allenyl Au(I)/vinylidene Au(I) intermediate 408. This 
species (408) would then undergo 5-exo-trig cyclisation to generate intermediate 409. A ring 
expansion of this adduct via a 1,2-shift of the vinyl C−C bond to the central carbon of the 
vinylidene Au(I) would form the 6-membered ring intermediate 411,156 which is consistent with 
a few examples in the literature.154, 159 At this stage, a 1,2-H/D shift may occur to form the 
intermediate 412, followed by deprotonation-aromatisation to deliver the digold isoindolinone 
species 413. This step is in agreement with the loss of D incorporation in the C-4 position in 
the deuterium labeling experiments in Scheme 4.11, as either D or H can be lost to generate the 
benzene ring. This intermediate (413) then undergoes a double protodeauration with the aid of 
the starting material 415 and the catalyst ((LAu)3O+) to provide the final isoindolinone product 
416 as well as the gold acetylide 407. This step is also in agreement with the presence of D in 
the C-5 and C-7 positions of the isoindolinone 386c-d' (Scheme 4.11) as either H or D can do 














































Scheme 4.14. Proposed mechanism of the Au(I)-catalysed cycloaromatisation of unconjugated (E)-enediyne. 
 
 
In order to gain more insight into the proposed reaction mechanism and to support the 
proposed reaction cycle above, a series of DFT calculations were performed by collaborators 
Prof. Brian F. Yates, Dr. Alireza Ariafard and Mr. Rasool Babaahmadi (PhD student) from the 
University of Tasmania in active collaboration with the UOW group. A DFT investigation was 
conducted through mapping the reaction profile by using a model system based on the 
experimental catalytic system, which consisted of the (E)-enediyne model 380a in the presence 
of [(Ph3PAu)3O]BF4 complex (Scheme 4.15). The computational study confirmed the proposed 
mechanism by showing the possible intermediates and transition states which could be formed 
with low energy barriers. According to the DFT calculations, the overall reaction is highly 
favourable starting from 0.00 kcal/mol to –32.2 kcal/mol (Scheme 4.15a), rendering it 
exothermic.        
These calculations further showed that initially, the trigold oxo complex 
























































































4.15a). Intramolecular deprotonation of this Au-activated species is energetically favoured, 
resulting in the relatively stable Au-acetylide intermediate 419. An energetically uphill 
sequence is then necessary – commencing with the digold hydroxide complex dissociating from 
419 and forming the Brønsted basic LAu-OH and Lewis-acidic cationic gold LAu+ via the gold 
acetylide 380a-Au. The LAu+ activates the triple bond of the enyne moiety of the gold-acetylide 
by 𝜋-coordination to form the highly reactive intermediate 420. This key intermediate can 
cyclise by a nucleophilic attack of the Au-acetylide onto the activated enyne to afford 423 via 
the transition state 421, with an energy barrier of 9.5 kcal/mol. This intermediate 423 is 
particularly reactive as it has a nucleophilic allenyl gold and an electrophilic vinylidene gold 
moiety held in close proximity. Either a direct pseudo-6𝜋-electrocyclisation-type pathway or a 
stepwise route involving a three-centre-two-electron transition state 425 were both shown to be 
possible and are likely competing with each other. The stepwise pathway proceeds via 
nucleophilic attack of the allenyl gold moiety on the vinylidene gold to give the 5-membered 
gold-carbenoid 424, which subsequently undergoes ring-expansion via the transition state 425 
to give 426 with concomitant shift of the gold. No intermediate(s) for the direct pathway could 
be located given the highly favourable nature of the process. The 6-membered intermediate 426 
can be converted to the isoindolinone product (381-(4)d' and 381-(5)d') via several potential 
pathways. As indicated above, at least one of these should include a 1,2-hydride/deuterium 
transfer to account for the presence of deuterium at the C-4 and C-5 positions of the product 
(381-(4)d' and 381-(5)d'). For example, the deuterated intermediate 426-d' can undergo a 1,2-
H/D shift process to give the species 427-d' via a low energy barrier of 4.6 kcal/mol. This 
moiety can then simultaneously lose H+ or D+ and undergo the proto/deutero-deauration to yield 
gem-diaurated intermediates 428-(4)d' or 428-(5)d' with deuterium incorporated at C-4 or C-5, 
respectively (Scheme 4.15b). This 1,2-H/D shift/loss can also explain the incomplete deuterium 
retention observed in the D labeling experiment in Scheme 4.11. Further, gem-diaurated 
moieties with an aurophilic interaction are well-known competent intermediates in gold-
catalysed transformations, which can contribute to the overall stability of the gold 





products (381-(4)d' and 381-(5)d') by conversion to the aryl-Au species (429-(4)d' and 429-
(5)d') by reaction with a new molecule of substrate 380a-d' that concurrently forms Au-
coordinated species 380a-d'(Au). Finally, protodemetallation by the terminal propiolamide sp 
proton of 380a-d'(Au) generates the final isoindolinone products (381-(4)d' and 381-(5)d') as 
well as 420-d' to turn-over the catalytic cycle. This last protodemetallation step is also 
consistent with the observation that the deuterium in 385c-d is predominantly transferred to the 
C-7 position of isoindolinone product 386c-d (Scheme 4.10). This is likely because 385c-d 
would transfer its deuterium to this position selectively by deutero-deauration process (Scheme 
4.16). This deutro-deauration process can also explain the incomplete deuterium retention 
observed in the D labeling experiment in Scheme 4.10. 
It is also important to mention that an alternative cyclisation of the gold acetylide 380a-
Au in the absence of coordination to cationic gold showed a higher energy transition state 422 
(Scheme 4.15). This calculation supported that the proposed dual-gold-catalysed reaction 
mechanism is more favourable than the Diels-Alder pathway – this calculation is also consistent 







Scheme 4.15. (a) Calculated mechanism for the cascade cycloaromatisation reaction. (b) Selected pathway for aromatisation and 
protodemetallation pathways from deuterated 380a-d'. The relative Gibbs energies obtained from M06-CPCM/6-
31+G(d,p)//B3LYP-CPCM/6-31G(d) calculations are given in kcal/mol. (Performed by Prof. Brian F. Yates, Dr. Alireza Ariafard, 
and Mr. Rasool Babaahmadi (PhD student) from University of Tasmania) in conjunction with detailed feedback and guidance by 




















































































































































































































































In this Chapter, it was demonstrated that the N-Bn allenyloxazolidinones 230 could be 
selectively transformed to the novel 1,3-(E)-enynes 253 upon treatment with an excess amount 
of NaH through a decarboxylative conjugate elimination process. This reaction highlights just 
one potential reaction pathway of these intriguing synthetic building blocks. The 
enantioenriched 1,3-(E)-enynes were utilised to synthesise a series of novel unconjugated (E)-
enediynes 254 and 380. These versatile scaffolds could undergo a cascade Au(I)-catalysed 
cycloaromatisation reaction to offer enantioenriched versions of a wide range of biologically 
relevant isoindolines 255 and isoindolinones (381 and 386). Initially, the cycloisomerisation 
reaction of the propargylated enediynes 254 was found to be capricious and inconstant low 
yields were obtained upon repetition due to instability of the isoindoline product. Based on the 
isolation of the 5-memebred ring intermediate 365, it was proposed that the known single 
cleavage skeletal rearrangement is involved as one of the possible reaction mechanisms for the 
gold-catalysed cycloisomerisation of the propargylated enediynes 254.  
The instability challenge of the initial isoindoline product 255 in this project was 
successfully solved through the design and synthesis of the N-propiolic enediynes (380 and 
385). These novel enediynes offered an efficient direct access to the enantiomerically enriched 
isoindolinones (381 and 386), which were stable upon column chromatography and storage. As 
such, this methodology would enable the formation of a carbon-carbon bond along with the 
creation of a benzene ring in a one pot process. Furthermore, formation of an unexpected isomer 
of the isoindolinones led us to believe that the reaction proceeded through a more novel dual-
gold activation pathway rather than the known skeletal rearrangement pathway. Combined 
experimental and computational investigations provided evidence for a new dual-gold reaction 
mechanism pathway based on electronic differentiation of the triple bonds in the substrates to 
direct gold acetylide formation to the propiolic unit. It has been shown that a rare intermediate 
complex 423 containing allenyl σ-gold and vinylidene gold moieties was formed in this reaction 
– such reactive intermediates were previously not known. This is the first example of using 





Furthermore, σ-gold allenyl moieties are almost unknown in gold-catalysed processes, except 
for two studies where they were isolated in a stoichiometric fashion,160-161 highlighting the 
importance of this finding. The presence of both nucleophilic allenyl σ-gold species and the 
electrophilic vinylidene gold in a single structure should present potential interesting chemical 
reactivity for future reaction design that harness dual-gold mechanistic pathways in organic 
synthesis. 
 
4.5. Future Directions and Summary 
Oxazolidinones can potentially undergo decarboxylative ring cleavage pathways as the 
analogues of aziridines. In this Chapter, the base-promoted decarboxylative ring opening 
reaction of stereodefined N-Bn allenyloxazolidinones to enantiomerically enriched 1,3-(E)-
enynes was developed. These powerful oxazolidinones could have more synthetic versatility 
when the allene unit is activated by transition metals such as Pd(0). For example, 
allenyloxazolidinone 175 could be utilised in Pd(0)-catalysed nucleophilic ring-opening 
reaction in the presence of boronic acids to form 1,3-dienes 430 and 431 (Scheme 4.17a). In 
the presence of a base, Pd(0) catalyst may undergo a decarboxylative oxidative addition to the 
allene to give the intermediate 432. Transmetalation and subsequent reductive elimination 
could then occur to generate the final diene products. It is important to note that this proposed 
methodology has recently been performed in the Hyland research group by PhD candidate Mr. 
R. W. Brown. By introducing a new double bond on the nitrogen as a dienophile, these 
stereodefined dienes 433 are expected to undergo intramolecular Diels–Alder reactions to 
provide medicinally relevant isoindolinones 434 (Scheme 4.17b). By the possible formation of 
three chiral centres in the isoindolinone scaffold, controlling diastereoselectivity of this reaction 








Scheme 4.17. (a) Reactivity of allenyloxazolidinones with boronic acids under Pd(0) catalysis. (b) Proposed intramolecular 
Diels-Alder reaction of the tethered 1,3-diene to give an isoindolinone scaffold. 
 
The new dual-gold-catalysed cycloaromatisation reaction of N-propiolic enediynes to 
give isoindolinones was demonstrated in this Chapter. The novel combination of allenyl gold 
and vinlylidene gold intermediates should be harnessed to form other ring systems through the 
variation of the tether between them. 
For example, it will be interesting to see how this catalytic system would perform in a 
gold-catalysed cycloaromatisation reaction of the N-butynoic enediynes 437 to obtain 3,4-
dihydroisoquinolinones 438 (Scheme 4.18). Due to the presence of the acidic alkyne proton 
similar to N-propiolic enediynes, the formation of the gold-acetylide 440 would be expected to 
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the core skeleton in many bioactive natural occurring alkaloids.162-163 However, synthetic 
methods to obtain isoquinolinones and dihydroisoquinolinones are not widely reported in the 
literature.162, 164-167 Therefore, the possible gold-catalysed cycloaromatisation reaction of N-
butynoic enediynes 437 to access stereodefined dihydroisoquinolinone 438 would be an 
interesting topic of investigation in the future.    
 
Scheme 4.18. Proposed synthetic route for 3,4-dihydroisoquinolinone via gold-catalysed cycloisomerisation of N-butynoic 
enediyne. 
	
In summary, the initial aims of this PhD project were to synthesise novel allenylamino 
alcohols containing two nitrogen and oxygen heteroatoms and utilise them in the synthesis of 
the allenyl-pendent heterocycles (Scheme 4.19). It was further attempted to manipulate these 
novel heterocycles in the ring-opening reactions in order to obtain enantiomerically enriched 
bioactive molecules. The syntheses of a series of cis N-Boc allenylamino alcohols 206 and trans 
N-Bn,N-Boc allenylamino alcohols were demonstrated in Chapter 2. These allene products 
were then utilised to synthesise the corresponding allenylaziridine 182, the 5-
allenyloxazolidinones 229, and the 2,5-dihydrofurans 250. Since the N-protected α-amino 































































oxazolidinones and the 2,5-dihydrofurans were evaluated by two methods such as chiral 
auxiliary and chiral HPLC analysis. It was also shown that the 5-allenyloxazolidinones 229 can 
act as equivalents of the 2-allenylaziridine 182 in ring-opening reactions (Scheme 4.19). 
 The synthesis of a range of novel N-pendant 1,3-(E)-enynes 253 from the 5-
allenyloxazolidinones 229 was described in Chapter 4. Introducing of an extra triple bond to 
the enynes by incorporation of either propargyl and propiolic groups then provided a series of 
novel unconjugated (E)-enediynes (254, 380 and 385). We explored the potential of these 
versatile scaffolds to undergo cascade Au(I)-catalysed cycloaromatisation reactions to offer 
enantioenriched versions of a wide range of biologically relevant isoindolines 255 and 
isoindolinones 381 (Scheme 4.19). It was demonstrated that the cycloaromatisation of the 
enediynes 380 and 385 proceeded via a new dual-gold reaction mechanism including a rare 
intermediate complex 423 containing allenyl σ-gold and vinylidene gold moieties. The 
proposed mechanism was supported by deuterium experiments and DFT calculations.  
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Commercial reagents were purchased and used as received without any purification. Dry 
reaction solvents were passed through activated alumina columns to obtain dryness before 
being stored under nitrogen over 4Å molecular sieves. All reactions using air/moisture sensitive 
reagents were performed in oven-dried glassware, under an atmosphere of nitrogen equipped 
with a stir bar. Reactions were monitored by thin-layer chromatography (TLC) on aluminum 
backed silica gel sheets, visualizing with UV-light (254 nm) fluorescence quenching, followed 
by staining of the plates with potassium permanganate or p-anisaldehyde stains. Column 
chromatography used for compound purification was performed using pre-packed flash grade 
silica gel (40-75 nm) as the stationary phase. 1H NMR and 13C NMR spectra were recorded 
either at 300, 400 and 500 MHz 1H NMR for or at 75, 100 and 125 MHz for 13C NMR. All 1H 
NMR and 13C{1H} NMR were recorded in deuterated chloroform (CDCl3) containing 0.1% 
(v/v) tetramethylsilane (TMS). Abbreviations used in the description of resonances are: singlet 
(s), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), broad (br) and multiplet (m). 
All coupling constants (J) were measured in hertz (Hz). NMR chemical shift abbreviations were 
reported in parts per millions (ppm) from tetramethylsilane (TMS) and were corrected to 0.00 
ppm (TMS) for 1H NMR and 77.00 ppm (CDCl3 centre line) for 13C NMR. Optical rotations 
were measured on a JASCO P-2000 polarimeter, using a 10 mL cell with a 1.0 dm path length. 
High-performance liquid chromatography (HPLC) was performed with two different devices; 
including a Waters 1525 with a PDA detector or a Shimadzu Nexera X2 UHPLC with a PDA 
detector. Phenomenex Lux i-Cellulose-5 (250 x 30 mm) and Phenomenex Lux Cellulose-3 (250 
x 30 mm) were used as chiral HPLC columns. The α-amino amino methyl ester hydrochlorides 
were prepared from commercially available α-amino acids using a previously reported 






X-ray crystal data for 386c. C25H25NO2 (Mr = 371.46): recorded at 100 K with 
synchrotron radiation (0.9537 Å), crystal dimensions 0.05 mm x 0.02 mm x 0.02 mm, µ = 0.170 
mm-1, monoclinic, space group P21, a = 8.828(3), b = 5.279(3), c = 20.671(8) Å, 𝛽 = 
91.0640(19)°, V = 963.2(7) Å3, Z = 2, 𝜌calcd = 1.281, max/min residuals = 0.129 and -0.136 eÅ-
3, Flack parameter = -0.1(3), R = 0.029 for 2210 (I > 2𝜎(I)) data and wR = 0.076 for 2231 all 
data (2𝜃max = 64.37 °, Rint = 0.050). Data were collected at 100 K on a crystal mounted on a 
Hampton Scientific cryoloop at the MX2 beamline, Australian Synchrotron, Victoria. The 
structure was solved by direct methods with SHELXS-97, refined using full-matrix least-
squares routines against F2 with SHELXL-97, and visualised using OLEX2. All non-hydrogen 
atoms were anisotropically refined, while, all hydrogen atoms were positioned in calculated 
locations and refined using a riding model with fixed C–H distances of 0.95 Å (sp2CH), 0.99 Å 
(CH2), 0.98 Å (CH3). The thermal parameters of all hydrogen atoms were estimated as Uiso(H) 
= 1.2Ueq(C) except for CH3 where Uiso(H) = 1.5Ueq(C). CCDC 1867833 contains the 
supplementary crystallographic data for this paper. These data can be obtained free of charge 







In a microwave tube, glycolaldehyde dimer 179 (0.25 mmol, 0.03 g) was dissolved in methanol 
(0.50 mL) at room temperature. Then, the solution was mixed with the allenylboronic acid 
pinacol ester 71 (90.0 μL, 0.50 mmol, 2.0 equiv.) and benzylamine 180 (55.0 μL, 0.50 mmol, 
2.0 equiv.). The reaction mixture was then heated at 120 °C in a microwave reactor at 300 W 
for 20 min. The resulting brownish mixture was concentrated under reduced pressure and 
purified by flash column chromatography (EtOAc/hexane = 7:3) to obtain the pure allenic 
amino alcohol 181. White solid (0.051 g, 54%). Mp = 58-60 °C (lit. ref. = 60-61 °C).54 Rf 








(dd, 1H, J = 8.0, 10.5 Hz, CH-O), 3.64 (dd, 1H, J = 4.5, 10.5 Hz, CH-O), 3.73 (d, 1H, J = 13.0 
Hz, CHPh), 3.94 (d, 1H, J = 13.0 Hz, CHPh), 4.84-4.86 (m, 2H, CH2=C=), 5.12 (q, 1H, J = 6.5 
Hz, CH=C=), 7.21-7.48 (m, 5H, CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 51.1, 57.6, 64.9, 






A solution of allene 181 (0.050 g, 0.26 mmol), CBr4 (0.11 g, 0.33 mmol, 1.30 equiv.) and Et3N 
(54.0 μL, 0.39 mmol, 1.50 equiv.) in CH2Cl2 (2.0 mL) was cooled to -10 °C. PPh3 (0.088 g, 
0.33 mmol, 1.30 equiv.) was then added slowly over 10 min with vigorous stirring. The reaction 
mixture was then heated at reflux under a nitrogen atmosphere with reaction monitoring by thin 
liquid chromatography (TLC). After 5 min, the reaction was quenched by washing with 
aqueous saturated NaHCO3 solution (3×5 mL), followed by extraction with CH2Cl2 (10 mL). 
The mixture was then dried (Na2SO4), concentrated under reduced pressure, and purified by 
flash column chromatography (EtOAc/hexane/Et3N 2:8 with 3% Et3N for packing the column) 
to obtain the pure allenylaziridine 182. Light yellow oil (0.030 g, 67%). Rf (EtOAc/hexane = 
2:8) = 0.40. 1H NMR (500 MHz, CDCl3) δ 1.67 (d, 1H, J  = 6.5 Hz, NCH), 1.89 (d, 1H, J = 6.5 
Hz, NCH), 2.04-2.08 (m, 1H, NCH), 3.51 (d, 1H, J = 15.0 Hz, CHPh), 3.59 (d, 1H, J = 15.0 
Hz, CHPh), 4.86-4.89 (m, 2H, CH2=C), 5.05-5.08 (m, 1H, CH=C), 7.28-7.40 (m, 5H, 5CHAr), 
13C{1H} NMR (125 MHz, CDCl3) δ 34.5, 37.5, 64.3, 76.9, 91.3, 127.0, 127.8, 128.3, 138.9, 
198.7. IR (νmax/cm-1) 2925 (w), 2854 (w), 1953 (m), 1757 (s), 1647 (s), 1495 (m, 1452 (m), 
1355 (m), 1074 (s), 848 (s), 731 (m), 695 (s). HRMS (ESI-TOF) m/z calcd for C12H14N [M+H]+ 











n-BuLi in Et2O (0.44 mL, 1.60 mol/L, 0.70 mmol, 4.00 equiv.) was added to a stirred slurry of 
CuCN (0.030 g, 0.348 mmol, 4.00 equiv.) in THF (1 mL) at −78 °C under a nitrogen 
atmosphere. The mixture was then allowed to warm to 0 °C and stirred for 15 min. The mixture 
was cooled to −78 °C and a solution of allenylaziridine 182 (0.030 g, 0.175 mmol) in dry THF 
(1 mL) and then BF3∙Et2O (33.0 μL, 0.26 mmol, 1.50 equiv.) were added and stirred at −78 °C 
for 1 h. The mixture was then warmed to room temperature and stirred for 18 h. It was then 
quenched with aqueous saturated NH4Cl (5 mL) and NH4OH (5 mL) solutions and extracted 
by EtOAc (3×5 mL). The filtrate was dried (Na2SO4), concentrated under reduced pressure, and 
purified by flash column chromatography (EtOAc/hexane = 2:8) to obtain the pure diene 201. 
Light yellow oil (0.032 g, 81%). Rf (EtOAc/hexane = 2:8) = 0.78. 1H NMR (500 MHz, CDCl3) 
δ 0.86-0.92 (m, 3H, CH3), 1.25-1.37 (m, 3H, CH2 and NH), 1.42-1.49 (m, 2H, CH2), 2.19 (t, 
2H, J = 8.0 Hz, CH2), 3.33 (d, 2H, J = 6.0 Hz, CH2-N), 3.79 (s, 2H, CH2Ph), 4.92 (d, 2H, J = 
11.0 Hz, CH2=C), 5.78-5.81 (m, 1H, CH=CH), 6.19 (d, 1H, J = 15.5 Hz, CH=CH), 7.24-7.32 
(m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 14.0, 22.7, 30.5, 31.9, 51.2, 53.4, 114.6, 
127.0, 127.4, 128.2, 128.4, 133.9, 140.2, 146.0. HRMS (ESI-TOF) m/z calcd for C16H24N 













Synthesis of N-Boc α-Amino Aldehydes (205a-g) 
    
 
L-α-Amino acids were first transformed to their α-amino methyl esters by esterification using 
SOCl2 (2.00 equiv.) and MeOH (0.50 M) at room temperature for 4 h. The corresponding α-
amino methyl ester hydrochlorides 203a-g were obtained after evaporation of the solvent.  
To a solution of α-amino methyl ester hydrochlorides 203a-g in CH2Cl2 (60 mL) at 0 
°C, was added Et3N (1.10 equiv.), followed by di-tert-butylpyrocarbonate (Boc2O) (1.20 
equiv.). Stirring was continued for 1 h at 0 °C, and then overnight at room temperature. The 
reaction mixture was then washed with saturated sodium bicarbonate (30 mL) and brine (30 
mL) solutions, dried (Na2SO4). The solution was filtered and concentrated in vacuum to yield 
the corresponding N-Boc α-amino esters 204a-g.  
To a solution of N-Boc α-amino ester 204 in Et2O at −78 °C, was added dropwise 
diisobutylaluminum hydride (DIBAL-H) (1.00 M solution in hexane, 2.00 equiv.) over a period 
of 45 min. The mixture was stirred at the same temperature for 1.5 h, and then quenched by the 
addition of precooled MeOH (1 mL). The reaction mixture was allowed to warm to room 
temperature, ice (5 g) was added with heavy agitation. The mixture was filtered through a 
sintered funnel and the filtrate was extracted with CH2Cl2. The organic layer was washed with 
brine (10 mL), dried (Na2SO4), and concentrated under reduced pressure to yield the title 
aldehyde 205, which was used for the next step without purification. 
 
tert-Butyl (S)-(1-oxopropan-2-yl)carbamate (205a) 
 
Methyl 2-aminopropanoate hydrochloride 203a was prepared following the general procedure 


























(55 mL). White solid (4.51 g, 96%). 1H NMR (500 MHz, CDCl3) δ 1.72 (d, 3H, J = 5.0 Hz, 
CH3), 3.81 (s, 3H, CH3), 4.30 (br s, 1H, CH), 8.64 (br s, 3H, NH3). 13C{1H} NMR (125 MHz, 
CDCl3) δ 16.0, 49.3, 53.3, 170.6. The NMR data matched with those previously reported.168 
Methyl 2-(tert-butoxycarbonylamino) propanoate 204a was obtained following the 
general procedure using methyl 2-aminopropanoate hydrochloride 203a (4.00 g, 28.65 mmol), 
Boc2O (4.50 g, 34.38 mmol, 1.20 equiv.) and Et3N 4.51 mL, 31.51 mmol, 1.1 equiv.) in CH2Cl2 
(60 mL). Colorless oil (5.70 g, 98%). 1H NMR (300 MHz, CDCl3) δ 1.31 (d, 3H, J = 6.9 Hz, 
CH3), 1.46 (s, 9H, C(CH3)3), 3.68 (s, 3H, CH3), 4.21-4.23 (m, 1H, CH), 5.11 (br s, 1H, NH). 
13C{1H} NMR (75 MHz, CDCl3) δ 18.5, 27.3, 49.0, 52.2, 79.7, 155.0, 173.8. The NMR data 
matched with those previously reported.168 
The title aldehyde 205a was obtained following the general procedure using methyl 2-
(tert-butoxycarbonylamino) propanoate 204a (0.35 g, 1.71 mmol) and DIBAL-H (1.00 M 
solution in hexane, 3.42 mL, 3.42 mmol, 2.00 equiv.) in Et2O (5 mL). White solid (0.26 g, 
98%). 1H NMR (500 MHz, CDCl3) δ 1.34 (d, 3H, J = 7.5 Hz, CH3), 1.45 (s, 9H, C(CH3)3), 
4.22-4.25 (m, 1H, CH), 5.11 (br s, 1H, NH), 9.56 (s, 1H, CHO). 13C{1H} NMR (125 MHz, 
CDCl3) δ 14.8, 28.3, 55.5, 80.1, 155.3, 199.7. The NMR data matched with those previously 
reported.168 
 
tert-Butyl (S)-(1-oxopentan-2-yl)carbamate (205b)   
 
 
Methyl 2-aminopentanoate hydrochloride 203b was obtained following the general procedure 
using L-norvaline (1.00 g, 8.54 mmol) and SOCl2 (1.24 mL, 17.08 mmol, 2.00 equiv.) in MeOH 
(15 mL). White solid (1.38 g, 97%). 1H NMR (500 MHz, CDCl3) δ 0.97 (t, 3H, J = 7.0 Hz, 
CH3), 1.47-1.54 (m, 1H, CH), 1.57-1.65 (m, 1H, CH), 2.03 (m, 2H, CH2), 3.82 (s, 3H, CH3), 
4.10 (br s, 1H, CH), 8.82 (br s, 3H, NH3). 13C{1H} NMR (125 MHz, CDCl3) δ 13.5, 18.5, 32.4, 







Methyl 2-((tert-butoxycarbonyl)amino)pentanoate 204b was obtained following the 
general procedure using methyl 2-aminopentanoate hydrochloride 203b (1.00 g, 5.96 mmol), 
di-tert-butylpyrocarbonate (1.56 g, 7.16 mmol, 1.20 equiv.) and Et3N (0.94 mL, 6.55 mmol, 
1.10 equiv.) in CH2Cl2 (15 mL). Colorless oil (1.29 g, 93%). Rf (Et2O/hexane = 2:8) = 0.42. 
[𝛼]+,,= +84.6 (c 2.0 CHCl3). 1H NMR (500 MHz, CDCl3) δ 0.94 (t, 3H, J = 7.0 Hz, CH3), 1.38 
(br s, 2H, CH2), 1.45 (s, 9H, C(CH3)3), 1.58-1.64 (m, 1H, CH), 1.77 (br s, 1H, CH), 3.74 (s, 3H, 
CH3), 4.30 (br s, 1H, CH), 5.19 (br s, 1H, NH). 13C{1H} NMR (125 MHz, CDCl3) δ 13.5, 18.5, 
28.1, 34.6, 52.0, 53.1, 79.5, 155.3, 173.4. IR (νmax/cm-1) 3370 (w), 2963 (m), 2934 (m), 1743 
(s), 1713 (s), 1507 (s), 1365 (s), 1249 (s), 1159 (s), 1011 (m), 779 (m). HRMS (ESI) m/z calcd 
for C11H21NO4Na [M + Na]+ 254.1368, found 254.1361. 
The title compound 205b was obtained following the general procedure using methyl 
2-((tert-butoxycarbonyl)amino)pentanoate 204b (0.19 g, 0.82 mmol) and DIBAL-H (dissolved 
in 0.30 mL n-hexane, 0.27 mL, 1.64 mmol, 2.00 equiv.) in Et2O (2 mL). Colorless oil (0.149 g, 
91%). [𝛼]+,,= +80.3 (c 1.0 CHCl3). 1H NMR (500 MHz, CDCl3) δ 0.95 (t, 3H, J = 7.0 Hz, 
CH3), 1.40-1.41 (m, 2H, CH2), 1.45 (s, 9H, C(CH3)3), 1.52-1.58 (m, 1H, CH), 1.83 (br s, 1H, 
CH), 4.20-4.22 (m, 1H, CH), 5.30 (br s, 1H, NH), 9.58 (s, 1H, CHO). 13C{1H} NMR (125 MHz, 
CDCl3) δ 13.7, 18.4, 28.21, 31.1, 59.6, 79.8, 155.6, 200.2. IR (νmax/cm-1) 3370 (s), 2963 (m), 
2934 (m), 1743 (s), 1713 (s), 1507 (s), 1365 (s), 1249 (s), 1159 (s), 1054 (m), 779 (m). HRMS 
(ESI) m/z calcd for C10H19NO3Na [M + Na]+ 224.1263, found 224.1277. 
 
tert-Butyl (S)-(4-methyl-1-oxopentan-2-yl)carbamate (205c) 
 
2-Amino-4-methylpentanoate hydrochloride 203c was obtained following the general 
procedure using L-leucine (1.00 g, 7.62 mmol) and SOCl2 (1.1 mL, 15.25 mmol, 2.00 equiv.) 
in MeOH (15 mL). White solid (1.30 g, 94%). 1H NMR (500 MHz, CDCl3): δ = 0.98 (d, 6H, J 







CH), 8.80 (br s, 3H, NH3). 13C{1H} NMR (125 MHz, CDCl3) δ 21.9, 22.3, 24.4, 39.5, 51.8, 
53.1, 170.0. The NMR data matched with those previously reported.170 
Methyl (tert-butoxycarbonyl) leucinate 204c was obtained following the general 
procedure using methyl 2-amino-4-methylpentanoate hydrochloride 203c (1.00 g, 5.50 mmol), 
Boc2O (1.44 g, 6.60 mmol, 1.20 equiv.) and Et3N (0.86 mL, 6.05 mmol, 1.10 equiv.) in CH2Cl2 
(15 mL). Colorless oil (1.28 g, 95%). 1H NMR (500 MHz, CDCl3) δ 0.94 (br d, 6H, J = 6.0 Hz, 
2CH3), 1.44 (s, 9H, C(CH3)3), 1.47-1.53 (m, 1H, CH), 1.60 (br d, 1H, J = 5.5 Hz, CH), 1.69-
1.71 (m, 1H, CH), 3.73 (s, 3H, CH3), 4.32 (br s, 1H, CH), 5.06 (br s, 1H, NH). 13C{1H} NMR 
(125 MHz, CDCl3) δ 21.7, 22.7, 24.7, 28.2, 41.6, 51.9, 52.0, 79.6, 155.4, 173.9. The NMR data 
matched with those previously reported.171 
The title compound 205c was obtained following the general procedure using using 
methyl (tert-butoxycarbonyl) leucinate 204c (0.30 g, 1.22 mmol) and DIBAL-H (dissolved in 
0.40 mL n-hexane, 0.41 mL, 2.44 mmol, 2.00 equiv.) in Et2O (3 mL). Colorless oil (0.21 g, 
95%). 1H NMR (500 MHz, CDCl3) δ 0.96 (d, 6H, J = 6.5 Hz, 2CH3), 1.40 (br s, 1H, CH), 1.45 
(s, 9H, C(CH3)3), 1.65 (br s, 1H, CH), 1.76-1.79 (m, 1H, CH), 4.23 (br s, 1H, CH), 5.18 (br s, 
1H, NH), 9.58 (s, 1H, CHO). 13C{1H} NMR (125 MHz, CDCl3) δ 21.8, 23.0, 24.5, 28.2, 37.9, 
58.3, 79.8, 155.6, 200.5. The NMR data matched with those previously reported.172 
 
tert-Butyl (S)-(1-oxo-3-phenylpropan-2-yl)carbamate (205d) 
 
Methyl 2-amino-3-phenylpropanoate hydrochloride 203d was obtained following the general 
procedure using L-phenylalanine (1.00 g, 6.05 mmol) and SOCl2 (0.87 mL, 12.1 mmol, 2.00 
equiv.) in MeOH (15 mL). White solid (1.24 g, 95%). 1H NMR (500 MHz, CDCl3) δ 3.38-3.47 
(m, 2H, CH2), 3.69 (s, 3H, CH3), 4.37-4.41 (m, 1H, CH), 7.26-7.30 (m, 5H, 5CHAr), 8.72 (br s, 
3H, NH3). 13C{1H} NMR (125 MHz, CDCl3) δ 36.5, 53.2, 54.7, 127.9, 129.1, 129.8, 134.1, 







Methyl (tert-butoxycarbonyl) phenylalaninate 204d was obtained following the 
general procedure using methyl 2-amino-3-phenylpropanoate hydrochloride 203d (1.75 g, 8.11 
mmol), Boc2O (2.03 g, 9.32 mmol, 1.20 equiv.) and Et3N (1.28 mL, 8.92 mmol, 1.10 equiv.) in 
CH2Cl2 (20 mL). Colorless oil (2.15 g, 95%). 1H NMR (500 MHz, CDCl3) δ 1.39 (s, 9H, 
C(CH3)3), 2.99-3.11 (m, 2H, CH2Ph), 3.66 (s, 3H, CH3), 4.56 (br d, 1H, J = 6.5 Hz, CH), 5.08 
(br d, 1H, J = 6.5 Hz, NH), 7.10 (d, 2H, J = 6.5 Hz, 2CHAr), 7.18-7.21 (m, 1H, CHAr), 7.24-
7.27 (m, 2H, 2CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 28.4, 38.5, 52.2, 54.7, 79.9, 127.1, 
128.7, 129.4, 136.3, 155.3, 172.5. The NMR data matched with those previously reported.174 
The title compound 205d was obtained following the general procedure using methyl 
(tert-butoxycarbonyl) phenylalaninate 204d (0.20 g, 0.716 mmol) and DIBAL-H (dissolved in 
0.30 mL n-hexane, 0.26 mL, 1.50 mmol, 2.10 equiv.) in Et2O (2 mL). White solid (0.174 g, 
98%). 1H NMR (500 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3), 3.10 (m, 2H, CH2Ph), 4.40 (br d, 
1H, J = 6.0 Hz, CH), 5.12 (br s, 1H, NH), 7.16 (d, 2H, J = 7.5 Hz, 2CHAr), 7.22-7.25 (m, 1H, 
CHAr), 7.28-7.31 (m, 2H, 2CHAr), 9.61 (s, 1H, CHO). 13C{1H} NMR (125 MHz, CDCl3) δ 28.2, 
35.4, 60.8, 80.1, 127.0, 128.7, 129.3, 135.8, 155.4, 199.5. The NMR data matched with those 
previously reported.175 
 
tert-Butyl (S)-(3-methyl-1-oxobutan-2-yl)carbamate (205e) 
 
2-Amino-3-methylbutanoate hydrochloride 203e was obtained following the general procedure 
using L-valine (1.00 g, 8.54 mmol) and SOCl2 (1.24 mL, 17.08 mmol, 2.00 equiv.) in MeOH 
(15 mL). White solid (1.37 g, 97%). 1H NMR (500 MHz, CDCl3) δ 1.15 (d, 6H, J = 5.0 Hz, 
2CH3), 2.47 (br s, 1H, CH), 3.84 (s, 3H, CH3), 3.94 (br s, 1H, CH), 8.83 (br s, 3H, NH3). 13C{1H} 
NMR (125 MHz, CDCl3) δ 18.3, 18.4, 29.9, 58.2, 58.7, 168.7. The NMR data matched with 







Methyl (tert-butoxycarbonyl) valinate 204e was obtained following the general 
procedure using methyl 2-amino-3-methylbutanoate hydrochloride 203e (2.0 g, 11.93 mmol), 
Boc2O (3.08 g, 14.31 mmol, 1.20 equiv.) and Et3N (1.88 mL, 13.12 mmol, 1.10 equiv.) in 
CH2Cl2 (20 mL). Colorless oil (2.62 g, 95%). 1H NMR (500 MHz, CDCl3) δ 0.89 (d, 3H, J = 
6.5 Hz, CH3), 0.95 (d, 3H, J = 7.0 Hz, CH3), 1.44 (s, 9H, C(CH3)3), 2.11-2.13 (m, 1H, CH), 
3.73 (s, 3H, CH3), 4.20-4.23 (m, 1H, CH), 5.21 (br d, 1H, J = 8.0 Hz, NH). 13C{1H} NMR (125 
MHz, CDCl3) δ 17.5, 18.8, 28.1, 31.1, 51.7, 58.4, 79.4, 155.5, 172.7. The NMR data matched 
with those previously reported.171 
The title compound 205e was obtained following the general procedure using methyl 
(tert-butoxycarbonyl) valinate 204e (0.23 g, 0.994 mmol) and DIBAL-H (dissolved in 0.40 mL 
n-hexane, 0.34 mL, 1.99 mmol, 2.00 equiv.) in Et2O (2 mL). Colorless oil (0.174 g, 95%). 1H 
NMR (500 MHz, CDCl3) δ 0.94 (d, 3H, J = 7.0 Hz, CH3), 1.03 (d, 3H, J = 7.0 Hz, CH3), 1.45 
(s, 9H, C(CH3)3), 2.27-2.29 (m, 1H, CH), 4.22-4.25 (m, 1H, CH), 5.21 (br s, 1H, NH), 9.65 (s, 
1H, CHO). 13C{1H} NMR (125 MHz, CDCl3) δ 17.5, 19.0, 28.2, 28.9, 64.1, 79.8, 155.8, 200.4. 
The NMR data matched with those previously reported.171 
 
tert-Butyl (S)-(2-oxo-1-phenylethyl)carbamate (205f) 
 
Methyl aminophenylacetate hydrochloride 203f was obtained following the general procedure 
using L-phenylglycine (4.00 g, 26.46 mmol) and SOCl2 (3.84 mL, 52.92 mmol, 2.00 equiv.) in 
MeOH (60 mL). White solid (4.97 g, 93%). 1H NMR (500 MHz, DMSO-d6) δ 3.71 (s, 3H, 
CH3), 5.30 (s, 1H, CH), 7.45-7.48 (m, 5H, 5CHAr), 8.89 (br s, 3H, NH3). 13C{1H} NMR (125 
MHz, DMSO-d6) δ 53.7, 55.7, 128.6, 129.5, 130.0, 133.0, 169.4. The NMR data matched with 
those previously reported.177 
Methyl 2-((tert-butoxycarbonyl)amino)-2-phenylacetate 204f was obtained following 
the general procedure using methyl aminophenylacetate hydrochloride 203f (1.14 g, 5.65 








CH2Cl2 (20 mL). White solid (1.41 g, 94%). 1H NMR (500 MHz, CDCl3) δ 1.42 (s, 9H, 
C(CH3)3), 3.69 (s, 3H, CH3), 5.32 (d, 1H, J = 7.5 Hz, CH), 5.62 (br d, 1H, J = 5.5 Hz, NH), 
7.30-7.36 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 28.3, 52.6, 57.6, 80.1, 127.1, 
128.4, 128.9, 136.9, 154.8, 171.6. The NMR data matched with those previously reported.178  
The title compound 205f was obtained following the general procedure using methyl 
2-((tert-butoxycarbonyl)amino)-2-phenylacetate 204f (0.20 g, 0.75 mmol) and DIBAL-H 
(dissolved in 0.40 mL n-hexane, 0.27 mL, 1.50 mmol, 2.00 equiv.) in Et2O (2 mL). Colorless 
oil (0.174 g, 95%). 1H NMR (500 MHz, CDCl3) δ 1.40 (s, 9H, C(CH3)3), 5.29 (br s, 1H, CH), 
5.83 (br s, 1H, NH), 7.26-7.37 (m, 5H, 5CHAr), 9.49 (s, 1H, CHO). 13C{1H} NMR (125 MHz, 
CDCl3) δ 28.4, 64.8, 80.3, 128.7, 128.9, 129.0, 129.3, 129.6, 134.0, 155.2, 195.3. The NMR 





Methyl tryptophanate hydrochloride 203g was obtained following the general procedure using 
L-tryptophan (3.00 g, 14.69 mmol) and SOCl2 (2.13 mL, 29.38 mmol, 2.00 equiv.) in MeOH 
(30 mL). Off-white solid (3.71 g, 99%). 1H NMR (500 MHz, DMSO-d6) δ 3.30-3.32 (m, 2H, 
CH2), 3.71 (s, 3H, CH3), 4.28-4.30 (m, 1H, CH), 7.05 (t, 1H, J = 7.0 Hz, CHAr), 7.14 (t, 1H, J 
= 8.0 Hz, CHAr), 7.27 (br s, 1H, CHAr), 7.41 (d, 1H, J = 8.0 Hz, CHAr), 7.53 (d, 1H, J = 8.0 Hz, 
CHAr), 8.42 (br s, 3H, NH3), 11.10 (s, 1H, NH). 13C{1H} NMR (125 MHz, DMSO-d6) δ 26.8, 
40.8, 53.3, 107.0, 112.2, 118.6, 119.3, 121.8, 125.6, 127.5, 136.9, 170.4. The NMR data 
matched with those previously reported.179 
Et3N (0.56 mL, 3.92 mmol, 1.00 equiv.) was added dropwise to a stirred solution of 









Boc2O (1.71 g, 7.85 mmol, 2.00 equiv.) and DMAP (0.72 g, 5.88 mmol, 1.50 equiv.) were 
added and the mixture was stirred overnight at room temperature. The reaction mixture was 
concentrated under reduced pressure, and the tert-butyl 3-(2-((tert-butoxycarbonyl)amino)-3-
methoxy-3-oxopropyl)-1H-indole-1-carboxylate 204g was obtained after flash column 
chromatography (EtOAc/hexane = 3:7). Colorless oil (1.59 g, 97%). 1H NMR (500 MHz, 
CDCl3) δ 1.43 (s, 9H, C(CH3)3), 1.66 (s, 9H, C(CH3)3), 3.15-3.28 (m, 2H, CH2), 3.68 (s, 3H, 
CH3), 4.64-4.65 (m, 1H, CH), 5.16 (br d, 1H, J = 7.0 Hz, NH), 7.21-7.23 (m, 1H, CHAr), 7.28-
7.31 (m, 1H, CHAr), 7.39 (s, 1H, CHAr), 7.49 (d, 1H, J = 8.0 Hz, CHAr), 8.11 (br s, 1H, CHAr). 
13C{1H} NMR (125 MHz, CDCl3) δ 27.8, 28.2, 28.3, 52.3, 53.7, 79.9, 83.6, 115.1, 115.2, 118.9, 
122.5, 124.0, 124.5, 130.5, 135.3, 149.5, 155.1, 172.3. The NMR data matched with those 
previously reported.180 
The title compound 205g was obtained following the general procedure using tert-butyl 
3-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate 204g 
(0.11 g, 0.26 mmol) and DIBAL-H (dissolved in 0.10 mL n-hexane, 0.10 mL, 0.59 mmol, 2.20 
equiv.) in Et2O (1 mL). Colorless gummy oil (0.064 g, 99%). [𝛼]+,,	= +53.5 (c 3.2 CHCl3). 1H 
NMR (500 MHz, CDCl3) δ 1.44 (s, 9H, C(CH3)3), 1.66 (s, 9H, C(CH3)3), 3.22 (br s, 2H, 
CH2Ph), 4.48 (br s, 1H, CH), 5.22 (br s, 1H, NH), 7.25 (br s, 1H, CHAr), 7.32 (br s, 1H, CHAr), 
7.43 (br s, 1H, CHAr), 7.54 (br s, 1H, CHAr), 8.13 (br s, 1H, CHAr), 9.65 (s, 1H, CHO). 13C{1H} 
NMR (125 MHz, CDCl3) δ 25.0, 28.2, 28.3, 59.6, 80.2, 83.8, 114.8, 115.3, 119.0, 122.7, 124.2, 
124.7, 130.2, 135.5, 149.5, 155.4, 199.5. IR (νmax/cm-1) 3371 (w), 2979 (m), 2361 (w), 1730 
(s), 1700 (s), 1507 (s), 1452 (s), 1367 (s), 1253 (s), 1154 (s), 1086 (s), 856 (m), 766 (s), 744 (s). 










Synthesis of N-Ts α-Amino Aldehyde (208) 
 
To an ice-cooled mixture of methyl 2-aminopropanoate hydrochloride 203a (1.00 g, 7.16 
mmol) and TsCl (1.36 g, 7.16 mmol, 1.00 equiv.) in CH2Cl2 (15 mL), was added dropwise Et3N 
(2.00 mL, 14.32 mmol, 2.00 equiv.) and the suspension was stirred for 1 h at 0 °C and 3 h at 
room temperature. The reaction was filtered, washed with water (30 mL), dried (Na2SO4), and 
concentrated under reduced pressure to obtain methyl 2-[(4-methylphenyl)sulfonylamino] 
propanoate 226. Light yellow oil (1.66 g, 90%). 1H NMR (300 MHz, CDCl3) δ 1.36 (d, 3H, J 
= 3.6 Hz, CH3), 2.41 (s, 3H, CH3), 3.51 (s, 3H, CH3), 3.97 (m, 1H, CH), 5.29 (br s, 1H, NH), 
7.29 (d, 2H, J = 8.1 Hz, 2CHAr), 7.72 (d, 2H, J = 8.1 Hz, 2CHAr). 13C{1H} NMR (75 MHz, 
CDCl3) δ 19.8, 21.5, 51.4, 52.5, 127.2, 129.6, 136.7, 143.6, 172.6. The NMR data matched with 
those previously reported.181  
 DIBAL-H (1.00 M solution in cyclohexane, 3.1 mL, 3.10 mmol, 2.00 equiv.) was 
added dropwise to a solution of methyl 2-[(4-methylphenyl)sulfonylamino] propanoate 226 
(0.40 g, 1.55 mmol) at −78 °C in Et2O (5 mL) over a period of 15 min. The mixture was stirred 
at the same temperature for 3 h and quenched by MeOH (5 mL). The reaction mixture was then 
allowed to warm to room temperature and filtered through silica pad. The organic layer was 
washed with brine (10 mL), dried (Na2SO4), and concentrated under reduced pressure to yield 
the title aldehyde 208, which was used for the next step without purification. Colourless oil 
(0.26 g, 98%). 1H NMR (300 MHz, CDCl3) δ 1.07 (d, 3H, J = 6.9 Hz, CH3), 2.45 (s, 3H, CH3), 
4.28 (q, 1H, J = 7.2, 6.9 Hz, CH), 7.32 (d, 2H, J = 7.8 Hz, 2CHAr), 7.68 (d, 2H, J = 8.1 Hz, 




















Synthesis of N-Fmoc α-Amino Aldehyde (211) 
 
 
To a mixture of methyl 2-aminopropanoate hydrochloride 203a (0.20 g, 1.43 mmol) and Fmoc-
Cl (0.40 g, 1.57 mmol, 1.1 equiv.) in CH3CN (5 mL), was added K2CO3 (0.40 g, 2.86 mmol, 
2.00 equiv.) and the mixture was stirred at room temperature for 5 h. The reaction mixture was 
then washed with saturated aqueous NH4Cl solution (10 mL) and water (15 mL), dried 
(Na2SO4), and concentrated under reduced pressure. Methyl-(((9H-fluoren-9-
yl)methoxy)carbonylamino)propanoate 227 was obtained by flash column chromatography 
(EtOAc/hexane = 2:8). White gummy oil (0.25 g, 54%). 1H NMR (500 MHz, CDCl3) δ 1.41 
(d, 3H, J = 7.0 Hz, CH3), 3.71 (s, 3H, CH3), 4.19 (t, 1H, J = 7.0 Hz, CH), 4.35-4.40 (br m, 3H, 
CH and CH2), 5.50 (d, 1H, J = 7.5 Hz, NH), 7.28 (t, 2H, J = 7.0 Hz, 2CHAr), 7.36 (m, 2H, 
2CHAr), 7.58 (t, 2H, J = 7.0 Hz, 2CHAr), 7.72 (d, 2H, J = 7.0 Hz, 2CHAr). 13C{1H} NMR (125 
MHz, CDCl3) δ 18.6, 47.1, 49.6, 52.53, 67.0, 120.0, 125.15, 125.18, 127.12, 127.7, 141.3, 
143.8, 143.9, 155.7, 173.6. The NMR data matched with those previously reported.182 
DIBAL-H (1.00 M solution in cyclohexane, 3.10 mL, 3.10 mmol, 2.00 equiv.) was 
added dropwise to a solution of methyl-(((9H-fluoren-9-
yl)methoxy)carbonylamino)propanoate 227 (0.23 g, 0.70 mmol) at −78 °C in Et2O (5 mL) over 
a period of 30 min. The mixture was stirred at the same temperature for 4 h and was quenched 
by MeOH (5 mL). the reaction mixture was then allowed to warm to room temperature and 
filtered through silica pad. The organic layer was washed with brine (10 mL), dried (Na2SO4), 
and concentrated under reduced pressure to yield the title aldehyde 211, which was used for the 
next step without purification. White gummy oil (0.14 g, 68%). 1H NMR (500 MHz, CDCl3) δ 
1.41 (d, 3H, J = 7.0 Hz, CH3), 4.27 (m, 1H, CH), 4.34-4.44 (m, 3H, CH2, CH), 7.29 (t, 2H, J = 
7.5 Hz, 7.0 Hz, 2CHAr), 7.38 (t, 2H, J = 7.5 Hz, 7.0 Hz, 2CHAr), 7.58 (m, 2H, 2CHAr), 7.74 (d, 


















67.0, 67.9, 120.0, 125.1, 127.5, 127.8, 143.7, 155.9, 199.2. The NMR data matched with those 
previously reported.183 
 
Synthesis of N-Tr α-Amino Aldehyde (214) 
 
 
To a solution of methyl 2-aminopropanoate hydrochloride 203a (4.85 g, 34.74 mmol) in CH2Cl2 
(60 mL) at 0 °C, was added dropwise Et3N (20.24 mL, 69.50 mmol, 2.00 equiv.). TrCl (9.68 g, 
34.74 mmol, 1.00 equiv.) was then added and the stirring was continued for 1 h at 0 °C, and 
then at room temperature overnight. The reaction mixture was next washed with saturated 
aqueous NaHCO3 (50 mL) solution and brine (50 mL), dried (Na2SO4), and purified with flash 
column chromatography (Et2O/hexane = 1:9) to yield methyl tritylalaninate 228. Colourless oil 
(8.59 g, 71%). Rf (Et2O/hexane = 1:9) = 0.40. [𝛼]+,,	= +25.9 (c 2 CHCl3). 1H NMR (500 MHz, 
CDCl3) δ 1.33 (d, 3H, J = 7.0 Hz, CH3), 2.69 (d, 1H, J = 10.5 Hz, NH), 3.12 (s, 3H, OCH3), 
3.35-3.38 (m, 1H, CH), 7.12 (t, 2H, J = 7.5 Hz, 2CHAr), 7.21 (t, 6H, J = 7.5 Hz, 6CHAr), 7.49 
(d, 7H, J = 7.0 Hz, 7CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 21.8, 51.6, 52.1, 71.3, 126.5, 
127.9, 128.9, 146.1, 176.4. IR (νmax/cm-1) 3316 (w), 3056 (w), 2977 (w), 1734 (s), 1447 (s), 
1205 (s), 1139 (s), 1062 (s), 734 (s), 704 (s). HRMS (ESI) m/z calcd for C23H23NO2Na [M + 
Na]+ 368.1626, found 368.1638. 
DIBAL-H (0.32 mL in 0.30 mL hexane, 1.62 mmol, 2.00 equiv.) was added dropwise 
to a solution of methyl tritylalaninate 228 (0.28 g, 0.81 mmol) at −78 °C in Et2O (1 mL) over a 
period of 20 min. The mixture was stirred at the same temperature for 1.5 h, and was quenched 
by methanol (5 mL). The reaction mixture was then allowed to warm to room temperature and 
filtered. The organic layer was washed with water (10 mL), dried (Na2SO4), and concentrated 
under reduced pressure to yield the title aldehyde 214, which was used for the next step without 
purification. Colorless oil (0.24 g, 98%). [𝛼]+,,	= +30.3 (c 2.5 CHCl3). 1H NMR (500 MHz, 

















(m, 10H, 10CHAr), 7.49-7.56 (m, 5H, 5CHAr), 8.98 (s, 1H, CHO). 13C{1H} NMR (125 MHz, 
CDCl3) δ 19.8, 60.2, 73.7, 129.2, 130.5, 131.1, 148.5, 205.4. IR (νmax/cm-1) 3205 (w), 2976 (w), 
1723 (w), 1472 (s), 1447 (s), 1372 (s), 1328 (s), 1144 (s), 850 (m), 745 (m), 705 (s). HRMS 
(ESI) m/z calcd for C22H21NONa [M + Na]+ 338.1521, found 338.1512. 
 
Synthesis of N-Bn,N-Boc α-Amino Esters (248a-f) 
 
 
All the N-diprotected amino esters 248a-f were synthesised via two steps, N-benzylation 
followed by N-Boc protection.  
To a stirred mixture of the α-amino methyl ester hydrochloride 203 and BnBr (1.00 
equiv.) in CH3CN, was added K2CO3 (2.00 equiv.) and the mixture was stirred overnight at 
room temperature. The reaction mixture was washed with aqueous saturated NH4Cl solution 
(30 mL) and water (30 mL), dried (Na2SO4), concentrated under reduced pressure and purified 
by flash column chromatography to obtain the N-benzylated products 247. 
Et3N (2.00 equiv.) was added dropwise to a stirred solution of the N-benzylated amino 
methyl esters 247 and Boc2O (1.24 equiv.) in CH2Cl2, and the reaction mixture was stirred for 
24 h at room temperature. The reaction was washed with aqueous solution of HCl (1 M) (15 
mL), dried (Na2SO4), and concentrated under reduced pressure. Purification was carried out by 
flash column chromatography to yield the N-Bn,N-Boc α-amino esters 248. 
 
Methyl N-benzyl-N-(tert-butoxycarbonyl)-L-alaninate (248a) 
 
 
Methyl N-benzyl amino propanoate 247a was obtained following the general procedure using 


















mmol, 1.00 equiv.) and K2CO3 (5.5 g, 40.12 mmol, 2.00 equiv.) in CH3CN (30 mL). Light 
yellow oil (2.75 g, 71%). 1H NMR (500 MHz, CDCl3) δ 1.24 (d, 3H, J = 7.0 Hz, CH3), 1.89 
(br s, 1H, NH), 3.31 (q, 1H, J = 7.0 Hz, 7.0 Hz, CH), 3.59 (d, 1H, J = 13.0 Hz, CH), 3.61 (s, 
3H, CH3), 3.72 (d, 1H, J = 13.0 Hz, CH), 7.16-7.28 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, 
CDCl3) δ 19.0, 51.5, 51.8, 55.7, 126.9, 128.1, 128.3, 139.8, 175.9. The NMR data matched with 
those previously reported.184 
Methyl N-benzyl-N-(tert-butoxycarbonyl)-L-alaninate 248a was obtained following 
the general procedure using methyl N-benzyl amino propanoate 247a (2.35 g, 12.16 mmol), 
Boc2O (3.29 g, 15.07 mmol, 1.24 equiv.) and Et3N (7.10 mL, 24.32 mmol, 2.00 equiv.) in 
CH2Cl2 (30 mL). Colourless oil (2.51 g, 70%). 1H NMR (300 MHz, CDCl3) (mixture of 
rotamers) δ 1.33 (s, 3H, CH3), 1.39 (br s, 4H, C(CH3)3), 1.46 (br s, 5H, C(CH3)3), 3.64 (s, 3H, 
CH3), 3.93 (br s, 0.5H, CHPh), 4.33 (d, 0.5H, J = 15.9 Hz, CHPh), 4.54 (br s, 2H, CHPh, CH), 
7.23-7.29 (m, 5H, 5CHAr). 13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers) δ 15.4, 15.8, 
27.3, 28.2, 49.5, 50.8, 51.9, 54.5, 55.3, 80.5, 85.0, 126.8, 127.2, 127.9, 128.3, 138.1, 139.1, 
146.7, 155.2, 155.5, 172.5, 172.7. The NMR data matched with those previously reported.185   
 
Methyl (S)-2-(benzyl(tert-butoxycarbonyl)amino)pentanoate (248b)  
 
Methyl 2-(benzylamino)pentanoate 247b was obtained following the general procedure using 
2-aminopentanoate hydrochloride 203b (1.30 g, 7.75 mmol), BnBr (0.90 mL, 7.75 mmol, 1.00 
equiv.), and K2CO3 (2.14 g, 15.50 mmol, 2.00 equiv.) in CH3CN (20 mL). Colourless oil (1.25 
g, 73%). Rf (Et2O/hexane = 1:9) = 0.16. [𝛼]+,,	= –35.4 (c 5.5 CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz, CH3), 1.33-1.43 (m, 2H, CH2), 1.57-1.64 (m, 2H, CH2), 1.79 
(s, 1H, NH), 3.26 (t, 1H, J = 6.6 Hz, CH), 3.61 (d, 1H, J = 13.2 Hz, CHPh), 3.67 (s, 3H, CH3), 
3.80 (d, 1H, J = 13.2 Hz, CHPh), 7.22-7.31 (m, 5H, 5CHAr). 13C{1H} NMR (75 MHz, CDCl3) 







3031 (w), 2957 (m), 1734 (s), 1456 (m), 1339 (m), 1267 (m), 976 (m), 732 (m), 698 (s). HRMS 
(ESI-TOF) m/z calcd for C13H20NO2 [M + H]+ 222.1494, found 222.1492.  
Methyl (S)-2-(benzyl(tert-butoxycarbonyl)amino)pentanoate 248b was obtained 
following the general procedure using methyl 2-(benzylamino)pentanoate 247b (1.00 g, 4.51 
mmol), Boc2O (1.47 g, 6.77 mmol, 1.50 equiv.) and Et3N (2.58 mL, 9.02 mmol, 2.00 equiv.) in 
CH2Cl2 (10 mL). Colourless oil (0.89 g, 62%). Rf (Et2O/hexane = 1:9) = 0.23. [𝛼]+,,	= –50.4 (c 
9.5 CHCl3). 1H NMR (300 MHz, CDCl3) (mixture of rotamers) δ 0.79 (br s, 3H, CH3), 1.24 (br 
s, 2H, CH2), 1.40 (br s, 4.2H, C(CH3)3), 1.45 (br s, 4.8H, C(CH3)3), 1.62-1.75 (m, 1H, CH), 
1.84-1.94 (m, 1H, CH), 3.55 (s, 3H, CH3), 3.90-4.80 (m, 3H, CH2Ph, CH), 7.19-7.28 (m, 5H, 
5CHAr). 13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers, minor rotamer indicated by 
asterisk) δ 13.5, 19.5, 28.1, 31.6, 32.3*, 32.4, 49.4, 50.7*, 51.5, 58.5, 59.1*, 80.2, 126.8, 127.1, 
128.0, 128.3, 138.0, 138.9*, 155.6, 172.1. IR (νmax/cm-1) 3031 (w), 2961 (m), 2875 (w), 1739 
(s), 1700 (s), 1452 (s), 1319 (m), 1248 (m), 1163 (m), 979 (m), 862 (m), 734 (m), 699 (s). 
HRMS (ESI-TOF) m/z calcd for C18H27NO4Na [M + Na]+ 344.1838, found 344.1833. 
 
Methyl N-benzyl-N-(tert-butoxycarbonyl)-L-leucinate (248c) 
 
Methyl N-benzyl leucinate 247c was obtained following the general procedure using methyl 
leucinate hydrochloride 203c (1.00 g, 5.50 mmol), BnBr (0.70 mL, 6.05 mmol, 1.10 equiv.) 
and K2CO3 (1.52 g, 11.00 mmol, 2.00 equiv.) in CH3CN (20 mL). Light yellow oil (0.996 g, 
77%). 1H NMR (500 MHz, CDCl3) δ 0.84 (d, 3H, J = 6.5 Hz, CH3), 0.91 (d, 3H, J = 7.0 Hz, 
CH), 1.45-1.48 (m, 2H, CH2), 1.74 (s, 1H, NH), 1.75-1.80 (m, 1H, CH), 3.29 (t, 1H, J = 7.5 Hz, 
CH), 3.60 (d, 1H, J = 13.0 Hz, CH), 3.69 (s, 3H, CH3), 3.79 (d, 1H, J = 13.0 Hz, CH), 7.29-
7.32 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 22.1, 22.8, 24.9, 42.8, 51.5, 52.2, 








Methyl N-benzyl-N-(tert-butoxycarbonyl) leucinate 248c was obtained following the 
general procedure using methyl N-benzyl leucinate 247c (0.59 g, 2.50 mmol), Boc2O (0.67 g, 
3.10 mmol, 1.24 equiv.) and Et3N (0.81 mL, 2.75 mmol, 1.10 equiv.) in CH2Cl2 (5 mL). 
Colourless oil (0.59 g, 70%). 1H NMR (300 MHz, CDCl3) (mixture of rotamers) δ 0.72 (br s, 
3H, CH3), 0.83 (br d, 3H, J = 15.3 Hz, CH3), 1.40 (br s, 4H, C(CH3)3), 1.47 (br s, 5H, C(CH3)3), 
1.56-1.60 (m, 2H, CH2), 1.75 (m, 1H, CH), 3.56 (s, 3H, CH3), 4.16 (br s, 0.5H, CHPh), 4.28-
4.42 (br m, 1H, CHPh), 4.56 (m, 1H, CH), 4.72 (br s, 0.5H, CHPh), 7.22 (dd, 5H, J = 4.5, 12.6 
Hz, 5CHAr). 13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers) δ 21.8, 22.6, 24.6, 28.2, 
38.4, 39.2, 49.2, 50.2, 51.7, 56.8, 57.5, 80.3, 126.8, 127.1, 128.1, 128.2, 138.1, 139.0, 155.7, 
172.3, 172.5. The NMR data matched with those previously reported.187  
 
Methyl N-benzyl-N-(tert-butoxycarbonyl)-L-phenylalaninate (248d) 
 
Methyl N-benzyl phenylalaninate 247d was obtained following the general procedure using 
methyl 2-amino-3-phenylpropanoate hydrochloride 203d (3.00 g, 13.91 mmol), BnBr (1.60 
mL, 13.91 mmol, 1.00 equiv.) and K2CO3 (3.84 g, 27.80 mmol, 2.00 equiv.) in CH3CN (40 
mL). Colourless oil (2.96 g, 79%). 1H NMR (300 MHz, CDCl3) δ 1.85 (s, 1H, NH), 2.93 (d, 
2H, J = 6.6 Hz, CH2Ph), 3.51 (t, 1H, J = 6.3 Hz, CH), 3.57 (s, 3H, OCH3), 3.59 (d, 1H, J = 13.2 
Hz, CHPh), 3.77 (d, 1H, J = 13.2 Hz, CHPh), 7.11-7.25 (m, 10H, 10CHAr). 13C{1H} NMR (75 
MHz, CDCl3) δ 39.8, 51.6, 52.0, 62.1, 126.7, 127.1, 128.2, 128.4, 128.5, 129.3, 137.4, 139.7, 
175.0. The NMR data matched with those previously reported.188 
Methyl N-benzyl-N-(tert-butoxycarbonyl)-L-phenylalaninate 248d was obtained 
following the general procedure using methyl N-benzyl phenylalaninate 247d (1.66 g, 6.16 
mmol), Boc2O (1.67 g, 7.64 mmol, 1.24 equiv.) and Et3N (1.98 mL, 6.77 mmol, 1.10 equiv.) in 
CH2Cl2 (10 mL). Colourless oil (1.46 g, 65%). 1H NMR (300 MHz, CDCl3) (mixture of 
rotamers) δ 1.38 (br s, 4H, C(CH3)3), 1.48 (br s, 5H, C(CH3)3), 3.02-3.21 (m, 0.5H, CH), 3.30 







J = 15.6 Hz, CHPh), 4.35 (br d, 1H, J = 15.6 Hz, CHPh), 4.54 (d, 1H, J = 15.6 Hz, CHPh), 
7.05-7.26 (m, 10H, 5CHAr). 13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers) δ 28.3, 
35.6, 36.6, 51.3, 51.6, 51.9, 60.8, 61.0, 80.5, 80.8, 126.5, 126.9, 127.2, 127.6, 128.1, 128.5, 
128.6, 129.3, 137.2, 138.0, 138.1, 155.1, 171.3. The NMR data matched with those previously 
reported.189 
 
Methyl N-benzyl-N-(tert-butoxycarbonyl)-L-valinate (248e) 
 
Methyl N-benzyl valinate 247e was obtained following the general procedure using methyl 2-
amino-3-methylbutanoate hydrochloride 203e (2.00 g, 11.92 mmol), BnBr (1.38 mL, 11.92 
mmol, 1.00 equiv.) and K2CO3 (3.28 g, 23.84 mmol, 2.00 equiv.) in CH3CN (30 mL). Colorless 
oil (1.86 g, 71%). 1H NMR (500 MHz, CDCl3) δ 0.92 (d, 3H, J = 6.5 Hz, CH3), 0.94 (d, 3H, J 
= 7.0 Hz, CH3), 1.78 (br s, 1H, NH), 1.91 (q, 1H, J = 7.0 Hz, 6.5 Hz, CH), 3.01 (d, 1H, J = 6.0 
Hz, CH), 3.57 (d, 1H, J = 13.5 Hz, CH), 3.68 (s, 3H, OCH3), 3.81 (d, 1H, J = 13.5 Hz, CH), 
7.20-7.33 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 18.6, 19.3, 31.7, 51.3, 52.5, 
66.6, 127.0, 128.2, 128.3, 140.1, 175.7. The NMR data matched with those previously 
reported.190 
Methyl N-benzyl-N-(tert-butoxycarbonyl) valinate 248e was obtained following the 
general procedure using methyl N-benzyl valinate 247e (1.28 g, 5.78 mmol), Boc2O (2.14 g, 
9.82 mmol, 1.70 equiv.) and Et3N (3.32 mL, 11.56 mmol, 2.00 equiv.) in CH2Cl2 (15 mL). 
Colourless oil (1.18 g, 63%). Rf (Et2O/hexane = 1:9) = 0.29. [𝛼]+,,	= –74.7 (c 3.1 CHCl3). 1H 
NMR (300 MHz, CDCl3) (mixture of rotamers) δ 0.81-0.96 (m, 6H, 2 × CH3), 1.35 (br s, 6H, 
C(CH3)3), 1.47 (br s, 3H, C(CH3)3), 2.31 (br s, 1H, CH), 3.41 (s, 3H, OCH3), 4.34-4.58 (m, 3H, 
CH2Ph, CH), 7.22 (m, 5H, 5CHAr). 13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers, 
minor rotamer indicated by asterisk) δ 18.5, 19.7, 20.7*, 27.2*, 28.1, 47.9, 49.5*, 51.2, 63.4, 







(s), 1452 (m), 1365 (s), 1249 (s), 1161 (s), 1138 (s), 1010 (m), 698 (s). HRMS (ESI) m/z calcd 
for C18H27NO4Na [M + Na]+ 344.1838, found 344.1825. 
 
 Methyl (S)-2-(benzyl(tert-butoxycarbonyl)amino)-2-phenylacetate (248f) 
 
Methyl 2-(benzylamino)-2-phenylacetate 247f was obtained following the general procedure 
using methyl aminophenylacetate hydrochloride 203f (2.50 g, 12.39 mmol), BnBr (1.45 mL, 
12.39 mmol, 1.00 equiv.) and K2CO3 (3.42 g, 24.79 mmol, 2.00 equiv.) in CH3CN (35 mL). 
Colourless oil (2.15 g, 68%). Rf (Et2O/hexane = 6:4) = 0.64. [𝛼]+,,	= +84.6 (c 2 CHCl3). 1H 
NMR (300 MHz, CDCl3) δ 2.34 (s, 1H, NH), 3.56 (s, 3H, OCH3), 3.68 (s, 2H, CH2Ph), 4.36 
(s, 1H, CH), 7.17-7.36 (m, 10H, 10CHAr). 13C{1H} NMR (75 MHz, CDCl3) δ 51.4, 52.1, 64.4, 
127.2, 127.6, 128.1, 128.3, 128.4, 128.7, 138.2, 139.6, 173.4. IR (νmax/cm-1) 3336 (w), 3026 
(w), 2950 (w), 2845 (w), 1735 (s), 1600 (m), 1436 (m), 1378 (m), 1266 (m), 1199 (s), 1131 
(m), 1009 (m), 908 (m), 801 (m), 728 (s), 695 (s). HRMS (ESI) m/z calcd for C16H17NO2Na 
[M + Na]+ 278.1157, found 278.1164.  
Methyl (S)-2-(benzyl(tert-butoxycarbonyl)amino)-2-phenylacetate 248f was obtained 
following the general procedure using methyl 2-(benzylamino)-2-phenylacetate 247f (2.00 g, 
7.83 mmol), Boc2O (2.12 g, 9.71 mmol, 1.24 equiv.) and triethylamine (4.55 mL, 15.66 mmol, 
2.00 equiv.) in CH2Cl2 (15 mL). Colourless oil (1.61 g, 58%). Rf (EtOAc/hexane = 2:8) = 0.29. 
[𝛼]+,,	= +47.8 (c 1 CHCl3). 1H NMR (300 MHz, CDCl3) (mixture of rotamers) δ 1.39 (br s, 9H, 
C(CH3)3), 3.69 (s, 3H, CH3), 4.15 (d, 1H, J = 15.0 Hz, CHPh), 4.65 (br d, 1H, J = 15.0 Hz, 
CHPh), 5.79 (br s, 1H, CH), 6.95 (br s, 2H, 2CHAr), 7.06-7.16 (m, 4H, 4CHAr), 7.22 (br s, 4H, 
4CHAr). 13C NMR (75 MHz, CDCl3) (mixture of rotamers) δ 28.2, 28.5, 49.1, 49.4, 52.1, 52.2, 
63.1, 63.3, 80.6, 81.1, 126.5, 126.7, 127.0, 127.3, 127.6, 127.8, 128.1, 128.3, 128.4, 128.6, 
128.7, 129.4, 129.6, 134.5, 134.8, 139.0, 156.0, 171.3, 171.6. IR (νmax/cm-1) 2979 (w), 1747 
(s), 1691 (s), 1454 (m), 1365 (s), 1253 (m), 1155 (s), 1006 (m), 856 (m), 748 (m), 696 (s). 












Methyl tryptophanate hydrochloride 203g (3.60 g, 14.13 mmol) was neutralized into the free 
base by dissolving in Et2O (20 mL) followed by washing with saturated aqueous K2CO3 
solution (20 mL). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure to obtain a light yellow oil. To a stirred suspension of the neutralised tryptophan 
methyl ester and MgSO4 (2.70 g) in CH2Cl2 (40 mL), was added benzaldehyde (1.43 mL, 14.13 
mmol, 1.00 equiv.) and the mixture was stirred for 5 h at room temperature. The imine product 
was obtained after filtration and concentration, which was used for the next step without 
purification. The imine compound was dissolved in dry MeOH (30 mL) and NaBH4 (0.58 g, 
15.54 mmol, 1.10 equiv.) was added slowly at 0 °C. The solvent was evaporated after 1 h at 0 
°C. Then the mixture was washed by NH4OH (5%, 20 mL), extracted with ethyl acetate and 
dried (Na2SO4). The methyl Nb-benzyl tryptophanate 247g was obtained after flash column 
chromatography (EtOAc/hexane = 2:8). Colourless gummy oil (3.12 g, 72%). 1H NMR (300 
MHz, CDCl3) δ 1.74 (br s, 2H, 2NH), 3.14 (dd, 1H, J = 6.3, 14.4 Hz, CH), 3.18 (dd, 1H, J = 
5.4, 14.4 Hz, CH), 3.62 (s, 3H, CH3), 3.67 (d, 2H, J = 3.9 Hz, CH2), 3.82 (d, 1H, J = 13.2 Hz, 
CH), 7.02 (d, 1H, J = 2.4 Hz, CHAr), 7.09 (t, 1H, J = 7.2, 7.5 Hz, CHAr), 7.17 (d, 1H, J = 8.1 
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7.5 Hz, CHAr), 8.01 (br s, 1H, CHAr). 13C{1H} NMR (75 MHz, CDCl3) δ 29.3, 51.6, 52.1, 61.2, 
111.0, 111.4, 118.8, 119.4, 122.0, 122.7, 126.9, 127.5, 128.1, 128.3, 136.1, 139.6, 175.3. The 
NMR data matched with those previously reported.179  
Et3N (2.85 mL, 9.92 mmol, 2.00 equiv.) was added dropwise to a stirred solution of 
methyl Nb-benzyl tryptophanate 247g (1.53 g, 4.96 mmol) and Boc2O (1.02 g, 4.71 mmol, 0.95 
equiv.) in CH2Cl2 (20 mL), and was stirred for 24 h at room temperature. The crude reaction 
mixture was concentrated under reduced pressure. Then title compound 248g was obtained after 
flash column chromatography (EtOAc/hexane = 2:8). Colourless gummy oil (1.37 g, 67%). 1H 
NMR (300 MHz, CDCl3) δ 1.40 (br s, 3.6H, C(CH3)3), 1.44 (br s, 5.4H, C(CH3)3), 3.21-3.29 
(br m, 1H, CH), 3.45-3.51 (br m, 2H, CH2), 3.55 (s, 3H, CH3), 3.77 (br d, 0.6H, J = 15.3 Hz, 
CHPh), 4.00 (br d, 0.4H, J = 15.3 Hz, CHPh), 4.17 (br s, 0.6H, NH), 4.34 (br d, 0.4H, J = 15.9 
Hz, CHPh), 4.50 (br d, 1H, J = 15.9 Hz, CHPh, NH), 6.88 (m, 1H, CHAr), 7.05 (d, 2H, J = 5.7 
Hz, 2CHAr), 7.14 (br s, 4H, 4CHAr), 7.27-7.41 (m, 2H, 2CHAr), 8.35 (m, 1H, CHAr). 13C{1H} 
NMR (75 MHz, CDCl3) (mixture of rotamers, minor rotamer indicated by asterisk) δ 25.2, 
26.0, 28.2, 51.2, 51.7, 59.6, 59.9*, 80.4*, 80.7, 111.2, 111.4*, 118.2, 119.1, 121.7, 122.9*, 
123.2, 126.8*, 127.0, 127.4, 127.9, 128.3, 136.0, 137.2, 138.0, 155.3, 171.6. The NMR data 
matched with those previously reported.179      
To a stirred solution of methyl Nb-benzyl-Nb-(tert-butoxycarbonyl) tryptophanate 248g 
(1.07 g, 2.62 mmol) and Boc2O (0.85 g, 3.93 mmol, 1.50 equiv.) in CH2Cl2 (15 mL), was added 
DMAP (0.063 g, 0.52 mmol, 0.20 equiv.) and the mixture was stirred overnight at room 
temperature. The reaction mixture was diluted with EtOAc (10 mL) and washed with water (30 
mL) and saturated aqueous NaHCO3 solution (30 mL) and brine (30 mL). The organic layer 
was dried (Na2SO4) and the filtrate was concentrated under reduced pressure. The title 
compound 248g' was obtained after flash column chromatography (EtOAc/hexane = 2:9). 
Colourless gummy oil (1.15 g, 86%). Rf (EtOAc/hexane = 2:9) = 0.48. [𝛼]+,,	= –67.2 (c 1.0 
CHCl3). 1H NMR (300 MHz, CDCl3) (mixture of rotamers) δ 1.48 (s, 9H, 3CH3), 1.65 (s, 9H, 
3CH3), 3.10-3.39 (m, 2H, CH2), 3.62 (s, 3H, CH3), 4.15-4.39 (m, 3H, CH2, CH), 7.01-7.42 (m, 





rotamers, minor rotamer indicated by asterisk) δ 24.9*, 25.9, 28.2*, 28.3, 51.8*, 52.0, 59.6, 
59.8*, 80.5*, 80.8, 83.2*, 83.4, 115.2, 115.3*, 116.5, 116.7*, 118.5, 118.7, 118.9*, 122.4, 
124.00*, 124.09, 124.4, 124.3*, 126.9, 127.0, 127.1*, 127.6*, 127.9, 128.1*, 128.3, 128.5, 
130.2*, 130.5, 135.4, 137.2, 137.6*, 149.5, 155.2, 171.4, 174.9*. IR (νmax/cm-1) = 2976 (m), 
2931 (m), 2357 (w), 2167 (w), 1732 (s), 1695 (s), 1452 (s), 1365 (s), 1253 (s), 1155 (s), 1083 
(s), 1016 (m), 858 (m), 742 (s), 698 (s). HRMS (ESI) m/z calcd for C29H36N2O6Na [M + Na]+ 
531.2471, found 531.2492. 
 
1-(tert-Butyl) 2-methyl (S)-pyrrolidine-1,2-dicarboxylate (248h)  
 
Methyl prolinate hydrochloride 203h was obtained following the general procedure using L-
pyroline (3.00 g, 26.06 mmol) and thionyl chloride (2.08 mL, 28.67 mmol, 1.10 equiv.) in 
MeOH (30 mL) after heating at reflux for 1 h. Light yellow oil (4.60 g, 99%). 1H NMR (300 
MHz, CDCl3) δ 2.06-2.14 (m, 2H, CH2), 2.16-2.23 (m, 1H, CH), 2.37-2.46 (m, 1H, CH), 3.52-
3.59 (br m, 2H, CH2), 3.83 (s, 3H, CH3), 4.50 (br s, 1H, CH), 9.21 (br s, 1H, NH), 10.52 (br s, 
1H, HCl). 13C{1H} NMR (75 MHz, CDCl3) δ 23.4, 28.5, 45.7, 53.3, 59.0, 169.2. The NMR 
data matched with those previously reported.191 
To a solution of methyl prolinate hydrochloride 203h (4.60 g, 35.61 mmol) in CH2Cl2 
(50 mL) at 0 °C, was added dropwise Et3N (18.40 mL, 64.00 mmol, 1.80 equiv.). After 10 min, 
Boc2O (5.67 g, 26.00 mmol, 0.73 equiv.) was added over 30 min. The reaction mixture was 
stirred at room temperature for 24 h. The mixture was filtered, and the filtrate was diluted with 
Et2O (50 mL) and washed with aqueous HCl solution (2 M, 10 mL), aqueous saturated NaHCO3 
solution (20 mL) and brine (20 mL), and dried (Na2SO4). The 1-(tert-butyl) 2-methyl 
pyrrolidine-1,2-dicarboxylate 248h was obtained after flash column chromatography 
(EtOAc/hexane = 2:8). Colourless oil (6.46 g, 79%). 1H NMR (500 MHz, CDCl3) (mixture of 



















2.52 (m, 1H, CH2), 3.38-3.58 (m, 2H, NCH2), 3.72 (s, 3H, CH3), 4.22 (d, 0.6H, J = 6.5 Hz, 
NCH), 4.32 (d, 0.4H, J = 6.5 Hz, NCH). 13C{1H} NMR (125 MHz, CDCl3) (mixture of 
rotamers) δ 23.8, 24.4, 28.4, 28.5, 30.0, 31.0, 46.4, 46.6, 52.0, 52.1, 58.8, 59.2, 79.8, 79.9, 
153.9, 154.5, 173.6, 173.8. The NMR data matched with those previously reported.192      
 
Methyl N-benzyl-N-tosyl-L-alaninate (S220) 
 
To an ice-cooled mixture of methyl 2-aminopropanoate hydrochloride 203a (3.0 g, 21.49 
mmol) and TsCl (4.09 g, 21.49 mmol, 1.00 equiv.) in CH2Cl2 (45 mL) 0 °C, was added dropwise 
Et3N (6.0 mL, 42.98 mmol, 2 equiv.) and the suspension was stirred for 1 h at 0 °C and 3 h at 
room temperature. The reaction mixture was filtered, washed with water (30 mL), dried 
(Na2SO4), and concentrated under reduced pressure. K2CO3 (2.37 g, 17.32 mmol, 2.00 equiv.) 
and BnBr (1.50 mL, 13.00 mmol, 1.50 equiv.) in CH3CN (30 mL) were then added to the crude 
reaction mixture and the mixture was stirred overnight at room temperature. The reaction 
mixture was then washed with aqueous saturated NH4Cl solution (50 mL) and water (50 mL), 
dried (Na2SO4), concentrated under reduced pressure and purified by flash column 
chromatography (EtOAc/hexane = 3:7) to obtain the methyl N-benzyl-N-tosyl-L-alaninate 
S220. Colourless oil (2.74 g, 88%). Rf (EtOAc/hexane = 3:7) = 0.54. [𝛼]+,,	= –42.5 (c 2.5 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 1.26-1.28 (m, 3H, CH3), 2.42 (br s, 3H, CH3), 3.42 (br 
s, 3H, CH3), 4.42 (br d, 1H, J = 16.0 Hz, CHPh), 4.55 (br d, 1H, J = 16.0 Hz, CHPh), 4.61-4.63 
(m, 1H, CH), 7.23-7.32 (m, 7H, 7CHAr), 7.71 (br d, 2H, J = 5.5 Hz, 2CHAr). 13C{1H} NMR 
(125 MHz, CDCl3) δ 16.4, 21.5, 49.1, 52.0, 55.0, 127.4, 127.5, 128.0, 128.3, 129.5, 137.1, 
137.3, 143.4, 171.6. IR (νmax/cm-1) 2950 (w), 1742 (s), 1456 (m), 1339 (s), 1152 (s), 1089 (m), 
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Methyl dibenzyl-L-alaninate (S223) 
 
To a mixture of methyl 2-aminopropanoate hydrochloride 203a (1.00 g, 7.16 mmol) and BnBr 
(1.48 mL, 15.01 mmol, 2.10 equiv.) in CH3CN (15 mL), was added K2CO3 (3.96 g, 28.64 mmol, 
4.00 equiv.) and the mixture was stirred for 24 h under reflux conditions. The reaction mixture 
was filtered, washed with water (30 mL) and brine (30 mL), dried (Na2SO4), and purified by 
flash column chromatography (Et2O/hexane = 1:9) to obtain methyl dibenzyl alaninate S223. 
Light yellow oil (1.73 g, 90%). 1H NMR (300 MHz, CDCl3) δ 1.29 (d, 3H, J = 7.2 Hz, CH3), 
3.46-3.53 (m, 1H, CH), 3.26 (d, 2H, J = 14.1 Hz, 2CHPh), 3.60 (s, 3H, OCH3), 3.81 (d, 2H, J 
= 14.1 Hz, 2CHPh), 7.15-7.38 (m, 10H, 10CHAr). 13C{1H} NMR (75 MHz, CDCl3) δ 151.1, 
51.2, 54.6, 56.2, 127.1, 128.3, 128.7, 140.0, 174.1. The NMR data matched with those 
previously reported.193            
 
Synthesis of N,N-diprotected α-amino aldehydes  
 
N,N-diprotected α-amino aldehydes were prepared by three different methods including 
reduction of esters with DIBAL-H method, or reduction of esters followed by oxidation with 
TEMPO method and Swern method. 
DIBAL-H method. To a solution of the N,N-diprotected amino ester 248 in Et2O at −78 
































mixture was stirred at the same temperature for 1 h, and was quenched with methanol (1 mL). 
The reaction mixture was allowed to warm to room temperature, followed by adding water (2 
mL). The crude mixture was filtered through a sintered glass funnel and the filtrate was washed 
with brine (20 mL). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure to yield the desired aldehyde. All the aldehyde products prepared by the DIBAL-H 
method were purified by flash column chromatography. 
Reduction by LiAlH4. To a solution of LiAlH4 (1 M solution in THF, 2.00 equiv.) at 0 
°C, was added dropwise the amino ester 248 in THF (0.2 M) and the mixture was stirred at the 
same temperature for 30 min. The reaction was then quenched with water (1 mL), filtered, and 
concentrated under reduced pressure. The crude reaction mixture was purified by flash column 
chromatography and the resulting alcohol 249 was utilised in the next oxidation step.  
TEMPO oxidation.194 To a stirred solution of the amino alcohol 249 in CH2Cl2 (0.05M) 
at 0 °C, was added saturated aqueous NaHCO3 solution (CH2Cl2/NaHCO3 2:1), KBr (1.00 
equiv.) and TEMPO (0.05 equiv.). NaOCl (1.20 equiv.) was then added with a syringe pump 
over 30 min. The reaction was stirred for another 15 min at 0 °C. Then, the reaction mixture 
was quenched with saturated aqueous Na2S2O3 solution (15 mL) and extracted into CH2Cl2 
(3×10 mL). The combined organic layers were dried (Na2SO4) and concentrated under reduced 
pressure to afford the desired aldehyde. All the aldehyde products prepared by TEMPO method 
were used for the next step without purification. 
Swern oxidation.195 To a solution of oxalyl chloride (2.00 equiv.) in CH2Cl2 (0.8 M) at 
−78 °C, was added DMSO (4.00 equiv.) dropwise and stirred for 15 min. A solution of amino 
alcohol 249 in CH2Cl2 (0.5 M) was then added and the mixture was stirred at −78 °C for 1 h. 
Et3N (16.00 equiv.) was then added dropwise and the reaction mixture was allowed to warm to 
room temperature and stirred for 1 h. The reaction mixture was quenched with aqueous 
saturated NaHCO3 solution (5 mL) and extracted into CH2Cl2 (3×3 mL). The combined organic 
layers were washed with brine (10 mL), dried (Na2SO4) and concentrated under reduced 
pressure to yield the desired aldehyde. All the aldehyde products prepared by the Swern method 





tert-Butyl (S)-benzyl(1-oxopropan-2-yl)carbamate (217a) 
  
The corresponding amino alcohol 249a was obtained following the LiAlH4 general procedure 
using N-benzyl-N-(tert-butoxycarbonyl)-amino propanoate 248a (1.5 g, 5.11 mmol) and 
LiAlH4 (1 M solution in THF, 10.22 mL, 10.22 mmol, 2 equiv.) in THF (20 mL). Colourless 
oil (1.10 g, 81%). Rf (EtOAc/hexane = 4:6) = 0.41. 1H NMR (500 MHz, CDCl3) δ 1.11 (br s, 
3H, CH3), 1.39 (br s, 9H, C(CH3)3), 3.57 (br s, 2H, CH2O), 4.04 (br s, 1H, CH), 4.38-4.41 (m, 
2H, CH2Ph), 7.20-7.31 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 14.4, 28.1, 48.4, 
55.0, 65.8, 80.5, 126.6, 128.6, 139.4, 156.7. The NMR data matched with those previously 
reported.196  
The title aldehyde 217a was obtained following the general TEMPO procedure using 
tert-butyl benzyl(1-hydroxypropan-2-yl)carbamate 249a (0.42 g, 1.58 mmol), saturated 
aqueous NaHCO3 solution (15 mL), KBr (0.18 g, 1.58 mmol, 1.00 equiv.), TEMPO (12.35 mg, 
0.079 mmol, 0.05 equiv.), and NaOCl (3.79 mL, 1.89 mmol, 1.20 equiv.) in CH2Cl2 (30 mL). 
Colourless oil (0.38 g, 91%). The ee was determined by chiral HPLC analysis of the 
corresponding alcohol (obtained by NaBH4 reduction of a small quantity of the unpurified 
aldehyde) using a Phenomenex Lux i-Cellulose-5 column; hexane/isopropanol (95:5); flow rate 
= 0.5 mL/min; 210 nm; tmajor = 23.29 min, tminor = 25.15 min, 91% ee. 1H NMR (300 MHz, 
CDCl3) (mixture of rotamers) δ 1.26 (br d, 3H, J = 5.4 Hz, CH3), 1.44 (s, 9H, C(CH3)3), 3.44 
(br s, 0.6H, CH), 3.69 (br s, 0.4H, CH), 4.28 (d, 1H, J = 15.3 Hz, CHPh), 4.65 (d, 0.4H, J = 
15.3 Hz, CHPh), 4.82 (d, 0.6H, J = 15.3 Hz, CHPh), 7.26-7.35 (m, 5H, 5CHAr), 9.42 (br s, 0.6H, 
CHO). 9.46 (br s, 0.4H, CHO). 13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers, minor 
rotamer indicated by asterisk) δ 11.8*, 12.6, 28.2, 50.9*, 51.1, 61.4, 81.1*, 81.6, 127.4*, 127.7, 
128.1*, 128.7, 137.7, 138.1*, 154.9, 155.3*, 199.3. The NMR data matched with those 









(S)-tert-Butyl benzyl(1-oxopentan-2-yl)carbamate (217b) 
 
The corresponding amino alcohol 249b was obtained following the LiAlH4 general procedure 
using methyl 2-(benzyl(tert-butoxycarbonyl)amino) pentanoate 248b (0.80 g, 2.49 mmol) and 
LiAlH4 (1 M solution in THF, 4.98 mL, 4.98 mmol, 2.00 equiv.) in THF (3 mL). Colourless oil 
(0.60 g, 82%). Rf (EtOAc/hexane = 4:6) = 0.61. [𝛼]+,,	= +16.3 (c 4.6 CHCl3). 1H NMR (500 
MHz, CDCl3) (mixture of rotamers) δ 0.84 (br s, 3H, CH3), 1.26 (br s, 2H, CH2), 1.37 (br s, 7H, 
C(CH3)3, CH), 1.49 (br s, 4H, C(CH3)3, CH), 3.40-3.60 (m, 3H), 3.84-3.86 (m, 1H), 4.21-4.70 
(m, 2H, CH2Ph), 7.21-7.27 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) (mixture of 
rotamers, minor rotamer indicated by asterisk) δ 13.9, 19.7, 28.3, 30.9, 31.7*, 48.2*, 49.3, 59.2, 
64.1, 80.1, 126.9, 127.6, 128.3, 139.6, 156.9. IR (νmax/cm-1) 3446 (m), 2959 (m), 2930 (m), 
2873 (m), 1665 (s), 1465 (m), 1410 (s), 1341 (m), 1243 (m), 1166 (s), 1053 (w), 701 (s). HRMS 
(ESI-TOF) m/z calcd for C17H27NO3Na [M + Na]+ 316.1889, found 319.1891.  
The title aldehyde 217b was obtained following the general Swern procedure using 
methyl tert-butyl benzyl(1-hydroxypentan-2-yl)carbamate 249b (0.59 g, 2.01 mmol), oxalyl 
chloride (0.37 mL, 4.02 mmol, 2.00 equiv.), DMSO (0.61 mL, 8.04 mmol, 4.00 equiv.) and 
Et3N 4.56 mL, 32.17 mmol, 16.00 equiv.) in CH2Cl2 (15 mL). Colourless oil (0.50 g, 85%). Rf 
(EtOAc/hexane = 1:9) = 0.43. [𝛼]+,,	= –92.3 (c 7.0 CHCl3). 1H NMR (300 MHz, CDCl3) 
(mixture of rotamers) δ 0.89 (t, 3H, J = 7.2 Hz, CH3), 1.34-1.41 (m, 2H, CH2), 1.45 (br s, 9H, 
C(CH3)3), 1.49-1.80 (m, 1H, CH), 1.89-1.99 (m, 1H, CH), 3.45 (br s, 0.6H, CH), 3.76 (br s, 
0.4H, CH), 4.11-4.22 (m, 1H, CHPh), 4.70 (br d, 0.4H, J = 15.0 Hz, CHPh), 4.98 (br d, 0.6H, 
J = 15.0 Hz, CHPh), 7.26-7.35 (m, 5H, 5CHAr), 9.35 (br s, 0.6H, CHO), 9.44 (br s, 0.4H, CHO). 
13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers, minor rotamer indicated by asterisk) δ 
13.8, 19.5, 28.1, 29.2*, 30.4, 51.4*, 51.8, 65.5, 80.9*, 81.3, 127.6, 128.3, 128.6, 137.7, 138.1*, 
155.1, 199.5. IR (νmax/cm-1) 2965 (m), 2933 (m), 2876 (w), 1739 (s), 1692 (s), 1452 (s), 1405 
(s), 1365 (s), 1249 (s), 1180 (s), 1002 (m), 864 (m), 735 (s), 699 (s). HRMS (ESI-TOF) m/z 







(S)-tert-Butyl benzyl(4-methyl-1-oxopentan-2-yl)carbamate (217c)  
 
The title compound 217c was obtained following the general DIBAL-H procedure using methyl 
N-benzyl-N-(tert-butoxycarbonyl) leucinate 248c (0.58 g, 1.74 mmol) and DIBAL-H 
(dissolved in 0.70 mL n-hexane, 0.70 mL, 3.49 mmol, 2.00 equiv.) in Et2O (3 mL). Colorless 
oil (0.35 g, 65%). Rf (EtOAc/hexane = 4:6) = 0.52. [𝛼]+,,	= –98.6 (c 6 CHCl3). 1H NMR (500 
MHz, CDCl3) (mixture of rotamers) δ 0.85-0.90 (m, 6H, 2CH3), 1.46 (s, 9H, C(CH3)3), 1.59-
1.66 (m, 2H, CH2), 1.83-1.85 (m, 1H, CH), 3.55 (br s, 0.6H, CH), 3.89 (br s, 0.4H, CH), 4.12 
(d, 0.6H, J = 15.5 Hz, CHPh), 4.20 (d, 0.4H, J = 15.5 Hz, CHPh), 4.70 (d, 0.4H, J = 15.5 Hz, 
CHPh), 4.99 (d, 0.6H, J = 15.5 Hz, CHPh), 7.27-7.34 (m, 5H, 5CHAr), 9.34 (br s, 0.6H, CHO), 
9.44 (br s, 0.4H, CHO). 13C{1H} NMR (125 MHz, CDCl3) (mixture of rotamers) δ 22.0, 23.0, 
24.8, 28.2, 36.1, 37.4, 51.1, 51.4, 63.8, 81.0, 81.5, 127.6, 127.8, 128.3, 128.8, 137.8, 138.2, 
155.2, 155.6, 200.1, 200.2. IR (νmax/cm-1) 2957 (m), 2870 (w), 1735 (s), 1684 (s), 1454 (s), 
1419 (s), 1366 (s), 1245 (s), 1162 (s), 701 (s). HRMS (ESI) m/z calcd for C18H27NO3Na [M + 
Na]+ 328.1889, found 328.1898. 
 
(S)-tert-Butyl benzyl(1-oxo-3-phenylpropan-2-yl)carbamate (217d) 
 
The title compound 217d was obtained following the general DIBAL-H procedure using 
methyl N-benzyl-N-(tert-butoxycarbonyl) phenylalaninate 248d (0.54 g, 1.46 mmol) and 
DIBAL-H (dissolved in 0.6 mL n-hexane, 0.58 mL, 2.92 mmol, 2 equiv.) in Et2O (3 mL). 
Colourless oil (0.31 g, 63%). 1H NMR (500 MHz, CDCl3) (mixture of rotamers) δ 1.50 (s, 9H, 
C(CH3)3), 2.94 (m, 0.6H, CHPh), 3.12 (d, 1H, J = 14.5 Hz, CHPh), 3.24 (d, 0.4H, J = 15.5 Hz, 
CHPh), 3.30 (d, 1H, J = 14.5 Hz, CHPh), 3.57 (m, 1H, CH), 4.58 (d, 0.4H, J = 15.5 Hz, CHPh), 
4.87 (d, 0.6H, J = 15.5 Hz, CHPh), 7.08-7.16 (m, 5H, 5CHAr), 7.20-7.32 (m, 5H, 5CHAr), 9.35 










δ 28.3, 33.2, 34.3, 51.9, 52.4, 67.2, 67.6, 81.2, 81.9, 126.6, 126.8, 127.7, 127.8, 128.4, 128.7, 
128.8, 129.3, 137.4, 137.7, 138.0, 138.8, 154.8, 155.4, 198.4, 198.6. The NMR data matched 
with those previously reported.189 
 
(S)-tert-Butyl benzyl(3-methyl-1-oxobutan-2-yl)carbamate (217e) 
 
The corresponding amino alcohol 249e was obtained following the general procedure using 
methyl N-benzyl-N-(tert-butoxycarbonyl) valinate 248e (1.00 g, 3.11 mmol) and LiAlH4 (1 M 
solution in THF, 6.22 mL, 6.22 mmol, 2.00 equiv.) in THF (5 mL). Colourless oil (0.73 g, 
80%). 1H NMR (500 MHz, CDCl3) (mixture of rotamers) δ 0.87 (br s, 3H, CH3), 0.94 (br s, 
3H, CH3), 1.40 (br s, 5.4H, C(CH3)3), 1.48 (br s, 3.6H, C(CH3)3), 1.90 (br s, 0.4H, CH), 2.27 
(br s, 0.6H, CH), 3.2 (br s, 0.6H, CH), 3.70 (br s, 2.4H, CH2, CH), 4.20 (br d, 1H, J = 14.5 Hz, 
CHPh), 4.53 (br d, 1H, J = 14.5 Hz, CHPh), 7.22-7.28 (m, 5H, 5CHAr). 13C{1H} NMR (125 
MHz, CDCl3) (mixture of rotamers) δ 20.1, 26.7, 28.3, 52.0, 62.2, 63.2, 66.1, 67.2, 80.2, 127.1, 
127.4, 127.8, 128.4, 139.1, 157.0. The NMR data matched with those previously reported.198 
The title aldehyde 217e was obtained following the general TEMPO procedure using 
tert-butyl benzyl(1-hydroxypropan-2-yl)carbamate 249e (0.38 g, 1.08 mmol), saturated 
aqueous NaHCO3 solution (5 mL), KBr (0.128 g, 1.08 mmol, 1.00 equiv.), TEMPO (8.50 mg, 
0.054 mmol, 0.05 equiv.), and NaOCl (2.6 mL, 1.30 mmol, 1.20 equiv.) in CH2Cl2 (10 mL). 
Colourless oil (0.26 g, 83%). [𝛼]+,.	= -62.8 (c 1.0 CH3Cl). 1H NMR (500 MHz, CDCl3) 
(mixture of rotamers) δ 0.89 (d, 3H, J = 6.5 Hz, CH3), 1.03 (d, 3H, J = 6.5 Hz, CH3), 1.43 (s, 
9H, C(CH3)3), 2.41-2.48 (m, 1H, CH), 3.10 (br s, 0.6H, CH), 3.38 (br s, 0.4H, CH), 4.07 (br d, 
0.6H, J = 13.0 Hz, CHPh), 4.18 (br d, 0.4H, J = 13.0 Hz, CHPh), 4.68 (br d, 0.6H, J = 13.0 Hz, 
CHPh), 5.02 (br d, 0.4H, J = 13.0 Hz, CHPh), 7.23-7.33 (m, 5H, 5CHAr), 9.34 (br s, 0.6H, 







20.7, 21.4, 27.2, 27.8, 28.1, 52.6, 52.9, 71.2, 80.69, 81.1, 127.6, 128.3, 128.4, 128.5, 137.7, 
138.1, 155.1, 155.5, 198.2. The NMR data matched with those previously reported.195                        
 
tert-Butyl benzyl(2-oxo-1-phenylethyl)carbamate (217f) 
  
The title compound 217f was obtained following the general DIBAL-H procedure using methyl 
2-(benzyl(tert-butoxycarbonyl)amino)-2-phenylacetate 248f (0.76 g, 2.14 mmol) and DIBAL-
H (dissolved in 0.85 mL n-hexane, 0.85 mL, 4.29 mmol, 2.00 equiv.) in Et2O (3 mL). 
Colourless oil (0.41 g, 59%). Rf (E2O/hexane = 3:7) = 0.48. [𝛼]+,,	= –35.1 (c 2.0 CHCl3). 1H 
NMR (300 MHz, CDCl3) δ 1.45 (s, 9H, C(CH3)3), 3.99 (d, 1H, J = 15.6 Hz, CH2Ph), 4.71-5.09 
(m, 2H, CHPh and CH), 7.21-7.36 (m, 10H, 10CHAr), 9.61 (br s, 1H, CHO). 13C{1H} NMR (75 
MHz, CDCl3) δ 28.2, 50.6, 69.1, 81.7, 127.4, 127.6, 128.00, 128.06, 128.10, 128.18, 128.3, 
128.5, 128.7, 129.1, 133.6, 137.6, 156.0, 195.1. IR (νmax/cm-1) 2979 (m), 2819 (w), 1738 (s), 
1683 (s), 1452 (s), 1417 (s), 1366 (s), 1244 (s), 1155 (s), 1133 (s), 741 (s), 697 (s). HRMS 





The title aldehyde 217g was obtained following the general DIBAL-H procedure using tert-
butyl 3-(2-(benzyl(tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-indole-1-
carboxylate 248g' (0.55 g, 1.08 mmol) and DIBAL-H (dissolved in 0.40 mL n-hexane, 0.42 



















(EtOAc/hexane = 2:8) = 0.63. [𝛼]+,,	= –113.5 (c 9.8 CHCl3). 1H NMR (500 MHz, CDCl3) 
(mixture of rotamers) δ 1.49 (s, 9H, C(CH3)3), 1.67 (s, 9H, C(CH3)3), 3.04-3.09 (m, 0.5H, CH), 
3.29-3.31 (m, 0.5H, CH), 3.37-3.42 (m, 1H, CH), 3.52 (t, 1H, J = 16.0 Hz, CH), 3.76-3.77 (m, 
1H, CHPh), 4.50 (d, 0.5H, J = 15.0 Hz, CHPh), 4.76 (d, 0.5H, J = 15.0 Hz, CHPh), 7.00 (br s, 
2H, 2CHAr), 7.19-7.24 (m, 4H, 4CHAr), 7.31-7.41 (m, 3H, 3CHAr), 8.16 (br s, 1H, CHAr), 9.42 
(s, 0.5H, CHO), 9.53 (0.5H, CHO). 13C{1H} NMR (125 MHz, CDCl3) (mixture of rotamers) δ 
22.7, 23.8, 28.2, 28.3, 52.0, 52.7, 65.3, 66.0, 76.9, 77.2, 77.4, 81.2, 81.8, 83.5, 83.6, 115.4, 
115.5, 116.4, 116.7, 118.5, 118.7, 122.6, 124.2, 124.3, 124.5, 124.6, 127.6, 127.75, 127.78, 
128.4, 128.63, 128.65, 130.1, 130.4, 135.6, 137.3, 137.5, 149.5, 154.8, 155.3, 198.6, 199.0. IR 
(νmax/cm-1) 2978 (m), 2814 (w), 2364 (w), 2163 (w), 1730 (s), 1733 (s), 1683 (s), 1452 (s), 1365 
(s), 1308 (m), 1251 (s), 1154 (s), 1085 (s), 976 (m), 856 (s), 743 (s), 700 (s). HRMS (ESI) m/z 
calcd for C28H33N2O5 [M − H]+ 477.2389, found 477.2382. 
 
(S)-tert-Butyl 2-formylpyrrolidine-1-carboxylate (217h) 
 
The title aldehyde 217h was obtained following the general DIBAL-H procedure using 1-(tert-
butyl) 2-methyl pyrrolidine-1,2-dicarboxylate 248h (0.50 g, 2.18 mmol) and 
diisobutylaluminum hydride (dissolved in 1 mL n-hexane, 0.87 mL, 4.36 mmol, 2 equiv.) in 
diethyl ether (3 mL). Colorless oil (0.285 g, 65%). 1H NMR (300 MHz, CDCl3) (mixture of 
rotamers) δ 1.43 (s, 5.4H, C(CH3)3), 1.48 (s, 3.6H, C(CH3)3), 1.86-2.18 (m, 4H, 2CH2), 3.44-
3.57 (m, 2H, CH2), 4.04 (br m, 0.6H, CH), 4.18 (br m, 0.4H, CH), 9.46 (d, 0.6H, J = 2.7 Hz, 
CHO), 9.53 (br s, 0.4H, CHO). 13C{1H} NMR (75 MHz, CDCl3) (mixture of rotamers) 23.7, 
24.4, 26.5, 27.7, 28.0, 28.1, 46.5, 46.6, 64.7, 64.8, 79.8, 80.2, 153.7, 154.6, 200.0, 200.3. The 

















The title compound 220 was obtained following the general DIBAL-H procedure using methyl 
N-benzyl-N-tosyl-alaninate S220 (0.20 g, 0.57 mmol) and DIBAL-H (dissolved in 0.2 mL n-
hexane, 0.22 mL, 1.15 mmol, 2.00 equiv.) in Et2O (1 mL). Colourless oil (0.127 g, 70%). 1H 
NMR (500 MHz, CDCl3) δ 1.13 (d, 3H, J = 7.5 Hz, CH3), 2.43 (s, 3H, CH3), 4.12-4.16 (m, 1H, 
CH), 4.19 (d, 1H, J = 15.0 Hz, CHPh), 4.52 (d, 1H, J = 15.0 Hz, CHPh), 7.26-7.34 (m, 7H, 
7CHAr), 7.76 (d, 2H, J = 8.0 Hz, 2CHAr), 9.29 (s, 1H, CHO). 13C{1H} NMR (125 MHz, CDCl3) 
δ 11.2, 21.5, 49.2, 61.4, 127.3, 128.4, 128.85, 128.86, 130.0, 135.6, 137.0, 144.0, 198.9. The 




The title compound 223 was obtained following the general DIBAL-H procedure using methyl 
dibenzyl alaninate S223 (0.50 g, 1.85 mmol) and DIBAL-H (dissolved in 0.70 mL n-hexane, 
0.66 mL, 3.34 mmol, 1.80 equiv.) in diethyl ether (2 mL). Light yellow oil (0.285 g, 54%). 1H 
NMR (300 MHz, CDCl3) δ 1.16 (d, 3H, J = 11.5 Hz, CH3), 3.31 (q, 1H, J = 6.9 Hz, CH), 3.54 
(d, 2H, J = 13.8 Hz, 2CHPh), 3.71 (d, 1H, J = 13.8 Hz, 2CHPh), 7.20-7.40 (m, 10H, 10CHAr), 
9.70 (s, 1H, CHO). 13C NMR (125 MHz, CDCl3) δ 6.87, 55.0, 62.9, 127.4, 128.4, 128.8, 139.0, 




















General Procedure for Allenylation Reaction of Chiral Singly N-Protected α-
Amino Aldehydes 
 
To a solution of allenylboronic acid pinacol ester 71 (1.10 equiv.) and the amino aldehydes 
(205a-g, 208, 2011, 2014) in toluene at 0 °C, was added Et2Zn (1 M in toluene, 10 mol%) under 
nitrogen. The mixture was then stirred at 0 °C for 18 h. The reaction mixture was quenched 
with saturated aqueous NH4Cl solution (1 mL), and washed with saturated aqueous NaHCO3 
solution (15 mL) and water (10 mL). The organic layer was dried (Na2SO4), concentrated under 
reduced pressure and purified by flash column chromatography (EtOAc/hexane) to afford the 
allenyl amino alcohol products (206, 209, 212, 215). As mentioned in Chapter 2, no desired 
allene products 209 and 212 were obtained from the allenylation reaction of the aldehydes 208 
and 211.  
 
tert-Butyl ((2S,3S)-3-hydroxyhexa-4,5-dien-2-yl)carbamate (206a) 
 
 The title compound 206a was obtained after flash column chromatography (EtOAc/hexane = 
3:7) as a 2.6:1 mixture of syn and anti diasteresomers following the general procedure using 
tert-butyl (1-oxopropan-2-yl)carbamate 205a (0.06 g, 0.34 mmol), allenylboronic acid pinacol 
ester 71 (69.0 μL, 0.37 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 35.7 μL, 0.034 mmol, 
10 mol%)  in dry toluene (1 mL). Yellow oil (0.067 g, 92%). Rf (EtOAc/hexane = 3:7) = 0.36. 
1H NMR (500 MHz, CDCl3) (mixture of two allene diastereomers, relative integrations given 
for each diastereomer) δ 1.12 (d, 3H, J = 6.5 Hz, CH3, minor isomer), 1.19 (d, 3H, J = 7.0 Hz, 
























3.17 (br s, 1H, OH, minor isomer), 3.71-3.75 (m, 1H, CH, major isomer), 3.75-3.82 (m, 1H, 
CH, minor isomer), 4.09 (br s, 1H, CH, major isomer), 4.23 (br s, 1H, CH, minor isomer),  4.86-
4.90 (m, 2H, CH2=C=, for each isomer), 5.16-5.28 (m, 1H, CH=C=, for each isomer). 13C{1H} 
NMR (125 MHz, CDCl3) (mixture of two allene diastereomers, minor indicated by asterisk) δ 
18.8, 19.9, 20.1, 28.3, 29.8, 30.0*, 60.4, 60.8*, 69.3, 69.4*, 76.8, 79.1, 79.2*, 90.7*, 93.0, 
156.6, 156.7*, 207.4, 207.9*. IR (νmax/cm-1) 3378 (w), 2976 (w), 1955 (w), 1683 (s), 1506 (m), 
1365 (m), 1257 (m), 1162 (s), 1051 (s), 1024 (s). HRMS (ESI-TOF) m/z calcd for C11H18NO3 
[M − H]+ 212.1287, found 212.1289. 
 
tert-Butyl ((2S)-3-hydroxyhex-5-yn-2-yl)carbamate (207a) 
 
The title compound 207a was obtained after flash column chromatography (EtOAc/hexane = 
3:7) as a 1.1:1 mixture of syn and anti diasteresomers following the general procedure using 
tert-butyl (1-oxopropan-2-yl)carbamate 205a (0.06 g, 0.34 mmol), allenylboronic acid pinacol 
ester 71 (69.0 μL, 0.37 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 18.0 μL, 0.017 mmol, 5 
mol%)  in dry THF (1 mL). Yellow oil (0.044 g, 60%). Rf (EtOAc/hexane = 2:8) = 0.15. 1H 
NMR (500 MHz, CDCl3) (mixture of two allene diastereomers, relative integrations given for 
each diastereomer) δ 1.18 (d, 3H, J = 6.8 Hz, CH3, for minor isomer), 1.24 (d, 3H, J = 6.8 Hz, 
CH3, for minor isomer), 1.44 (s, 9H, C(CH3)3, for each isomer), 2.08 (t, 1H, J = 2.7 Hz, CH 
alkyne, for each isomer), 2.39-2.41 (m, 2H, CH2, for minor isomer), 2.42-2.45 (m, 2H, CH2, 
for major isomer), 3.00 (br s, 1H, OH, for major isomer), 3.13 (br s, 1H, OH, for minor isomer), 
3.70-3.85 (m, 2H, 2CH, for each isomer), 4.85-4.91 (m, 1H, NH, for each isomer). 13C{1H} 
NMR (125 MHz, CDCl3) (mixture of two allene diastereomers, minor indicated by asterisk) δ 
14.8, 18.2, 23.7*, 24.7, 28.3, 38.47*, 38.49, 49.5, 50.1*, 70.7, 72.7*, 72.9, 79.6*, 79.7, 80.7, 
155.9*, 156.2. IR (νmax/cm-1) 3368 (w), 2980 (w), 1955 (w), 1683 (s), 1506 (s), 1365 (s), 1244 









tert-Butyl ((4S,5S)-5-hydroxyocta-6,7-dien-4-yl)carbamate (206b) 
 
 The title compound 206b was obtained after flash column chromatography (EtOAc/hexane = 
2:8) as a 5.2:1 mixture of syn and anti diastereomers following the general procedure using 
tert-butyl(1-oxopentan-2-yl)carbamate 205b (0.149 g, 0.74 mmol), allenylboronic acid pinacol 
ester 71 (155.6 μL, 0.81 mmol, 1.1 equiv.) and Et2Zn (1 M in toluene, 79.17 μL, 0.074 mmol, 
10 mol%)  in dry toluene (2 mL). Colorless oil (0.145 g, 81%). Rf (EtOAc/hexane = 2:8) = 
0.45. 1H NMR (500 MHz, CDCl3) (mixture of two allene diastereomers, relative integrations 
given for each diastereomer) δ 0.92 (t, 3H, J = 7.0 Hz, CH3, for each isomer), 1.31-1.40 (m, 
3H, CH and CH2, for each isomer), 1.43 (s, 9H, C(CH3)3, for each isomer), 1.50-1.56 (m, H, 
CH, for each isomer), 3.00 (br s, 1H, OH, minor isomer), 3.17 (br s, 1H, OH, major isomer), 
3.59 (br s, 1H, CH, major isomer), 3.70-3.73 (m, 1H, CH, minor isomer), 4.16 (br s, 1H, CH, 
major isomer), 4.23 (br s, 1H, CH, minor isomer), 4.85-4.90 (m, 2H, CH2=C=, major isomer), 
4.94-4.96 (m, 2H, CH2=C=, minor isomer), 5.18-5.27 (m, 1H, CH=C=, for each isomer). 
13C{1H} NMR (125 MHz, CDCl3) (mixture of two allene diastereomers, minor indicated by 
asterisk) δ 13.9, 19.3, 28.3, 34.0, 34.2*, 54.9, 55.2*, 70.2*, 71.4, 77.3, 79.2, 79.4*, 90.5*, 92.3, 
156.4, 156.5*, 207.6. IR (νmax/cm-1) 3380 (m), 2959 (m), 1955 (m), 1683 (s), 1506 (s), 1365 
(s), 1248 (s), 1166 (s), 1055 (s), 1018 (s), 843 (s). HRMS (ESI-TOF) m/z calcd for 
C13H23NO3Na [M + Na]+ 264.1576, found 264.1573. 
 
tert-Butyl ((4S,5S)-5-hydroxy-2-methylocta-6,7-dien-4-yl)carbamate (206c) 
 











2:8) as a 5.7:1 mixture of syn and anti diastereomers following the general procedure using 
tert-butyl (4-methyl-1-oxopentan-2-yl)carbamate 205c (0.18 g, 0.83 mmol), allenylboronic 
acid pinacol ester 71 (176.56 μL, 0.92 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 88.80 μL, 
0.083 mmol, 10 mol%)  in dry toluene (2 mL). White solid (0.172 g, 81%). Mp = 38-40 °C. Rf 
(EtOAc/hexane = 2:8) = 0.37. 1H NMR (500 MHz, CDCl3) (mixture of two allene 
diastereomers, relative integrations given for each diastereomer) δ 0.92 (d, 6H, J = 6.0 Hz, 
2CH3, for each isomer), 1.27-1.39 (m, 1H, CH, for each isomer), 1.43 (s, 9H, C(CH3)3, for each 
isomer), 1.65-1.68 (m, 2H, CH2, for each isomer), 3.11 (br s, 1H, OH, major isomer), 2.95 (br 
s, 1H, OH, minor isomer), 3.68 (br s, 1H, CH, major isomer), 3.70-3.80 (br s, 1H, CH, minor 
isomer), 4.12 (br s, 1H, CH, major isomer), 4.22 (br s, 1H, CH, minor isomer), 4.79-4.90 (m, 
2H, CH2=C=, for each isomer), 5.18-5.20 (m, 1H, CH=C=, minor isomer), 5.25-5.27 (m, 1H, 
CH=C=, major isomer). 13C{1H} NMR (125 MHz, CDCl3) (mixture of two allene 
diastereomers, minor indicated by asterisk) δ 22.0*, 23.2, 24.8, 28.3, 40.8, 41.3*, 53.2, 53.9*, 
71.7, 72.5*, 76.8, 79.2, 79.7*, 91.2*, 92.3, 156.3, 156.5*, 207.6. IR (νmax/cm-1) 3361 (m), 2956 
(m), 1955 (m), 1682 (s), 1504 (s), 1365 (s), 1248 (s), 1166 (s), 1047 (s), 843 (s). HRMS (ESI-
TOF) m/z calcd for C14H25NO3Na [M + Na]+ 278.1732, found 278.1720.  
 
tert-Butyl ((2S,3S)-3-hydroxy-1-phenylhexa-4,5-dien-2-yl)carbamate (206d)  
 
The title compound 206d was obtained after flash column chromatography (EtOAc/hexane = 
3:7) as a 2.5:1 mixture of syn and anti diastereomers following the general procedure using 
tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate 205d (0.093 g, 0.373 mmol), allenylboronic 
acid pinacol ester 71 (78.78 μL, 0.41 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 40.00 μL, 
0.0373 mmol, 10 mol%)  in dry toluene (1 mL). White solid (0.087 g, 80%). Mp = 60-62 °C. 
Rf (EtOAc/hexane = 3:7) = 0.53. 1H NMR (500 MHz, CDCl3) (mixture of two allene 









isomer), 1.43 (s, 9H, C(CH3)3, major isomer), 2.61 (br s, 1H, OH, major isomer), 2.88-2.96 (m, 
2H, CH2Ph, for each isomer), 3.76 (br s, 1H, CH, minor isomer), 3.82 (br s, 1H, CH, major 
isomer), 4.15 (br s, 1H, CH, major isomer), 4.27 (br s, 1H, CH, minor isomer), 4.85-4.91 (m, 
2H, CH2=C=, for each isomer), 5.24-5.29 (m, 1H, CH=C=, for each isomer), 7.19-7.29 (m, 5H, 
5CHAr, for each isomer). 13C{1H} NMR (125 MHz, CDCl3) (mixture of two allene 
diastereomers, minor indicated by asterisk) δ 28.5, 36.1*, 38.2, 56.1*, 56.4, 69.4, 77.9*, 78.0, 
79.4, 79.8*, 91.2*, 92.6, 126.3*, 126.6, 128.4, 129.2*, 129.32*, 129.37, 138.0*, 138.2, 156.0, 
207.4*, 207.6. IR (νmax/cm-1) 3379 (m), 2981 (w), 2358 (s), 1954 (w), 1675 (s), 1521 (s), 1452 
(m), 1248 (s), 1168 (s), 1002 (m), 837 (s), 759 (m), 703 (s). HRMS (ESI-TOF) m/z calcd for 
C17H24NO3 [M + H]+ 290.1756, found 290.1751.   
 
tert-Butyl ((3S,4S)-4-hydroxy-2-methylhepta-5,6-dien-3-yl)carbamate (206e) 
 
The title compound 206e was obtained after flash column chromatography (EtOAc/hexane = 
2:8) as a 9:1 mixture of syn and anti diastereomers following the general procedure using tert-
butyl (3-methyl-1-oxobutan-2-yl)carbamate 205e (0.10 g, 0.496 mmol), allenylboronic acid 
pinacol ester 71 (103.75 μL, 0.54 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 37.14 μL, 
0.035 mmol, 7 mol%)  in dry toluene (1 mL). White solid (0.106 g, 88%). Mp = 39-41 °C. Rf 
(EtOAc/hexane = 2:8) = 0.35. 1H NMR (500 MHz, CDCl3) (mixture of two allene 
diastereomers, relative integrations given for each diastereomer) δ 0.94 (d, 3H, J = 6.5 Hz, CH3, 
for each isomer), 0.99 (d, 3H, J = 6.5 Hz, CH3, for each isomer), 1.44 (s, 9H, C(CH3)3, for each 
isomer), 1.87-1.93 (m, 1H, CH, for each isomer), 2.68 (br s, 1H, OH, minor isomer), 2.80 (br 
s, 1H, OH, major isomer), 3.20-3.23 (m, 1H, CH, minor isomer), 3.26-3.29 (m, 1H, CH, major 
isomer), 4.28 (br s, 1H, CH, minor isomer), 4.33 (br s, 1H, CH, major isomer), 4.85-4.93 (m, 
2H, CH2=C=, for each isomer), 5.19-5.21 (m, 1H, CH=C=, minor isomer), 5.25-5.26 (m, 1H, 








diastereomers, minor indicated by asterisk) δ 18.8, 19.9, 20.1, 28.3, 29.8, 30.0*, 60.4, 60.8*, 
69.3, 69.4*, 76.8, 79.1, 79.2*, 90.7*, 93.0, 156.6, 156.7*, 207.4, 207.9*. IR (νmax/cm-1) 3373 
(m), 2979 (m), 2361 (m), 1955 (w), 1662 (s), 1525 (s), 1367 (s), 1245 (s), 1166 (s), 1018 (m), 
869 (m), 684 (m). HRMS (ESI-TOF) m/z calcd for C13H23NO3Na [M + Na]+ 264.1576, found 
264.1581.  
 
tert-Butyl ((1S,2S)-2-hydroxy-1-phenylpenta-3,4-dien-1-yl)carbamate (206f) 
 
The title compound 206f was obtained after flash column chromatography as a 5.5:1 mixture 
of syn and anti diastereoisomers following the general procedure using tert-butyl (2-oxo-1-
phenylethyl)carbamate 205f (0.15 g, 0.637 mmol), allenylboronic acid pinacol ester 71 (133.80 
μL, 0.70 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 68.00 μL, 0.0637 mmol, 10 mol%)  in 
dry toluene (2 mL). White solid (0.124 g, 70%). Mp = 96-98 °C. Rf (EtOAc/hexane = 3:7) = 
0.51. 1H NMR (500 MHz, CDCl3) (mixture of two allene diastereomers, relative integrations 
given for each diastereomer) δ 1.42 (br s, 9H, C(CH3)3, for each isomer), 2.71 (br s, 1H, OH, 
for each isomer), 4.39 (br s, 1H, CH, for each isomer), 4.71-4.87 (m, 3H, CH2=C= and CH, for 
each isomer), 5.22 (q, 1H, J = 6.0 Hz, CH=C=, for minor isomer), 5.47-5.52 (m, 2H, CH2=C=, 
for major isomer), 7.25-7.32 (m, 5H, 5CHAr, for each isomer). 13C{1H} NMR (125 MHz, 
CDCl3) (mixture of two allene diastereomers, minor indicated by asterisk) δ 28.3, 59.1, 72.3*, 
72.7, 77.9, 79.8, 91.0*, 91.9, 126.7*, 127.0, 127.5, 127.6*, 128.3*, 128.5, 140.0, 156.0, 156.1*, 
207.6*, 207.7. IR (νmax/cm-1) 3392 (m), 2979 (w), 2358 (s), 1949 (w), 1683 (s), 1507 (s), 1368 
(m), 1166 (m), 1019 (m), 838 (m), 699 (s). HRMS (ESI) m/z calcd for C16H21NO3Na [M + Na]+ 














The title compound 206g was obtained after flash column chromatography (EtOAc/hexane = 
2:8) as a 2.5:1 mixture of syn and anti diastereomers following the general procedure using 
tert-butyl 3-(2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-indole-1-carboxylate 205g 
(0.05 g, 0.128 mmol), allenylboronic acid pinacol ester 71 (27.00 μL, 0.14 mmol, 1.10 equiv.) 
and Et2Zn (1 M in toluene, 14.00 μL, 0.0128 mmol, 10 mol%)  in dry toluene (1 mL). Colourless 
oil (0.043 g, 78%). Rf (EtOAc/hexane = 2:8) = 0.33. 1H NMR (500 MHz, CDCl3) (mixture of 
two allene diastereomers, relative integrations given for each diastereomer) δ 1.39 (s, 9H, 
C(CH3)3, minor isomer), 1.42 (s, 9H, C(CH3)3, major isomer), 1.65 (s, 9H, C(CH3)3, for each 
isomer), 2.52 (br s, 1H, OH, major isomer), 2.91-3.06 (m, 2H, CH2, for each isomer), 3.93 (br 
s, 1H, CH, major isomer), 4.06 (br s, 1H, CH, minor isomer), 4.23 (br s, 1H, CH, major isomer), 
4.32 (br s, 1H, CH, minor isomer),  4.87-5.04 (m, 2H, CH2=C=, for each isomer), 5.26-5.32 (m, 
1H, CH=C=, for each isomer), 7.22-7.66 (m, 4H, 4CHAr, for each isomer), 8.13 (br s, 1H, CHAr, 
for each isomer). 13C{1H} NMR (125 MHz, CDCl3) (mixture of two allene diastereomers, 
minor indicated by asterisk) δ 28.2, 28.3*, 54.7, 55.3*, 69.3, 71.7*, 78.1*, 78.3, 79.5, 79.8*, 
83.5, 91.3*, 92.6, 115.21, 115.27*, 116.8*, 117.0, 119.0, 119.2*, 122.5, 123.9, 124.41, 
124.46*, 130.7, 135.4, 149.7, 156.1, 207.4, 207.5*. IR (νmax/cm-1) 3385 (w), 2975 (w), 2930 
(w), 1955 (w), 1730 (s), 1684 (s), 1507 (m), 1452 (s), 1367 (s), 1252 (s), 1157 (s), 1085 (s), 
1015 (m), 852 (m), 744 (s). HRMS (ESI-TOF) m/z calcd for C24H32N2O5Na [M + Na]+ 














The title compound 215 was obtained after flash column chromatography (Et2O/hexane = 2:8) 
as a 1.3:1 mixture of syn and anti diastereomers following the general procedure using 2-
(tritylamino)propanal 214 (0.10 g, 0.317 mmol), allenylboronic acid pinacol ester 71 (78.00 
μL, 0.41 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 34.0 μL, 0.0317 mmol, 10 mol%)  in 
dry toluene (1 mL). Colourless oil (0.093 g, 82%). Rf (Et2O/hexane = 2:8) = 0.41. 1H NMR 
(300 MHz, CDCl3) (mixture of two allene diastereomers, relative integrations given for each 
diastereomer) δ 0.43 (d, 3H, J = 6.6 Hz, CH3, minor isomer), 0.75 (d, 3H, J = 6.6 Hz, CH3, 
major isomer), 2.23 (br s, 1H, NH, for each isomer), 2.69-2.77 (m, 1H, CH, for each isomer), 
3.40-3.43 (m, 1H, CH, for each isomer), 4.74-4.77 (m, 2H, CH2=C, major isomer), 4.80-4.83 
(m, 2H, CH2=C, minor isomer), 4.98 (q, 1H, J = 6.0, 6.3 Hz, CH=C, major isomer), 5.22 (q, 
1H, J = 6.6 Hz, CH=C, minor isomer), 7.15-7.28 (m, 10H, 10CHAr, for each isomer), 7.54 (d, 
5H, J = 7.8 Hz, 5CHAr, for each isomer). 13C{1H} NMR (75 MHz, CDCl3) (mixture of two 
allene diastereomers, minor indicated by asterisk) δ 15.9, 17.1*, 52.6, 53.0*, 71.2, 71.3*, 73.2*, 
76.6, 91.7*, 92.2, 126.4, 127.9, 128.7, 128.8*, 146.73, 146.76*, 207.1, 207.9*. IR (νmax/cm-1) 
3385 (w), 3056 (w), 2970 (w), 1952 (m), 1490 (s), 1447 (s), 1031 (s), 845 (s), 744 (s), 705 (s). 
HRMS (ESI-TOF) m/z calcd for C25H26NO [M + H]+ 356.2014, found 356.2011. 
 
General Procedure for Base-catalyzed Cyclization of N-Boc Allenylamino 
Alcohols  
 
To a solution of the allenyl product 206 in dry THF was added NaH (60% in mineral oil, 2.00 


















reaction mixture was quenched by saturated aqueous NH4Cl solution, washed with water (10 
mL), dried (MgSO4), and then purified by flash column chromatography (acetone/n-pentane) 
to afford the corresponding oxazolidinone products 229. 
 
(4S,5S)-4-Methyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (229a)  
 
The title compound 229a was obtained as a single diastereomer following the general procedure 
using 206a (0.060 g, 0.28 mmol) and NaH (60% in mineral oil, 18.81 mg, 0.56 mmol, 2.00 
equiv.) in THF (1.0 mL). Colourless oil (0.024 g, 61%). Rf (2% CH2Cl2/Et2O) = 0.52. [𝛼]+,,	= 
–30.3 (c 1.2 CHCl3). 1H NMR (500 MHz, CDCl3) δ 1.28 (d, 3H, J = 6.0 Hz, CH3), 3.75-3.80 
(m, 1H, CH), 4.55 (t, 1H, J = 7.0 Hz, CH), 4.93-5.00 (m, 2H, CH2=C=), 5.32 (q, 1H, J = 7.0 
Hz, CH=C=), 6.02 (br s, 1H, NH). 13C{1H} NMR (125 MHz, CDCl3) δ 20.0, 54.0, 78.6, 81.6, 
89.0, 158.9, 209.2. IR (νmax/cm-1) 3272 (m), 2926 (w), 1955 (w), 1739 (s), 1378 (m), 1003 (s), 





 The title compound 229b was obtained as s single diastereomer after column chromatography 
(acetone/n-pentane = 2:8) following the general procedure using 206b (0.067 g, 0.28 mmol) 
and NaH (60% in mineral oil, 18.81 mg, 0.56 mmol, 2.00 equiv.) in THF (1.0 mL). Colorless 
oil (0.026 g, 55%). Rf (acetone/n-pentane = 2:8) = 0.45. [𝛼]+,,	= –24.9 (c 1.3 CHCl3). 1H NMR 
(500 MHz, CDCl3) δ 0.95 (t, 3H, J = 7.0, 7.5 Hz, CH3), 1.32-1.43 (m, 2H, CH2), 1.54-1.57 (m, 











5.34 (q, 1H, J = 6.5, 7.0 Hz, CH=C=), 6.51 (br s, 1H, NH). 13C{1H} NMR (125 MHz, CDCl3) 
δ 73.7, 78.6, 96.7, 117.8, 138.4, 140.0, 149.4, 219.0, 268.8. IR (νmax/cm-1) 3266 (m), 2959 (m), 
2932 (m), 1955 (m), 1742 (s), 1387 (s), 1239 (s), 1239 (s), 978 (s), 852 (s), 767 (s). HRMS 
(ESI-TOF) m/z calcd for C9H12NO2 [M − H]+ 166.0862, found 166.0870.  
 
(4S,5S)-4-Isobutyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (229c)  
 
The title compound 229c was obtained as s single diastereomer after column chromatography 
(acetone/n-pentane = 2:8) following the general procedure using 206c (0.05 g, 0.195 mmol) 
and NaH (60% in mineral oil, 18.81 mg, 0.39 mmol, 2.00 equiv.) in THF (1 mL). Colorless oil 
(0.021 g, 58%). Rf (acetone/n-pentane = 2:8) = 0.30. [𝛼]+,,	= –32.6 (c 1 CHCl3). 1H NMR (500 
MHz, CDCl3) δ 0.91-0.93 (m, 6H, 2CH3), 1.38-1.43 (m, 1H, CH), 1.48-1.53 (m, 1H, CH), 1.61-
1.68 (m, 1H, CH), 3.70-3.74 (m, 1H, CH), 4.58-4.61 (m, 1H, CH), 4.93-5.00 (m, 2H, CH2=C=), 
5.33 (q, 1H, J = 6.5 Hz, CH=C=), 6.28 (br s, 1H, NH). 13C{1H} NMR (125 MHz, CDCl3) δ 
22.2, 23.1, 25.2, 44.1, 56.5, 78.6, 80.5, 89.5, 159.1, 209.1. IR (νmax/cm-1) 3256 (m), 2962 (m), 
1956 (w), 1742 (s), 1387 (m), 1228 (m), 993 (m), 852 (m), 734 (m). HRMS (ESI-TOF) m/z 




The title compound 229d was obtained as a 4.3:1 mixture of two diastereomers after column 
chromatography (acetone/n-pentane = 2:8) following the general procedure using 206d (0.10 
g, 0.414 mmol) and NaH (60% in mineral oil, 27.88 mg, 0.83 mmol, 2.00 equiv.) in THF (1 











CDCl3) (mixture of two diastereomers, relative integrations given for each diastereomer) δ 0.94 
(br d, 3H, J = 6.5 Hz, CH3, major isomer), 0.98 (br d, 3H, J = 6.0 Hz, CH3, major isomer), 0.99 
(br d, 3H, J = 6.0 Hz, CH3, minor isomer), 1.77 (br s, 1H, CH, major isomer), 1.90 (br s, 1H, 
CH, minor isomer), 3.45 (br s, 1H, CH, major isomer), 3.61-3.63 (m, 1H, CH, major isomer), 
4.74 (br s, 1H, CH, major isomer), 4.92-4.97 (m, 2H, CH2=C=, for each isomer), 5.04-5.06 (m, 
1H, CH, minor isomer), 5.32-5.37 (m, 1H, CH=C=, for each isomer), 6.58 (br s, 1H, NH, minor 
isomer), 6.66 (br s, 1H, NH, major isomer). 13C{1H} NMR (125 MHz, CDCl3) (mixture of two 
diastereomers, minor indicated by asterisk) δ 17.93, 17.97, 28.1*, 32.3, 62.3*, 63.5, 75.5*, 78.0, 
78.6, 78.7*, 85.9*, 90.4, 159.1, 159.8*, 208.7, 210.0*. IR (νmax/cm-1) 3260 (m), 2963 (m), 1955 
(w), 1743 (s), 1387 (m), 1228 (m), 993 (m), 851 (m), 734 (m). HRMS (ESI-TOF) m/z calcd for 
C9H13NO2Na [M + Na]+ 190.0838, found 190.0840.  
 
 
(4S,5S)-4-Benzyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one (229e)  
 
The title compound 229e was obtained as a 3:1 mixture of two diastereomers after column 
chromatography (acetone/n-pentane = 2:8) following the general procedure using 206e (0.087 
g, 0.30 mmol) and NaH (60% in mineral oil, 20.16 mg, 0.60 mmol, 2.00 equiv.) in THF (1.0 
mL). Colorless oil (0.041 g, 63%). Rf (acetone/n-pentane = 2:8) = 0.31. 1H NMR (500 MHz, 
CDCl3) (mixture of two diastereomers, relative integrations given for each diastereomer) δ 
2.70-2.75 (m, 2H, CH2Ph, minor isomer), 2.86-2.90 (m, 2H, CH2Ph, major isomer), 3.90 (q, 
1H, J = 6.5 Hz, CH, major isomer), 4.10-4.14 (m, 1H, CH, minor isomer), 4.72 (t, 1H, J = 6.0 
Hz, CH, major isomer), 4.84-4.93 (m, 2H, CH2=C=, major isomer), 4.96-4.98 (m, 2H, CH2=C=, 
minor isomer), 5.13 (t, 1H, J = 8.0 Hz, CH, minor isomer), 5.24 (q, 1H, J = 6.5, 7.0 Hz, CH=C=, 








isomer), 6.19 (br s, 1H, NH, major isomer), 7.16 (d, 2H, J = 7.5 Hz, 2CHAr, for each isomer), 
7.22-7.25 (m, 1H, CHAr, for each isomer), 7.29-7.32 (m, 2H, 2CHAr, for each isomer). 13C{1H} 
NMR (125 MHz, CDCl3) (mixture of two diastereomers, minor indicated by asterisk) δ 37.5*, 
40.9, 57.5*, 59.3, 78.0*, 78.3*, 78.7, 79.3, 86.3*, 89.5, 127.33, 127.39*, 129.10, 129.18*, 
129.2*, 129.4, 136.0, 136.9*, 158.7, 209.0, 210.0*. IR (νmax/cm-1) 3267 (w), 2917 (w), 1955 
(w), 1743 (s), 1386 (m), 1230 (m), 992 (s), 854 (s), 699 (s). HRMS (ESI-TOF) m/z calcd for 




The title compound 229f was obtained as a single diastereoisomer after careful column 
chromatography following the general procedure from 206f (0.094 g, 0.34 mmol) and NaH 
(60% in mineral oil, 22.88 mg, 0.68 mmol, 2.00 equiv.) in THF (1.0 mL). White solid (0.050 
g, 66%). Mp = 68-70 °C. Rf (2% CH2Cl2/Et2O) = 0.78. [𝛼]+,,	= –38.5 (c 2.2 CHCl3). 1H NMR 
(500 MHz, CDCl3) δ 4.78 (s, 2H, 2CH), 4.96-5.04 (m, 2H, CH2=C=), 5.43-5.44 (m, 1H, 
CH=C=), 6.33 (s, 1H, NH), 7.33-7.40 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 
61.7, 78.9, 82.2, 88.8, 126.2, 128.8, 129.1, 138.6, 158.8, 209.2. IR (νmax/cm-1) 3266 (m), 3160 
(m), 1958 (w), 1717 (s), 1387 (s), 1228 (s), 1012 (m), 857 (m), 736 (m), 700 (s). HRMS (ESI) 
m/z calcd for C12H11NO2Na [M + Na]+ 224.0687, found 224.0692.    














indole-1-carboxylate (229g)  
 
The title compound 229g was obtained as a single diastereomer after careful column 
chromatography (acetone/n-pentane = 2:8) following the general procedure using 206g (0.036 
g, 0.084 mmol) and NaH (60% in mineral oil, 5.68 mg, 0.168 mmol, 2.00 equiv.) in THF (1.0 
mL). Colourless gummy oil (0.015 g, 50%). Rf (acetone/n-pentane = 2:8) = 0.26. [𝛼]+,,	= –35.8 
(c 0.7 CHCl3). 1H NMR (500 MHz, CDCl3) δ 1.68 (s, 9H, C(CH3)3), 2.90-2.94 (m, 1H, CH), 
3.00-3.04 (m, 1H, CH), 4.03 (br s, 1H, CH), 4.81 (br s, 1H, CH), 4.96 (br s, 2H, CH2=C=),  5.19 
(br s, 1H, NH), 5.37 (br d, 1H, J = 6.5 Hz, CH=C=), 7.26 (br s, 1H, CHAr), 7.34-7.37 (m, 1H, 
CHAr), 7.46 (br s, 2H, 2CHAr), 8.15 (br s, 1H, CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 28.2, 
30.5, 57.5, 78.8, 79.4, 84.0, 89.2, 114.9, 115.5, 118.5, 122.8, 123.9, 124.9, 129.7, 135.6, 149.4, 
157.7, 208.8. IR (νmax/cm-1) 3277 (w), 2982 (w), 2357 (w), 1955 (w), 1751 (s), 1730 (s), 1452 
(s), 1368 (s), 1255 (s), 1155 (s), 1086 (m), 854 (m). HRMS (ESI-TOF) m/z calcd for 
C20H23N2O4 [M + H]+ 355.1658, found 355.1664. 
 
(4S,5R)-3-Benzyl-4-methyl-5-(propa-1,2-dien-1-yl)oxazolidin-2-one  (230a) 
 
 To a solution of the allenyl product 218a (0.09 g, 0.29 mmol) in dry THF (1 mL) was added 
NaH (60% in mineral oil, 16.00 mg, 0.59 mmol, 2.00 equiv.) at 0 °C. The reaction was stirred 
at room temperature for 60 min. Then, the reaction mixture was quenched with saturated 
aqueous NH4Cl solution (5 mL), washed with water (10 mL) and dried (MgSO4). Purification 
by flash column chromatography (EtOAc/hexane = 3:7) afforded the corresponding 











[𝛼]+,,	= –56.7 (c 1.7 CHCl3). 1H NMR (300 MHz, CDCl3) δ 1.14 (d, 3H, J = 6.6 Hz, CH3), 
3.69-3.78 (m, 1h, CH), 4.03 (d, 1H, J = 15.3 Hz, CHPh), 4.82 (d, 1H, J = 15.0 Hz, CHPh), 4.86-
4.98 (m, 3H, CH2=C= and CH), 5.17-5.24 (m, 1H, CH=C=), 7.25-7.37 (m, 5H, 5CHAr). 13C{1H} 
NMR (75 MHz, CDCl3) δ 13.7, 45.7, 53.3, 76.1, 77.6, 86.1, 127.9, 128.0, 128.8, 135.9, 157.5, 
209.7. IR (νmax/cm-1) 2924 (w), 2358 (w), 1358 (w), 1743 (s), 1675 (m), 1414 (s), 1243 (m), 
1159 (m), 761 (m), 700 (s). HRMS (ESI-TOF) m/z calcd for C14H15NO2Na [M + Na]+ 252.1000, 
found 252.1003. 
 
Synthesis of O-Protected α-Hydroxy Aldehydes (242a-c) 
 
O-protected α-hydroxy aldehydes 242a-c were prepared from commercially available ethyl (S)-
lactate including O-protection reaction followed by reduction with    DIBAL-H. 
To a solution of O-protected α-hydroxy ester S242 in Et2O at −78 °C, was added 
dropwise diisobutylaluminum hydride (DIBAL-H) (1 M solution in hexane, 1.05 equiv.) over 
a period of 45 min. The mixture was stirred at the same temperature for 1.5 h, and then quenched 
by the addition of precooled MeOH (1 mL). The reaction mixture was allowed to warm to room 
temperature, ice (5 g) was added with heavy agitation, filtered through a sintered funnel and 
the filtrate was extracted with CH2Cl2. The organic layer was washed with brine (10 mL), dried 
(Na2SO4), and concentrated under reduced pressure to yield the title aldehyde 188a-c, which 






















Ethyl (S)-2-(benzyloxy)propanoate (S242a) 
 
To a solution of ethyl (S)-lactate (2.00 mL, 17.64 mmol) and BnBr (2.22 mL, 19.40 mmol, 1.10 
equiv.) in THF (15 mL) at 0 °C, was added NaH (0.83 g, 21.17 mmol, 1.20 equiv.) under 
nitrogen. The mixture was then stirred at 0 °C for 15 min followed by stirring at room 
temperature for 18 h. The reaction mixture was quenched with saturated aqueous NaHCO3 
solution (1 mL), and then washed with water (20 mL). The organic layer was dried (Na2SO4), 
concentrated under reduced pressure, and purified by flash column chromatography 
(Et2O/hexane = 2:8) to afford the resulting O-Bn α-hydroxy ester S242a. Colourless oil (2.89 
g, 79%). 1H NMR (500 MHz, CDCl3) δ 1.26 (t, 3H, J = 7.0 Hz, CH3), 1.42 (d, 3H, J = 7.0 Hz, 
CH3), 4.03 (q, 1H, J = 7.0, 6.5 Hz, CH), 4.16-4.21 (m, 2H, CH2), 4.43 (d, 1H, J = 11.5 Hz, 
CHPh), 4.68 (d, 1H, J = 11.5 Hz, CHPh), 7.24-7.36 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, 
CDCl3) δ 14.2, 18.7, 60.8, 71.98, 71.99, 74.0, 127.8, 127.9, 128.4, 137.6, 173.2. The NMR data 




The title aldehyde 242a was obtained following the general DIBAL-H procedure using ethyl 
(S)-2-(benzyloxy)propanoate S242a (0.287 g, 1.38 mmol) and DIBAL-H (dissolved in 0.30 mL 
n-hexane, 0.28 mL, 1.45 mmol, 1.05 equiv.) in Et2O (5 mL). Colourless oil (0.147 g, 65%). 1H 
NMR (500 MHz, CDCl3) δ 1.32 (dd, 3H, J = 6.9, 4.1 Hz, CH3), 3.86-3.91 (m, 1H, CH), 4.57-
4.66 (m, 2H, CH2Ph), 7.29-7.36 (m, 5H, 5CHAr), 9.60 (s, 1H, CHO). 13C{1H} NMR (125 MHz, 
CDCl3) δ 15.3, 72.0, 79.4, 127.9, 128.0, 128.1, 128.6, 137.3, 203.4. The NMR data matched 











Ethyl (S)-2-((tert-butyldimethylsilyl)oxy)propanoate (S242b) 
 
To a solution of ethyl (S)-lactate (1.00 mL, 8,82 mmol) and TBSCl (2.22 mL, 17.62 mmol, 2.00 
equiv.) in DMF (15 mL), was added imidazole (1.50 g, 22.05 mmol, 2.50 equiv.) under nitrogen 
and stirred at room temperature for 24 h. The reaction mixture was then poured into water (20 
mL) and extracted with EtOAc (3×10 mL). The organic layer was washed with water (10 mL), 
dried (Na2SO4), concentrated under reduced pressure, and purified by flash column 
chromatography (Et2O/hexane = 2:8) to afford the resulting O-TBS α-hydroxy ester S242b. 
Colourless oil (1.85 g, 90%). 1H-NMR (500 MHz, CDCl3) δ 0.04 (s, 3H, CH3 for TBS), 0.07 
(s, 3H, CH3 for TBS), 0.89 (s, 9H, (CH3)3 in TBS), 1.25 (t, 3H, J = 7.1 Hz, CH3), 1.36 (d, 3H, 
J = 6.7 Hz, CH3), 4.11-4.19 (m, 2H, CH2), 4.28 (q, 1H, J = 6.5, 7.0 Hz, CH). 13C{1H} NMR 
(125 MHz, CDCl3) δ -5.3, -5.0, 14.1, 18.2, 21.2, 25.65, 25.66, 60.6, 68.3, 173.9. The NMR data 
matched with those previously reported.203 
 
(S)-2-((tert-Butyldimethylsilyl)oxy)propanal (242b)  
 
The title aldehyde 242b was obtained following the general DIBAL-H procedure using ethyl 
(S)-2-((tert-butyldimethylsilyl)oxy)propanoate S242b (0.95 g, 4.088 mmol) and DIBAL-H 
(dissolved in 1.0 mL n-hexane, 0.80 mL, 4.29 mmol, 1.05 equiv.) in Et2O (5 mL). Colourless 
oil (0.561 g, 73%). 1H NMR (500 MHz, CDCl3) δ 0.05 (s, 3H, CH3 for TBS), 0.06 (s, 3H, CH3 
for TBS), 0.89 (s, 9H, (CH3)3 in TBS), 4.05 (q, 1H, J = 7.0 Hz, CH), 9.56 (s, 1H, CHO).  13C{1H} 
NMR (125 MHz, CDCl3) δ -4.67, -4.61, 18.3, 18.6, 25.85, 25.88, 73.9, 204.0. The NMR data 











Ethyl (S)-2-(trityloxy)propanoate (S242c) 
 
To a solution of ethyl (S)-lactate (1.00 mL, 8,82 mmol) and TrCl (2.95 g, 10.58 mmol, 1.20 
equiv.) in CH2Cl2 (15 mL), was added DBU (1.84 mL, 12.35 mmol, 1.40 equiv.) under nitrogen 
and stirred at room temperature for 48 h. The reaction mixture was then quenched with water 
(5 mL), washed with brine (3×10 mL), and extracted by CH2Cl2 (3×10 mL). The organic layer 
was then dried (Na2SO4), concentrated under reduced pressure, and purified by flash column 
chromatography (Et2O/hexane = 2:8) to afford the resulting O-Tr α-hydroxy ester S242c. White 
solid (1.98 g, 62%). 1H NMR (500 MHz, CDCl3) δ 0.98 (t, 3H, J = 7.0 Hz, CH3), 1.33 (d, 3H, 
J = 6.5 Hz, CH3), 4.18 (q, 1H, J = 6.5 Hz, CH), 3.57-3.65 (m, 2H, CH2), 7.07-7.34 (m, 9H, 
9CHAr), 7.36-7.62 (m, 6H, 6CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 14.1, 20.3, 60.4, 69.9, 
82.1, 88.2, 127.3, 127.4, 127.9, 127.9, 128.01, 128.02, 128.04, 128.1, 128.20, 129.25, 144.1, 




The title aldehyde 242c was obtained following the general DIBAL-H procedure using ethyl 
(S)-2-(trityloxy)propanoate S242c (0.270 g, 0.74 mmol) and DIBAL-H (dissolved in 0.2 mL n-
hexane, 0.14 mL, 0.78 mmol, 1.05 equiv.) in Et2O (5 mL). White solid (0.16 g, 68%). 1H NMR 
(500 MHz, CDCl3) δ 1.28 (d, 3H, J = 7.0 Hz, CH3), 4.00 (m, 1H, CH), 7.21-7.30 (m, 9H, 
9CHAr), 7.46-7.51 (m, 6H, 6CHAr), 8.72 (d, 1H, J = 3.2 Hz, CHO). 13C{1H} NMR (125 MHz, 
CDCl3) δ 17.5, 75.5, 88.1, 127.46, 127.49, 127.8, 128.0, 128.1, 128.2, 128.3, 129.0, 129.3, 












General Pocedure for Allenylation of O-Protected Hydroxy Aldehydes 
 
To a solution of allenylboronic acid pinacol ester 71 (1.10 equiv.) and the hydroxy aldehydes 
(242a-c) in toluene at 0 °C, was added Et2Zn (1 M in toluene, 10 mol%) under nitrogen. The 
mixture was then stirred at 0 °C for 18 h. The reaction mixture was quenched with saturated 
aqueous NH4Cl solution (1 mL), and washed with saturated aqueous NaHCO3 solution (15 mL) 
and water (10 mL). The organic layer was dried (Na2SO4), concentrated under reduced pressure 
and purified by flash column chromatography (EtOAc/hexane) to afford the allenyl hydroxy 




The title compound 243a was obtained after flash column chromatography (EtOAc/hexane = 
3:7) as a 1.4:1 mixture of syn and anti diasteresomers following the general procedure using 
(S)-2-(benzyloxy)propanal 242a (0.051 g, 0.32 mmol), allenylboronic acid pinacol ester 71 
(65.0 μL, 0.34 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 33.0 μL, 0.032 mmol, 10 mol%)  
in dry toluene (1 mL). Colourless oil (0.048 g, 76%). Rf (EtOAc/hexane = 2:8) = 0.45. 1H NMR 
(500 MHz, CDCl3) (mixture of two allene diastereomers, relative integrations given for each 
diastereomer) δ 1.19-1.25 (m, 3H, CH3, for each isomer), 2.33 (br s, 1H, OH, minor isomer), 
2.77 (br s, 1H, OH, major isomer), 3.48-3.53 (m, 1H, CH, major isomer), 3.60-3.65 (m, 1H, 
CH, minor isomer), 4.04 (br s, 1H, CH, major isomer), 4.24 (br s, 1H, CH, minor isomer), 4.47-
4.54 (m, 1H, CHPh, for each isomer), 4.63-4.68 (m, 1H, CHPh, for each isomer), 4.82-4.89 (m, 





















6.8 Hz, CH=C, minor isomer), 7.25-7.36 (m, 5H, 5CHAr, for each isomer). 13C{1H} NMR (125 
MHz, CDCl3) (mixture of two allene diastereomers, minor indicated by asterisk) δ 14.5*, 15.5, 
71.0, 71.3*, 72.0*, 72.3, 76.8, 77.8*, 78.3, 90.6*, 91.0, 127.6, 127.7*, 127.82*, 127.84, 128.4*, 
128.5, 138.2, 138.4*, 208.0*, 208.5. IR (νmax/cm-1) 3409 (w), 2975 (w), 2874 (w), 1956 (m), 
1453 (m), 1374 (m), 1064 (s), 843 (s), 735 (s), 696 (s). HRMS (ESI-TOF) m/z calcd for 




The title compound 243b was obtained after flash column chromatography (EtOAc/hexane = 
3:7) as a 1.1:1 mixture of syn and anti diasteresomers following the general procedure using 
(S)-2-((tert-butyldimethylsilyl)oxy)propanal 242b (0.162 g, 0.86 mmol), allenylboronic acid 
pinacol ester 71 (180.0 μL, 0.94 mmol, 1.10 equiv.) and Et2Zn (1 M in toluene, 92.0 μL, 0.086 
mmol, 10 mol%)  in dry toluene (5 mL). Colourless oil (0.14 g, 70%). Rf (Et2O/hexane = 1:9) 
= 0.37. 1H-NMR (500 MHz, CDCl3) (mixture of two allene diastereomers, relative integrations 
given for each diastereomer) δ 0.01 (br s, 6H, 2CH3 in TBS, for each isomer), 0.82 (s, 9H, 
(CH3)3 in TBS, for each isomer), 1.05 (d, 3H, J = 7.0 Hz, CH3, minor isomer), 1.09 (d, 3H, J = 
7.0 Hz, CH3, major isomer), 2.18 (br s, 1H, OH, major isomer), 2.48 (br s, 1H, OH, major 
isomer), 3.67 (br s, 1H, CH, minor isomer), 3.78 (br s, 1H, CH, minor isomer), 3.82 (br s, 1H, 
CH, major isomer), 3.95 (br s, 1H, CH, major isomer), 4.75 (br s, 2H, CH2=C, for each isomer), 
5.09-5.14 (m, 1H, CH=C, for each isomer). 13C{1H} NMR (125 MHz, CDCl3) (mixture of two 
allene diastereomers, minor indicated by asterisk) δ -4.8, -4.4, -4.2*, 18.0*, 18.4, 19.8, 25.75, 
25.77, 25.8, 25.9, 71.6*, 71.9, 73.8*, 73.9, 76.8*, 77.0, 90.4*, 91.6, 208.2. IR (νmax/cm-1) 3441 
(w), 2928 (m), 2859 (m), 1955 (m), 1463 (m), 1373 (m), 1254 (s), 1057 (s), 834 (s), 774 (s), 











The title compound 243c was obtained after flash column chromatography (Et2O/hexane = 1:9) 
as a single diasteresomer following the general procedure using (S)-2-(trityloxy)propanal 242c 
(0.10 g, 0.316 mmol), allenylboronic acid pinacol ester 71 (67.0 μL, 0.35 mmol, 1.10 equiv.) 
and Et2Zn (1 M in toluene, 34.0 μL, 0.0316 mmol, 10 mol%)  in dry toluene (5 mL). Colourless 
oil (0.046 g, 41%). Rf (Et2O/hexane = 3:7) = 0.41. 1H NMR (500 MHz, CDCl3) δ 0.85 (br s, 
3H, CH3), 2.03 (s, 1H, OH), 3.51 (br s, 1H, CH), 3.71 (br s, 1H, CH), 4.77 (br s, 2H, CH2=C), 
5.21 (br s, 1H, CH=C), 7.16-7.23 (m, 9H, 9CHAr), 7.43 (d, J = 7.0 Hz, 6H, 6CHAr). 13C{1H} 
NMR (125 MHz, CDCl3) δ 16.2, 71.4, 72.6, 77.7, 87.0, 91.3, 127.1, 127.7, 128.8, 144.8, 207.5. 
IR (νmax/cm-1) 3441 (w), 3054 (w), 2982 (w), 1953 (m), 1490 (m), 1448 (s), 1374 (s), 1065 (s), 
845 (s), 745 (s), 697 (s). HRMS (ESI-TOF) m/z calcd for C25H24O2Na [M+Na]+ 379.1674, 
found 379.1668.  
 
General Procedure for Allenylation of N-Bn,N-Boc Amino Aldehydes and 
Subsequent Au(I)-Catalysed Cyclisation 
 
To a solution of allenylboronic acid pinacol ester 71 (1.30 equiv.) and the aldehyde (217a-h) 
in toluene at 0 °C, was added Et2Zn (1 M in toluene, 10 mol%) under nitrogen. The mixture 
was then stirred at 0 °C for 18 h. The reaction mixture was quenched with saturated aqueous 
NH4Cl solution (1 mL), and then washed with saturated aqueous NaHCO3 solution (15 mL) and 















R2 = H, Bn 













pressure to afford the resulting allenyl amino alcohol product. Then, to a solution of this crude 
product (218a-h) in dry DCE was added AuPPh3NTf2 (10 mol%). The reaction was stirred at 
60 °C for 8 h and then filtered through a pad of silica gel and the crude product was used in the 
next step without purification. Chlorotrimethylsilane (5.00 equiv.) was added to a solution of 
the crude dihydrofuran in dry MeOH. The reaction mixture was stirred at room temperature 
overnight, and then was neutralized by the addition of saturated aqueous NaHCO3 solution to 
about pH = 7, followed by purification via flash column chromatography to afford the 
corresponding Boc-deprotected dihydrofuran products 250a-h. 
The NMR spectra for the direct allenylation products 218a-h were complicated by the 
presence of a mixture of rotamers, diastereoisomers, and regioisomers. Therefore, 
dihydrofurans 250a-h were targeted as the final desired products. In the case of the product 
218a was purified by column chromatography as part of the optimization study, and 
characterized to verify formation of the desired allenyl products.  
tert-Butyl benzyl((2S,3R)-3-hydroxyhexa-4,5-dien-2-yl)carbamate (218a)  
 
The title compound 218a was prepared following the general procedure using tert-butyl 
benzyl(1-oxopropan-2-yl)carbamate 217a (0.065 g, 0.24 mmol), allenylboronic acid pinacol 
ester 71 (61 μL, 0.32 mmol, 1.30 equiv.) and Et2Zn (1 M in toluene, 25 μL, 0.024 mmol, 10 
mol%) in dry toluene (2 mL). The crude product was purified by flash column chromatography 
(EtOAc/hexane = 2:8) as a 19:1 mixture of anti and syn diastereomers. Colorless oil (0.07 g, 
96%). Rf (EtOAc/hexane = 2:8) = 0.31. [𝛼]+,,= +7.31 (c 7.2 CH3Cl). 1H NMR (500 MHz, 
CDCl3) (mixture of rotamers) δ 1.17 (d, 0.7H, J = 7.0 Hz), 1.20 (d, 2.3H, J = 7.0 Hz), 1.33-1.45 
(br s, 9H, C(CH3)3), 3.70-3.76 (m, 1H, CH), 4.01-4.12 (m, 0.7H), 4.35-4.49 (m, 3.3H), 4.80 (m, 
2H, CH2=C=), 5.12-5.17 (m, 1H, CH=C=), 7.23-7.33 (m, 5H, 5CHAr). 13C{1H} NMR (125 
MHz, CDCl3) (mixture of rotamers, minor rotamer indicated by asterisk) δ 11.9, 28.3, 51.1, 








207.1. IR (νmax/cm-1) 3473 (m), 2976 (m), 1956 (m), 1680 (s), 1452 (s), 1365 (s), 1332 (m), 
1250 (m), 1164 (s), 1012 (s), 860 (s), 699 (s). HRMS (ESI-TOF) m/z calcd for C18H25NO3Na 




Following the general procedure the crude allenyl product 218a was treated with AuPPh3NTf2 
(17.50 mg, 0.024 mmol, 10 mol%), followed by Boc-deprotection of the crude product by 
treatment with TMSCl (0.14 mL, 1.20 mmol, 5.00 equiv.) in MeOH (2 mL). The title compound 
250a was obtained as a single diastereomer after purification by flash column chromatography 
(Et2O/hexane = 7:3). The isolated yield was calculated for the three steps starting from the 
aldehyde 217a. Colourless oil (0.03 g, 60%). Rf (Et2O/hexane = 7:3) = 0.15. The ee was 
determined by chiral HPLC of the corresponding alcohol using a Phenomenex Lux Cellulose-
3 column; hexane/isopropanol (98:2); flow rate = 0.5 mL/min; 210 nm; tmajor = 9.83 min, tminor 
= 10.95 min, 91% ee. [𝛼]+,,	= +104.5 (c 0.9 CHCl3). 1H NMR (500 MHz, CDCl3) δ 1.06 (d, 
3H, J = 6.5 Hz, CH3), 1.69 (s, 1H, NH), 2.85-2.88 (m, 1H, CH), 3.79 (d, 1H, J = 13.5 Hz, 
CHPh), 3.90 (d, 1H, J = 13.5 Hz, CHPh), 4.62-4.69 (m, 2H, CH2), 4.87-4.88 (m, 1H, CH), 5.81-
5.82 (m, 1H, CH), 5.95-5.97 (m, 1H, CH), 7.21-7.33 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, 
CDCl3) δ 15.6, 51.4, 55.5, 75.7, 89.4, 126.8, 127.0, 127.7, 128.0, 128.3, 140.7. IR (νmax/cm-1) 
3327 (w), 3026 (w), 2964 (w), 2845 (m), 1683 (m), 1630 (m), 1494 (m), 1452 (m), 1355 (m), 
1269 (m), 1068 (s), 1028 (s), 950 (s), 847 (m), 731 (s), 696 (s). HRMS (ESI-TOF) m/z calcd 














The allenyl precursor was prepared following the general procedure using tert-butyl benzyl(1-
oxopentan-2-yl)carbamate 217b (0.485 g, 1.66 mmol), allenylboronic acid pinacol ester 71 
(0.41 mL, 2.16 mmol, 1.30 equiv.) and Et2Zn (1 M in toluene, 180 μL, 0.048 mmol, 10 mol%)  
in dry toluene (5 mL). Following the general procedure, the crude allenyl product 218b was 
treated with AuPPh3NTf2 (0.117 g, 0.16 mmol, 10 mol%) in dry DCE (5 mL). Boc-deprotection 
of the resulting dihydrofuran with TMSCl (0.95 mL, 8.00 mmol, 5.00 equiv.) in MeOH (5 mL) 
gave the title compound 250b as a 4.3:1 mixture of syn and anti diastereomers after purification 
by flash column chromatography (Et2O/hexane = 2:8). The isolated yield was calculated for the 
three steps starting from the aldehyde 217b. Colourless oil (0.26 g, 68%), Rf (Et2O/hexane = 
2:8) = 0.30. 1H NMR (300 MHz, CDCl3) (mixture of two diastereomers, relative integrations 
given for each diastereomer) δ 0.88 (t, 3H, J = 6.30, 6.9 Hz, CH3, for each isomer), 1.28-1.49 
(br m, 2H, CH2, for each isomer), 2.50-2.60 (m, 1H, CH, minor isomer), 2.69 (q, 1H, J = 8.5, 
10.5 Hz, CH, major isomer), 3.80 (s, 2H, CH2Ph, minor isomer), 3.83 (s, 2H, CH2Ph, major 
isomer), 4.58-4.70 (m, 2H, CH2, for each isomer), 4.84-4.86 (m, 1H, CH, minor isomer), 4.93-
4.94 (m, 1H, CH, major isomer), 5.81-5.83 (m, 1H, CH=, for each isomer), 5.90-5.96 (m, 1H, 
CH=, for each isomer), 7.18-7.30 (m, 5H, 5CHAr, for each isomer). 13C{1H} NMR (75 MHz, 
CDCl3) (mixture of two diastereomers, minor indicated by asterisk) δ 14.3, 14.4*, 19.3*, 19.5, 
33.1*, 33.3, 51.8*, 52.3, 60.2, 60.3*, 75.3*, 75.4, 88.3*, 88.6, 126.7, 127.2, 127.4*, 127.7, 
127.8, 128.0*, 128.2, 140.9. IR (νmax/cm-1) 3735 (w), 2956 (m), 2871 (m), 2844 (m), 1457 (m), 
1354 (w), 1073 (s), 734 (s), 696 (s). HRMS (ESI-TOF) m/z calcd for C15H21NONa [M + Na]+ 












The allenyl precursor was prepared following the general procedure using tert-butyl benzyl(4-
methyl-1-oxopentan-2-yl)carbamate 217c (0.198 g, 0.65 mmol), allenylboronic acid pinacol 
ester 71 (160 μL, 0.84 mmol, 1.3 equiv.) and Et2Zn (1 M in toluene, 70 μL, 0.065 mmol, 10 
mol%)  in dry toluene (2 mL).  Following the general procedure, the crude allenyl product 218c 
was treated with AuPPh3NTf2 (44.90 mg, 0.06 mmol, 10 mol%) in dry DCE (2 mL). Boc-
deprotection of the resulting dihydrofuran with TMSCl (0.38 mL, 3.25 mmol, 5.00 equiv.) in 
MeOH (3 mL) gave the title compound 250c as a 3.2:1 mixture of syn and anti diastereomers 
after purification by flash column chromatography (Et2O/hexane = 2:8). The isolated yield was 
calculated for the three steps starting from the aldehyde 217c. Colorless oil (0.097 g, 62%), Rf 
(Et2O/hexane = 2:8) = 0.36. 1H NMR (300 MHz, CDCl3) (mixture of two diastereomers, 
relative integrations given for each diastereomer) δ 0.81-0.92 (m, 6H, 2CH3, for each isomer), 
1.22-1.33 (m, 1H, CH, for each isomer), 1.74-2.00 (m, 1H, CH, for each isomer), 2.77-2.81 (m, 
1H, CH, major isomer), 2.85-2.89 (m, 1H, CH, minor isomer), 3.28 (s, 1H, NH, minor isomer), 
3.34 (s, 1H, NH, major isomer), 3.82-3.92 (m, 2H, CH2Ph, for each isomer), 4.65-4.69 (m, 2H, 
CH2O, for each isomer), 4.97-5.00 (m, 1H, CH, for each isomer), 5.80-5.82 (m, 1H, CH=, for 
each isomer), 5.97-6.00 (m, 1H, CH=, for each isomer), 7.23-7.35 (m, 5H, 5CHAr, for each 
isomer). 13C{1H} NMR (75 MHz, CDCl3) (mixture of two diastereomers, minor indicated by 
asterisk) δ 22.3, 23.5, 24.9, 40.4, 52.3, 54.0*, 58.2, 75.5, 88.8, 127.1, 126.8, 127.9*, 128.2, 
128.33*, 128.36, 140.9. IR (νmax/cm-1) 3735 (w), 2956 (m), 2926 (m), 2868 (m), 1457 (m), 
1131 (m), 1074 (m), 740 (m), 697 (m), 619 (m). HRMS (ESI-TOF) m/z calcd for C16H24NO 












 The allenyl precursor was prepared following the general procedure using tert-butyl benzyl(1-
oxo-3-phenylpropan-2-yl)carbamate 217d (0.278 g, 0.82 mmol), allenylboronic acid pinacol 
ester 71 (0.20 mL, 1.06 mmol, 1.30 equiv.) and Et2Zn (1 M in toluene, 85.00 μL, 0.082 mmol, 
10 mol%)  in dry toluene (2 mL). Following the general procedure, the crude allenyl product 
218d was treated with AuPPh3NTf2 (60.00 mg, 0.08 mmol, 10 mol%) in dry DCE (3 mL). Boc-
deprotection of the resulting dihydrofuran with TMSCl (0.52 mL, 4.10 mmol, 5.00 equiv.) in 
MeOH (3 mL) gave the title compound 250d as a 8.3:1 mixture of syn and anti diastereomers 
after purification by flash column chromatography (EtOAc/hexane = 3:7). The isolated yield 
was calculated for the three steps starting from the aldehyde 217d. Light yellow oil (0.133 g, 
58%). Rf (EtOAc/hexane = 3:7) = 0.34. 1H NMR (500 MHz, CDCl3) (mixture of two 
diastereomers, relative integrations given for each diastereomer) δ 2.70-2.74 (m, 1H, CHPh, 
for each isomer), 2.80-2.83 (m, 1H, CHPh, for each isomer), 2.90 (s, 1H, CH, minor isomer), 
2.98 (br s, 1H, CH, major isomer), 3.77 (q, 2H, J = 13.5 Hz, CH2Ph, for each isomer), 4.63-
4.73 (m, 2H, 2CH−O, for each isomer), 4.89 (br s, 1H, CH, for each isomer), 5.78 (br s, 1H, 
CH=, minor isomer), 5.89 (br s, 1H, CH=, major isomer), 5.98 (br s, 1H, CH=, for each isomer), 
7.12-7.27 (m, 10H, 10CHAr, for each isomer). 13C{1H} NMR (125 MHz, CDCl3) (mixture of 
two diastereomers, minor indicated by asterisk) δ 37.1, 37.4*, 52.10, 52.16*, 61.80, 61.85*, 
75.5*, 75.6, 87.8*, 88.0, 126.1*, 126.2, 126.7, 127.2, 127.73*, 127.79*, 128.0, 128.3, 128.4, 
129.3, 139.2, 139.5*, 140.5. IR (νmax/cm-1) 3333 (w), 3026 (w), 2844 (m), 1494 (m), 1452 (m), 













The allenyl precursor was prepared following the general procedure using tert-butyl benzyl(3-
methyl-1-oxobutan-2-yl)carbamate 217e (0.53 g, 1.84 mmol), allenylboronic acid pinacol ester 
71 (454 μL, 2.40 mmol, 1.30 equiv.) and Et2Zn (1 M in toluene, 197 μL, 0.184 mmol, 10 mol%)  
in dry toluene (5 mL). Following the general procedure, the crude allenyl product 218e was 
treated with AuPPh3NTf2 (0.13 g, 0.18 mmol, 10 mol%) in dry DCE (5 mL). Boc-deprotection 
of the resulting dihydrofuran with TMSCl (1.12 mL, 9.20 mmol, 5.00 equiv.) in MeOH (5 mL) 
gave the title compound 250e as a single diastereomer after purification by flash column 
chromatography (Et2O/hexane = 2:8). The isolated yield was calculated for the three steps 
starting from the aldehyde 217e. Colorless oil (0.263 g, 61%). Rf (Et2O/hexane = 2:8) = 0.22. 
[𝛼]+,,	= –43.3 (c 0.65 CHCl3). 1H NMR (500 MHz, CDCl3) δ 0.98 (d, 6H, J = 6.5 Hz, 2CH3), 
1.84-1.87 (br m, 2H, CH, NH), 2.37 (br d, 1H, J = 3.0 Hz, CH), 3.83 (dd, 2H, J = 13.0, 12.5 
Hz, CH2Ph), 4.64 (br d, 2H, J = 13.0 Hz, CH2), 4.95 (br s, 1H, CH), 5.80 (br s, 1H, CH=), 5.93 
(br s, 1H, CH=), 7.22-7.32 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 19.28, 20.2, 
30.7, 53.9, 65.7, 75.6, 87.9, 126.9, 127.2, 128.4, 129.2, 141.5. IR (νmax/cm-1) 2955 (m), 2872 
(m), 2359 (w), 1457 (m), 1070 (s), 1028 (s), 739 (s), 697 (s). HRMS (ESI-TOF) m/z calcd for 




The allenyl precursor was prepared following the general procedure using tert-butyl benzyl(2-
oxo-1-phenylethyl)carbamate 217f (0.26 g, 0.82 mmol), allenylboronic acid pinacol ester 71 
(202.00 μL, 1.06 mmol, 1.30 equiv.) and Et2Zn (1 M in toluene, 88.5 μL, 0.082 mmol, 10 










was treated with AuPPh3NTf2 (60.62 mg, 0.08 mmol, 10 mol%) in dry DCE (3 mL). Boc-
deprotection of the resulting dihydrofuran with TMSCl (0.52 mL, 4.10 mmol, 5.00 equiv.) in 
MeOH (3 mL) gave the title compound 250f as a single diastereoisomer after purification by 
flash column chromatography (Et2O/hexane = 3:7). The isolated yield was calculated for the 
three steps starting from the aldehyde 217f. Colourless oil (0.117 g, 54%). Rf (Et2O/hexane = 
3:7) = 0.27. [𝛼]+,,	= –12.8 (c 1 CHCl3). 1H NMR (500 MHz, CDCl3) δ 2.10 (br s, 1H, NH), 
3.51 (d, 1H, J = 13.5 Hz, CH), 3.61 (d, 1H, J = 8.0 Hz, CH), 3.67 (d, 1H, J = 13.5 Hz, CH), 
4.61-4.63 (m, 2H, CH2Ph), 4.81-4.87 (m, 1H, CH), 5.42-5.44 (m, 1H, CH=), 5.84-5.89 (m, 1H, 
CH=), 7.20-7.42 (m, 10H, 10CHAr). 13C NMR (125 MHz, CDCl3) δ 51.0, 67.6, 75.4, 90.5, 
126.7, 127.4, 127.5, 127.6, 128.1, 128.30, 128.38, 128.4, 140.1, 140.6. IR (νmax/cm-1) 3326 (w), 
3060 (w), 3026 (w), 2848 (m), 2364 (w), 1452 (s), 1071 (s), 1028 (m), 748 (s), 693 (s). HRMS 





The allenyl precursor was prepared following the general procedure using tert-butyl 3-(2-
(benzyl(tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-indole-1-carboxylate 217g (0.389 g, 
0.81 mmol), allenylboronic acid pinacol ester 71 (0.20 mL, 1.05 mmol, 1.30 equiv.) and Et2Zn 
(1 M in toluene, 87.30 μL, 0.081 mmol, 10 mol%)  in dry toluene (3 mL). Following the general 
procedure, the crude allenyl product 218g was treated with AuPPh3NTf2 (59.15 mg, 0.08 mmol, 
10 mol%) in dry DCE (4 mL). Boc-deprotection of the resulting dihydrofuran with TMSCl 
(0.52 mL, 4.05 mmol, 5.00 equiv.) in MeOH (5 mL) gave the title compound 250g as a single 
diastereomer after purification by flash column chromatography (EtOAc/hexane = 3:7). The 
isolated yield was calculated for the three steps starting from the aldehyde 217g. Light yellow 








(300 MHz, CDCl3) δ 1.66 (br s, 9H, C(CH3)3), 2.76-2.92 (m, 2H, CH2), 3.07-3.13 (m, 1H, CH), 
3.81 (m, 2H, CH2Ph), 4.63-4.78 (m, 2H, CH2), 4.95 (br s, 1H, CH), 5.93 (m, 1H, CH=), 6.01 
(d, 1H, J = 6.3 Hz, CH=), 7.16-7.21 (br m, 5H, 5CHAr), 7.25-7.32 (m, 2H, 2CHAr), 7.44 (t, 2H, 
J = 7.8 Hz, 2CHAr), 8.12 (m, 1H, CHAr). 13C{1H} NMR (75 MHz, CDCl3) δ 26.3, 28.2, 52.1, 
60.0, 75.6, 83.3, 88.1, 115.2, 117.7, 119.1, 122.3, 123.6, 124.3, 126.7, 127.2, 127.9, 128.0, 
128.2, 130.7, 135.5, 140.3, 149.6. IR (νmax/cm-1) 3670 (w), 2978 (w), 2842 (w), 1729 (s), 1451 
(s), 1367 (s), 1255 (s), 1155 (s), 1072 (s), 1015 (m), 935 (m), 856 (m), 743 (s), 697 (s). HRMS 
(ESI-TOF) m/z calcd for C26H31N2O3 [M + H]+ 419.2335, found 419.2346. 
 
tert-Butyl (S)-2-((R)-2,5-dihydrofuran-2-yl)pyrrolidine-1-carboxylate (250h) 
 
 The allenyl precursor was prepared following the general procedure using tert-butyl 2-
formylpyrrolidine-1-carboxylate 217h (0.29 g, 1.45 mmol), allenylboronic acid pinacol ester 
71 (0.36 mL, 1.89 mmol, 1.30 equiv.) and Et2Zn (1 M in toluene, 156.3 μL, 0.145 mmol, 10 
mol%) in dry toluene (3 mL). Following the general procedure, the crude allenyl product 218h 
was treated with AuPPh3NTf2 (107.4 mg, 0.145 mmol, 10 mol%) in dry DCE (3 mL). The title 
compound 250h was obtained as a 1.6:1 mixture of syn and anti diastereomers after purification 
by flash column chromatography (Et2O/hexane = 3:7). The isolated yield was calculated for the 
two steps starting from the aldehyde 217h. Colorless oil (0.21 g, 59%), Rf (Et2O/hexane = 3:7) 
= 0.18. 1H NMR (500 MHz, DMSO, 80 °C) (mixture of two diastereomers, relative integrations 
given for each diastereomer) δ 1.41 (s, 9H, C(CH3)3, for each isomer), 1.70 (br s, 2H, 2CH2, 
major isomer), 1.80-1.85 (m, 4H, 2CH2, minor isomer) 3.14-3.22 (m, 2H, CH2, major isomer), 
3.31 (br s, 2H, CH2, minor isomer), 3.75 (s, 1H, CH, major isomer), 3.90 (s, 1H, CH, minor 
isomer),  4.47-4.54 (m, 2H, CH2, for each isomer), 4.97 (br s, 1H  CH, for each isomer), 5.79-
5.81 (m, 1H, CH=, for each isomer), 6.02 (br s, 1H, CH=, for each isomer). 13C{1H} NMR (125 








28.61, 28.66*, 46.9*, 47.1, 59.7*, 60.6, 75.6, 78.7, 78.8*, 87.4, 127.2*, 128.0, 128.3, 128.4*, 
154.0, 154.3*. IR (νmax/cm-1) 2972 (m), 2878 (m), 2845 (m), 2355 (w), 1687 (s), 1456 (m), 
1388 (s), 1363 (s), 1255 (m), 1165 (s), 1109 (s), 1072 (s), 769 (m), 678 (m). HRMS (ESI-TOF) 





 The major diastereomer of the title compound 221 was obtained after purification by flash 
column chromatography (EtOAc/hexane = 3:7) following the general procedure using N-
benzyl-4-methyl-N-(1-oxopropan-2-yl)benzenesulfonamide 220 (0.072 g, 0.226 mmol), 
allenylboronic acid pinacol ester 71 (56.50 μL, 0.29 mmol, 1.30 equiv.) and Et2Zn (1 M in 
toluene, 24.00 μL, 0.0226 mmol, 10 mol%)  in dry toluene (1 mL). Colourless oil (0.044 g, 
54%). Rf (EtOAc/hexane = 3:7) = 0.44. [𝛼]+,,	= +35.2 (c 2.5 CHCl3). 1H NMR (500 MHz, 
CDCl3) δ 1.01 (d, 3H, J = 7.0 Hz, CH3), 1.84 (d, 1H, J = 4.0 Hz, OH), 2.42 (s, 3H, CH3), 3.88-
3.91 (m, 1H, CH), 4.03 (br s, 1H, CH), 4.27 (d, 1H, J = 15.5 Hz, CHPh), 4.60 (d, 1H, J = 16.0 
Hz, CHPh), 4.78-4.80 (m, 2H, CH2=C=), 5.15 (q, 1H, J = 6.5, 6.5 Hz, CH=C=), 7.23-7.31 (m, 
5H, 5CHAr), 7.37 (d, 2H, J = 7.5 Hz, 2CHAr), 7.69 (d, 2H, J = 8.5 Hz, 2CHAr). 13C{1H} NMR 
(125 MHz, CDCl3) δ 12.4, 21.5, 48.5, 58.6, 71.8, 78.3, 93.0, 127.1, 127.5, 128.2, 128.5, 129.7, 
137.7, 137.9, 143.3, 207.0. IR (νmax/cm-1) 3502 (m), 2984 (w), 2922 (w), 1954 (m), 1598 (m), 
1333 (s), 1150 (s), 1088 (s), 1002 (s), 863 (S), 732 (s), 657 (s). HRMS (ESI-TOF) m/z calcd 














 The major diastereomer of the title compound 224 was obtained after purification by flash 
column chromatography (Et2O/hexane = 1:9) following the general procedure using 2-
(dibenzylamino)propanal 223 (0.096 g, 0.339 mmol), allenylboronic acid pinacol ester 71 
(84.00 μL, 0.44 mmol, 1.30 equiv.) and Et2Zn (1 M in toluene, 36.00 μL, 0.0339 mmol, 10 
mol%) in dry toluene (1 mL). Colourless oil (0.05 g, 50%). Rf (Et2O/hexane = 1:9) = 0.25. 
[𝛼]+,,	= –36.2 (c 4.1 CHCl3). 1H NMR (500 MHz, CDCl3) δ 1.12 (d, 3H, J = 11.5 Hz, CH3), 
2.85-2.89 (m, 1H, CH), 3.42 (d, 2H, J = 23.0 Hz, 2CHPh), 3.82 (d, 2H, J = 23.0 Hz, 2CHPh), 
4.07-4.12 (m, 1H, CH), 4.77-4.81 (m, 2H, CH2=C=), 5.30 (q, 1H, J = 10.5, 10.5 Hz, CH=C=), 
7.19-7.34 (m, 10H, 10CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 9.2, 54.9, 57.7, 71.1, 76.8, 
93.6, 127.2, 128.5, 129.0, 139.9, 207.6. IR (νmax/cm-1) 3379 (w), 3027 (w), 2926 (w), 2801 (w), 
1952 (m), 1452 (m), 1368 (m), 1244 (w), 1027 (s), 845 (s), 744 (s), 696 (s). HRMS (ESI-TOF) 
m/z calcd for C20H24NO [M + H]+ 294.1858, found 294.1852. 
 
Determination of Enantiomeric Excess (ee) of Oxazolidinones Using (S)-10-
Camphorsulfonyl Chloride  
 
 
The enantiomeric excess (ee) of each diastereomerically pure allenyl oxazolidinone was 
determined by derivatizing with enantiomerically pure (S)-10-camphorsulfonyl chloride and 1H 







































integration of clearly resolved resonances arising from the corresponding allenyl methane 
(CH2SO2) protons in each diastereomer. The resonances used are listed at the end of the 
characterization data for each compound.  
To a solution of the oxazolidinone in dry THF (2 mL) was added sodium hydride (60% 
in mineral oil, 4.00 equiv.) at 0 °C. The reaction mixture was stirred at room temperature for 
30 min then (S)-10-camphorsulfonyl chloride (2.00 equiv.) was added and the reaction mixture 
was stirred for 3 h. The reaction was quenched with NH4Cl (5 mL), washed with water (10 mL) 
and NaHCO3 (10 mL), dried (Na2SO4) and concentrated under vacuum.  
 
229a (96% ee): 1H NMR (500 MHz, CDCl3) d 3.35 (d, 1H, J = 15.0 Hz, CHSO2, minor isomer), 
3.65 (dd, 2H, J = 15.0, 16.0 Hz, CH2SO2, major isomer), 4.13 (d, 1H, J = 14.5 Hz, CHSO2, 
minor isomer), ratio = 98:2. 
229b (94% ee): 1H NMR (500 MHz, CDCl3) d 3.32 (d, 1H, J = 15.0 Hz, CHSO2, minor isomer), 
3.66 (br s, 2H, CH2SO2, major isomer), 4.06 (d, 1H, J = 15.0 Hz, CHSO2, minor isomer), ratio 
= 97:3. 
229c (86% ee): 1H NMR (500 MHz, CDCl3) d 3.32 (d, 1H, J = 15.0 Hz, CHSO2, minor isomer), 
3.70 (dd, 2H, J = 16.5, 14.5 Hz, CH2SO2, major isomer), 4.08 (d, 1H, J = 15.0 Hz, CHSO2, 
minor isomer), ratio = 93:7. 
229f (8% ee): 1H NMR (500 MHz, CDCl3) δ 2.85 (d, 1H, J = 15.2 Hz, CHSO2, minor isomer), 
3.21 (d, 1H, J = 14.5 Hz, CHSO2, major isomer), 3.45 (d, 1H, J = 15.2 Hz, CHSO2, minor 
isomer), 3.63 (d, 1H, J = 14.5 Hz, CHSO2, major isomer), ratio = 54:46. 
229g (92% ee): 1H NMR (500 MHz, Methanol-d4) d 3.60 (dd, 2H, J = 14.5, 17.5 Hz, CH2SO2, 








Determination of enantiomeric excess (ee) of aldehydes (167a) and (155c) and 
dihydrofuran (194a) by chiral HPLC analysis 
Racemic aldehydes for chiral HPLC were achieved by heating the corresponding 
aldehyde to reflux in triethylamine for 2 hours.206 Then, it was dried under vacuum and then 
reduced with NaBH4/MeOH to the corresponding alcohol for chiral HPLC analysis using 
Phenomenex Lux Cellulose-3 or i-Cellulose-5 columns; hexane/isopropanol; flow rate = 0.5 
mL/min with detection at 210 nm.  
A comparison between the enantiomeric purity of the final product 229c (determined 
from its chiral sulfonamide derivative by 1H NMR analysis) and the corresponding aldehyde 
205c (determined by chiral HPLC) showed no erosion of enantiomeric purity during the 
reaction steps. 
In the case of 2,5-dihydrofurans, a representative diastereomerically pure product 250a 
was tested by comparing the enantiomeric purity of the final product and the aldehyde 217a, 
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Synthesis of 1,3-(E)-Enynes (253) 
 
To a solution of N-Bn,N-Boc allenyl amino alcohols 218a-e in anhydrous THF (0.6 M) at 0 °C, 
was slowly added NaH (60% in mineral oil, 2.00 equiv.) in four approximately equal portions. 
The mixture was stirred at the same temperature for 3 h, and then quenched by the addition of 
saturated aqueous NH4Cl solution (5 mL). The reaction mixture was allowed to warm to room 
temperature, diluted with water (10 mL) and extracted with dichloromethane (3×10 mL). The 
organic layer was dried (Na2SO4) and concentrated under reduced pressure. The desired enyne 
product was obtained after flash column chromatography.  
Enantiomeric purity of the enyne 253a was tested as a representative enyne product by 
chiral HPLC analysis using Phenomenex Lux Cellulose-3 column; hexane/isopropanol (99:1); 
flow rate = 0.2 mL/min with detection at 254 nm. The result was compared with racemic enyne 















 toluene, 0 oC
(R1 = Me, Bn, nPr, iBu, iPr)
+
Et2Zn (10 mol%)
















































































































































The title compound 253a was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using tert-butyl benzyl(3-hydroxyhexa-4,5-dien-2-
yl)carbamate 218a (0.32 g, 1.06 mmol) and NaH (60% in mineral oil, 0.085 g, 2.12 mmol, 2.00 
equiv.) in THF (1.80 mL). The isolated yield was calculated for the two steps starting from the 
aldehyde. Yellow oil (0.141 g, 69%). Rf (Et2O/hexane = 3:7) = 0.32. [𝛼]+,/	= –74.2 (c 0.3 
CHCl3). The enantiopurity was determined by chiral HPLC using a Phenomenex Lux 
Cellulose-3 column; hexane/isopropyl alcohol (99:1); flow rate = 0.2 mL/min; 254 nm; single 
peak, t = 47.71 min, >99% ee. Racemic 253a, prepared from racemic N-Bn,N-Boc alanal 218a, 
showed two peaks at t = 46.99 min and t = 48.65 min (peak area ratios = 1:1) with the same 
solvent system and flow rate. 1H NMR (400 MHz, CDCl3) δ 1.18 (d, 3H, J = 6.5 Hz, CH3), 
1.48 (br s, 1H, NH), 2.85 (dd, 1H, J = 2.2, 0.6 Hz, CH alkyne), 3.25-3.29 (m, 1H, CH), 3.66 (d, 
1H, J = 12.5 Hz, CHPh), 3.79 (d, 1H, J = 12.5 Hz, CHPh), 5.61 (ddd, 1H, J = 16.0, 2.3, 1.1 Hz, 
=CH), 6.14 (ddd, 1H, J = 16.0, 7.7, 0.6 Hz, =CH), 7.22-7.33 (m, 5H, 5CHAr). 13C{1H} NMR 
(100 MHz, CDCl3) δ 21.5, 51.4, 54.9, 77.0, 82.0, 108.8, 127.0, 128.0, 128.4, 140.3, 149.6. IR 
(νmax/cm-1) 3288 (m), 3027 (w), 2964 (m), 2841 (w), 1452 (s), 1154 (m), 1104 (m), 958 (s), 732 
(s), 697 (s), 623 (s). HRMS (ESI-TOF) m/z calcd for C13H16N [M + H]+ 186.1283, found 
186.1279. 
 
(S,E)-N-Benzyloct-5-en-7-yn-4-amine (253b)  
 
The title compound 253b was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using tert-butyl benzyl(5-hydroxyocta-6,7-dien-4-







equiv.) in THF (1.5 mL). The isolated yield was calculated for the two steps starting from the 
aldehyde. Yellow oil (0.156 g, 75%). Rf (Et2O/hexane = 3:7) = 0.43. [𝛼]+,/	= –49.5 (c 0.4 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 0.86 (t, 3H, J = 10.0 Hz, 5.0 Hz, CH3), 1.18 (br s, 1H, 
NH), 1.25-1.31 (m, 2H, CH2), 1.32-1.47 (m, 2H, CH2), 2.85 (d, 1H, J = 2.2 Hz, CH alkyne), 
3.03 (q, 1H, J = 7.0 Hz, CH), 3.57 (d, 1H, J = 13.5 Hz, CHPh), 3.76 (d, 1H, J = 13.5 Hz, CHPh), 
5.24 (dd, 1H, 16.0, 2.0 Hz, =CH), 6.06 (dd, 1H, J = 16.0, 8.2 Hz, =CH), 7.18-7.28 (m, 5H, 
5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 14.1, 19.1, 37.8, 51.3, 59.8, 77.1, 82.1, 109.7, 
126.9, 128.1, 128.4, 140.5, 148.8. IR (νmax/cm-1) 3287 (m), 2956 (s), 2930 (s), 2872 (m), 2364 
(w), 1453 (s), 1102 (m), 958 (s), 731 (s), 697 (s). HRMS (ESI-TOF) m/z calcd for C15H20N [M 




The title compound 253c was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using tert-butyl benzyl(5-hydroxy-2-methylocta-6,7-dien-4-
yl)carbamate 218c (0.40 g, 1.157 mmol) and NaH (60% in mineral oil, 0.093 g, 2.31 mmol, 
2.00 equiv.) in THF (2.0 mL). The isolated yield was calculated for the two steps starting from 
the aldehyde. Yellow oil (0.198 g, 71%). Rf (Et2O/hexane = 3:7) = 0.47. [𝛼]+,/	= –54.0 (c 0.4 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 0.85 (t, 6H, J = 6.5 Hz, 2CH3), 1.27-1.37 (m, 3H, NH 
and CH2), 1.62-1.67 (m, 1H, CH), 2.86 (dd, 1H, J = 2.3, 0.6 Hz, CH alkyne), 3.12 (q, 1H, J = 
7.5 Hz, CH), 3.59 (d, 1H, J = 13.0 Hz, CHPh), 3.80 (d, 1H, J = 13.0 Hz, CHPh), 5.57 (ddd, 1H, 
J = 16.0, 2.2, 0.8 Hz, =CH), 6.04 (ddd, 1H, J = 16.0, 8.3, 0.6 Hz, =CH), 7.22-7.29 (m, 5H, 
5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 22.5, 22.8, 24.6, 44.9, 51.3, 58.1, 76.9, 82.0, 109.5, 
126.9, 128.1, 128.4, 140.4, 148.9. IR (νmax/cm-1) 3297 (m), 2956 (s), 2919 (m), 2869 (m), 1494 
(m), 1466 (s), 1453 (s), 1366 (m), 1103 (m), 959 (s), 732 (s), 697 (s), 644 (s). HRMS (ESI-








The title compound 253d was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using tert-butyl benzyl(3-hydroxy-1-phenylhexa-4,5-dien-2-
yl)carbamate 218d (0.57 g, 1.52 mmol) and NaH (60% in mineral oil, 0.121 g, 3.04 mmol, 2.00 
equiv.) in THF (2.5 mL). The isolated yield was calculated for the two steps starting from the 
aldehyde. Colorless oil (0.31 g, 81%). Rf (Et2O/hexane = 3:7) = 0.36. [𝛼]+,/	= –56.5 (c 0.4 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 1.50 (br s, 1H, NH), 2.70-2.85 (m, 2H, CH2Ph), 2.86 
(d, 1H, J = 2.3 Hz, CH alkyne), 3.33-3.38 (m, 1H, CH), 3.57 (d, 1H, J = 16.0 Hz, CHPh), 3.79 
(d, 1H, J = 16.0 Hz, CHPh), 5.59 (ddd, 1H, J = 15.9, 2.3, 1.0 Hz, =CH), 6.15 (dd, 1H, J = 16.0, 
7.8 Hz, =CH), 7.08-7.24 (m, 10H, 10CHAr).  13C{1H} NMR (100 MHz, CDCl3) δ 42.0, 51.2, 
60.7, 77.3, 82.0, 110.0, 126.5, 126.9, 127.9, 128.3, 128.5, 129.3, 137.7, 140.0, 147.8. IR 
(νmax/cm-1) 3283 (m), 3026 (w), 2917 (w), 2101 (w), 1602 (w), 1494 (s), 1453 (s), 1109 (m), 
958 (s), 732 (s), 696 (s), 645 (s). HRMS (ESI-TOF) m/z calcd for C19H20N [M + H]+ 262.1596, 
found 262.1585. 
 
 (S,E)-N-benzyl-2-methylhept-4-en-6-yn-3-amine (253e) 
 
The title compound 253e was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using tert-butyl benzyl((3S)-4-hydroxy-2-methylhepta-5,6-
dien-3-yl)carbamate 218e (0.30 g, 0.90 mmol) and NaH (60% in mineral oil, 0.072 g, 1.81 
mmol, 2.00 equiv.) in THF (1.5 mL). The isolated yield was calculated for the two steps starting 
from the aldehyde. Colourless oil (0.115 g, 57%). Rf (Et2O/hexane = 3:7) = 0.48. [𝛼]+,/	= –65.5 
(c 0.4 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.87 (d, 3H, J = 6.8 Hz, CH3), 0.92 (d, 3H, J = 








J = 2.3, 0.6 Hz, CH alkyne), 3.58 (d, 1H, J = 12.0 Hz, CHPh), 3.82 (d, 1H, J = 12.0 Hz, CHPh), 
5.55 (ddd, 1H, J = 16.0, 2.3, 0.9 Hz, =CH), 6.07 (ddd, 1H, J = 16.0, 8.4, 0.6 Hz, =CH), 7.20-
7.33 (m, 5H, 5CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 18.4, 19.3, 32.5, 51.4, 65.6, 76.7, 
82.1, 110.4, 126.8, 128.0, 128.3, 140.5, 146.8. IR (νmax/cm-1) 3289 (m), 3027 (w), 2958 (m), 
2872 (m), 2101 (w), 1453 (s), 1366 (m), 1100 (m), 960 (s), 732 (s), 697 (s), 606 (s). HRMS 
(ESI-TOF) m/z calcd for C15H20N [M + H]+ 214.1596, found 214.1597. 
 
Synthesis of Unconjugated (E)-Enediynes (254a-g)  
 
The enediynes 254 were prepared following a previously reported procedure.207 Potassium 
carbonate (4.00 equiv.) was added to a stirred solution of the enyne 253 in CH3CN (0.2 M). 
Then, propargyl bromide (80% in toluene, 2.00 equiv.) was added dropwise and the mixture 
was stirred and heated at reflux for 24 h. The reaction mixture was cooled, then washed with 
saturated aqueous NaHCO3 solution (5 mL) and water (10 mL), dried (Na2SO4), concentrated 





The title compound 254a was obtained after flash column chromatography (EtOAc/hexane = 
2:8) following the general procedure using (S,E)-N-benzylhex-3-en-5-yn-2-amine 253a (0.07 
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carbonate (0.21g, 1.51 mmol, 4.00 equiv.) in CH3CN (2.0 mL). Yellow oil (0.056 g, 66%). Rf 
(EtOAc/hexane = 2:8) = 0.73. [𝛼]+,/= –32.0 (c 1.0 CHCl3). 1H NMR (500 MHz, CDCl3) δ 1.26 
(d, 3H, J = 6.5 Hz, CH3), 2.21 (s, 1H, CH), 2.86 (d, 1H, J = 2.2 Hz, CH), 3.29 (ABq, 2H, J = 
16.5 Hz, CH2), 3.41-3.44 (m, 1H, CH), 3.61 (d, 1H, J = 13.0 Hz, CHPh), 3.74 (d, 1H, J = 13.0 
Hz, CHPh), 5.67 (dd, 1H, J = 16.1, 2.3 Hz, =CH), 6.29 (dd, 1H, J = 16.0, 7.7 Hz, =CH), 7.24-
7.34 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 17.9, 38.5, 54.1, 58.2, 73.0, 77.3, 
79.5, 82.0, 109.6, 127.1, 128.3, 128.8, 139.0, 148.5. IR (νmax/cm-1) 3291 (m), 2957 (m), 2871 
(w), 2103 (w), 1602 (w), 1454 (m), 1362 (m), 1105 (m), 961 (s), 738 (s), 698 (s), 635 (s). 
HRMS (ESI-TOF) m/z calcd for C16H17NNa [M + Na]+ 246.1259, found 246.1267. 
 
 (S,E)-N-Benzyl-N-(prop-2-yn-1-yl)oct-5-en-7-yn-4-amine (254b) 
 
The title compound 254b was obtained after flash column chromatography (Et2O/hexane = 2:8) 
following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253b (0.10 g, 0.47 
mmol), potassium carbonate (0.26 g, 1.88 mmol, 4.0 equiv.) and propargyl bromide (80% in 
toluene, 0.10 mL, 2.0 equiv.) in CH3CN (2 mL). Orange oil (0.091 g, 77%). Rf (Et2O/hexane = 
2:8) = 0.71. [𝛼]+,/= –33.8 (c 1.0 CHCl3). 1H NMR (500 MHz, CDCl3) δ 0.90 (t, 3H, J = 7.0 Hz, 
CH3), 1.32-1.40 (m, 2H, CH2), 1.42-1.48 (m, 1H, CH), 1.68-1.72 (m, 1H, CH), 2.20 (d, 1H, J 
= 2.0 Hz, CH), 2.86 (d, 1H, J = 1.5 Hz, CH), 3.21-3.32 (m, 3H, CH and CH2), 3.53 (d, 1H, J = 
13.5 Hz, CHPh), 3.82 (d, 1H, J = 13.5 Hz, CHPh), 3.61 (dd, 1H, J = 16.0, 1.5 Hz, =CH), 6.25 
(dd, 1H, J = 16.0, 7.7 Hz, =CH), 7.21-7.33 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) 
δ 14.1, 19.2, 34.3, 38.6, 54.0, 62.9, 72.7, 77.0, 80.1, 82.0, 111.0, 127.0, 128.3, 128.8, 139.1, 
146.1. IR (νmax/cm-1) 3291 (m), 2957 (m), 2871 (w), 1602 (w), 1454 (m), 1362 (m), 1105 (m), 










The title compound 254c was obtained after flash column chromatography (Et2O/hexane = 2:8) 
following the general procedure using (S,E)-N-benzyl-2-methyloct-5-en-7-yn-4-amine 253c 
(0.10 g, 0.44 mmol), potassium carbonate (0.24 g, 1.76 mmol, 4.00 equiv.) and propargyl 
bromide (80% in toluene, 0.10 mL, 0.88 mmol, 2.00 equiv.) in CH3CN (2.0 mL). Orange oil 
(0.084 g, 72%). Rf (Et2O/hexane = 2:8) = 0.66. [𝛼]+,/= –44.4 (c 0.6 CHCl3). 1H NMR (500 
MHz, CDCl3) δ 0.88 (t, 6H, J = 6.0, 6.5 Hz, 2CH3), 1.29-1.35 (m, 1H, CH), 1.56-1.62 (m, 1H, 
CH), 1.66-1.70 (m, 1H, CH), 2.20 (s, 1H, CH), 2.86 (d, 1H, J = 1.5 Hz, CH), 3.25 (m, 2H, CH2), 
3.35 (q, 1H, J = 8.5, 6.5 Hz, CH), 3.49 (d, 1H, J = 14.0 Hz, CHPh), 3.84 (d, 1H, J = 14.0 Hz, 
CHPh), 5.60 (dd, 1H, J = 16.0, 1.5 Hz, =CH), 6.24 (dd, 1H, J = 16.0, 8.0 Hz, =CH), 7.21-7.33 
(m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 22.3, 23.0, 24.7, 38.7, 41.4, 53.9, 60.9, 
72.6, 77.0, 80.5, 82.0, 111.0, 127.0, 128.3, 128.8, 139.1, 145.7. IR (νmax/cm-1) 3294 (m), 2955 
(m), 2923 (m), 1454 (m), 1366 (m), 1109 (m), 962 (s), 736 (s), 697 (s), 630 (s). HRMS (ESI-




The title compound 254d was obtained after flash column chromatography (EtOAc/hexane = 
2:8) following the general procedure using (S,E)-N-benzyl-1-phenylhex-3-en-5-yn-2-amine 
253d (0.33 g, 1.26 mmol), potassium carbonate (0.70 g,   5.04 mmol, 4.00 equiv.) and propargyl 
bromide (80% in toluene, 0.27 mL, 2.52 mmol, 2.00 equiv.) in CH3CN (5.0 mL). Colourless 
oil (0.23 g, 80%). Rf (Et2O/hexane = 1:9) = 0.48. [𝛼]+,/	= –47.2 (c 0.8 CHCl3). 1H NMR (500 
MHz, CDCl3) δ 2.22 (t, 1H, J = 2.5 Hz, CH alkyne), 2.68 (m, 1H, CHPh), 2.80 (d, 1H, J = 2.2 








3.53-3.57 (m, 1H, CH), 3.63 (d, 1H, J = 14.0 Hz, CHPh), 3.84 (d, 1H, J = 14.0 Hz, CHPh), 5.44 
(dd, 1H, J = 16.0, 2.2 Hz, =CH), 6.23 (dd, 1H, J = 16.0, 8.1 Hz, =CH), 7.12-7.28 (m, 10H, 
10CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 38.2, 38.9, 54.2, 64.6, 73.0, 77.3, 80.1, 81.8, 
111.4, 126.2, 127.1, 128.2, 128.3, 128.7, 129.4, 138.6, 138.7, 144.7. IR (νmax/cm-1) 3280 (s), 
3027 (w), 2814 (w), 1601 (w), 1493 (m), 1453 (m), 1058 (m), 973 (s), 739 (s), 695 (s), 631 (s). 





The title compound 254e was obtained after flash column chromatography (Et2O/hexane = 2:8) 
following the general procedure using (S,E)-N-benzyl-2-methyloct-5-en-7-yn-4-amine 253c 
(0.18 g, 0.79 mmol), potassium carbonate (0.43 g, 3.16 mmol, 4.00 equiv.) and 4-bromo-1-
butyne (0.22 mL, 2.37 mmol, 3.00 equiv.) in CH3CN (2 mL) under reflux conditions. Light 
yellow oil (0.12 g, 54%). Rf (Et2O/hexane = 2:8) = 0.77. [𝛼]+,/	= –71.1 (c 1.0 CHCl3). 1H NMR 
(500 MHz, CDCl3) δ 0.77 (d, 3H, J = 6.5 Hz, CH3), 0.82 (d, 3H, J = 6.5 Hz, CH3), 1.21-1.26 
(m, 1H, CH), 1.47-1.53 (m, 1H, CH), 1.67-1.71 (m, 1H, CH), 1.93 (t, 1H, J = 2.5 Hz, CH), 
2.24-2.28 (m, 2H, CH2), 2.54-2.59 (m, 1H, CH), 2.74-2.80 (m, 1H, CH), 2.86 (d, 1H, J = 1.5 
Hz, CH), 3.10-3.15 (q, 1H, J = 7.5, 8.0 Hz, CH), 3.46 (d, 1H, J = 14.0 Hz, CHPh), 3.78 (d, 1H, 
J = 14.0 Hz, CHPh), 5.52 (dd, 1H, J = 16.0, 2.3 Hz, =CH), 6.19 (dd, 1H, J = 16.0, 8.5 Hz, 
=CH), 7.21-7.33 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, CDCl3) δ 19.2, 22.6, 22.7, 24.4, 
41.1, 48.8, 54.9, 59.5, 69.0, 77.3, 82.0, 83.0, 110.8, 126.9, 128.2, 128.6, 140.0, 145.0. IR 
(νmax/cm-1) 3294 (m), 2954 (m), 1452 (m), 1365 (m), 1113 (m), 962 (s), 735 (s), 698 (s), 634 











The title compound 254f was obtained after flash column chromatography (Et2O/hexane = 1:9) 
following the general procedure using (S,E)-N-benzyl-2-methyloct-5-en-7-yn-4-amine 253c 
(0.16 g, 0.70 mmol), potassium carbonate (0.39 g, 2.81 mmol, 4.00 equiv.) and 3-chloro-1-
phenyl-1-propyne (0.19 mL, 1.40 mmol, 2.00 equiv.) in CH3CN (3 mL). Yellow oil (0.20 g, 
83%). Rf (Et2O/hexane = 1:9) = 0.23. [𝛼]+,/	= –70.4 (c 0.6 CHCl3). 1H NMR (500 MHz, CDCl3) 
δ 0.9 (t, 6H, J = 7.5, 7.0 Hz, 2CH3), 1.36 (ddd, 1H, J = 13.8, 8.1, 6.1 Hz, CH), 1.56-1.67 (m, 
1H, CH), 1.70-1.85 (m, 1H, CH), 2.85 (d, 1H, J = 2.2 Hz, CH alkyne), 3.40-3.57 (m, 5H, CH, 
CH2Ph and CHPh), 3.90 (d, 1H, J = 13.0 Hz, CHPh), 5.63 (dd, 1H, J = 16.0, 2.3 Hz, =CH), 
6.34 (dd, 1H, J = 16.0, 8.9 Hz, =CH), 7.23 (t, 1H, J = 7.2 Hz, CHAr), 7.26-7.32 (m, 5H, 5CHAr), 
7.36 (d, 2H, J = 7.0 Hz, 2CHAr), 7.44 (dd, 2H, J = 6.6, 3.0 Hz, 2CHAr). 13C{1H} NMR (125 
MHz, CDCl3) δ 22.5, 23.0, 24.7, 39.6, 41.3, 54.2, 61.3, 77.1, 82.2, 85.1, 86.4, 110.9, 123.4, 
127.1, 128.0, 128.3, 128.4, 128.9, 131.7, 139.3, 146.0. IR (νmax/cm-1) 3290 (m), 3030 (w), 2953 
(m), 1714 (w), 1598 (w), 1490 (s), 1453 (m), 1365 (m), 1104 (m), 961 (s), 755 (s), 736 (s), 690 





The title compound 254g was obtained after flash column chromatography (Et2O/hexane = 1:9) 
following the general procedure using (S,E)-N-benzyl-2-methyloct-5-en-7-yn-4-amine 253c 
(0.148 g, 0.65 mmol), potassium carbonate (0.36 g, 2.60 mmol, 4.00 equiv.) and 3-bromo-1-









(0.094 g, 43%). Rf (Et2O/hexane = 1:9) = 0.29. [𝛼]+,/	= –82.0 (c 0.7 CHCl3). 1H NMR (500 
MHz, CDCl3) δ 0.18 (s, 9H, (CH3)3Si-), 0.89 (t, 6H, J = 7.0 Hz, 2CH3), 1.32 (dt, 1H, J = 14.0, 
7.1 Hz, CH), 1.60 (dt, 1H, J = 14.0, 7.0 Hz, CH), 1.70 (dt, 1H, J = 13.4, 6.7 Hz, CH), 2.85 (d, 
1H, J = 2.2 Hz, CH alkyne), 3.13-3.31 (m, 2H, CH2), 3.37 (q, 1H, J = 7.8 Hz, CH), 3.47 (d, 1H, 
J = 13.5 Hz, CHPh), 3.83 (d, 1H, J = 13.5 Hz, CHPh), 5.58 (dd, 1H, J = 16.0, 2.2 Hz, =CH), 
6.29 (dd, 1H, J = 16.0, 8.9 Hz, =CH), 7.22-7.32 (m, 5H, 5CHAr). 13C{1H} NMR (125 MHz, 
CDCl3) δ 0.1, 22.4, 23.0, 24.7, 39.7, 41.1, 53.9, 61.1, 76.9, 82.1, 89.7, 103.1, 110.7, 127.0, 
128.3, 128.8, 139.2, 145.9. IR (νmax/cm-1) 3309 (w), 2956 (m), 2165 (w), 1455 (m), 1248 (s), 
1100 (m), 982 (s), 962 (s), 839 (s), 759 (s), 736 (s), 697 (s), 632 (s). HRMS (ESI-TOF) m/z 
calcd for C22H32N [M + H]+ 338.2304, found 338.2301. 
           
Au(I)-Catalysed Cycloaromatisation of Enediynes     
 
To a solution of enediyne 254a-g in anhydrous toluene, was added IPrAuCl (10 mol%), AgSbF6 
(10 mol%) under an atmosphere of N2. The mixture was stirred and heated at reflux for 18 h 
and then filtered through a pad of silica gel, followed by purification by flash column 
chromatography to afford the corresponding isoindoline product 255a-g. 
Many attempted Au(I)-catalysed cycloaromatisation reactions of the enediynes 254a-
g resulted in no desired product, and the 1H NMR spectrum of the crude reaction mixture 
indicated complete decomposition of the enediyne starting material. Only the alanine- and 
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The title compound 255a was obtained after flash column chromatography (Et2O/pentane = 
1:9) following the general procedure using (S,E)-N-benzyl-N-(prop-2-yn-1-yl)hex-3-en-5-yn-
2-amine 254a  (0.034 g, 0.152 mmol) and IPrAuCl (0.0094 g, 0.0152 mmol, 0.10 equiv.), 
AgSbF6 (0.0052 g, 0.0152 mmol, 0.10 equiv.) in toluene (1.0 mL). Yellow oil (0.024 g, 70%). 
Rf (Et2O/pentane = 3:7) = 0.74. [𝛼]+,,	= –99.2 (c 0.3 CHCl3). 1H NMR (500 MHz, CDCl3) δ 
1.47 (d, 3H, J = 6.5 Hz, CH3), 3.57-3.59 (m, 2H, CH2N), 3.93-3.97 (m, 1H, CH), 4.05 (d, 1H, 
J = 13.0 Hz, CHPh), 4.23 (d, 1H, J = 13.0 Hz, CHPh), 7.12-7.42 (m, 9H, 9CHAr). 13C{1H} 
NMR (125 MHz, CDCl3) δ 18.8, 57.8, 58.0, 63.7, 121.8, 122.2, 126.7, 126.8, 127.0, 128.3, 
128.9, 139.3, 139.4, 144.7. HRMS (ESI-TOF) m/z calcd for C16H18N [M + H]+ 224.1439, found 
224.1450. This compound rapidly decomposed and a satisfactory IR spectrum could not be 
obtained. 
  
(S)-1,2-Dibenzylisoindoline (255d)   
 
The title compound 255d was obtained after flash column chromatography (Et2O/pentane = 
1:9) following the general procedure using (S,E)-N-benzyl-1-phenyl-N-(prop-2-yn-1-yl)hex-3-
en-5-yn-2-amine 254d (0.030 g, 0.100 mmol) and IPrAuCl (0.0062 g, 0.010 mmol, 0.10 
equiv.), AgSbF6 (0.0034 g, 0.010 mmol, 0.10 equiv.) in toluene (1.0 mL). Yellow oil (0.007 g, 
24%). Rf (Et2O/pentane = 1:9) = 0.80. [𝛼]+,,	= –107.0 (c 0.2 CHCl3).  1H NMR (500 MHz, 
CDCl3) δ 3.11 (dd, 1H, J = 6.5 Hz, 13.5 Hz, CHPh), 3.20 (dd, 1H, J = 6.5 Hz, 13.5 Hz, CHPh), 
3.56 (d, 1H, J = 13.5 Hz, CHPh), 3.63 (d, 1H, J = 13.5 Hz, CHPh), 4.04 (d, 1H, J = 13.0 Hz, 
C(3)HH), 4.09 (d, 1H, J = 13.0 Hz, C(3)HH), 4.36-4.39 (m, 1H, CH), 6.92 (d, 1H, J = 7.0 Hz, 








300.1752, found 300.1740. This compound rapidly decomposed and satisfactory 13C NMR and 




The title compound 365 was obtained after flash column chromatography (Et2O/pentane = 1:9) 
following the general procedure using (S,E)-N-benzyl-N-(prop-2-yn-1-yl)hex-3-en-5-yn-2-
amine 254a (0.020 g, 0.090 mmol) and IPrAuCl (0.0056 g, 0.009 mmol, 0.10 equiv.), AgSbF6 
(0.0031 g, 0.009 mmol, 0.10 equiv.) in DCE (1.0 mL). Yellow oil (0.002 g, 10%). The 
corresponding isoindoline 255a was also isolated (25%). 365: Rf (Et2O/pentane = 1:9) = 0.75. 
1H NMR (mixture of two isomers (ca. 1.0:1.5 cis/trans)) (500 MHz, CDCl3) δ 1.21 (d, 3H, J = 
6.0 Hz, CH3, trans isomer), 1.24 (d, 3H, J = 6.0 Hz, CH3, cis isomer), 2.99 (d, 1H, J = 2.0 Hz, 
CH alkyne, trans isomer), 3.05 (d, 1H, J = 14.5 Hz, CH, cis isomer), 3.15 (d, 1H, J = 2.5 Hz, 
CH alkyne, cis isomer), 3.23-3.30 (m, 3H, CH2 cis isomer, CH cis isomer), 3.47-3.52 (m, 2H, 
CH2 trans isomer), 3.55 (d, 1H, J = 13.5 Hz, CHPh, trans isomer), 3.70-3.74 (m, 2H, CHPh 
trans isomer, CH cis isomer), 3.80 (d, 1H, J = 13.5 Hz, CHPh, cis isomer), 4.05 (d, 1H, J = 
13.5 Hz, CHPh, trans isomer), 5.12 (s, 1H, =C(4)H, cis isomer), 5.29 (d, 1H, J = 16.0 Hz, =CH, 
trans isomer), 5.77 (s, 1H, =C(4)H, trans isomer), 5.89-5.92 (m, 1H, =CH, cis isomer), 6.71-
6.76 (m, 2H, =CH cis isomer and =CH trans isomer), 7.23-7.36 (m, 10H, 2 × 5CHAr cis and 
trans isomers). The compound rapidly decomposed and satisfactory 13C NMR, IR, and HRMS 











Synthesis of Unconjugated (E)-Enediynes (380 and 385) 
 
 
General Sonogashira Coupling Method for the Synthesis of 384 
The enyne 253 was dissolved in anhydrous THF (0.50 M), and the solution was added to a 
mixture of aryliodide (1.20 equiv.), CuI (0.04 equiv.) and Pd(PPh3)2Cl2 (0.02 equiv.) in Et3N 
(2.00 equiv.). The reaction mixture was stirred at room temperature for 18 h, followed by 
filtration through a pad of Celite. Purification by column chromatography on silica gel 
(Et2O/hexane) provides the desired product 384. 
 
Synthesis of Enediynes (380 and 385)  
The enediynes 380 were prepared via amide coupling reactions of enynes (253 and 384) with 
propiolic acid following a procedure reported in the literature.208 To a solution of propiolic acid 
(1.50 equiv.) in anhydrous CH2Cl2 (0.2 M) was added the enyne and DMAP (0.30 equiv.) at 0 
°C. Then, DCC (1.50 equiv.) was added slowly and the mixture was stirred at room temperature 
for 48 h. The reaction mixture was quenched by adding a few drops of HOAc at 0 °C, and the 
mixture was filtered off through a pad of Celite. The organic layer was successively washed 
with 10% HCl solution (5 mL), saturated aqueous NaHCO3 solution (5 mL) and saturated 
aqueous NaCl solution (5 mL), dried (Na2SO4), and concentrated under reduced pressure. The 
residue was dissolved in dichloromethane and kept in the freezer for 12 h. The heterogeneous 
R1
NHBn
R1 = Me, Bn, nPr, iBu, iPr
R2 = C6H5, 4-(C6H5)NO2, 4-(C6H5)OMe, 4-(C6H5)F, 4-(C6H5)CHO, 2-thiophenyl, 1-naphthyl
































mixture was then filtered and the filtrate was then purified by column chromatography on silica 




The title compound 384a was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253b (0.12 g, 0.56 
mmol), 4-iodobenzene (0.075 mL, 0.67 mmol, 1.20 equiv.), CuI (0.0045 g, 0.022 mmol, 4 
mol%) and Pd(PPh3)2Cl2 (0.008 g, 0.011 mmol, 2 mol%), and Et3N (0.15 mL, 1.12 mmol, 2.00 
equiv.) in THF (1.0 mL). Colourless oil (0.083 g, 51%). Rf (Et2O/hexane = 3:7) = 0.35. [𝛼]+,/	= 
–100.6 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.89 (t, 3H, J = 8.0 Hz, CH3), 1.32-1.53 
(m, 4H, 2CH2), 3.10-3.16 (m, 1H, CH-N), 3.65 (d, 1H, J = 12.0 Hz, CHPh), 3.86 (d, 1H, J = 
12.0 Hz, CHPh), 5.81 (dd, 1H, J = 15.9, 0.8 Hz, =CH), 6.05 (dd, 1H, J = 15.9, 8.2 Hz, =CH), 
7.22-7.33 (m, 9H, 9CHAr), 7.43-7.45 (m, 1H, CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 14.0, 
19.1, 37.9, 51.3, 60.0, 87.8, 89.0, 110.8, 123.4, 126.9, 128.0, 128.1, 128.2, 128.4, 131.4, 140.5, 
146.9. IR (νmax/cm-1) 3329 (w), 3026 (w), 2956 (m), 2928 (m), 2201 (w), 1595 (m), 1489 (s), 
1101 (m), 1028 (s), 753 (s), 689 (s). HRMS (ESI-TOF) m/z calcd for C21H24N [M + H]+ 




The title compound 384b was obtained after flash column chromatography (Et2O/hexane = 3:7) 








0.87 mmol), 1-iodo-4-nitrobenzene (0.26 g, 1.04 mmol, 1.20 equiv.), CuI (0.007 g, 0.035 mmol, 
4 mol%) and Pd(PPh3)2Cl2 (0.012 g, 0.017 mmol, 2 mol%), and Et3N (0.23 mL, 1.74 mmol, 
2.00 equiv.) in THF (3.0 mL). Orange oil (0.24 g, 82%). Rf (Et2O/hexane = 4:6) = 0.48. [𝛼]+,/	= 
–130.0 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.90 (t, 3H, J = 8.0 Hz, CH3), 1.32-1.54 
(m, 4H, 2CH2), 3.13-3.19 (m, 1H, CH), 3.65 (d, 1H, J = 13.2 Hz, CHPh), 3.84 (d, 1H, J = 13.2 
Hz, CHPh), 5.85 (dd, 1H, J = 15.9, 0.9 Hz, =CH), 6.17 (dd, 1H, J = 15.9, 8.1 Hz, =CH), 7.21-
7.34 (m, 5H, 5CHAr), 7.51-7.54 (m, 2H, 2CHAr), 8.14 (m, 2H, 2CHAr). 13C{1H} NMR (100 
MHz, CDCl3) δ 14.1, 19.1, 37.8, 51.4, 60.0, 87.4, 93.4, 109.9, 123.6, 127.0, 128.1, 128.4, 130.4, 
132.1, 140.4, 146.8, 149.5. IR (νmax/cm-1) 3329 (w), 3026 (w), 2956 (m), 2160 (m), 1589 (s), 
1514 (s), 1337 (s), 1106 (s), 957 (s), 852 (s), 697 (s). HRMS (ESI-TOF) m/z calcd for 




The title compound 384c was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253b (0.156 g, 
0.73 mmol), 4-iodoanisole (0.20 g, 0.876 mmol, 1.20 equiv.), CuI (0.006 g, 0.03 mmol, 4 
mol%) and Pd(PPh3)2Cl2 (0.010 g, 0.014 mmol, 2 mol%), and Et3N (0.19 mL, 1.46 mmol, 2.00 
equiv.) in THF (3.0 mL). Orange oil (0.12 g, 50%). Rf (Et2O/hexane = 4:6) = 0.31. [𝛼]+,/	= –
110.6 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.89 (t, 3H, J = 8.0 Hz, CH3), 1.34-1.53 
(m, 4H, 2CH2), 3.09-3.15 (m, 1H, CH), 3.65 (d, 1H, J = 12.0 Hz, CHPh), 3.81 (s, 3H, OCH3), 
3.85 (d, 1H, J = 12.0 Hz, CHPh), 5.80 (dd, 1H, J = 15.9, 0.8 Hz, =CH), 6.01 (dd, 1H, J = 15.9, 
8.3 Hz, =CH), 6.82-6.86 (m, 2H, 2CHAr), 7.22-7.40 (m, 7H, 7CHAr). 13C{1H} NMR (100 MHz, 
CDCl3) δ 14.0, 19.1, 38.0, 51.3, 55.2, 60.1, 86.5, 89.0, 111.1, 114.0, 115.5, 126.9, 128.1, 128.4, 







1602 (s), 1507 (s), 1454 (s), 1290 (s), 1245 (s), 1172 (s), 1033 (s), 955 (s), 830 (s), 697 (s). 




The title compound 384d was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253b (0.148 g, 
0.69 mmol), 4-fluoroiodobenzene (0.10 ml, 0.83 mmol, 1.20 equiv.), CuI (0.0055 g, 0.0277 
mmol, 4 mol%) and Pd(PPh3)2Cl2 (0.010 g, 0.014 mmol, 2 mol%), and Et3N (0.18 mL, 1.386 
mmol, 2.00 equiv.) in THF (3.0 mL). Yellow oil (0.177 g, 83%). Rf (Et2O/hexane = 4:6) = 0.46. 
[𝛼]+,/	= –117.0 (c 0.6 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.89 (t, 3H, J = 8.0 Hz, CH3), 
1.33-1.51 (m, 4H, 2CH2), 3.10-3.16 (m, 1H, CH), 3.65 (d, 1H, J = 13.2 Hz, CHPh), 3.85 (d, 
1H, J = 13.2 Hz, CHPh), 5.79 (dd, 1H, J = 15.9, 0.8 Hz, =CH), 6.05 (dd, 1H, J = 15.9, 8.2 Hz, 
=CH), 6.97-7.03 (m, 2H, 2CHAr), 7.22-7.27 (m, 1H, CHAr), 7.29-7.35 (m, 4H, 4CHAr), 7.39-
7.44 (m, 2H, 2CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 14.0, 19.1, 37.9, 51.3, 60.0, 87.50, 
87.52, 88.0, 110.6, 115.6 (d, JC,F = 22.0 Hz), 119.5 (d, JC,F = 3.6 Hz), 126.9, 128.15, 128.19, 
128.4, 133.3 (d, JC,F = 9.0 Hz), 140.5, 147.0, 162.4 (d, JC,F = 247.0 Hz). IR (νmax/cm-1) 3327 
(w), 3026 (w), 2957 (m), 2929 (m), 2190 (w), 1598 (m), 1504 (s), 1454 (s), 1229 (s), 1154 (s), 















The title compound 384e was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253b (0.20 g, 0.94 
mmol), 4-iodobenzaldehyde (0.27 ml, 1.13 mmol, 1.20 equiv.), CuI (0.0075 g, 0.038 mmol, 4 
mol%) and Pd(PPh3)2Cl2 (0.0135 g, 0.019 mmol, 2 mol%), and Et3N (0.26 mL, 1.88 mmol, 
2.00 equiv.) in THF (3.0 mL). Orange oil (0.212 g, 71%). Rf (Et2O/hexane = 5:5) = 0.40. [𝛼]+,/	= 
–155.5 (c 0.4 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.89 (t, 3H, J = 8.0 Hz, CH3), 1.32-1.51 
(m, 4H, 2CH2), 3.12-3.17 (m, 1H, CH), 3.65 (d, 1H, J = 12.0 Hz, CHPh), 3.84 (d, 1H, J = 12.0 
Hz, CHPh), 5.85 (dd, 1H, J = 15.9, 0.9 Hz, =CH), 6.14 (dd, 1H, J = 15.9, 8.1 Hz, =CH), 7.22-
7.34 (m, 5H, 5CHAr), 7.54-7.57 (d, 2H, J = 8.4 Hz, 2CHAr), 7.80 (d, 2H, J = 8.4 Hz, 2CHAr), 
9.95 (s, 1H, CHO). 13C{1H} NMR (100 MHz, CDCl3) δ 14.1, 19.1, 37.8, 51.4, 60.0, 88.3, 92.1, 
110.2, 127.0, 128.1, 128.4, 129.5, 129.7, 132.0, 135.3, 140.4, 148.8, 191.3. IR (νmax/cm-1) 3324 
(w), 3026 (w), 2956 (m), 2928 (m), 2197 (m), 1698 (s), 1597 (s), 1453 (m), 1205 (s), 1164 (m), 





The title compound 384f was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253c (0.17 g, 
0.796 mmol), 2-iodothiophene (0.10 ml, 0.955 mmol, 1.20 equiv.), CuI (0.0076 g, 0.032 mmol, 









2.00 equiv.) in THF (2.0 mL). Light yellow oil (0.123 g, 50%). Rf (Et2O/hexane = 3:7) = 0.37. 
[𝛼]+,/	= –144.6 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.86 (d, 3H, J = 5.6 Hz, CH3), 
0.88 (d, 3H, J = 5.6 Hz, CH3), 1.26-1.43 (m, 2H, CH2), 1.64-1.71 (m, 1H, CH), 3.15-3.20 (m, 
1H, CH), 3.64 (d, 1H, J = 13.2 Hz, CHPh), 3.84 (d, 1H, J = 13.2 Hz, CHPh), 5.82 (dd, 1H, J = 
15.8, 0.7 Hz, =CH), 6.02 (dd, 1H, J = 15.8, 8.3 Hz, =CH), 6.94-6.97 (m, 1H, CHAr), 7.19 (d, 
1H, J = 4.8 Hz, CHAr), 7.21-7.27 (m, 2H, 2CHAr), 7.32 (d, 4H, J = 4.4 Hz, 4CHAr). 13C{1H} 
NMR (100 MHz, CDCl3) δ 22.4, 22.9, 24.6, 45.0, 51.3, 58.3, 82.3, 91.6, 110.3, 123.4, 126.9, 
127.0, 128.1, 128.4, 131.6, 140.4, 147.1. IR (νmax/cm-1) 3318 (w), 3025 (w), 2953 (m), 2912 
(m), 2197 (w), 1494 (m), 1453 (s), 1197 (m), 955 (s), 828 (s), 695 (s). HRMS (ESI-TOF) m/z 




The title compound 384g was obtained after flash column chromatography (Et2O/hexane = 4:6) 
following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253c (0.17 g, 
0.796 mmol), 1-iodonaphthalene (0.10 ml, 0.955 mmol, 1.20 equiv.), CuI (0.0045 g, 0.0228 
mmol, 4 mol%) and Pd(PPh3)2Cl2 (0.008 g, 0.0114 mmol, 2 mol%), and Et3N (0.16 mL, 1.14 
mmol, 2.00 equiv.) in THF (3.0 mL). Light yellow oil (0.121 g, 60%). Rf (Et2O/hexane = 4:6) 
= 0.36. [𝛼]+,/	= –49.0 (c 0.2 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.89 (d, 3H, J = 8.0 Hz, 
CH3), 0.91 (d, 3H, J = 8.0 Hz, CH3), 1.37-1.49 (m, 2H, CH2), 1.68-1.78 (m, 1H, CH), 3.22-3.28 
(m, 1H, CH), 3.70 (d, 1H, J = 12.0 Hz, CHPh), 3.91 (d, 1H, J = 12.0 Hz, CHPh), 5.97 (dd, 1H, 
J = 15.9, 0.7 Hz, =CH), 6.15 (dd, J = 15.9, 8.3 Hz, 1H, =CH), 7.23-7.27 (m, 1H, CHAr), 7.30-
7.37 (m, 4H, 4CHAr), 7.43 (t, 1H, J = 7.2 Hz, CHAr), 7.50-7.60 (m, 2H, 2CHAr), 7.68 (d, 1H, J 
= 8.0 Hz, CHAr), 7.80-7.86 (m, 2H, 2CHAr), 7.35 (d, 1H, J = 8.0 Hz, CHAr). 13C{1H} NMR (100 






126.6, 126.9, 128.1, 128.2, 128.4, 128.5, 130.2, 133.21, 133.24, 140.5, 147.1. IR (νmax/cm-1) 
3322 (w), 3026 (w), 2953 (s), 2921 (m), 2195 (w), 1453 (s), 1154 (m), 955 (s), 798 (s), 772 (s), 




The title compound 380a was obtained after flash column chromatography (Et2O/pentane = 
4:6) following the general procedure using (S,E)-N-benzylhex-3-en-5-yn-2-amine 253a (0.10 
g, 0.54 mmol), propiolic acid (0.053 mL, 0.81 mmol, 1.50 equiv.), DMAP (0.02 g, 0.16 mmol, 
0.30 equiv.) and DCC (0.17 g, 0.81 mmol, 1.50 equiv.) in CH2Cl2 (2.0 mL). Yellow oil (0.079 
g, 56%). Rf (Et2O/pentane = 4:6) = 0.38. [𝛼]+,/	= –74.2 (c 0.3 CHCl3). 1H NMR (500 MHz, 
CDCl3) (mixture (ca. 45:55) of two rotamers) δ 1.14 (d, 3H major, J = 7.0 Hz, CH3), 1.24 (d, 
3H min, J = 7.0 Hz, CH3), 2.86 (d, 1H major, J = 2.0 Hz, CH alkyne), 2.93 (d, 1H minor, J = 
2.0 Hz, CH alkyne), 3.07 (s, 1H major, CH alkyne), 3.22 (s, 1H minor, CH alkyne), 4.28 (d, 
1H minor, J = 15.5 Hz, CHPh), 4.62 (d, 1H major, J = 15.5 Hz, CHPh), 4.75 (d, 1H minor, J = 
15.5 Hz, CHPh), 4.86 (d, 1H major, J = 15.5 Hz, CHPh), 4.96-4.99 (m, 1H major, CH), 5.20-
5.23 (m, 1H minor, CH), 5.48 (dt, 1H major, J = 16.1, 2.0 Hz, =CH), 5.58 (dt, 1H minor, J = 
16.1, 2.1 Hz, =CH), 6.13 (m, 1H major and minor), 7.22-7.36 (m, 10H major and minor, 
10CHAr). 13C{1H} NMR (125 MHz, CDCl3) (mixture (ca. 45:55) of two rotamers) δ 17.0, 18.1, 
45.1, 50.1, 51.8, 55.7, 75.7, 76.2, 78.5, 78.9, 79.1, 80.1, 80.8, 81.2, 110.9, 111.1, 127.1, 127.2, 
127.5, 127.7, 128.5, 128.7, 137.3, 137.7, 143.6, 144.0, 153.8. IR (νmax/cm-1) 3289 (m), 2982 
(w), 2104 (m), 1620 (s), 1411 (s), 1329 (m), 1168 (m), 958 (s), 725 (s), 647 (s). HRMS (ESI) 










(S,E)-N-Benzyl-N-(oct-5-en-7-yn-4-yl)propiolamide (380b)  
 
The title compound 380b was obtained after flash column chromatography (Et2O/pentane = 
3:7) following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253b (0.14 
g, 0.65 mmol), propiolic acid (0.065 mL, 0.98 mmol, 1.50 equiv.), DMAP (0.024 g, 0.195 
mmol, 0.30 equiv.) and DCC (0.21 g, 0.98 mmol, 1.50 equiv.) in CH2Cl2 (4.0 mL). Yellow oil 
(0.078 g, 45%). Rf (Et2O/pentane = 3:7) = 0.40. [𝛼]+,,	= –84.4 (c 0.4 CHCl3). 1H NMR (500 
MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 0.77 (t, 6H two rotamers, J = 7.5 Hz, 
2CH3), 1.11-1.27 (m, 4H two rotamers, 2CH2), 1.51-1.56 (m, 4H two rotamers, 2CH2), 2.83 (d, 
1H one rotamer, J = 2.3 Hz, CH alkyne), 2.90 (d, 1H one rotamer, J = 2.3 Hz, CH alkyne), 
3.08 (d, 1H one rotamer, J = 1.7 Hz, CH alkyne), 3.20 (s, 1H one rotamer, CH alkyne), 4.36 
(d, 1H one rotamer, J = 16.0 Hz, CHPh), 4.63-4.70 (m, 3H two rotamers, 2CHPh and CH), 
4.81 (d, 1H one rotamer, J = 16.0 Hz, CHPh), 5.01 (q, 1H one rotamer, J = 7.5 Hz, CH), 5.36-
5.51 (m, 1H one rotamer, =CH), 5.61 (dd, 1H one rotamer, J = 16.0, 2.1 Hz, =CH), 6.09 (dt, 
2H, J = 16.0, 7.5 Hz, 2(=CH)), 7.23-7.36 (m, 10H two rotamers, 10CHAr).  13C{1H} NMR (125 
MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 13.5, 13.6, 19.2, 19.5, 33.4, 34.0, 45.3, 
51.0, 57.2, 60.6, 76.9, 76.3, 78.2, 78.8, 80.1, 80.9, 81.2, 111.7, 111.9, 127.3, 127.5, 127.9, 
128.0, 128.4, 128.6, 137.0, 137.6, 142.6, 143.1, 153.8, 154.2. IR (νmax/cm-1) 3283 (m), 2958 
(m), 2930 (m), 2104 (m), 1623 (s), 1411 (s), 1338 (m), 1228 (m), 1167 (m), 956 (s), 737 (s), 














The title compound 380c was obtained after flash column chromatography (Et2O/pentane = 
3:7) following the general procedure using (S,E)-N-benzyl-2-methyloct-5-en-7-yn-4-amine 
253c (0.098 g, 0.43 mmol), propiolic acid (0.041 mL, 0.64 mmol, 1.50 equiv.), DMAP (0.016 
g, 0.13 mmol, 0.30 equiv.) and DCC (0.135 g, 0.64 mmol, 1.50 equiv.) in CH2Cl2 (1.0 mL). 
Yellow oil (0.066 g, 55%). Rf (Et2O/pentane = 3:7) = 0.50. [𝛼]+,/	= –91.6 (c 0.4 CHCl3). 1H 
NMR (500 MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 0.64 (d, 3H one rotamer, J = 
6.0 Hz, CH3), 0.68 (d, 3H one rotamer, J = 6.5 Hz, CH3), 0.82 (d, 3H one rotamers, J = 6.5 Hz, 
CH3), 0.88 (d, 3H one rotamer, J = 6.5 Hz, CH3), 1.31-1.53 (m, 6H two rotamers, 2CH and 
2CH2), 2.84 (d, 1H one rotamer, J = 2.3 Hz, CH alkyne), 2.91 (d, 1H one rotamer, J = 2.3 Hz, 
CH alkyne), 3.08 (s, 1H one rotamer, CH alkyne), 3.22 (s, 1H one rotamer, CH alkyne), 4.29 
(d, 1H one rotamer, J = 15.0 Hz, CHPh), 4.66-4.82 (m, 4H two rotamers, 3CHPh and CH), 
5.08-5.12 (m, 1H one rotamer, CH), 5.45 (dt, 1H one rotamer, J = 16.0, 1.7 Hz, =CH), 5.61 
(dt, 1H, J = 16.0, 2.0 Hz, =CH), 6.06-6.13 (m, 2H two rotamers, 2(=CH)), 7.23-7.36 (m, 10H 
two rotamers, 10CHAr). 13C{1H} NMR (125 MHz, CDCl3) (mixture (ca. 50:50) of two 
rotamers) δ 22.0, 22.24, 22.28, 22.6, 24.3, 24.7, 40.2, 40.9, 45.3, 50.9, 55.4, 58.9, 75.9, 76.3, 
78.2, 78.92, 78.94, 80.0, 80.9, 81.2, 111.73, 111.78, 127.3, 127.5, 127.9, 128.0, 128.4, 128.6, 
137.0, 137.7, 142.9, 143.3, 153.3, 153.3. IR (νmax/cm-1) 3287 (m), 2931 (m), 2103 (m), 1620 
(s), 1412 (s), 1231 (s), 958 (s), 737 (s), 634 (s). HRMS (ESI-TOF) m/z calcd for C19H22NO [M 













The title compound 380b was obtained after flash column chromatography (Et2O/pentane = 
3:7) following the general procedure using (S,E)-N-benzyl-1-phenylhex-3-en-5-yn-2-amine 
253d (0.25 g, 0.956 mmol), propiolic acid (0.091 mL, 1.43 mmol, 1.50 equiv.), DMAP (0.035 
g, 0.287 mmol, 0.30 equiv.) and DCC (0.30 g, 1.43 mmol, 1.50 equiv.) in CH2Cl2 (5.0 mL). 
Yellow oil (0.150 g, 50%). Rf (Et2O/pentane = 3:7) = 0.26. [𝛼]+,/	= –95.5 (c 0.4 CHCl3). 1H 
NMR (500 MHz, CDCl3 (mixture (ca. 60:40) of two rotamers) δ 2.81-2.97 (m, 4H major and 
minor, 2CHPh and 2CH alkyne), 3.05-3.16 (m, 4H major and minor, 2CHPh and 2CH alkyne), 
4.29 (d, 1H major, J = 16.0 Hz, CHPh), 4.40-4.70 (m, 2H major and minor, CHPh and CH), 
4.70 (d, 1H minor, J = 16.0 Hz, CHPh), 4.77 (d, 1H major, J = 16.0 Hz, CHPh), 5.22-5.27 (m, 
1H major and minor, CH and =CH), 5.53 (d, 1H minor, J = 16.0 Hz, =CH), 6.11-6.15 (m, 1H 
minor, =CH), 6.31 (m, 1H major, =CH), 7.04 (d, 4H major and minor, J = 6.5 Hz, 4CHAr), 
7.19-7.32 (m, 16H major and minor, 16CHAr). 13C{1H} NMR (125 MHz, CDCl3) (mixture (ca. 
60:40) of two rotamers) δ 37.9, 39.2, 46.0, 52.9, 60.6, 61.8, 75.8, 76.3, 78.4, 78.7, 79.2, 80.1, 
80.8, 81.2, 111.9, 112.3, 126.7, 127.0, 127.4, 127.7, 128.01, 128.06, 128.6, 128.71, 128.78, 
129.1, 136.3, 136.4, 137.3, 137.4, 141.7, 141.9, 153.6, 154.0. IR (νmax/cm-1) 3288 (m), 2931 
(m), 2103 (m), 1623 (s), 1496 (s), 1455 (s), 1351 (s), 1152 (m), 956 (s), 732 (s), 697 (s). HRMS 




The title compound 380e was obtained after flash column chromatography (Et2O/pentane = 










253e (0.085 g, 0.40 mmol), propiolic acid (0.04 mL, 0.60 mmol, 1.50 equiv.), DMAP (0.015 g, 
0.12 mmol, 0.30 equiv.) and DCC (0.13 g, 0.60 mmol, 1.50 equiv.) in CH2Cl2 (2.0 mL). 
Colourless oil (0.044 g, 52%). Rf (Et2O/pentane = 3:7) = 0.58. [𝛼]+,/	= –111.0 (c 0.4 CHCl3). 
1H NMR (400 MHz, CDCl3) (mixture of (ca. 55:45) two rotamers) δ 0.80-0.92 (m, 6H major 
and minor, 2CH3), 1.94-2.00 (m, 1H minor, CH), 2.15-2.24 (m, 1H major, CH), 2.79 (dd, 1H 
major, J = 2.3, 0.7 Hz, CH alkyne), 2.85 (dd, 1H minor, J = 2.3, 0.7 Hz, CH alkyne), 3.09 (s, 
1H major, CH alkyne), 3.23 (s, 1H minor, CH alkyne), 3.94 (t, 1H major, J = 10.0 Hz, CH), 
4.41 (d, 1H minor, J = 16.0 Hz, CHPh), 4.49-4.54 (m, 1H minor, CH), 4.69-4.81 (m, 3H major 
and minor, CH2Ph and CHPh), 5.31 (ddd, 1H major, J = 16.0, 2.2, 0.8 Hz, =CH), 5.62 (ddd, 
1H minor, J = 16.0, 2.3, 1.0 Hz, =CH), 6.01 (ddd, 1H minor, J = 16.0, 8.7, 0.7 Hz, =CH), 6.12 
(ddd, 1H major, J = 16.0, 9.4, 0.6 Hz, =CH), 7.21-7.38 (m, 10H major and minor, 10CHAr). 
13C{1H} NMR (100 MHz, CDCl3) (mixture (ca. 55:45) of two rotamers) δ 19.5, 20.18, 20.19, 
28.9, 29.9, 45.7, 52.4, 65.5, 68.1, 76.1, 76.4, 77.8, 78.6, 78.8, 80.3, 80.0, 81.2, 112.8, 113.1, 
127.3, 127.9, 128.01, 128.06, 128.4, 128.6, 136.5, 137.2, 142.02, 142.07, 153.7, 154.1. IR 
(νmax/cm-1) 3286 (m), 2963 (m), 2103 (m), 1617 (s), 1496 (s), 1387 (s), 1225 (s), 960 (s), 739 
(s), 697 (s). HRMS (ESI-TOF) m/z calcd for C18H19NONa [M + Na]+ 288.1364, found 
288.1366. 
 
 (S,E)-N-Benzyl-N-(8-phenyloct-5-en-7-yn-4-yl)propiolamide (385a) 
 
The title compound 385a was obtained after flash column chromatography (Et2O/pentane = 
3:7) following the general procedure using (S,E)-N-benzyl-8-phenyloct-5-en-7-yn-4-amine 
384a (0.043 g, 0.19 mmol), propiolic acid (0.02 mL, 0.285 mmol, 1.50 equiv.), DMAP (0.007 
g, 0.057 mmol, 0.30 equiv.) and DCC (0.06 g, 0.285 mmol, 1.50 equiv.) in CH2Cl2 (2.0 mL). 







1H NMR (400 MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 0.78 (t, 6H two rotamers, 
J = 8.0 Hz, 2CH3), 1.13-1.31 (m, 4H two rotamers, 2CH2), 1.54-1.64 (m, 4H two rotamers, 
2CH2), 3.07 (s, 1H one rotamer, CH alkyne), 3.21 (s, 1H one rotamer, CH alkyne), 4.37 (d, 1H 
two rotamers, J = 16.0 Hz, CHPh), 4.80-4.64 (m, 3H two rotamers, CH and 2CHPh), 4.85 (d, 
1H one rotamer, J = 16.0 Hz, CHPh), 5.01-5.11 (m, 1H one rotamer, CH), 5.71 (dd, 1H one 
rotamer, J = 16.0, 1.2 Hz, =CH), 5.86 (dd, 1H one rotamer, J = 16.0, 1.5 Hz, =CH), 6.06-6.14 
(m, 2H two rotamers, 2(=CH)), 7.22-7.42 (m, 20H two rotamers, 20CHAr). 13C{1H} NMR (100 
MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 13.5, 13.6, 19.2, 19.5, 33.7, 34.2, 45.3, 
51.0, 57.4, 60.8, 76.0, 78.7, 80.0, 112.8, 113.0, 127.3, 127.5, 127.8, 128.0, 128.2, 128.32, 
128.37, 128.4, 128.6, 131.52, 131.55, 137.1, 137.7, 140.6, 141.0, 154.2.  IR (νmax/cm-1) 3278 
(m), 3062 (m), 2958 (m), 2103 (m), 1620 (s), 1489 (m), 1411 (s), 1229 (s), 953 (s), 755 (s), 690 




The title compound 385b was obtained after flash column chromatography (Et2O/pentane = 
3:7) following the general procedure using (S,E)-N-benzyl-8-(4-nitrophenyl)oct-5-en-7-yn-4-
amine 384b (0.20 g, 0.60 mmol), propiolic acid (0.058 mL, 0.9 mmol, 1.50 equiv.), DMAP 
(0.022 g, 0.18 mmol, 0.30 equiv.) and DCC (0.185 g, 0.90 mmol, 1.50 equiv.) in CH2Cl2 (5.0 
mL). Light yellow oil (0.122 g, 53%). Rf (Et2O/pentane = 3:7) = 0.26. [𝛼]+,/	= –175.3 (c 0.3 
CHCl3). 1H NMR (400 MHz, CDCl3) (mixture (ca. 45:55) of two rotamers) δ 0.80 (m, 6H 
major and minor, 2CH3), 1.17-1.29 (m, 4H major and minor, 2CH2), 1.59-1.65 (m, 4H major 
and minor, 2CH2), 3.11 (s, 1H major, CH alkyne), 3.24 (s, 1H minor, CH alkyne), 4.42 (d, 1H 
minor, J = 16.0 Hz, CHPh), 4.61-4.67  (m, 1H major, CH), 4.71-4.75 (m, 2H major and minor, 








major, J = 16.0, 1.2 Hz, =CH), 5.86 (dd, 1H minor, J = 16.0, 1.6 Hz, =CH), 6.14-6.24 (m, 2H 
major and minor, 2(=CH)), 7.22-7.40 (m, 10H major and minor, 10CHAr), 7.49-7.55 (m, 4H 
major and minor, 4CHAr), 8.15-8.20 (m, 4H major and minor, 4CHAr). 13C{1H} NMR (100 
MHz, CDCl3) (mixture (ca. 45:55) of two rotamers) δ 13.5, 13.6, 19.2, 19.5, 33.4, 34.0, 45.3, 
51.3, 57.6, 60.7, 75.9, 76.3, 78.9, 80.2, 88.3, 88.9, 91.8, 92.4, 111.91, 111.99, 123.60, 123.64, 
127.3, 127.6, 127.9, 128.0, 128.5, 128.7, 130.10, 132.17, 132.2, 136.9, 137.6, 143.1, 143.5, 
146.9, 153.8, 154.2. IR (νmax/cm-1) 3276 (m), 3031 (m), 2959 (m), 2104 (m), 1621 (s), 1590 (s), 
1514 (s), 1338 (s), 1107 (s), 953 (s), 853 (s), 737 (s), 695 (s). HRMS (ESI-TOF) m/z calcd for 




The title compound 385c was obtained after flash column chromatography (Et2O/pentane = 
3:7) following the general procedure using (S,E)-N-benzyl-8-(4-methoxyphenyl)oct-5-en-7-yn-
4-amine 384c (0.072 g, 0.225 mmol), propiolic acid (0.021 mL, 0.338 mmol, 1.50 equiv.), 
DMAP (0.008 g, 0.067 mmol, 0.30 equiv.) and DCC (0.07 g, 0.338 mmol, 1.50 equiv.) in 
CH2Cl2 (2.0 mL). Colourless oil (0.042 g, 50%). Rf (Et2O/pentane = 3:7) = 0.31. [𝛼]+,/	= –149.5 
(c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 0.77 (t, 6H 
two rotamers, J = 8.0 Hz, 2CH3), 1.14-1.27 (m, 4H two rotamers, 2CH2), 1.52-1.63 (m, 4H two 
rotamers, 2CH2), 3.07 (s, 1H one rotamer, CH alkyne), 3.20 (s, 1H one rotamer, CH alkyne), 
3.80 (s, 6H two rotamers, 2(OCH3)), 4.35 (d, 1H one rotamer, J = 16.0 Hz, CHPh), 4.68-4.88 
(m, 4H two rotamers, 3CHPh and CH), 5.02-5.08 (m, 1H one rotamer, CH), 5.70 (dd, 1H one 
rotamer, J = 16.0, 1.5 Hz, 4.0 Hz, =CH), 5.85 (dd, 1H one rotamer, J = 16.0, 1.5 Hz =CH), 
6.02-6.10 (m, 2H two rotamers, 2(=CH)), 6.81-6.86 (m, 4H two rotamers, 4CHAr), 7.22-7.38 








rotamers) δ 13.5, 13.6, 19.2, 19.5, 33.7, 34.2, 45.3, 51.0, 55.2, 55.3, 57.5, 60.8, 76.0, 76.4, 78.7, 
79.9, 85.5, 85.8, 90.5, 91.1, 113.1, 113.3, 113.9, 114.0, 115.0, 115.2, 127.2, 127.5, 127.8, 128.0, 
128.4, 128.6, 132.9, 133.0, 137.1, 137.7, 139.7, 140.1, 153.8, 154.2, 159.6, 159.7. IR (νmax/cm-
1) 3273 (m), 2958 (m), 2103 (m), 1622 (s), 1602 (s), 1508 (s), 1411 (s), 1246 (s), 1171 (s), 1080 
(s), 952 (s), 831 (s), 737 (s), 697 (s). HRMS (ESI-TOF) m/z calcd for C25H25NO2Na [M + Na]+ 




The title compound 385d was obtained after flash column chromatography (Et2O/pentane = 
3:7) following the general procedure using (S,E)-N-benzyl-8-(4-fluorophenyl)oct-5-en-7-yn-4-
amine 384d (0.075 g, 0.244 mmol), propiolic acid (0.023 mL, 0.366 mmol, 1.50 equiv.), DMAP 
(0.009 g, 0.073 mmol, 0.30 equiv.) and DCC (0.077 g, 0.366 mmol, 1.50 equiv.) in CH2Cl2 (2.0 
mL). Colourless oil (0.043 g, 49%). Rf (Et2O/pentane = 3:7) = 0.39. [𝛼]+,/	= –144.6 (c 0.3 
CHCl3). 1H NMR (400 MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 0.78 (t, 6H two 
rotamers, J = 8.0 Hz, 2CH3), 1.14-1.26 (m, 4H two rotamers, 2CH2), 1.54-1.60 (m, 4H two 
rotamers, 2CH2), 3.08 (s, 1H one rotamer, CH alkyne), 3.22 (s, 1H one rotamer, CH alkyne), 
4.37 (d, 1H one rotamer, J = 16.0 Hz, CHPh), 4.63-4.77 (m, 3H two rotamers, CH and 2CHPh), 
4.85 (d, 1H one rotamer, J = 16.0 Hz, CHPh), 5.03-5.09 (m, 1H one rotamer, CH), 5.68 (dd, 
1H one rotamer, J = 16.0, 1.2 Hz, =CH), 5.85 (dd, 1H one rotamer, J = 16.0 Hz, 1.6 Hz, =CH), 
6.05-6.14 (m, 2H two rotamers, 2(=CH)), 6.97-7.03 (m, 4H two rotamers, 4CHAr), 7.23-7.40 
(m, 14H two rotamers, 14CHAr). 13C{1H} NMR (100 MHz, CDCl3) (mixture (ca. 50:50) of two 
rotamers) δ 13.5, 13.6, 19.2, 19.5, 33.6, 34.2, 45.3, 51.1, 57.5, 60.8, 76.0, 76.4, 78.8, 80.0, 
86.44, 86.46, 86.81, 86.80, 89.2, 89.9, 112.6, 112.8, 115.6 (d, JC,F = 22.0 Hz), 115.8, 119.1 (d, 








140.7, 141.1, 153.8, 154.2, 161.2, 161.3, 162.5 (d, JC,F = 247.0 Hz). IR (νmax/cm-1) 3282 (m), 
3219 (m), 2959 (m), 2103 (m), 1622 (s), 1505 (s), 1411 (s), 1222 (s), 953 (s), 834 (s), 737 (s), 




The title compound 385e was obtained after flash column chromatography (Et2O/pentane = 
4:6) following the general procedure using (S,E)-4-(5-(benzylamino)oct-3-en-1-yn-1-
yl)benzaldehyde 384e (0.17 g, 0.55 mmol), propiolic acid (0.05 mL, 0.83 mmol, 1.50 equiv.), 
DMAP (0.020 g, 0.165 mmol, 0.30 equiv.) and DCC (0.17 g, 0.83 mmol, 1.50 equiv.) in CH2Cl2 
(3.0 mL). Light yellow oil (0.118 g, 58%). Rf (Et2O/pentane = 4:6) = 0.40. [𝛼]+,/	= –190.5 (c 
0.4 CHCl3). 1H NMR (400 MHz, CDCl3) (mixture (ca. 53:47) of two rotamers) δ 0.80 (t, 6H 
major and minor, J = 8.0 Hz, 2CH3), 1.16-1.30 (m, 4H major and minor, 2CH2), 1.58-1.64 (m, 
4H major and minor, 2CH2), 3.11 (s, 1H major, CH alkyne), 3.24 (s, 1H minor, CH alkyne), 
4.41 (d, 1H minor, J = 16.0 Hz, CHPh), 4.65-4.76 (m, 3H major and minor, CH and 2CHPh), 
4.86 (d, 1H major, J = 16.0 Hz, CHPh), 5.07-5.09 (m, 1H minor, CH), 5.70 (dd, 1H major, J = 
16.0, 1.7 Hz, =CH), 5.87 (dd, 1H minor, J = 16.0, 1.6 Hz, =CH), 6.12-6.22 (m, 2H major and 
minor, 2(=CH)), 7.23-7.39 (m, 10H major and minor, 10CHAr), 7.51-7.56 (m, 4H major and 
minor, 4CHAr), 7.81-7.84 (m, 4H major and minor, 4CHAr), 9.99 (s, 1H major, CHO), 10.00 (s, 
1H minor, CHO). 13C{1H} NMR (100 MHz, CDCl3) (mixture (ca. 53:47) of two rotamers) δ 
13.5, 13.6, 19.2, 19.5, 33.5, 34.1, 45.3, 51.2, 57.5, 60.7, 75.9, 76.3, 78.9, 80.2, 89.3, 89.9, 90.6, 
91.1, 112.2, 112.3, 127.3, 127.5, 127.9, 128.0, 128.4, 128.7, 129.4, 129.53, 129.57, 132.01, 
132.04, 135.4, 135.5, 136.9, 137.6, 142.4, 142.7, 153.8, 154.2, 191.33, 191.37. IR (νmax/cm-1) 








(s), 953 (m), 828 (s), 732 (s). HRMS (ESI-TOF) m/z calcd for C25H23NO2Na [M + Na]+ 





The title compound 385f was obtained after flash column chromatography (Et2O/pentane = 4:6) 
following the general procedure using (S,E)-N-benzyl-2-methyl-8-(thiophen-2-yl)oct-5-en-7-
yn-4-amine 384f (0.08 g, 0.258 mmol), propiolic acid (0.025 mL, 0.387 mmol, 1.50 equiv.), 
DMAP (0.0095 g, 0.077 mmol, 0.30 equiv.) and DCC (0.081 g, 0.387 mmol, 1.50 equiv.) in 
CH2Cl2 (2.0 mL). Colourless oil (0.059 g, 63%). Rf (Et2O/pentane = 5:5) = 0.60. [𝛼]+,/	= –188.0 
(c 0.2 CHCl3). 1H NMR (500 MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 0.65 (d, 
3H one rotamer, J = 6.5 Hz, CH3), 0.69 (d, 3H one rotamer, J = 6.5 Hz, CH3), 0.83 (d, 3H one 
rotamer, J = 6.5 Hz, CH3), 0.89 (d, 3H one rotamer, J = 6.5 Hz, CH3), 1.3-1.5 (m, 6H two 
rotamers, 2CH2 and 2CH), 3.10 (s, 1H one rotamer, CH alkyne), 3.20 (s, 1H one rotamer, CH 
alkyne), 4.30 (d, 1H one rotamer, J = 15.0 Hz, CHPh), 4.69 (d, 1H one rotamer, J = 15.0 Hz, 
CHPh), 4.72-4.86 (m, 3H two rotamers, 2CHPh and CH), 5.13-5.17 (m, 1H one rotamer, CH), 
5.70 (dd, 1H one rotamer, J = 16.0 Hz, 1.2 Hz, =CH), 5.85 (dd, 1H one rotamer, J = 16.0, 1.6 
Hz, =CH), 6.03-6.16 (m, 2H two rotamers, 2(=CH)), 6.95-6.99 (m, 2H two rotamers, 2CHArS), 
7.15 (d, 1H one rotamer, J = 2.5 Hz, CHArS), 7.18 (d, 1H one rotamer, J = 2.5 Hz, CHArS), 
7.21-7.37 (m, 12H two rotamers, 10CHAr and 2CHArS). 13C{1H} NMR (125 MHz, CDCl3) 
(mixture (ca. 50:50) of two rotamers) δ 22.0, 22.2, 22.3, 22.7, 24.3, 24.7, 40.4, 41.0, 45.4, 51.0, 
55.7, 59.1, 76.0, 76.4, 78.8, 80.8, 83.6, 84.3, 90.5, 90.9, 112.5, 112.6, 122.9, 123.1, 127.1, 
127.31, 127.34, 127.57, 127.59, 127.6 127.8, 128.0, 128.4, 128.6, 131.8, 132.0, 137.0, 137.7, 








1198 (m), 1080 (m), 953 (m), 737 (s), 696 (s). HRMS (ESI-TOF) m/z calcd for C23H24NOS [M 





The title compound 385g was obtained after flash column chromatography (Et2O/pentane = 
4:6) following the general procedure using (S,E)-N-benzyl-2-methyl-8-(naphthalen-1-yl)oct-5-
en-7-yn-4-amine 384g (0.054 g, 0.152 mmol), propiolic acid (0.015 mL, 0.228 mmol, 1.50 
equiv.), DMAP (0.0056 g, 0.0456 mmol, 0.30 equiv.) and DCC (0.047 g, 0.228 mmol, 1.50 
equiv.) in CH2Cl2 (2.0 mL). Colourless oil (0.035 g, 57%). Rf (Et2O/pentane = 2:8) = 0.24. 
[𝛼]+,/	= –104.0 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) (mixture (ca. 50:50) of two 
rotamers) δ 0.70 (d, 3H two rotamers, J = 6.4 Hz, CH3), 0.74 (d, 3H two rotamers, J = 6.4 Hz, 
CH3), 0.87 (d, 3H two rotamers, J = 6.4 Hz, CH3), 0.83 (d, 3H two rotamers, J = 6.4 Hz, CH3), 
1.39-1.61 (m, 6H two rotamers, 2CH2 and 2CH), 3.09 (s, 1H one rotamer, CH alkyne), 3.25 (s, 
1H one rotamer, CH alkyne), 4.43 (d, 1H one rotamer, J = 16.0 Hz, CHPh), 4.77-4.90 (m, 4H 
two rotamers, 3CHPh and CH), 5.21-5.24 (m, 1H one rotamer, CH), 5.86 (dd, 1H one rotamer, 
J = 16.0, 1.2 Hz, =CH), 6.00 (dd, 1H one rotamer, J = 16.0, 1.5 Hz, =CH), 6.14-6.23 (m, 2H 
two rotamers, 2(=CH)), 7.23-7.44 (m, 12H two rotamers, 12CHAr), 7.50-7.65 (m, 6H two 
rotamers, 6CHAr), 7.79-7.86 (m, 2H two rotamers, 4CHAr), 8.21-8.26 (m, 2H two rotamers, 
2CHAr). 13C{1H} NMR (100 MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 22.0, 22.2, 
22.3, 22.7, 24.3, 24.7, 40.4, 41.0, 45.3, 50.9, 55.6, 59.1, 76.0, 76.4, 78.8, 80.0, 88.4, 89.1, 91.5, 
92.0, 112.8, 112.9, 120.5, 120.7, 125.23, 125.24, 126.10, 126.19, 126.42, 126.48, 126.72, 
126.79, 127.3, 127.6, 127.9, 128.1, 128.2, 128.3, 128.4, 128.70, 128.77, 128.9, 130.3, 130.4, 







2956 (m), 2103 (m), 1621 (s), 1496 (s), 1230 (s), 1158 (s), 954 (s), 799 (s), 730 (s), 696 (s). 




The title compound 380b-Me was obtained after flash column chromatography (Et2O/pentane 
= 3:7) following the general procedure using (S,E)-N-benzyloct-5-en-7-yn-4-amine 253b 
(0.083 g, 0.39 mmol), butynoic acid (0.052 g, 0.59 mmol, 1.50 equiv.), DMAP (0.014 g, 0.12 
mmol, 0.30 equiv.) and DCC (0.124 g, 0.59 mmol, 1.50 equiv.) in CH2Cl2 (2.0 mL). Colourless 
oil (0.046 g, 55%). Rf (Et2O/pentane = 3:7) = 0.46. [𝛼]+,/	= –95.0 (c 0.4 CHCl3). 1H NMR (400 
MHz, CDCl3) (mixture (ca. 50:50) of two rotamers) δ 0.77 (dt, 6H two rotamers, J = 4.0 Hz, 
CH3), 1.14-1.18 (m, 4H two rotamers, CH2), 1.49-1.55 (m, 4H two rotamers, CH2), 1.94 (s, 3H 
one rotamer, CH3), 2.03 (s, 3H one rotamer, CH3), 2.83 (dd, 1H one rotamer, J = 2.2, 0.6 Hz, 
CH alkyne), 2.90 (dd, 1H one rotamer, J = 2.2, 0.6 Hz, CH alkyne), 4.33 (d, 1H one rotamer, 
J = 16.0 Hz, CHPh), 4.63-4.71 (m, 4H two rotamers, 2CHPh and 2CH), 4.79 (d, 1H one 
rotamer, J = 16.0 Hz, CHPh), 4.98-5.04 (m, 1H one rotamer, CH), 5.45 (ddd, 1H one rotamer, 
J = 16.0, 2.3, 1.3 Hz, =CH), 5.59 (ddd, 1H one rotamer, J = 16.0, 2.3, 1.7 Hz, =CH), 5.99-6.26 
(m, 2H two rotamers, 2=CH), 7.19-7.37 (m, 10H two rotamers, 10CHAr). IR (νmax/cm-1) 3288 
(m), 2959 (m), 2239 (m), 2102 (w), 1616 (s), 1431 (s), 1334 (s), 1202 (s), 955 (s), 735 (s), 697 
(s). HRMS (ESI-TOF) m/z calcd for C19H21NONa [M + Na]+ 302.1521, found 302.1534. 
 
Au(I)-Catalysed Cycloaromatisation of Enediynes  
To a solution of the unconjugated (E)-enediynes (380 and 385) in anhydrous toluene (0.07 M) 
was added [(PPh3Au)3O]BF4 (2.5 mol%) under an atmosphere of N2. The mixture was stirred 







purification by flash column chromatography to afford the corresponding isoindolinone 




The title compound 381a was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyl-N-(hex-3-en-5-yn-2-yl)propiolamide 
380a (0.02 g, 0.075 mmol) and [(PPh3Au)3O]BF4 (0.003 g, 0.0019 mmol, 0.025 equiv.) in 
toluene (1.0 mL). Colourless oil (0.016 g, 80%). Rf (Et2O/hexane = 5:5) = 0.37. [𝛼]+,/	= –90.6 
(c 0.3 CHCl3). The enantiopurity was determined by chiral HPLC using a Phenomenex Lux 
Cellulose-3 column; hexane/isopropyl alcohol (90:10); flow rate = 0.5 mL/min; 254 nm; single 
peak, t = 16.75 min, >99% ee. Racemic 381a, prepared from racemic the amino alanal 217a 
showed two peaks at t = 16.11 min and t = 16.84 min (peak area ratios 1:1) with the same 
solvent system and flow rate. 1H NMR (400 MHz, CDCl3) δ 1.43 (d, 3H, J = 8.0 Hz, CH3), 
4.26 (d, 1H, J = 16.0 Hz, CHPh), 4.35-4.40 (m, 1H, CH), 5.34 (d, 1H, J = 16.0 Hz, CHPh), 
7.26-7.53 (m, 8H, 8CHAr), 7.89 (d, 1H, J = 8.0 Hz, CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 
18.0, 43.7, 54.9, 121.9, 123.8, 127.5, 128.0, 128.1, 128.7, 131.5, 131.7, 137.3, 147.0, 168.0. IR 
(νmax/cm-1) 3027 (w), 2970 (w), 1672 (s), 1406 (s), 1153 (m), 976 (m), 693 (s). HRMS (ESI-
TOF) m/z calcd for C16H15NONa [M + Na]+ 260.1051, found 260.1058. 
 
 (S)-2-Benzyl-3-propylisoindolin-1-one (381b) 
 









4:6) following the general procedure using (S,E)-N-benzyl-N-(oct-5-en-7-yn-4-
yl)propiolamide 380b (0.020 g, 0.075 mmol) and [(PPh3Au)3O]BF4 (0.003 g, 0.0019 mmol, 
0.025 equiv.), in toluene (1.0 mL). Yellow oil (0.0159 g, 79%). Rf (Et2O/hexane = 4:6) = 0.26. 
[𝛼]+,/	= –93.0 (c 0.2 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.76-0.87 (m, 4H, CH3 and CH), 
1.05-1.12 (m, 1H, CH), 1.88-1.92 (m, 2H, CH2), 4.15 (d, 1H, J = 16.0 Hz, CHPh), 4.42 (t, 1H, 
J = 4.0 Hz, CH), 5.38 (d, 1H, J = 16.0 Hz, CHPh), 7.26-7.52 (m, 8H, 8CHAr), 7.89 (d, 1H, J = 
8.0 Hz, CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 13.9, 15.7, 32.5, 43.8, 58.6, 122.0, 123.7, 
127.5, 128.0, 128.1, 128.7, 131.3, 132.4, 137.2, 145.4, 168.6. IR (νmax/cm-1) 2952 (m), 2869 
(m), 1669 (s), 1412 (s), 1355 (s), 1240 (s), 981 (m), 725 (s), 696 (s). HRMS (ESI-TOF) m/z 
calcd for C18H19NONa [M + Na]+ 288.1364, found 288.1357. 
 
(S)-2-Benzyl-3-isobutylisoindolin-1-one (381c) 
          
The title compound 381c was obtained after flash column chromatography (Et2O/hexane = 3:7) 
following the general procedure using (S,E)-N-benzyl-N-(2-methyloct-5-en-7-yn-4-
yl)propiolamide 380c (0.020 g, 0.071 mmol) and [(PPh3Au)3O]BF4 (0.0026 g, 0.0018 mmol, 
0.025 equiv.), in toluene (1.0 mL). Yellow oil (0.0165 g, 82%). Rf (Et2O/hexane = 3:7) = 0.22. 
[𝛼]+,/	= -98.6 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.73 (d, 3H, J = 6.5 Hz, CH3), 0.88 
(d, 3H, J = 6.5 Hz, CH3), 1.65-1.72 (m, 2H, CH and CH), 1.81-1.85 (m, 1H, CH), 4.17 (d, 1H, 
J = 15.2 Hz, CHPh), 4.37-4.40 (m, 1H, CH), 5.44 (d, 1H, J = 15.2 Hz, CHPh), 7.23-7.53 (m, 
8H, 8CHAr), 7.90 (d, 1H, J = 8.0 Hz, CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 22.8, 23.8, 
24.3, 40.1, 43.9, 57.6, 122.5, 123.9, 127.5, 128.0, 128.1, 128.7, 131.2, 132.1, 137.1, 146.1, 
168.4. IR (νmax/cm-1) 2954 (m), 2918 (m), 2849 (m), 1673 (s), 1454 (m), 1413 (s), 1235 (m), 










The title compound 381d was obtained after flash column chromatography (Et2O/hexane = 4:6) 
following the general procedure using (S,E)-N-benzyl-N-(1-phenylhex-3-en-5-yn-2-
yl)propiolamide 380d (0.022 g, 0.070 mmol) and [(PPh3Au)3O]BF4 (0.0026 g, 0.0018 mmol, 
0.025 equiv.), in toluene (1.0 mL). Yellow oil (0.017 g, 77%). Rf (Et2O/hexane = 4:6) = 0.33. 
[𝛼]+,/	= –86.6 (c 0.2 CHCl3). 1H NMR (400 MHz, CDCl3) δ 2.80-2.85 (m, 1H, CHPh), 3.35-
3.40 (m, 1H, CHPh), 4.22 (d, 1H, J = 15.1 Hz, CHPh), 4.57 (dd, 1H, J = 4.8, 8.0 Hz, CH), 5.46 
(d, 1H, J = 15.1 Hz, CHPh), 6.87 (d, 1H, J = 8.0 Hz, CHAr), 6.91-7.04 (m, 2H, 2CHAr), 7.11-
7.52 (m, 10H, 10CHAr), 7.71-8.00 (m, 1H, CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 38.4, 
44.2, 59.5, 122.9, 123.8, 127.0, 127.6, 128.1, 128.1, 128.5, 128.7, 129.4, 131.0, 132.0, 136.0, 
137.1, 145.1, 168.4. IR (νmax/cm-1) 3031 (w), 2926 (m), 1684 (s), 1496 (m), 1408 (s), 1288 (m), 




   
The title compound 381e was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyl-N-(2-methylhept-4-en-6-yn-3-
yl)propiolamide 380e (0.020 g, 0.075 mmol) and [(PPh3Au)3O]BF4 (0.003 g, 0.0019 mmol, 
0.025 equiv.), in toluene (1.0 mL). Yellow oil (0.016 g, 80%). Rf (Et2O/hexane = 5:5) = 0.36. 
[𝛼]+,/	= –90.6 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.51 (d, 3H, J = 8.0 Hz, CH3), 1.16 










J = 4.0 Hz, CH), 5.46 (d, 1H, J = 16.0 Hz, CHPh), 7.24-7.34 (m, 5H, 5CHAr), 7.40-7.51 (m, 
3H, 3CHAr), 7.91-7.92 (m, 1H, CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 14.9, 19.0, 28.6, 
43.8, 63.7, 123.2, 123.8, 127.5, 128.0, 128.7, 131.0, 133.1, 137.1, 143.5, 168.7. IR (νmax/cm-1) 
2960 (m), 2874 (m), 1671 (s), 1616 (m), 1420 (s), 1295 (m), 736 (s), 695 (s). HRMS (ESI-
TOF) m/z calcd for C18H19NONa [M + Na]+ 288.1364, found 288.1373. 
  
  (S)-2-Benzyl-6-phenyl-3-propylisoindolin-1-one (386a) 
   
The title compound 386a was obtained after flash column chromatography (Et2O/hexane = 4:6) 
following the general procedure using (S,E)-N-benzyl-N-(8-phenyloct-5-en-7-yn-4-
yl)propiolamide 385a (0.020 g, 0.058 mmol) and [(PPh3Au)3O]BF4 (0.002 g, 0.00146 mmol, 
0.025 equiv.), in toluene (1.0 mL). Yellow oil (0.017 g, 85%). Rf (Et2O/hexane = 4:6) = 0.33. 
[𝛼]+,/	= –103.3 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.82 (t, 3H, J = 8.0 Hz, CH3), 
0.85-0.97 (m, 1H, CH), 1.07-1.18 (m, 1H, CH), 1.91-1.96 (m, 2H, CH2), 4.18 (d, 1H, J = 16.0 
Hz, CHPh), 4.46 (t, 1H, J = 4.4 Hz, CH), 5.41 (d, 1H, J = 16.0 Hz, CHPh), 7.26-7.49 (m, 9H, 
9CHAr), 7.62-7.65 (m, 2H, 2CHAr), 7.75 (d, 1H, J = 8.0 Hz, CHAr), 8.11 (s, 1H, CHAr). 13C{1H} 
NMR (100 MHz, CDCl3) δ 14.0, 15.8, 32.5, 43.9, 58.5, 122.2, 122.4, 127.2, 127.5, 127.7, 
128.1, 128.7, 128.9, 130.4, 133.1, 137.2, 140.2, 141.4, 144.3, 168.5. IR (νmax/cm-1) 2952 (m), 
2870 (m), 1670 (s), 1430 (s), 1405 (s), 905 (m), 757 (s), 737 (s), 692 (s). HRMS (ESI-TOF) 
m/z calcd for C24H23NONa [M + Na]+ 364.1677, found 364.1672.   
                                            
 
 









The title compound 386b was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyl-N-(8-(4-nitrophenyl)oct-5-en-7-yn-4-
yl)propiolamide 385b (0.020 g, 0.052 mmol) and [(PPh3Au)3O]BF4 (0.002 g, 0.00140 mmol, 
0.025 equiv.), in toluene (1.0 mL). Orange oil (0.0146 g, 73%). Rf (Et2O/hexane = 5:5) = 0.26. 
[𝛼]+,/	= –162.0 (c 0.2 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.80-0.91 (m, 4H, CH3 and CH), 
1.10-1.20 (m, 1H, CH), 1.94-1.99 (m, 2H, CH2), 4.19 (d, 1H, J = 16.0 Hz, CHPh), 4.50 (t, 1H, 
J = 4.0 Hz, CH), 5.41 (d, 1H, J = 16.0 Hz, CHPh), 7.26-7.36 (m, 5H, 5CHAr), 7.49 (d, 1H, J = 
8.0 Hz, CHAr), 7.77-7.81 (m, 3H, 3CHAr), 8.15 (s, 1H, CHAr), 8.31-8.35 (m, 2H, 2CHAr). 
13C{1H} NMR (100 MHz, CDCl3) δ 14.0, 15.8, 32.4, 44.0, 58.6, 122.6, 122.9, 124.3, 127.7, 
127.9, 128.1, 128.8, 130.5, 133.6, 137.0, 139.0, 145.9, 146.6, 147.4, 168.0. IR (νmax/cm-1) 2957 
(m), 2871 (w), 1682 (s), 1514 (s), 1410 (s), 1342 (s), 1258 (s), 829 (s), 745 (s), 699 (s). HRMS 
(ESI-TOF) m/z calcd for C24H22N2O3Na [M + Na]+ 409.1528, found 409.1521. 
 
(S)-2-Benzyl-6-(4-methoxyphenyl)-3-propylisoindolin-1-one (386c) 
     
The title compound 386c was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyl-N-(8-(4-methoxyphenyl)oct-5-en-7-yn-
4-yl)propiolamide 385c (0.020 g, 0.054 mmol) and [(PPh3Au)3O]BF4 (0.002 g, 0.00140 mmol, 
0.025 equiv.), in toluene (1.0 mL). White solid (0.014 g, 70%). Mp = 187-189 oC. Rf 











(t, 3H, J = 5.6 Hz, CH3), 0.86-0.93 (m, 1H, CH), 1.08-1.17 (m, 1H, CH), 1.90-1.95 (m, 2H, 
CH2), 3.86 (s, 3H, OCH3), 4.16 (d, 1H, J = 16.0 Hz, CHPh), 4.45 (t, 1H, J = 4.0 Hz, CH), 5.41 
(d, 1H, J = 16.0 Hz, CHPh), 6.98-7.02 (m, 2H, 2CHAr), 7.26-7.35 (m, 6H, 6CHAr), 7.39 (d, 1H, 
J = 8.0 Hz, CHAr), 7.56-7.60 (m, 2H, 2CHAr), 7.71 (d, 1H, J = 8.0 Hz, CHAr), 8.07 (s, 1H, CHAr). 
13C{1H} NMR (100 MHz, CDCl3) δ 14.0, 15.8, 32.6, 43.9, 55.3, 58.5, 114.3, 121.6, 122.4, 
127.5, 128.1, 128.2, 128.7, 130.0, 132.7, 133.1, 137.2, 141.0, 143.6, 159.4, 168.6. IR (νmax/cm-
1) 2922 (m), 2850 (w), 1687 (s), 1605 (m), 1440 (s), 1254 (s), 1028 (s), 814 (s), 733 (s), 694 




The title compound 386d was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyl-N-(8-(4-fluorophenyl)oct-5-en-7-yn-4-
yl)propiolamide 385d (0.020 g, 0.055 mmol) and [(PPh3Au)3O]BF4 (0.002 g, 0.00140 mmol, 
0.025 equiv.), in toluene (1.0 mL). Light yellow oil (0.013 g, 65%). Rf (Et2O/hexane = 5:5) = 
0.38. [𝛼]+,/	= –159.0 (c 0.2 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.80-0.93 (m, 4H, CH3 and 
CH), 1.10-1.16 (m, 1H, CH), 1.91-1.96 (m, 2H, CH2), 4.16 (d, 1H, J = 15.2 Hz, CHPh), 4.46 
(t, 1H, J = 4.0 Hz, CH), 5.41 (d, 1H, J = 15.2 Hz, CHPh), 7.13-7.17 (m, 2H, 2CHAr), 7.26-7.33 
(m, 5H, 5CHAr), 7.40-7.43 (m, 1H, CHAr), 7.57-7.61 (m, 2H, 2CHAr), 7.70 (dd, 1H, J = 4.0 Hz, 
6.0 Hz, CHAr), 8.06 (s, 1H, CHAr). 13C{1H} NMR (100 MHz, CDCl3) δ 14.0, 15.8, 32.5, 43.9, 
58.5, 115.8 (d, JC,F = 21.4 Hz), 122.0, 122.5, 127.6, 128.1, 128.7, 128.8 (d, JC,F = 8.0 Hz), 130.2, 
133.2, 136.4 (d, JC,F = 3.3 Hz), 137.1, 140.4, 144.3, 162.7 (d, JC,F = 245.0 Hz), 168.4. IR 
(νmax/cm-1) 3282 (w), 2959 (m), 2103 (m), 1622 (s), 1505 (s), 1411 (s), 1222 (s), 953 (s), 834 











The title compound 386e was obtained after flash column chromatography (Et2O/hexane = 4:6) 
following the general procedure using (S,E)-N-benzyl-N-(8-(4-formylphenyl)oct-5-en-7-yn-4-
yl)propiolamide 385e (0.020 g, 0.054 mmol) and [(PPh3Au)3O]BF4 (0.002 g, 0.00140 mmol, 
0.025 equiv.), in toluene (1.0 mL). Yellow oil (0.013 g, 65%). Rf (Et2O/hexane = 4:6) = 0.30. 
[𝛼]+,/	= –196.0 (c 0.2 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.80-0.93 (m, 4H, CH3 and CH), 
1.10-1.16 (m, 1H, CH), 1.93-1.98 (m, 2H, CH2), 4.18 (d, 1H, J = 16.0 Hz, CHPh), 4.49 (t, 1H, 
J = 4.0 Hz, CH), 5.41 (d, 1H, J = 16.0 Hz, CHPh), 7.23-7.36 (m, 5H, 5CHAr), 7.46-7.49 (m, 
1H, 1CHAr), 7.78-7.82 (m, 3H, 3CHAr), 7.97-8.00 (m, 2H, 2CHAr), 8.16 (s, 1H, CHAr), 10.08 (s, 
1H, CHO). 13C{1H} NMR (100 MHz, CDCl3) δ 14.0, 15.8, 32.5, 43.9, 58.6, 122.5, 122.8, 127.6, 
127.8, 128.1, 128.7, 130.4, 130.5, 133.4, 135.5, 137.0, 140.0, 145.5, 146.1, 168.1, 191.8. IR 
(νmax/cm-1) 2958 (m), 2871 (w), 1702 (s), 1680 (s), 1603 (s), 1400 (s), 1213 (s), 817 (s), 733 (s), 




The title compound 386f was obtained after flash column chromatography (Et2O/hexane = 5:5) 
following the general procedure using (S,E)-N-benzyl-N-(2-methyl-8-(thiophen-2-yl)oct-5-en-
7-yn-4-yl)propiolamide 385f (0.020 g, 0.054 mmol) and [(PPh3Au)3O]BF4 (0.002 g, 0.00140 
mmol, 0.025 equiv.), in toluene (1.0 mL). Yellow oil (0.016 g, 80%). Rf (Et2O/hexane = 5:5) = 











CH3), 0.90 (d, 3H, J = 8.0 Hz, CH3), 1.65-1.75 (m, 2H, CH2), 1.82-1.87 (m, 1H, CH), 4.18 (d, 
1H, J = 16.0 Hz, CHPh), 4.38-4.41 (m, 1H, CH), 5.45 (d, 1H, J = 16.0 Hz, CHPh), 7.09-7.11 
(m, 1H, CHAr), 7.25-7.40 (m, 8H, 8CHAr), 7.45 (d, 1H, J = 8.0 Hz, CHAr), 8.14 (s, 1H, CHAr). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.8, 23.8, 24.3, 40.1, 44.0, 57.6, 120.9, 123.0, 123.7, 
125.4, 127.6, 128.1, 128.2, 128.7, 129.0, 133.0, 134.7, 137.0, 143.3, 145.0, 168.1. IR (νmax/cm-
1) 3063 (w), 2954 (m), 2867 (w), 1681 (s), 1402 (s), 1276 (m), 818 (m), 734 (s), 696 (s). HRMS 
(ESI-TOF) m/z calcd for C23H24NOS [M + H]+ 362.1579, found 362.1579. 
 
 (S)-2-Benzyl-3-isobutyl-6-(naphthalen-1-yl)isoindolin-1-one (386g) 
 
The title compound 386g was obtained after flash column chromatography (Et2O/hexane = 4:6) 
following the general procedure using (S,E)-N-benzyl-N-(2-methyl-8-(naphthalen-1-yl)oct-5-
en-7-yn-4-yl)propiolamide 385g (0.020 g, 0.049 mmol) and [(PPh3Au)3O]BF4 (0.0018 g, 
0.00123 mmol, 0.025 equiv.), in toluene (1.0 mL). Light yellow oil (0.016 g, 80%). Rf 
(Et2O/hexane = 4:6) = 0.36. [𝛼]+,/	= –113.3 (c 0.3 CHCl3). 1H NMR (400 MHz, CDCl3) δ 0.83 
(d, 3H, J = 5.2 Hz, CH3), 0.95 (d, 3H, J = 5.2 Hz, CH3), 1.71-1.76 (m, 1H, CH), 1.80-1.86 (m, 
1H, CH), 1.89-1.94 (m, 1H, CH), 4.22 (d, 1H, J = 12.0 Hz, CHPh), 4.47-4.49 (m, 1H, CH), 
5.49 (d, 1H, J = 12.0 Hz, CHPh), 7.25-7.45 (m, 5H, 5CHAr), 7.49-7.55 (m, 5H, 5CHAr), 7.64 
(dd, 1H, J = 2.0 Hz, 4.8 Hz, CHAr), 7.85-7.93 (m, 3H, 3CHAr), 8.05 (s, 1H, CHAr). 13C{1H} 
NMR (100 MHz, CDCl3) δ 22.7, 23.9, 24.4, 40.3, 44.0, 57.6, 122.5, 125.3, 125.4, 125.7, 125.9, 
126.3, 127.2, 127.6, 128.1, 128.2, 128.3, 128.7, 131.4, 132.4, 133.2, 133.8, 137.1, 139.1, 140.9, 
145.1, 168.3. IR (νmax/cm-1) 3043 (w), 2954 (m), 2867 (w), 1682 (s), 1430 (s), 1397 (s), 1199 
(m), 777 (s), 700 (s), 632 (m). HRMS (ESI-TOF) m/z calcd for C29H27NONa [M + Na]+ 








Deuterium Labeling Study (a) 
 
The deuterated propiolamide 385c-d was prepared from the enediyne 385c following a 





To a solution of propiolamide 385c (0.02 g, 0.054 mmol) in CH3CN (1.00 mL) was added 
K2CO3 (0.011 g, 1.50 equiv.), and the mixture was stirred at room temperature for 1 h. Then, 
D2O (0.050 mL, 50.0 equiv.) was added and the mixture was stirred for 1 h at room temperature. 
The reaction mixture was then diluted by CH2Cl2 (3.00 mL) and dried (Na2SO4) to obtain the 
deuterated propiolamide 385c-d with 98% deuterium purity, determined by 1H NMR analysis. 
Colourless oil (0.018 g, 90%). Rf (Et2O/hexane = 4:6) = 0.41. [𝛼]+,,	= –139.8 (c 0.5 CHCl3). 1H 
NMR (400 MHz, CDCl3) (mixture (ca. 1:1) of two rotamers) δ 0.77 (t, 3H, J = 8.0 Hz, CH3), 
1.14-1.28 (m, 2H, CH2), 1.52-1.60 (m, 2H, CH2), 3.81 (s, 3H, OCH3), 4.35 (d, 0.5H, J = 16.0 
Hz, CHPh), 4.68-4.88 (m, 2H, CHPh and CH), 5.01-5.18 (m, 0.5H, CH), 5.70 (dd, 0.5H, J = 
1.5, 16.0 Hz, =CH), 5.85 (dd, 0.5H, J = 1.5, 16.0 Hz, =CH), 6.02-6.10 (m, 1H, =CH), 6.81-6.86 
(m, 2H, 2CHAr), 7.22-7.38 (m, 7H, 7CHAr). 13C{1H} NMR (mixture (ca. 1:1) of two rotamers) 
(100 MHz, CDCl3) δ 13.5, 13.6, 19.3, 19.5, 33.7, 34.3, 45.3, 51.0, 55.2, 55.3, 57.5, 60.8, 85.5, 




























128.6, 132.9, 133.0, 137.2, 139.7, 140.1, 153.9, 154.3, 159.6, 159.7. HRMS (ESI-TOF) m/z 




The title compound 386c-d was obtained after flash column chromatography (Et2O/hexane = 
4:6) following the general gold-catalysed reaction procedure using (S,E)-N-benzyl-N-(8-(4-
methoxyphenyl)oct-5-en-7-yn-4-yl)propiolamide-d 385c-d (0.017 g, 0.0456 mmol) and 
[(PPh3Au)3O]BF4 (0.0017 g, 0.00114 mmol, 0.025 equiv.), in toluene (1.0 mL). Light yellow 
oil (0.011 g, 65%). Rf (Et2O/hexane = 5:5) = 0.42. [𝛼]+,,	= –128.1 (c 0.3 CHCl3).  1H NMR 
(400 MHz, CDCl3) (mixture of d-product and H-product) δ 0.82 (t, 3H, J = 5.6 Hz, CH3), 0.86-
0.93 (m, 1H, CH), 1.09-1.15 (m, 1H, CH), 1.90-1.95 (m, 2H, CH2), 3.86 (s, 3H, OCH3), 4.16 
(d, 1H, J = 12.0 Hz, CHPh), 4.45 (t, 1H, J = 4.0 Hz, CH), 5.41 (d, 1H, J = 12.0 Hz, CHPh), 
7.00 (d, 2H, J = 8.0 Hz, 2CHAr), 7.26-7.34 (m, 5H, 5CHAr), 7.39 (d, 1H, J = 8.0 Hz, CHAr), 7.58 
(d, 2H, 2CHAr), 7.71 (d, 0.93H, J = 6.4 Hz, CHAr), 8.07 (d, 0.60H, J = 4.0 Hz, CHAr). 13C{1H} 
NMR (100 MHz, CDCl3) (mixture of d-product and H-product) δ 14.0, 15.8, 32.5, 43.8, 55.3, 
58.5, 114.3, 121.6, 122.4, 127.5, 128.1, 128.2, 128.7, 129.96, 129.98, 132.7, 133.1, 137.2, 
141.0, 143.6, 159.4, 168.6. HRMS (ESI-TOF) m/z calcd for C25H24DNO2Na [M + Na]+ 
395.1846, found 395.1847. The percentage of mono-deuteration determined by MS analysis 
was 41%, and the percentage of di-deuteration was 12% (LRMS m/z 372 C25H26NO2 [M + H]+ 


















Deuterium labeling study (b) 
 
The amino aldehyde 217b-d' was obtained using lithium aluminum deuteride (LiAlD4) 
reduction of the corresponding ester 248b, followed by TEMPO oxidation. 
 
tert-Butyl (S)-benzyl(1-hydroxypentan-2-yl-1,1-d2)carbamate (249b-d') 
 
To a solution of lithium aluminum deuteride (0.11 g in 5 mL THF, 2.50 mmol, 2.00 equiv.) at 
0 °C, was added dropwise a solution of the amino ester 248b (0.40 g, 1.25 mmol) in THF (5 
mL) and the mixture was stirred at the same temperature for 30 min. The reaction was quenched 
by the dropwise addition of acetone (5 mL), filtered, and concentrated under reduced pressure. 
The crude was purified by flash column chromatography (ethyl acetate/hexane = 3:7) to obtain 
the amino alcohol product 249b-d'. Colourless oil (0.26 g, 70%). Rf (Et2O/hexane = 3:7) = 
0.46. 1H NMR (400 MHz, CDCl3) (mixture (ca. 3:2) of romaters) δ 0.87 (t, 3H, J = 8.0 Hz, 
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CH3), 1.27 (br s, 2H, CH2), 1.42 (br s, 11H, C(CH3)3 and CH2), 3.03 (br s, 0.6H, OH), 3.77 (br 
s, 1H, CH), 4.32-4.50 (m, 2H, CH2Ph), 7.23-7.34 (m, 5H, 5CHAr). 13C{1H} NMR (100 MHz, 
CDCl3) (mixture (ca. 3:2) of romaters) δ 14.0, 19.6, 28.4, 30.8, 49.9, 59.5, 63.6 (br), 80.3, 
127.1, 128.5, 139.4, 157.0. HRMS (ESI-TOF) m/z calcd for C17H25D2NO3Na [M + Na]+ 
318.2014, found 318.2010. 
 
tert-Butyl (S)-benzyl(1-oxopentan-2-yl-1-d)carbamate (217b-d') 
 
To a stirred solution of tert-butyl (S)-benzyl(1-hydroxypentan-2-yl-1,1-d)carbamate 249b-d' 
(0.26 g, 0.88 mmol) in CH2Cl2 (10 mL) at 0 °C were added saturated aqueous NaHCO3 solution 
(5 mL), KBr (0.100 g, 0.88 mmol, 1.00 equiv.), and TEMPO (0.0070 g, 0.044 mmol, 0.05 
equiv). NaOCl (2.15 mL, 0.49 M, 1.053 mmol, 1.20 equiv.) was then added with a syringe 
pump over 30 min. Then, the reaction mixture was quenched with saturated aqueous Na2S2O3 
solution (5 mL) and extracted into CH2Cl2 (3 × 5 mL). The combined organic layers were dried 
(Na2SO4) and concentrated under reduced pressure to afford the aldehyde 217b-d', which was 
utilized for the next step without purification. Colorless oil (0.23 g, 70%). 1H NMR (400 MHz, 
CDCl3) (mixture (ca. 3:2) of rotamers) δ 0.90 (t, 3H, J = 8.0 Hz, CH3), 1.34-1.42 (m, 1H, CH), 
1.46 (br s, 9H, C(CH3)3), 1.66-1.71 (m, 1H, CH), 1.92-2.00 (m, 1H, CH), 3.44 (t, 0.6H, J = 8.0 
Hz, CH), 3.77 (br s, 0.4H, CH), 4.12 (d, 0.6H, J = 12.0 Hz, CHPh), 4.19 (d, 0.4H, J = 12.0 Hz, 
CHPh), 4.72 (d, 0.4H, J = 12.0 Hz, CHPh), 5.01 (d, 0.6H, J = 12.0 Hz, CHPh), 7.26-7.36 (m, 
5H, 5CHAr). 13C{1H} NMR (100 MHz, CDCl3) (mixture (ca. 3:2) of rotamers, minor rotamer 
indicated by an asterisk) δ 13.9, 19.6, 28.2, 29.2*, 30.4, 51.4*, 51.9, 65.3, 65.5*, 81.0*, 81.5, 
127.6, 127.8*, 128.3*, 128.8, 137.7, 138.2*, 155.2, 155.6*, 199.5 (t, JC,D = 22.0 Hz). HRMS 










tert-Butyl benzyl((4S)-5-hydroxyocta-6,7-dien-4-yl-5-d)carbamate (218b-d') 
 
The title compound 218b-d' was obtained after flash column chromatography (Et2O/hexane = 
3:7) following general allenylation reaction using tert-butyl (S)-benzyl(1-oxopentan-2-yl-1-
d)carbamate 217b-d' (0.23 g, 0.786 mmol), allenylboronic pinacol ester 71 (0.14 mL, 1.022 
mmol, 1.30 equiv.), and diethylzinc (0.05 mL, 0.055 mmol, 0.07 equiv.) in toluene (5.0 mL). 
Colourless oil (0.23 g, 88%). Rf (Et2O/hexane = 3:7) = 0.38. 1H NMR (400 MHz, CDCl3) 
(mixture of rotamers) δ 0.76-0.88 (m, 3H, CH3), 1.18-1.61 (m, 12H, C(CH3)3 and CH2 and CH), 
1.76-1.96 (m, 1H, CH), 3.42-3.58 (m, 1H, CH), 4.11-4.75 (m, 3H, CH2Ph and CH), 4.78 (d, 
2H, J = 8.0 Hz, =CH2 allene), 5.07-5.13 (m, 1H, =CH allene), 7.22-7.32 (m, 5H, 5CHAr). 
13C{1H} NMR (100 MHz, CDCl3) (mixture of rotamers) δ 13.8, 13.9, 14.0, 14.1, 19.7, 20.0, 
24.6, 24.7, 28.3, 28.4, 31.1, 52.1, 63.5, 70.4, 77.3, 80.5, 93.2, 127.10, 127.18, 127.3, 127.5, 
127.8, 128.0, 128.1, 128.3, 128.4, 138.9, 156.9, 207.1. HRMS (ESI-TOF) m/z calcd for 




The title compound 253b-d' was obtained following the general procedure using tert-butyl 
benzyl((4S)-5-hydroxyocta-6,7-dien-4-yl-5-d)carbamate 218b-d' (0.23 g, 0.69 mmol) and NaH 
(60% in mineral oil, 0.055 g, 1.38 mmol, 2.0 equiv.) in THF (1.20 mL). The crude was pure 
enough to use for the next step. Colourless oil (0.14 g, 95%). Rf (Et2O/hexane = 3:7) = 0.31. 
1H NMR (400 MHz, CDCl3) δ 0.88 (t, 3H, J = 8.0 Hz, CH3), 1.27-1.50 (m, 4H, 2CH2), 2.86 (d, 
1H, J = 2.4 Hz, CH alkyne), 3.08 (t, 1H, J = 6.4 Hz, CH), 3.61 (d, 1H, J = 12.0 Hz, CHPh), 
3.81 (d, 1H, J = 12.0 Hz, CHPh), 5.57 (d, 1H, J = 1.6 Hz, =CH), 7.21-7.33 (m, 5H, 5CHAr). 











128.4, 140.4, 148.4 (t, JC,D = 23.0 Hz). HRMS (ESI-TOF) m/z calcd for C15H19DN [M + H]+ 




The title compound 384c-d' was obtained after flash column chromatography (Et2O/hexane = 
4:6) following the general Sonogashira coupling procedure using (S,E)-N-benzyloct-5-en-7-yn-
5-d-4-amine 253b-d' (0.14 g, 0.94 mmol), 4-iodoanisole (0.33 g, 1.13 mmol, 1.50 equiv.), CuI 
(0.0073 g, 0.038 mmol, 0.04 equiv.) and Pd(PPh3)2Cl2 (0.0133 g, 0.019 mmol, 0.02 equiv.), and 
Et3N (0.27 mL, 1.90 mmol, 2.00 equiv.) in THF (1.5 mL). Yellow oil (0.138 g, 46%). Rf 
(Et2O/hexane = 3:7) = 0.35. 1H NMR (400 MHz, CDCl3) δ 0.89 (t, 3H, J = 8.0 Hz, CH3), 1.32-
1.51 (m, 4H, 2CH2), 3.12 (t, 1H, J = 8.0 Hz, CH), 3.66 (d, 1H, J = 12.0 Hz, CHPh), 3.81 (s, 3H, 
OCH3), 3.85 (d, 1H, J = 12.0 Hz, CHPh), 5.79 (s, 1H, =CH), 5.82-5.86 (m, 2H, 2CHAr), 7.23-
7.26 (m, 1H, CHAr), 7.32 (d, 4H, J = 8.0 Hz, 4CHAr), 7.36-7.40 (m, 2H, 2CHAr). 13C{1H} NMR 
(100 MHz, CDCl3) δ 14.0, 19.1, 38.0, 51.3, 55.2, 60.0, 86.4, 89.0, 111.0, 114.0, 115.5, 127.0, 
128.1, 128.4, 132.9, 140.5, 145.6 (t, JC,D = 23.4 Hz), 159.0. HRMS (ESI-TOF) m/z calcd for 


















The title compound 385c-d' was obtained after flash column chromatography (Et2O/pentane = 
4:6) following the general procedure using (S,E)-N-benzyl-8-(4-methoxyphenyl)oct-5-en-7-yn-
5-d-4-amine 384c-d' (0.137 g, 0.43 mmol), propiolic acid (0.041 mL, 0.645 mmol, 1.50 equiv.), 
DMAP (0.016 g, 0.13 mmol, 0.30 equiv.) and DCC (0.136 g, 0.645 mmol, 1.50 equiv.) in 
CH2Cl2 (2.0 mL). Orange oil (0.075 g, 47%). Rf (Et2O/pentane = 4:6) = 0.48. [𝛼]+,0	= –188.6 (c 
1.0 CHCl3).  1H NMR (500 MHz, CDCl3) (mixture (ca. 1:1) of rotamers) δ 0.76 (t, 3H, J = 7.5 
Hz, CH3), 1.14-1.30 (m, 3H, CH2 and CH), 1.50-1.60 (m, 1H, CH), 3.10 (s, 0.5H, CH alkyne), 
3.22 (s, 0.5H, CH alkyne), 3.81 (s, 3H, OCH3), 3.34 (0.5H, d, J = 15.0 Hz, CHPh), 3.67-3.71 
(m, 1H, CHPh and CH), 3.79 (0.5H, d, J = 15.0 Hz, CHPh), 3.86 (0.5H, d, J = 15.0 Hz, CHPh), 
5.06 (t, 0.5H, J = 7.5 Hz, CH), 5.07 (s, 0.5H, =CH), 5.85 (s, 0.5H, =CH), 6.83-6.90 (m, 2H, 
=CH), 7.23-7.48 (m, 7H, 7CHAr). 13C{1H} NMR (125 MHz, CDCl3) (mixture (ca. 1:1) of 
rotamers) δ 13.5, 13.6, 19.2, 19.5, 33.6, 34.1, 45.2, 51.0, 55.2, 55.3, 57.3, 60.0, 75.9, 76.3, 78.8, 
80.1, 85.4, 85.7, 90.4, 91.0, 112.9, 113.2, 113.9, 114.0, 114.8, 115.0, 127.2, 127.4, 127.7, 128.0, 
128.4, 128.6, 137.0, 137.7, 139.3 (t, JC,D = 24.0 Hz), 139.7 (t, JC,D = 24.0 Hz), 153.8, 154.2, 

















The title compound 386c-d' was obtained after flash column chromatography (Et2O/hexane = 
4:6) following the general procedure using (S,E)-N-benzyl-N-(8-(4-methoxyphenyl)oct-5-en-
7-yn-4-yl-5-d)propiolamide 385c-d' (0.020 g, 0.054 mmol) and [(PPh3Au)3O]BF4 (0.002 g, 
0.00134 mmol, 0.025 equiv.) in toluene (1.0 mL). Colourless oil (0.014 g, 70%). Rf 
(Et2O/hexane = 4:6) = 0.30. [𝛼]+,0	= –117.5 (c 0.2 CHCl3). 1H NMR (500 MHz, CDCl3) δ 0.80-
0.94 (m, 4H, CH3 and CH), 1.07-1.17 (m, 1H, CH), 1.91-1.95 (m, 2H, CH2), 3.87 (s, 3H, OCH3), 
4.16 (d, 1H, J = 15.0 Hz, CHPh), 4.45 (t, 1H, J = 4.0 Hz, CH), 5.43 (d, 1H, J = 15.0 Hz, CHPh), 
6.99-7.02 (m, 2H, 2CHAr), 7.26-7.35 (m, 5H, 5CHAr), 7.39-7.41 (m, 0.85H, CHAr), 7.57-8.00 
(m, 2H, 2CHAr), 7.70-7.72 (m, 0.76H, CHAr), 8.07 (s, 0.93H, CH). 13C{1H} NMR (125 MHz, 
CDCl3) δ 14.0, 15.6, 15.7, 32.45, 32.47, 43.8, 55.3, 58.40, 58.41, 114.3, 121.61, 121.63, 122.3, 
122.4, 127.5, 128.1, 128.2, 128.7, 129.8, 129.9, 132.6, 133.0, 137.1, 141.0, 143.6, 159.3, 168.6. 
HRMS (ESI-TOF) m/z calcd for C25H24DNO2Na [M + Na]+ 395.1846, found 395.1860. The 
percentage of mono-deuteration determined by MS analysis was 46%, and the percentage of di-
deuteration was 2% (LRMS m/z 372 C25H26NO2 [M + H]+ 52%, m/z 373 C25H25DNO2 [M + H]+ 





















yl)triphenylphosphine gold (385e-Au) 
 
To a solution of AuPPh3Cl (0.036 g, 0.073 mmol, 0.90 equiv.) in CH2Cl2/Et3N (1 mL/0.25 mL) 
was added (E)-N-benzyl-N-(8-(4-formylphenyl)oct-5-en-7-yn-4-yl)propiolamide 385e (0.030 
g, 0.81 mmol) under nitrogen atmosphere and the solution stirred in the dark at room 
temperature for 18 h. The reaction mixture was then passed through a pad of alumina to obtain 
the gold acetylide 385e-Au. White solid (0.050 g, 89%). Rf on silica TLC (EtOAc/hexane = 
2:8) = 0.53. Mp = 70-73 oC. [𝛼]+,1	= –198.1(c 0.6 CHCl3).  1H NMR (500 MHz, CDCl3) 
(mixture (ca. 1:1) of two rotamers) δ 0.74-0.80 (m, 3H, CH3), 1.13-1.35 (m, 2H, CH2), 1.51-
1.63 (m, 2H, CH2), 4.38 (d, 0.5H, J = 15.5 Hz, CHPh), 4.74-4.78 (m, 1H, CHPh and CH), 4.87 
(d, 0.5H, J = 15.5 Hz, CHPh), 5.06 (d, 0.5H, J = 15.5 Hz, CHPh), 5.51-5.55 (m, 0.5H, CH), 
5.65 (dd, 0.5H, J = 16.5, 1.4 Hz, CH=), 5.91 (dd, 0.5H, J = 16.5, 1.7 Hz, CH=), 6.17-6.22 (m, 
1H, CH=), 7.19-7.35 (m, 4H, CHAr), 7.42-7.55 (m, 18H, CHAr), 7.80-7.83 (m, 2H, CHAr), 10.00 
(2 × s, 1H, CHO). 13C{1H} NMR (125 MHz, CDCl3) (mixture (ca. 1:1) of two rotamers which 
complicates interpretation. This compound is unstable to heating, therefore a high temperature 
NMR experiment was not possible) δ 13.7, 13.8, 19.4, 19.6, 33.6, 34.0, 44.8, 51.5, 56.6, 60.5, 
88.7, 91.6, 91.8, 111.2, 111.3, 126.8, 127.3, 128.0, 128.1, 128.21, 128.28, 129.3, 129.52, 
129.55, 129.6, 129.7, 129.8, 131.7, 131.9, 132.0, 134.2, 134.3, 135.2, 135.3, 138.5, 138.9, 
144.1, 144.6, 155.5, 191.4, 191.5. 31P NMR (202 MHz, CDCl3) δ 41.5. IR (νmax/cm-1) 2961 
(w), 2112 (m), 1697 (s), 1595 (s), 1434 (s), 1099 (s), 827 (s), 691 (s), 535 (s), 499 (s). HRMS 














To a solution of (E)-(3-(benzyl(8-(4-formylphenyl)oct-5-en-7-yn-4-yl)amino)-3-oxoprop-1-
yn-1-yl)triphenylphosphine gold 385e-Au (0.015 g, 0.018 mmol) in toluene (1 mL) was added 
AuPPh3Cl (0.005 g, 0.0009 mmol, 0.05 equiv.) and then AgBF4 (0.002 g, 0.0009 mmol, 0.05 
equiv.) under nitrogen atmosphere and the solution stirred at room temperature for 5 min. The 
reaction mixture was then passed through a pad of alumina and purified by column 
chromatography using alumina (EtOAc/hexane = 3:7) to obtain the monogold complex 386e-
Au. The corresponding isoindolinone 386e was also isolated in 69% yield due to 
protodeauration by trace moisture. White solid (0.004 g, 27%). Rf on silica TLC 
(EtOAc/hexane = 3:7) = 0.76. Mp = 158-161 oC. 1H NMR (400 MHz, CD2Cl2) δ 0.80-0.91 (m, 
4H, CH3 and CH), 1.10-1.17 (m, 1H, CH), 1.90-1.96 (m, 2H, CH2), 4.16 (d, J = 15.5 Hz, 1H, 
CHHPh), 4.35 (t, J = 4.0 MHz, CH), 5.28 (d, J = 15.5 Hz, 1H, CHHPh), 7.15-7.57 (m, 22H, 
22CHAr), 7.66 (d, 2H, J = 8.0 MHz, 2CHAr)  7.94 (d, 2H, J = 8.0 MHz, 2CHAr), 9.89 (s, 1H, 
CHO). 13C{1H}-APT NMR (100 MHz, CD2Cl2) δ 192.0 (CHO), 171.0 (CO), 170.1 (d, J = 111 
Hz), 155.2 (ArC), 150.2 (ArC), 144.1 (ArC), 141.3 (ArC), 138.2 (ArC), 134.5 (d, J = 13.4 Hz), 
132.1 (ArC), 131.3 (d, J = 49.8 Hz), 131.1 (d, J = 2.4 Hz), 130.1 (ArCH), 129.2 (ArCH), 129.1 
(d, J = 11.0 Hz), 128.7 (ArCH), 128.2 (ArCH), 127.3 (ArCH), 119.4 (ArCH), 58.2 (CH), 43.9 
(CH2), 32.9 (CH2), 16.0 (CH2), 13.9 (CH3). 31P NMR (162 MHz, CD2Cl2) δ 42.9, 33.1 (minor 
impurity due to AuPPh3Cl). IR (νmax/cm-1) 2922 (m), 1670 (s), 1434 (s), 1099 (s), 818 (s), 691 
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